Sangamo Treatment Shows Resistance To HIV In Study - 500 Beiträge pro Seite

[benefactor [KommA]]

Sangamo Treatment Shows Resistance To HIV In Study
Peter Kang, 12.17.05, 1:30 PM ET

Sangamo Biosciences (nasdaq: SGMO - news - people ) announced new study data which indicated cells modified by the biotech firm`s novel treatment were resistant to HIV infection.

The Richmond, Calif.-based company said the preclinical data is the first evidence its gene-disruption technology can render CCR5 receptors, proteins seen pivotal to HIV infection, resistant to the virus. The company presented the new data today at the Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC, in Washington, D.C.

"It`s pretty exciting for us and will be interesting for the infectious disease community as well," Chief Executive Edward Lanphier said in an interview. "It`s an enormous step forward for HIV therapeutics and circumvents or leapfrogs all the conventional approaches."

The company expects to file an investigational new drug application with the U.S. Food and Drug Administration in the second half of 2006.

In the last few years a new class of experimental HIV drugs has emerged after a discovery in 1996 that a small population in Eastern Europe, descendants of bubonic plague survivors, had a natural mutation of the CCR5 gene and was resistant to HIV infection.

"Quite frankly, CCR5 is really the poster child for a gene where we know that the disruption of the normal expression has enormously positive therapeutic potential," said Lanphier.

However, recent safety concerns have emerged for some of these drugs. A clinical trial of a small molecule drug targeting the CCR5 receptor was recently halted by GlaxoSmithKline (nyse: GSK - news - people ) after liver toxicity was reported in a minority of patients. Schering-Plough (nyse: SGP - news - people ) and Pfizer (nyse: PFE - news - people ) are also both advancing their own versions through late-stage clinical trials.

Sangamo`s gene-modifying technology, which utilize DNA-binding proteins, avoid these potential issues. "It doesn`t have any of the safety issues that we`ve seen emerge with the high-dose drugs," said Lanphier.

Piper Jaffray called Sangamo`s new approach "revolutionary" in a Nov. 22 client note. "This approach could potentially complement multi-drug cocktails that kill HIV by actually promoting the patient`s immune system," wrote analyst Edward Tenthoff. The Piper Jaffray analyst maintained an "outperform" rating on the stock with an $8 price target.
http://www.forbes.com/2005/12/17/sangamo-hiv-fda-1217markets…

[substance]

Das ist sicherlich eine erfreuliche Mitteilung, allerdings wurde bereits im Sommer veröffentlicht, dass es Sangamo gelungen sei, Zellen so zu modifizieren, dass die Ausbildung des CCR5 Trägerproteins blockiert wurde und die Zellen damit resistent gegen HIV-Stränge waren. Die aktuelle Meldung dürfte daher eher eine nochmalige Bestätigung des bereits Erreichten sein. Ich habe den heutigen Hype jedenfalls (vorerst!) zum Ausstieg genutzt, da ich die Meldung als nicht so gewaltig einstufe wie der Kurssprung von heute es vermuten liesse.

Der CEO sieht das scheinbar auch so, denn er hat am 16. Dez., also nur einen Tag vor der Meldung 48500 Aktien verkauft. Bedenkt man, dass sein letzter Verkauf fast ein Jahr her ist, ist es sicher kein Zufall, dass er kurz vor einer solchen Meldung verkauft. `Kurz vor` vermutlich, damit man ihm keinen Insiderhandel vorwirft. Verkauft hat er nämlich nicht an der Börse, sondern ausserbörslich! Das lässt die Vermutung zu, dass derjenige, der die Aktien gekauft hat, sie in den Hype der Meldung von heute wieder verkauft. Würde mich wundern, wenn nicht auch Lanphier(CEO) davon in irgendeiner Form profitieren würde.

Wie auch immer, es wird sich zeigen wie der Kurs sich nach dem Hype entwickelt, ich jedenfalls spekuliere darauf, dass das Gap von heute wieder geschlossen wird.

Man sollte auch bedenken, dass die Resistenz nicht gegen alle HIV-Stämme wirkt, die Therapie wäre also erstens nicht bei allen Patienten einsetzbar und zweitens könnte HIV insgesamt sich dadurch anpassen und die Therapie unbrauchbar machen.

Gruss an die paar Leute, die das hier lesen...

[benefactor [KommA]]

Die Aktien wurden nicht verkauft.
Explanation of Responses:
(1)Shares transferred as a bona fide gift without consideration.

Der Kurs verhält sich allerdings bescheiden.

[substance]

Stimmt, Du hast Recht, bei Yahoo stand nur disposition. Nur wem schenkt man einfach soviel Aktien? Und wozu? Interessant auch, dass die Aktien in Portionen (also mal 5000, mal 2000 usw.) übertragen wurden. Hat er eine Party mit einer Tombola gemacht und die Aktien verlost nein, ernsthaft, ich kann das nicht deuten, ich kenne mich auch nicht mit dem amerikanischen Steuerrecht aus, als dass ich darüber zu einer Deutung kommen könnte, ich sehe nur, dass er nun weniger Aktien hält als vorher (obwohl er seinen Gesamtbestand nur geringfügig reduziert hat, das muss man auch sagen), auf jeden Fall hat er Aktien abgegeben und das zählt für mich, ich kann zwar an gute und gerechte Menschen glauben, aber an der Börse tue ich das lieber nicht . Vielleicht hat er sie aus dem Trust an seine Frau übertragen und die hat sie dann in den Hype verkauft. Ist aber auch nur Spekulation, auf jeden Fall ist es doch wohl kein Zufall, dass die Aktien nur einen Tag vor der Konferenz, und damit kurz vor einem vorhersehbaren Kurssprung, übertragen wurden.

Er hat übrigens schon mal Aktien als bona fide gift ("bona fide"? Im guten Glauben. Wann verschenkt man etwas bona fide? Wann und wozu benutzt man diesen Terminus? Weiss das jemand?) übertragen, vor ziemlich genau einem Jahr und der Zeitpunkt bei etwa $5,50 war gut gewählt, danach gings nochmal etwas rauf, aber dann gings abwärts bis runter auf $3,50.

Schaun mer mal, Technologie bleibt interessant.

[fire.fox]

[posting]19.350.843 von substance am 20.12.05 15:15:47[/posting]Lieber @substance,

du solltest mal wieder nach Sangamo sehen,

es deuten sich "scheinbar" interessante Entwicklungen"
an.

fire.fox

PS: Der Verfasser ist bei Sangamo investiert

[ottl2000]

Hallo

News von Sangamo

Sangamo BioSciences Announces Plans for Phase 2 Clinical Trial of ZFP Therapeutic in Diabetic Neuropathy at JPMorgan Healthcare Conference

SAN FRANCISCO, Jan 12, 2006 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that it will outline plans for a Phase 2 clinical trial of SB-509 in subjects with mild to moderate diabetic neuropathy at its presentation at the 24th annual JPMorgan Healthcare Conference. SB-509 is a novel ZFP Therapeutic(TM) designed to upregulate the expression of the patient`s own vascular endothelial growth factor (VEGF) gene to protect and stimulate the regeneration of peripheral nerve function in diabetics suffering from peripheral neuropathy. Edward Lanphier, Sangamo`s president and CEO, will present details of the study at the Conference at 1:30 p.m. today, Thursday, January 12, 2006 (PST).
"The progression of our first ZFP Therapeutic program into Phase 2 clinical trials is a significant clinical development milestone for Sangamo," said Mr. Lanphier. "We announced completion of enrollment of subjects in the Phase 1 study of SB-509 in November 2005 and did not observe any drug-related severe adverse events or dose-limiting toxicity. We expect to present data from the Phase 1 study at the American Academy of Neurology Meeting in San Diego in April 2006 and the American Diabetes Association Scientific Sessions in Washington, DC in June 2006. We are on track to initiate the Phase 2 study of SB-509 in the second half of 2006."

Sangamo is proposing to undertake a placebo-controlled, multi-treatment Phase 2 study in diabetic subjects with mild to moderate sensory/motor neuropathy. Subjects will be assigned to one of three treatment groups which will be administered a placebo, SB-509 every 2 months for three treatments or SB-509 every 3 months for three treatments. Subjects receiving SB-509 will be treated with the maximum tolerated dose of the ZFP Therapeutic by intramuscular injection in both legs. Safety will be monitored throughout the study. Clinical evaluations will include neurological examination and electrophysiological testing. The study will be conducted at multiple centers and subject enrollment is expected to take approximately twelve months.

About SB-509

SB-509 is administered as an injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)), designed to upregulate the VEGF-A gene. VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model, SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About Diabetic Neuropathy

Diabetic peripheral sensory motor neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This is gradually replaced by loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60% of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001 this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 18.3 million people with diabetes in the United States and that of those about 60% to 70% have mild to severe forms of neuropathy. According to the CDC, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

Deshalb ging der Kurs in den letzten Tagen auch unter anziehendem Volumen gut nach oben.

Wird auch langsam Zeit das sich was tut

Gruss Ottl

[benefactor [KommA]]

Wir haben ein neues 52-Wochenhoch.

[[KERN]Codex]

[fire.fox]

Liebe Freunde der Spekulation,

zur INFO:

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=BIOSHEAMTC…

fire.fox


PS:

Der Verfasser ist bei Sangamo investiert

[Bachalor]

[tokajo]

Hallo,

in der März Ausgabe der Technologyreview war ein sehr interessanter Artikel über Sangamo und ihrer Techniken.
Wenn nur ein Teil der Forschung in die Praxis umgesetzt wird, revolutioniert m.E sich die Medizin- und Biotechnik.


Die Gen-Chirurgen


Es war kein Forscher, kein in Laborarbeit vertieftes
Genie, das der Gentherapie ihre zweite Chance eröffnete.
Es war ein Manager, der sich anno 1994 mit den
Patentproblemen seines Unternehmens herumschlug. Zur Zerstreuung las Edward Lanphier, damals Finanzchef des Gentherapie-Startups Somatix, ein paar Arbeiten des Nobelpreisträgers Sir Aaron Klug. Der Biochemiker vom britischen Laboratory of Molecular Biology in Cambridge hatte Eiweiße mit den Eigenschaften eines Zielerfassungssystems entdeckt. Treffsicher aufs Atom genau – das perfekte Vehikel für die Genmedizin.

Während Molekularbiologen wie Klug nur darüber schrieben,
was damit möglich wäre, wurde der Geschäftsmann Lanphier
aktiv. Er verließ Somatix, lizenzierte die nötigen Patente, meldete selbst welche an und startete 1995 die Biotechfirma Sangamo BioSciences in Richmond bei San Francisco. Der Wechsel hat sich gelohnt: Mittlerweile haben Lanphiers Forscher aus der Idee eine Technik entwickelt, mit der defekte menschliche Gene gezielt repariert werden können.

Vergleichbares hat es nie zuvor gegeben, obwohl seit rund
15 Jahren tausende so genannter Gentherapien in klinischen Versuchen getestet wurden. Denn die meisten der Forscher, die sich Gentherapeuten nennen, sind in Wirklichkeit eher
Genschmuggler: Sie versuchen, zusätzlich zum kaputten Gen
eine intakte Version in die Zelle einzuschleusen, in der Hoffnung, dass diese sich durchsetzt. Doch häufig geht das kostbare Schmuggelgut auf dem Weg in die Zelle einfach verloren. In mindestens zwei Fällen endete der Austauschversuch sogar
tödlich: So starb 1999 ein 18-Jähriger an einer Überdosis von Viren, mit denen ein Gen in seine Zellen eingeschleust werden sollte. Und bei dem zunächst als Erfolg gefeierten Versuch, eine Gruppe von Kindern mit einer erblich bedingten Immunschwäche mittels Gentherapie zu heilen, erkrankten drei der Kinder an Blutkrebs – ausgelöst durch das heilversprechende Ersatzgen, das im Erbgut der Patienten zufällig ein Krebsgen eingeschaltet hatte. Zwei der Kinder konnten geheilt werden, eines starb an diesen Nebenwirkungen.

Seither war die Gentherapie-Szene im Schock erstarrt – bis
die Sangamo-Forscher im April 2005 an derselben Krankheit,
der SCID (Severe Combined Immunodeficiency), zeigen konnten, dass sich mit ihrer Technik solche Risiken vermeiden lassen. Ein „neuer Sicherheitsstandard“, jubelte der Molekularbiologe Scott Wolfe von der University of Massachusetts, von einem „beträchtlichen Fortschritt“ sprach die Präsidentin der amerikanischen Gentherapie-Gesellschaft Katherine High. Sangamo scheint auf dem besten Weg, gleich zwei Versprechen der modernen Wissenschaft einzulösen: Tatsächlich könnte es möglich werden, defekte Gene im Körper zu reparieren und so schwerste Krankheiten zu heilen. Und tatsächlich kommen dabei Werkzeuge zum Einsatz, die man getrost als Nanoroboter bezeichnen könnte: Proteine, die selbsttätig die fehlerhafte DNA-Stelle ansteuern und reparieren.

FINGER AUF DEN GENEN

Edward Lanphier hatte bereits Erfahrungen mit den Tücken
der Biotechnologie bei Pharmakonzernen wie Eli Lilly oder Synergen gesammelt, als er zu Somatix wechselte. Dort entwickelte man Transportvehikel, so genannte Vektoren, um Gene in die Zellen erbkranker Patienten zu schleusen. „Wir hatten aber keine therapeutischen Gene, die wir hätten hineinpacken können“, sagt der gelernte Biochemiker und versucht im fensterlosen Konferenzraum vergebens, den Beamer in Gang zu bringen: Die Rechte daran lagen bei Pharma- oder Biotech-Firmen wie Amgen oder Genentech. In dieser Situation stieß Lanphier in einer Fachzeitschrift auf die zielsicheren Proteine von Aaron Klug – „Zinkfinger“ hatte der britische Forscher seine Entdeckung getauft, denn die kleinen Eiweiße hatten eigentümliche, fingerähnliche Ausstülpungen, die an der Basis durch ein Zink-Atom in Form gehalten wurden.

Damit können sie buchstäblich nach DNA
greifen und sie abtasten, um zu überprüfen, aus welchen Bausteinen sie besteht. Wenn sie die richtige Kombination der vier DNA-Bausteine Adenin, Thymin, Cytosin und Guanin gefunden haben, krallen sie sich fest – so sind sie in der Lage, in einem Milliarden Bausteine langen DNA-Stück einen ganz bestimmten Abschnitt zu finden und daran kleben zu bleiben. Ein Finger erkennt dabei drei bis vier DNA-Bausteine. Welche das sind, ist vom Aufbau des Zinkfingers abhängig. Zwei Zinkfinger in einem Protein nebeneinander bleiben an einer sechs Bausteine langen DNA-Sequenz hängen, bei drei Fingern muss schon eine Abfolge von neun DNA-Bausteinen passen und so weiter.

„Man kann Zinkfinger wie Legosteine miteinander kombinieren“, erklärt Lanphier begeistert. „Ein einzigartiges Bauprinzip“, denn alle anderen bekannten DNA-bindenden Eiweiße bleiben eher zufällig an einer bestimmten DNA-Bausteinabfolge kleben. Allein bei den Zinkfingern steckt eine nachvollziehbare Logik dahinter. Entsprechend häufig nutzt die Natur das Prinzip: „Zinkfinger-Proteine finden sich in allen Organismen“, sagt Lanphier.

Fasziniert durchwühlte Lanphier die Literatur. Und las,
dass es gelungen war, an die Zinkfinger Teile anderer Eiweiße mit besonderen Fähigkeiten zu hängen – so genannte funktionelle Domänen. Das eröffnete die Möglichkeit, die chemische Aktivität eines Eiweißes an eine ganz bestimmte Stelle im Erbgut zu dirigieren. Nimmt man von einem Eiweiß, das die Aktivität von Genen stimulieren kann, jenen Teil, der dieses Aufputschmittel für Gene enthält, und fusioniert es mit einem Zinkfinger-Protein, dann wird der Aktivator nur dort wirken, wo der Zinkfinger seine Zielsequenz im Erbgut findet. Auf gleiche Weise lassen sich Gene abschalten, indem man dem Zinkfinger ein Stück Eiweiß mit drosselnder Funktion anhängt – oder zerschneiden, wenn der Zinkfinger mit einer Art molekularer Schere gekoppelt wird. Das ganze Arsenal molekularer Werkzeuge lässt sich so an jeden Punkt im Erbgut lotsen. Lanphier war Feuer und Flamme, denn diese Idee löste auch sein Patentproblem: „Wenn man die Zinkfinger so verändern kann, dass sie ein Gen in einer einzigartigen Art und Weise erkennen und dann verändern, dann hätte man eine neuartige, patentierbare Anwendung – unabhängig von den bisherigen Patenten auf dieses Gen.“

Auf diese Weise kommerziell abgesichert, testeten die Sangamo- Forscher ihre Technologie an den Blutzellen von immunschwachen SCID-Kindern. Sie hängten eine molekulare Schere an einen Zinkfinger, der sie zum SCID-auslösenden Gen führte. Genau an dieser Stelle zerschnitt die molekulare Schere die DNA, und das löste in der Zelle einen natürlichen Reparaturmechanismus aus. Dabei wurden die losen DNAEnden nicht nur wieder verbunden, sondern die DNABausteine vor und hinter dem Schnitt durch neue ersetzt – das defekte Gen war repariert.

Als Vorlage beim DNA-Flicken dient normalerweise die
intakte Kopie des Gens, denn im Zellkern gibt es von jedem
Gen eine väterliche und eine mütterliche Kopie. Bei SCIDPatienten sind jedoch beide Kopien defekt. Deshalb schleusten die Sangamo-Forscher außer den Genen für die Zinkfinger- Werkzeuge auch ein Stück DNA mit der korrekten Sequenz des SCID-Gens in die Zellen ein. Patente auf komplette Gene, wie sie Somatix behindert hatten, stehen dem nicht entgegen. In 18 Prozent der blutbildenden Zellen von SCID-Patienten konnten die Forscher so die Genmutation korrigieren. Und tatsächlich entwickelten sich daraufhin so viele intakte Immunzellen, dass SCID-Patienten einen ausreichenden Schutz vor Infektionen hätten – theoretisch, denn noch ist die Technik nicht an Patienten getestet worden, sondern nur an Zellkulturen aus dem Blut von SCID-Patienten.

Ob
die neue Technik, bei der keine Gene mehr unkontrolliert ins Erbgut eingebaut werden, wirklich sicherer ist als konventionelle Gentherapien, muss sich also erst noch zeigen. Doch der Erfolg im Reagenzglas spornt die Forscher an weiterzumachen. Neben Erbkrankheiten wie Sichelzellanämie und ß-Thalassämie, die Blutzellen betreffen, wollen sie laut Lanphier auch Aids bekämpfen. Dabei sollen Zinkfinger ein Gen in den Blutzellen zerstören, das die HI-Viren für die Infektion der Abwehrzellen benötigen. Ohne dieses CCR5- Gen, dessen Proteinprodukt an der Zelloberfläche sitzt, kann sich HIV nicht an den Blutzellen festhalten, weshalb Menschen, denen ein intaktes CCR5-Gen fehlt, resistent gegen eine HIV-Infektion sind. Mit Sangamos Therapieansatz sollte zumindest ein Teil der Blutzellen von HIV-Infizierten resistent gegen den Virusbefall werden. Klinische Tests sollen noch in diesem Jahr beginnen, sagt Lanphier.

Ebenfalls noch 2006 will
Sangamo mit den Herzkreislaufspezialisten der US-Pharmafirma Edwards LifeSciences die Ergebnisse der ersten klinischen Studien präsentieren, in denen die Zinkfinger-Technologie zur Behandlung von Gefäßerkrankungen eingesetzt wird. Doch in diesen frühen Tests geht es nur um Verträglichkeit und Dosisfindung – ob die elegante Technik tatsächlich keine nennenswerten Nebenwirkungen hat und robust genug für den klinischen Einsatz ist, zeigt sich frühestens in der zweiten Phase der klinischen Prüfung. Bis zur Zulassung des ersten Zinkfinger- Medikaments dürften mindestens noch vier Jahre vergehen.

TURBO FÜR DIE MEDIKAMENTENPRODUKTION

In der Zwischenzeit hat Sangamo die Möglichkeit, die Kasse
über Technologie-Dienstleistungen zu füllen. So will beispielsweise der Pharmakonzern Pfizer per Zinkfinger die Produktion von Medikamenten beschleunigen. „Firmen, die Antikörper oder andere Protein-Pharmazeutika produzieren, sind sehr an Technologien interessiert, die die Ausbeute und Geschwindigkeit der Protein-Produktion verbessern“, sagt Lanphier. Denn bisher ist es eine langwierige und mühsame Angelegenheit, Säugetierzellen gentechnisch so zu verändern, dass sie bestimmte Proteine produzieren, die dann als Medikamente eingesetzt werden können. Sangamos Zinkfinger-Proteine sollen die Gene stimulieren, die für die Herstellung der medikamententauglichen Eiweiße nötig sind, und so die Ausbeute erhöhen – quasi ein Turbolader für die Medikamentenproduktion.

Eine weitere Anwendung können die Zinkfinger in der Stammzellforschung finden. Denn die Technik macht es möglich, bestimmte Schlüsselgene zu regulieren, die die Entwicklung der Stammzellen in das gewünschte Gewebe anstoßen. „Wir haben das zum Beispiel für das Gen Oct-4 gezeigt“, sagt Sangamo-Forschungschef Philip Gregory, der bis 2000 an der Ludwig-Maximilians-Universität in München geforscht hatte, bevor er nach Kalifornien zog. Embryonale Stammzellen bleiben nur so lange im undifferenzierten Zustand, wie das Oct- 4-Gen normal aktiv ist. Wenn die Sangamo-Forscher das Gen jedoch über einen Zinkfinger mit eingebautem Genstopper stumm schalten, differenzieren die Zellen zu Gewebe, das für die Ernährung des Embryos nötig ist. Verstärkt man die Aktivität von Oct-4, verwandeln sich die Zellen in frühembryonale Gewebetypen. Und das, ohne dass irgendwelche Spuren der Manipulation in den Zellen zurückbleiben, denn die Zinkfinger verschwinden im Laufe der Zellteilungen.

„Wenn man
weiß, was man regulieren will, dann können wir die Zelle in jede gewünschte Entwicklungsrichtung treiben“, sagt Gregory. Doch in Zeiten, in denen Biotechs ohne fertige Produkte von Investoren misstrauisch beäugt werden, konzentriert man sich auch bei Sangamo lieber auf anwendungsnahe Projekte. Was dem börsennotierten Unternehmen derzeit zu akademisch ist, verfolgt Albert Jeltsch von der International University Bremen.

Der Biochemiker bastelt selbst ganz ähnliche
Werkzeuge. Er hängt an den DNA-bindenden Zinkfinger ein
Enzym namens Methyltransferase, das kleine Anhängsel an die
DNA klebt, so genannte Methylgruppen. Diese chemischen Anhängsel wirken auf die Gene wie ein Vorhängeschloss: Sie werden inaktiv, was zum Beispiel im Fall von viralen oder Krebsgenen wünschenswert wäre.

Tatsächlich gibt es bereits Versuche, Krebsgene über eine gesteigerte Methylierung abzuschalten. Aber dabei wird nur die natürlich vorkommende Methyltransferase in den Zellen stimuliert, was den Nachteil hat, dass nicht nur Krebsgene, sondern auch viele andere wichtige Gene stillgelegt werden. Mit der Sangamo-Technik ließe sich das Abschalten exakt steuern. Jeltsch hofft, auf diese Weise die Gene eines Virus stilllegen zu können, das beim Menschen Herpesbläschen verursacht. „Bei viralen Erkrankungen bieten die Zinkfinger-Proteine den Vorteil, dass sie nur in den Zellen eingreifen, in denen die Virusgene vorhanden sind“, sagt der Bremer Forscher. Erste Versuche, die Schlüsselgene für die Virusaktivierung abzuschalten, seien erfolgreich gewesen.

Allerdings kann Jeltsch noch nicht sagen, ob sein Werkzeug nicht auch an anderen Stellen der DNA unerwünschte Methylierungen setzt. Denn die Zinkfinger weisen dem Werkzeug zwar mit hoher Wahrscheinlichkeit den Weg zum richtigen Zielgen. Doch vereinzelte Irrtümer könnten ausreichen, das Erbgut an einer entscheidenden Stelle zum Negativen zu verändern. Eine unerwünschte Methylierung wäre da noch recht harmlos, aber was, wenn an dem Zinkfinger eine molekulare Schere hängt, die dann irgendwo im Erbgut herumschneidet?

Bevor man eine solche Technologie in der Therapie anwendet, müsse man da natürlich sicher sein, sagt Jeltsch: „Da haben wir das gleiche Problem wie die Kollegen in Kalifornien.“ Dort nimmt man die Sicherheitsbedenken durchaus ernst, doch bisher hätten Tests keinen Hinweis auf Fehlfunktionen der künstlichen Zinkfinger-Proteine ergeben, versichert Forschungschef Gregory. Zwar könnten die Fusionsproteine theoretisch auch ohne DNA-Bindung überall im Genom unkontrolliert aktiv werden, räumt er ein. Aber offenbar passiere das nicht. „Vielleicht, weil wir nichts machen, was die Natur nicht längst gelöst hätte“, sagt Gregory. Denn Kombinationen von DNA-Bindungsdomänen mit anderen funktionellen Domänen gibt es auch in natürlichen Proteinen.

NEUE TECHNIK, ALTE PROBLEME

Doch auch wenn Sangamos Technik eine neue Ära einläuten
mag, müssen sich die Sangamo-Forscher mit denselben Problemen herumschlagen, an denen ihre Zunft seit Anbeginn ihrer Existenz herumdoktert: Auch die maßgeschneiderten Zinkfinger müssen irgendwie in die Zellen hinein. Zwar sei es prinzipiell möglich, die Proteine direkt in die Zellen zu schleusen, sagt Gregory. Doch Sangamo geht auch hier einen eleganteren Weg: Die Forscher verabreichen den Zellen lediglich die Gene, mit deren Hilfe sie die Zinkfinger- Proteine selbst zusammenbauen können – in Form von DNA, die frei in der Zelle schwimmt. So wie die Zinkfinger-Proteine haben auch diese DNA-Stücke nur eine gewisse Überlebenszeit in der Zelle – gerade lang genug, um die gewünschte Veränderung im Erbgut der Zelle möglich zu machen, dann lösen sich die Gentech-Werkzeuge auf.

„Wir bekommen Zinkfinger also prinzipiell in die Zelle
hinein“, sagt Gregory, doch die Frage sei, bei wie vielen Zellen das gelingt. „Reicht es für einen therapeutischen Effekt, wenn wir 10, 20 oder 30 Prozent der Zellen erreichen?“ Im Fall der Behandlung von SCID reichten die 18 Prozent veränderter Blutzellen, um eine Körperabwehr zu etablieren. Bei anderen Krankheiten könnte es jedoch nötig sein, mehr Zellen zu verändern, bevor ein therapeutischer Effekt eintritt.

Schärfster technologischer Konkurrent der Zinkfinger ist
die so genannte RNA-Interferenz-Technologie (RNAi), die
Gene mit Hilfe kleiner RNA-Fragmente abschalten kann, und
zwar sehr effizient. Die Zinkfinger-Technologie beherrscht jedoch die ganze Palette von Stummschalten, Aktivieren und Reparieren. Aber mittlerweile kann jedes durchschnittliche molekularbiologische Labor RNA-Interferenz nachvollziehen und für die eigenen Experimente nutzen. Demgegenüber bedarf es eines reichen Erfahrungsschatzes, um den passenden Zinkfinger für eine gegebene Zielsequenz zu erstellen. „Die Konstruktion der Zinkfinger für eine bestimmte Zielsequenz ist keine Routine, sondern nach wie vor eine Kunst“, sagt Gregory. Zwar kennen die Forscher mittlerweile die Regeln, die bestimmen, aus welchen Proteinbausteinen ein Zinkfinger bestehen muss, damit er an bestimmten DNA-Bausteinen kleben bleiben kann. Doch es ist Erfahrung, wie sechs solcher Zinkfinger miteinander arrangiert werden müssen, damit sie die 18 DNA-Bausteine umfassende, einzigartige Zielsequenz im Erbgut erkennen.

"Wir verstehen immer noch
nicht genau, was da vor sich geht“, räumt Gregory ein.
Direkte Konkurrenz auf dem eigenen Fachgebiet jedenfalls
hat Sangamo kaum zu befürchten, denn es gibt kein anderes Unternehmen, das die Zinkfinger-Technologie beherrscht. Kurz nachdem Lanphier mit Sangamo gestartet war, entschied sich zwar auch Nobelpreisträger Aaron Klug, sein Wissen über Zinkfinger in ein Unternehmen zu investieren. Doch 2001 fusionierte seine britische Gendaq mit Sangamo, denn gegen ein Patent, das Sangamo laut Lanphier weltweite Rechte an „jedem Zinkfinger für die Regulation jedes Gens in jedem Zelltyp eines jeden Organismus“ einräumt, sahen die Gendaq- Anteilseigner wenig Chancen.

Die Komplexität verhindert zwar, dass sich jedes Labor
seine Zinkfinger selbst herstellt, der Produktion von Zinkfingern als Therapeutikum tut das jedoch keinen Abbruch. Denn im Vergleich zum Aufwand, den Pharmakonzerne bei der Suche nach neuen Wirkstoffen treiben, nimmt sich die Zinkfinger- Tüftelei harmlos aus, sagt Geschäftsführer Lanphier und lehnt sich zufrieden im schwarzen Sessel zurück. „Was es mit dem Logo von Sangamo auf sich hat?“ Lanphier folgt dem Blick auf die kupferne Schrift mit den wellenartig verzerrten Lettern. Der Name stamme von der Firma seines Großvaters aus dem Sangamon County in Illinois, die Strommessgeräte verkauft habe. „Die Wellen symbolisieren also elektrischen Strom“, sagt Lanphier und grinst: „Jedenfalls hat es nichts mit irgendwelchem San Francisco Surfing Stuff zu tun.“

Text entnommen aus TR 03/2006. Das Heft ist seit dem 23. Februar am Kiosk zu haben oder hier[1] portokostenfrei zu bestellen. (wst[2]/Technology Review)

URL dieses Artikels:
http://www.heise.de/tr/artikel/71061

Links in diesem Artikel:
[1] http://www.heise.de/abo/tr/hefte.shtml
[2] mailto:[e-mail]

------------------------------------------------------------------------
Copyright 2006 Heise Zeitschriften Verlag

[cyberhai]

Sehr interessanter Artikel, hatte ihn vor kurzem auch gelesen und habe die Zeitung jetzt im Abo.

Bin seit dieser Woche investiert - ergänzend zu Alnylam und Sirna mit der RNAi-Technik.

Gruß Cyberhai

[[KERN]Codex]

[tokajo]

ABGENIX INC Quick Quote: ABGX (no quote)

H. Ward Wolff elected to board of Sangamo
6/8/2006

Jun 08, 2006 (M2 EQUITYBITES via COMTEX News Network) --
Sangamo BioSciences Inc (Nasdaq:SGMO), a researcher and developer of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, has announced that H. Ward Wolff has been elected to the company's board of directors.

Most recently Wolff served as chief financial officer and senior vice president, Finance, of Abgenix Inc until April 2006 when the company was merged with Amgen Inc. Prior to joining Abgenix, from July 2002 to December 2003, Wolff served as CFO of QuantumShift.

In addition the company also announced that Jon E. M. Jacoby, who has served as a member of the board since April 2000, retired at the time of the annual stockholder's meeting.

Comments on this story may be sent to [e-mail]

(C)2006 M2 COMMUNICATIONS LTD http://www.m2.com


Meldung muß auch unter dem Gesichtspunkt der Firmengröße betrachtet werden.

Sangamo ist mit 225 Mio bewertet. Abgenix mit 2037 Mio. Wer wechselt schon zur "kleinen" Firma

[fire.fox]

Liebe Freunde der Spekulation,

bei Sangamo wird's jetzt interessant.

zur Info:

http://www.biospace.com/navigate/search.aspx?range=News&sear…

fire.fox

PS: Der Verfasser ist bei Sangamo investiert

[chatterhand1]

sehr heiss hier

rege nachfrage nach den papieren!

kann man nur hoffen das ihr rechtzeitig noch raus seit!

[tokajo]

Cantor Fitzgerald stuft SANGAMO BIOSCIENES auf Buy

Die Analysten von Cantor Fitzgerald bewerten in ihrer Analyse vom Donnerstag, 24. August 2006 die Aktie von Sangamo BioSciences Inc. nach wie vor mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 17 $.
Rating: Buy
Analyst: Cantor Fitzgerald
Kursziel: 17
Kurszielw?ung: n/A
SANGAMO BIOSCIENES

[tokajo]

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Clinical Data From Diabetic Neuropathy Program at Major European Diabetes Meeting

Sangamo on Track to Initiate Phase 2 Clinical Trial in 2006

RICHMOND, Calif., Sept 18, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preclinical and clinical data from its SB-509 ZFP Therapeutic(TM) program at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held in Copenhagen, Denmark, September 14 - 17, 2006. Sangamo is developing SB-509 for the treatment of diabetic neuropathy and intends to initiate a Phase 2 study later this year. SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)), designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A) which has been demonstrated to have direct neurotrophic and neuroprotective properties.

"We continue to be encouraged by clinical data from our Phase 1 studies," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "The annual EASD meeting is the key European conference focused on the exchange of ideas and the study of diabetes and we are pleased to have the opportunity to present these data and the supporting preclinical studies before this audience. Our clinical program is progressing well; we are looking forward to initiating a Phase 2 repeat-dosing study in the second half of this year."

Clinical data presented at the EASD meeting on Saturday, September 16 from Sangamo's ongoing Phase 1 studies, demonstrate that a single treatment of SB- 509 was well tolerated and that no drug-related severe adverse events were observed. Importantly, subjects in the top dose cohorts were treated within the pharmacologically effective dose range that had been demonstrated to be efficacious in preclinical animal studies. Injection site reactions were the most common adverse events reported and were mild and reversible. Clinicians observed anecdotal clinical improvements in quantitative sensory testing (QST) which measures perception of vibration, and improvements in average total neuropathy score (TNS), a composite of several measurements including neurologic exam, QST, electrophysiologic studies and neurologic symptoms. In the Phase 1b study, a placebo group, treated in both legs, provides an important control group and showed a mean deterioration in their average TNS over two months. In contrast, all subjects treated with SB-509 in one leg in the Phase 1a portion of the study, and all subjects treated in both legs with SB-509 in the Phase 1b portion of the study showed anecdotal improvements in neurologic exam with improved average TNS from baseline.

The preclinical animal efficacy studies in a diabetic rat model that were also presented at the EASD meeting and were recently published in the journal Diabetes showed SB-509 to be effective in protecting motor and sensory nerve function from disease-induced nerve damage. These positive trends in neurologic function highlight the potential for SB-509 to address the nerve damage of diabetic neuropathy and possibly nerve regeneration.

"We are encouraged by the initial data obtained in Phase 1 studies of our ZFP Therapeutic for the treatment of diabetic neuropathy and are swiftly moving forward with the next stage of clinical development, a Phase 2 clinical trial that we expect to initiate later this year," said Edward Lanphier, Sangamo's president and CEO. " We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and restore nerve function, in contrast to the current standard of care designed to address the pain associated with this condition. We are also investigating the potential of this therapeutic for the treatment of direct nerve injury."

About the SB-509 Clinical Program

In addition to assessments of clinical and laboratory safety, subjects in the Phase 1 studies of SB-509 are being evaluated for changes in pain, numbness, perception of vibration, strength, sensation, reflexes and nerve conduction studies. Pain was assessed using one of the most frequently used measurement scales in health care research, the Visual Analog Scale (VAS). Total neuropathy scores (TNS) were also assessed for each subject. The TNS represents is a composite score that combines measurements of neurologic symptoms, neurologic examination, nerve conduction velocity studies (NCV) and quantitative sensory tests (QST), each assessed on a 5-point scale and is designed to provide a single measure to quantify neuropathy.

Sangamo also plans to initiate a placebo-controlled, multi-treatment Phase 2 study in diabetics with mild to moderate sensory/motor neuropathy in the second half of this year. Safety will be monitored throughout the study. Clinical evaluations will include evaluation of pain intensity, TNS, neurological examination and electrophysiological testing as well as assessment of changes in nerve integrity by examining changes in the density of nerve fibers in the skin using punch biopsies. The Phase 2 study will be conducted at multiple centers.

About SB-509

SB-509 is administered as an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene. VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties.

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 18.3 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in subjects with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on macular degeneration, ischemic heart disease, congestive heart failure, neuropathic pain, and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as sickle cell anemia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com .

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB- 509 clinical trial, whether the SB-509 clinical trial will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., [phone], ext. 271, or [e-mail]; or Justin Jackson (media) of Burns McClellan, Inc., [phone], or [e-mail], for Sangamo BioSciences http://www.prnewswire.com

Copyright (C) 2006 PR Newswire. All rights reserved.

[tokajo]

1. Reaktionen von der gestrigen UBS Global Life Sciences Conference.
Sangamo steigt derzeit um ca 5 %


Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an overview of the company's business strategy and an update on the progress of Sangamo's therapeutic development programs on Monday, September 25, 2006 at 11:30 a.m. (ET) at the UBS Global Life Sciences Conference in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview" http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IR… . The presentation will be archived on the Sangamo website for two weeks after the event

[fire.fox]

Liebe Freunde der Spekulation,

zur Info:

http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-ne…


mit der entsprechenden Kursbewegung

fire.fox

PS:

Der Verfasser ist bei Sangamo investiert

[meislo]

Die "Z-Finger-Methode" - der größte medizinische Fortschritt seit 25 Jahren!
--------------------------------------------------------------------------------

Es handelt sich nicht um ein Medikament. Und auch nicht um eine Tablette. Dieser medizinische Durchbruch wird aber schon an den führenden medizinischen Instituten Amerikas genutzt - Harvard, MIT, Yale, Duke und das National Institutes of Health (NHI) greifen darauf zurück.

Sobald die Details über diese Methode im Herbst dieses Jahres veröffentlicht werden, könnte der Wert dieser winzigen Aktiengesellschaft mit all ihren Patenten ganz leicht um 650 % und mehr steigen ...



Liebe Leser,

nach 20 Jahren Forschungsarbeit steht eine neue Art medizinischer Behandlung ganz kurz davor, der breiten Öffentlichkeit vorgestellt zu werden.

"Z-Finger-Methode" wird dieser Durchbruch genannt. Sie wurde 1986 vom Wissenschaftler und Nobelpreis-Gewinner Dr. Aaron Klug entdeckt, der von der britischen Regierung für seine Arbeit zum Ritter geschlagen wurde.

In den vergangenen 20 Jahren machten viele der weltweit führenden Medizininstitute dort weiter, wo Dr. Klug aufgehört hatte...

Die renommierten und weltweit führenden medizinischen Institute Johns Hopkins, Yale University, Duke University, MIT, Harvard und sogar das National Institutes of Health (NHI) - die wichtigste Behörde für biomedizinische Forschung in den USA - sind unter den medizinischen Forschungseinrichtungen, die daran gearbeitet haben, diese Methode zu perfektionieren.

Jetzt ist diese Methode endgültig einsatzbereit

Der erste Beweis, dass die "Z-Finger-Methode" eine Krankheit heilen kann, wurde letzten April veröffentlicht. Damals berichtete Nature (das weltweit meist beachtete Wissenschaftsmagazin) detailliert über eine Behandlungsmethode für X-SCID, einer Erbkrankheit, die bei kleinen Kindern vorkommen kann.

Jetzt begreifen viele erst, welches immense Potenzial in der "Z-Finger-Methode" steckt. Und es wird die Medizin, so wie wir sie heute kennen, mit Sicherheit komplett verändern...

Die Zeitschrift The Scientist beschreibt die "Z-Finger-Methode" als die "nächste Revolution in der Medizin".

Nature Reviews erklärt, dass die "Z-Finger-Methode" eine alternative Strategie zur Bekämpfung von Krebs, Herz-Kreislauf-Erkrankungen, Virusinfektionen, Muskeldystrophie, Mukoviszidose, Diabetes, grüner Star und chronischen Schmerzen darstellen könnte.

Das wirklich Aufregende an der ganzen Sache: Sie können in das Unternehmen investieren, welches alle Schlüsselpatente für die "Z-Finger-Methode" besitzt, bevor große Finanzpublikationen wie Barron’s oder The Wall Street Journal darüber berichten.

Ich weiß von diesem medizinischen Durchbruch auch nur, weil ich sehr enge Kontakte zum Johns Hopkins pflege, welches laut dem U.S. News & World Report als das beste Krankenhaus in den USA gilt und an Platz zwei im Ranking der medizinischen Fakultäten steht.

Wie ich Ihnen gleich zeigen werde, handelt es sich hierbei um die faszinierendste Gelegenheit, die ich in den vergangenen Jahren entdeckt habe. Ich bin fest davon überzeugt, dass es völlig verrückt wäre, diese einmalige Renditechance ungenutzt verstreichen zu lassen.

Jetzt erkläre ich Ihnen genau, worum es geht ...

Das Ende von Medikamenten?
Es ist nicht schwer zu verstehen, warum die "Z-Finger-Methode" schon sehr bald ein Vermögen wert sein könnte.

Sie müssen einfach nur die Geschichte des kleinen Mädchens Ashi DeSilva lesen, die im Alter von zwei Jahren mit dem Tode rang.

Die kleine Ashi hatte im Grunde genommen überhaupt kein Immunsystem. Mindestens dreimal stand sie kurz vor dem Tod. Wenn Ashi nicht im Krankenhaus war, hatte sie chronische Hustenanfälle. Sie musste sich andauernd übergeben, was dazu führte, dass ihr Verdauungstrakt zerstört wurde.

Heute läuft sie mit ihren Freunden herum wie ein normales Kind. Sie geht auf Partys, schwimmt, spielt Basketball und hasst Hausaufgaben.

Diese Geschichte wäre nicht so erstaunlich, wenn es nicht eine Tatsache gäbe: Bei dem neuen medizinischen Verfahren, welches die kleine Ashi schließlich heilte, handelte es sich nicht um ein Medikament.

In den vergangenen 25 Jahren haben sich die meisten von uns daran gewöhnt, dass alle medizinischen Probleme mit Tabletten bekämpft werden.

Aber kürzlich weihte mich meine Kontaktperson vom Johns Hopkins in ein großes Geheimnis ein: Dieses Missverständnis wird dank eines kleinen kalifornischen Unternehmens schon bald beseitigt werden.

Klicken Sie hier! Und sichern Sie sich jetzt Ihre Taipan-Testausgabe - 30 Tage GRATIS!

Die kleine Ashi DeSilva litt an der Krankheit Adenosin-Desaminase-Mangel (ADA). Sie hatte im Grunde genommen gar kein Immunsystem.

Für Ashi war jede Grippe lebensbedrohlich. Das gleiche galt für Windpocken. Die Wahrscheinlichkeit, dass sie an Krebs erkranken würde, lag 10.000 Mal höher als bei der durchschnittlichen Bevölkerung.

Das Erstaunliche ist, dass Ashis Adenosin-Desaminase-Mangel von einem genetischen Fehler verursacht worden war, der so klein war, dass man es sich kaum vorstellen kann...

Wie Sie wahrscheinlich wissen, besteht der menschliche Körper aus Billionen von Zellen. In jeder Zelle sind unsere Chromosomen. Und innerhalb jedes Chromosoms sind DNA-Stränge, die Gene genannt werden.

Gene kontrollieren alles, was im Körper passiert. Sie enthalten sozusagen den "Masterplan" für jeden Herzschlag, Atemzug, Muskelkontraktion, Verdauung und Immunität. Stellen Sie sich die Gene in Ihrem Körper einfach als eine Art komplette Bedienungsanleitung vor.

Bestellen Sie jetzt Ihre GRATIS-Testausgabe - 30 Tage kostenlos zur Probe!

Bei Menschen sind 99,9 Prozent der Gene im Vergleich zu anderen Menschen gleich.

Bei der kleinen Ashi DeSilva sind die meisten Gene die gleichen wie bei Ihnen und bei mir. Mit einer Ausnahme: Sie hat eine winzige Mutation am Chromosom 20.

Diese Mutation zerstört Ashis T-Zellen, was dazu führt, dass ihr Immunsystem praktisch abgeschaltet ist. Als Ärzte dann allerdings in der Lage waren, Ashis Gen am Chromosom 20 zu ersetzen, erholte sich das kleine Mädchen innerhalb von nur 18 Monaten fast vollständig.

Kurz gesagt: Die Ärzte haben ein kaputtes Gen repariert. Es handelte sich um ein Wunder.

Was hat das alles mit der "Z-Finger-Methode" zu tun? Ich erkläre es Ihnen...

[tokajo]

Sangamo BioSciences and JDRF Announce Partnership for ZFP Therapeutic for Diabetic Neuropathy Program
NEW YORK and RICHMOND, Calif., Oct 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has established a partnership with the Juvenile Diabetes Research Foundation (JDRF) to provide financial support of Sangamo's Phase 2 human clinical studies of SB-509, a ZFP Therapeutic that is in development for the treatment of diabetic neuropathy (DN).

JDRF, the major charitable funding organization of research leading to a cure for type 1 diabetes and its complications, will provide up to $3 million toward the Phase 2 clinical trial based upon the achievement of certain milestones. The funding will enable Sangamo to accelerate development of its ZFP Therapeutic for the treatment of DN and conduct additional clinical tests that may provide important information related to the mechanistic basis for therapeutic efficacy.

"This partnership provides an opportunity to accelerate the progress of a potential treatment for a significant unmet medical need in diabetes," said Dr. Richard A. Insel, M.D., Executive Vice President for Research at JDRF. "Currently, more than fifty percent of patients with diabetes for ten years or longer will experience diabetic neuropathy and the treatments currently available are drugs that only address neuropathy-associated pain. Sangamo's novel approach to DN has the potential to modify the disease at a more fundamental level by modulating neuroprotective and neurotropic pathways."

"We are very pleased to have the confidence and support of JDRF as we advance the clinical development of SB-509," said Edward Lanphier, Sangamo's President and CEO. "This agreement demonstrates JDRF's commitment to ground-breaking clinical research and to the development of novel therapeutics that can potentially have an important impact on the quality of life for people with diabetes." He added: "We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and restore nerve function, in contrast to the current standard of care designed to address only the pain associated with this condition. Sangamo's ZFP technology provides a unique approach designed to upregulate vascular endothelial growth factor or VEGF, a factor that has been shown to have direct neuroprotective and neurotrophic effects. The goal is to preserve and possibly restore nerve health. The data collected from these Phase 2 studies will help establish the foundation and mechanism of our ZFP technology as a novel class of therapeutics."

JDRF funds diabetes research across a range of scientific areas, including beta cell regeneration, immunology, islet cell replacement, complications, genetics, and technological innovations and therapeutics. The agreement with Sangamo is a part of JDRF's innovative Industry Discovery and Development Partnership program, through which JDRF partners with pharmaceutical, biotech, and medical device businesses looking to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications.

About the SB-509 Clinical Program

Sangamo has completed a Phase 1a dose-escalation study and has an ongoing Phase 1b study of SB-509 in subjects with mild to moderate diabetic neuropathy. Later this year, the company intends to initiate a double-blind placebo-controlled, multi-treatment Phase 2 study in diabetics with mild to moderate sensory/motor neuropathy. Safety will be monitored throughout the study. Clinical evaluations will include evaluation of pain intensity, TNS, neurological examination and electrophysiological testing as well as assessment of changes in nerve integrity by examining changes in the density of nerve fibers in the skin using punch biopsies.

About SB-509

SB-509 is administered as an injectable formulation of plasmid DNA that encodes a zinc finger protein transcription factor, designed to upregulate the VEGF-A gene. VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties.

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. According to the Centers for Disease Control, the incidence of diabetes in the United States is growing rapidly. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About JDRF

JDRF was founded in 1970 by the parents of children with juvenile diabetes -- a disease that strikes children suddenly, makes them insulin dependent for life, and carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1 billion to diabetes research worldwide. More than 80 percent of JDRF's expenditures directly support research and education about research. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com .

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, funding obligations of JDRF based on milestones achieved by Sangamo, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation, ability to achieve milestones and completion of stages of the SB-509 clinical trial, whether the SB-509 clinical trial will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Eileen Brangan Mell of JDRF, [phone], or [e-mail]; or Elizabeth
Wolffe, Ph.D. of Sangamo BioSciences, Inc., [phone], ext. 271, or
[e-mail]; or Justin Jackson of Burns McClellan, Inc., [phone], or
[e-mail]

http://www.sangamo.com

[tokajo]

Und wieder fast 10 % im Plus.
Sangamo verringert seinen Verlust von 14 auf 8 Cent je Aktie

Sangamo BioSciences Corrects Third Quarter 2006 Financial Results

RICHMOND, Calif., Oct 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported the shares used in computing the basic and diluted net loss per common share for the third quarter ended September 30, 2006 were incorrect. As a result, the basic and diluted net loss per common share was incorrectly stated as $0.09 per share and should have been stated as $0.08 per share. Set forth below is a complete corrected Selected Financial Data schedule for the three and nine month periods ended September 30, 2006.

SELECTED FINANCIAL DATA (in thousands, except per share data) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2006 2005 2006 2005 Consolidated Statement of Operations Data: Revenues $1,779 $412 $5,692 $1,087 Operating expenses: Research and development 3,853 2,988 11,470 8,210 General and administrative 1,569 1,216 5,145 3,705 Total operating expenses 5,422 4,204 16,615 11,915 Loss from operations (3,643) (3,792) (10,923) (10,828) Interest income, net 798 125 2,007 228 Net loss $(2,845) $(3,667) $(8,916) $(10,600) Basic and diluted net loss per common share $(0.08) $(0.14) $(0.28) $(0.42) Shares used in computing basic and diluted net loss per common share 33,939 25,430 31,960 25,386 CONDENSED BALANCE SHEET DATA September 30, 2006 Dec. 31, 2005 Cash, cash equivalents, and investments 56,990 $47,174 Total assets 58,299 48,983 Total stockholders' equity 50,935 37,814 About Sangamo BioSciences, Inc.
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. Research at Sangamo is partially funded by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology (NIST). For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., [phone], ext. 271, or [e-mail]

http://www.sangamo.com

[tokajo]

Wieder ein weiterer Meilenstein erreicht. Bin auf die Reaktion in USA gespannt.


Dow AgroSciences and Sangamo BioSciences Announce the Achievement of Multiple Milestones in Their Plant Agriculture Collaboration
Successful Application of Sangamo's ZFN Technology in Plants
INDIANAPOLIS and RICHMOND, Calif., Nov 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of multiple research milestones as part of their Research and Commercial License Agreement initiated October 2005.

"We are delighted with the overall progress of the collaboration. The successful completion of these milestones demonstrates that Sangamo's ZFP Nuclease (ZFN(TM)) platform is proving to be as robust and powerful as expected, and we look forward to the successful achievement of additional milestones," said Dan Kittle, Ph.D., Vice President of Research and Development for Dow AgroSciences. "Our recent work at Dow AgroSciences employing ZFNs in plant systems confirms our conviction that the ZFP platform has the potential to truly transform the field of plant genetics."

The three-year agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology for the development of products in plants and plant cell cultures.

"Our ZFP technology can be used to both regulate and modify genes. Because ZFPs function at the DNA level, a molecule common to essentially every organism, our ZFP platform offers great versatility enabling us to address virtually any gene target in any species," said Philip Gregory, D. Phil., Sangamo's vice president of research. "Investments globally in plant genomics continue to uncover an increasing number of genes with the potential to substantially improve crop quality, expand crop uses and improve agronomic performance. All of these genes are potential targets for our ZFP technology, and it is therefore particularly exciting for all of us to have already achieved significant milestones validating the applications of our nuclease technology in plant agriculture. ZFNs provide the ability to make specific modifications to genes, to rapidly and reliably knock out specific genes and to insert genes reproducibly into specific target sites. Combined with the ZFP TF(TM) technology for the up or down-regulation of specific genes in plants, these capabilities hold the potential to revolutionize both the rate of development and the quality of plant products in applications in many different areas of plant agriculture."

"Dow AgroSciences has a strong tradition of innovation and early adoption of new technologies and is recognized as a world leader in innovative plant biotechnology," said Edward Lanphier, Sangamo's president and chief executive officer. "Coupled with Sangamo's expertise in the design and engineering of ZFPs, our combined forces have helped achieve an early competitive advantage for Dow AgroSciences that has the potential to maximize the commercial applications of this technology across the plant and agriculture fields. Because we are developing therapeutics, the application of ZFP TFs and ZFNs in plant agriculture tends to be overlooked. But this is a strategic collaboration for us and one that may realize significant financial return, and I am pleased that the Dow AgroSciences and Sangamo are working so well together as evidenced by the achievement of these early milestones."

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. The ability to selectively control specific genes is emerging as a critical tool in modern biotechnology. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP TFs(TM) that can control gene expression and consequently, cell function. For example, Sangamo has demonstrated that plant oils can be improved using ZFP TFs.

Sangamo has also developed sequence-specific ZFNs(TM) for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top tier agricultural company providing innovative crop protection, seeds, and biotechnology solutions to serve the world's growing population. A wholly owned subsidiary of The Dow Chemical Company, global sales for Dow AgroSciences are $3.4 billion. Visit dowagro.com for more information.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X- linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc's current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement and the application of Sangamo's ZFP TFs and ZFNs in plant agriculture. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Robyn Heine of Dow AgroSciences LLC, [phone]; or Elizabeth Wolffe, Ph.D. of
Sangamo BioSciences, Inc., [phone], ext. 271, or [e-mail]; or
media, Justin Jackson of Burns McClellan, Inc., [phone], or
[e-mail]

http://www.sangamo.com

[aktianer]

Da scheint Übernahmefantasie aufzukommen:

Analyst says Sangamo BioSciences could be target: magazine
Wed Nov 22, 2006 9:46pm ET135

NEW YORK (Reuters) - Sangamo BioSciences Inc. (SGMO.O: Quote, Profile, Research), which is developing products for congestive heart failure and HIV, could become a takeover target for big pharmaceutical companies, an analyst said on Wednesday.

Navdeep Jaikaria, a biotech analyst with Rodman & Renshaw believes Sangamo is just the kind of company "with novel science behind their products," that the drug companies would be interested in acquiring, according to BusinessWeek magazine.

Meanwhile, Pamela Bassett, of Cantor Fitzgerald, told the magazine that Sangamo's stock could rise to $17 in the next 12 months. It closed on the Nasdaq on Wednesday at $7.52.

In September the company that a protein it developed appeared to make human immune system cells permanently resistant to HIV infection.

Reuters Pictures
Photo

Editors Choice: Best pictures
from the last 24 hours.
View Slideshow

Sangamo officials couldn't be reached immediately for comment.

[fire.fox]

Antwort auf Beitrag Nr.: 25.618.927 von aktianer am 23.11.06 12:21:02

Lieber @aktianer,

ist ja interessant das du neben Mologen dich auch
um Sangamo kümmerst. !

Scheinst ja ein richtig "gutes Händchen" zu haben,

ich selbst bin auch schon seit geraumer Zeit bei Sangamo investiert
und habe natürlich zwischenzeitlich (wie bei Mologen) nicht
verkauft, ich glaube es wird noch ein gutes Investment.

zur Info:

http://stocks.us.reuters.com/stocks/fullDescription.asp?sym…

fire.fox

PS:

Der verfasser ist bei Sangamo investiert

[aktianer]

Antwort auf Beitrag Nr.: 25.619.919 von fire.fox am 23.11.06 13:24:04

@fire.fox,

der Schein trügt leider etwas; bin erst am Tag, an dem die Lizenzzahlung publiziert wurde, reingegangen; hatte diese Aktie schon länger im Visier (dank dir und Kerni), zögerte aber mit dem Einstieg angesichts der Erfahrungen mit Molo. Trotzdem habe ich aktuell bereits ein Plus von über 20%. Habe übrigens heute versucht, etwas Schriftliches über die Präsentation vom 16.11. bei der JMP Securities Healthcare Conference zu finden - dort sollte ja über die Strategie und Entwicklungsfortschritte berichtet werden. Leider bisher vergeblich.
Auf einen schönen Abend und gute Kurse am morgigen Tag

aktianer

[fire.fox]

Liebe Freunde der Spekulation,

zur Info:

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=BIOSBIO.st…

fire.fox

PS:

Der Verfasser ist bei Sangamo investiert

[fire.fox]

Liebe Freunde der Spekulation,

zur Info:

http://www.biospace.com/news_story.aspx?StoryID=38779&full=1

fire.fox

PS:

Der Verfasser ist bei Sangamo investiert

[tokajo]

Edwards' Angiogenesis Program to Be Acquired by Sangamo

Agreement Transfers Edwards' ZFP Therapeutics Program to Sangamo and Enables Coordinated Implementation of Future Clinical Trials

IRVINE, Calif. and RICHMOND, Calif., Dec 04, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Edwards Lifesciences Corporation (NYSE: EW) and Sangamo BioSciences, Inc. (Nasdaq: SGMO) jointly announced today that the two companies have entered into a definitive asset purchase agreement under which Sangamo will acquire Edwards' angiogenesis program. The Edwards program was originally initiated in 2000 in collaboration with and under license from Sangamo using their proprietary zinc finger protein (ZFP) platform. Under the agreement announced today, Edwards will transfer the assets of its program to Sangamo in exchange for 1 million shares of Sangamo common stock. Edwards will also receive royalties on certain products commercialized in the future based upon ZFP activation of the vascular endothelial growth factor (VEGF) gene. The transaction is expected to be completed by December 31, 2006.

"This transaction with Sangamo provides for focused, combined development of our respective ZFP therapeutics programs and resolves the ongoing issue between the two parties regarding the scope of our respective rights," said Michael Mussallem, Edwards' chairman and CEO. "We're proud that our program has developed products with the potential to help patients dealing with ischemic vascular and cardiovascular disease. Additionally, the transfer of these assets allows these important programs to continue under Sangamo's stewardship and frees up additional Edwards' resources to drive R&D priorities more central to our strategy."

"We are excited about the opportunity to add an additional clinical stage ZFP therapeutic program to our portfolio," said Edward Lanphier, founder, president and CEO of Sangamo BioSciences. "We initiated this program in 2000 and are pleased with the significant investment and progress that Edwards has made in the past six years. In addition to acquiring two clinical stage programs in peripheral vascular disease (PAD) and a late stage pre-clinical program in ischemic heart disease (IHD), this agreement will have a significant impact on Sangamo's future corporate partnering opportunities involving VEGF-ZFP therapeutic programs."

In January of 2000 Edwards, then a division of Baxter International, entered into an exclusive license and research funding agreement with Sangamo to develop and commercialize VEGF-ZFP therapeutics for the treatment and prevention of ischemic cardiovascular and peripheral vascular diseases. Edwards completed pre-clinical efficacy and toxicology studies and initiated a Phase 1 clinical trial in June of 2004 for EW-A-401, a drug based on the VEGF-ZFP transcription factor and designed to treat critical limb ischemia (CLI) as well as intermittent claudication, both painful and limiting conditions of vascular disease. Edwards has stated that early results from the CLI trial have been encouraging and has submitted for approval with the U.S. Food and Drug Administration to begin a randomized, placebo controlled, repeat dosing Phase 2 clinical trial in patients with CLI.

Independently, Sangamo has initiated clinical trials in diabetic neuropathy with a VEGF-ZFP therapeutic known as SB-509. SB-509 and EW-A-401 are nearly identical in design and function. Sangamo recently announced that it has initiated a multi-center, double-blind, placebo controlled, repeat-dosing Phase 2 clinical trial in patients with diabetic neuropathy.

Sangamo and Edwards will host a conference call at 9:00 a.m. EST, Monday, December 4, 2006. The conference call dial-in numbers are 866-543-6411 for domestic callers and 617-213-8900 for international callers. The passcode for the call is 10338848. Participants may access the live webcast via a link on the Sangamo BioSciences website http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IR… in the Investor Relations section under "Company Overview." For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 11:00 a.m. on December 4, 2006 to December 11, 2006. The conference call replay numbers for domestic and international callers are 888-286-8010 and 617-801-6888 respectively. The conference ID number for the replay is 16084942. The webcast will be available on the Sangamo website for two weeks after the call.

About Sangamo BioSciences

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2 clinical trial for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Statements in this announcement other than historical data and information constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause actual results, performance, achievements or industry results to be very different from the results, performance or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in each company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2005, and such other filings that Edwards and Sangamo make with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

SOURCE Edwards Lifesciences Corporation; Sangamo BioSciences, Inc.

[aktianer]

Es scheint vorwärts zu gehen:
07.12.2006:
7:07AM Sangamo BioSci announced update on its achieved milestones in 2006 and previewed objectives for 2007 (SGMO) 7.34 : Co says "the progress that we have made in 2006 places us in a strong position to advance our business strategy and clinical programs in 2007. By the second half of 2007, we expect to have two ongoing Phase 2 trials in patients with diabetic neuropathy and to be in a position to initiate two Phase 1 trials in patients with HIV infection and glioblastoma. These objectives, as well as additional progress in our collaboration with Dow AgroSciences, will be key to further enhancing a market-leading presence for our technology. As has become increasingly evident, an innovation gap is looming in the pharmaceutical sector, and we believe that our progress in advancing our technology platform, which is unique in its generation of novel highly differentiated therapies and products, will create interest among potential partners for our programs." Sangamo also gave financial guidance for 2007 estimating that it expects to end 2007 with approximately $35 in cash and cash equivalents, based on current expense projections and expected progress in existing corporate relationships.

[aktianer]

Antwort auf Beitrag Nr.: 26.001.485 von aktianer am 07.12.06 17:10:14

ergänzende Infos zum vorherigen Posting:

Sangamo sees two Phase 2 trials underway in H2 '07
Thu Dec 7, 2006 7:17am ET138

Sangamo sees two Phase 2 trials underway in H2 '07
Analyst says Sangamo BioSciences could be target-magazine
Sangamo says compound makes cells resistant to HIV

CHICAGO, Dec 7 (Reuters) - Sangamo Biosciences Inc. (SGMO.O: Quote, Profile , Research) said on Thursday it expected to have two ongoing Phase 2 trials in patients with diabetic neuropathy by the second half of 2007.

Also by the second half, the Richmond, California, bioscience company said it expected to be ready to start two Phase 1 trials in patients with HIV infection and glioblastoma.

Sangamo said it expects to end 2007 with about $35 million in cash and cash equivalents.

© Reuters 2006. All Rights Reserved.

[tokajo]

und wieder eine neue Zusammenarbeit - diesmal gegen Hirntumore

Sangamo BioSciences and City of Hope Announce License Agreement and Research Collaboration to Develop Treatment for Brain Cancer

Data Presented at the 48th Annual Meeting of the American Society of Hematology

DUARTE, Calif. and RICHMOND, Calif., Dec 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
City of Hope (COH), a leading California biomedical research facility and Comprehensive Cancer Center, and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that Sangamo has entered into an exclusive, worldwide license agreement with COH for intellectual property related to a chimeric immunoreceptor useful in treating human cancers. Sangamo and COH have also entered into a research collaboration to develop a novel cell therapy combining this technology with Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN(TM)) technology for treatment of glioblastoma multiforme (GM), a progressive and usually fatal brain cancer.

Sangamo scientists are collaborating with Michael C.V. Jensen, M.D., Associate Chair, Division of Cancer Immunotherapeutics and Tumor Immunology, City of Hope, who has developed novel chimeric immunoreceptors called zetakines that can be engineered into human immune cells to generate a population of cells that can specifically recognize and destroy cancer cells. Dr. Jensen is already using these engineered cells in clinical trials for malignant gliomas and lymphoma. The aim of the current collaboration is to use Sangamo's ZFN gene modification technology to enable deletion of the glucocorticoid receptor (GR), a gene that limits the benefit of this novel therapy. Glucocorticoids are steroids that are widely used in glioma patients. The specific deletion of GR in the zetakine, anti-glioma T-cells will allow this novel immune therapy to be used in the presence of glucocorticoids.

"We are excited to be collaborating with Dr. Jensen and City of Hope to develop a treatment for this aggressive and malignant disease," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Dr. Jensen has generated compelling data in animal models and has already successfully treated patients with his zetakine-modified T- cells in an ongoing clinical trial. However, he is currently unable to use this approach in patients who are receiving glucocorticoids to control swelling of the brain that is often a consequence of the disease, the related surgery, and its treatment. In addition, this approach is currently patient specific -- which makes it time and labor-intensive. We believe that our ZFN technology may provide a solution to this problem and enable us to develop an 'off the shelf' cell product that can be used in all GM patients. Our collaboration is going well and the early data related to the work have been presented this week at the annual meeting of the American Society of Hematology (ASH)."

Dr. Jensen has developed an IL-13 zetakine that, when expressed in cytotoxic or "killer" T-cells, enables them to seek out and destroy glioblastoma cells in the brain. In his current clinical protocol, T-cells are removed from a patient with GM and modified to express the zetakine. These modified cells are infused into the brain following surgery for the targeted elimination of residual tumor cells. Frequently, however, glucocorticoids must be administered to patients post-surgery to stop the brain from swelling. Glucocorticoids inactivate or kill the desirable T-cells through a protein on the T-cell surface known as the glucocorticoid receptor (GR). Cells without a functional GR are drug-resistant and are therefore available to destroy tumor cells. Dr. Jensen and his colleagues are collaborating with Sangamo scientists to generate zetakine positive, GR-negative T-cells.

"The combination of our two technologies holds tremendous promise for combating glioblastoma and other life threatening cancers," said Dr. Jensen. "This is an exciting opportunity to apply a novel technology for gene modification to T cell immunotherapy of brain cancers to create a cell product which can be used in combination with glucocorticoids to treat patients with GM."

Sangamo scientists have engineered ZFNs specifically targeted to the glucocorticoid receptor gene. Data were presented yesterday at the ASH annual meeting held in Orlando, Florida, that demonstrate that these ZFNs cleave their intended target sequences with high specificity and efficiency resulting in the knockout of GR and the creation of glucocorticoid resistant cells. Moreover, they demonstrated that these ZFNs can stimulate the integration of an IL-13 zetakine-encoding DNA molecule directly into the site of the GR gene. Thus, this procedure results in the simultaneous knockout of GR and addition of the IL-13 zetakine in a genetically defined manner. These data support the notion that ZFN-modified cells can be engineered to express chimeric antigen receptors from a predetermined genomic locus and may provide a general approach to generating effective cellular immunotherapies.

"We are excited about this approach and are committed to moving this program into the clinic as soon as possible," said Edward Lanphier, Sangamo's president and CEO. "We are very pleased to be working with COH and Mike Jensen and his team who have developed this novel approach to the treatment of GM. We believe that, in combination with our proprietary ZFN technology, we have the opportunity to broaden the patient population that could benefit from these advances."

Under the terms of the license agreement, Sangamo will pay COH an up-front license fee and annual maintenance fees. COH is also eligible for payments relating to clinical milestones, royalties and a portion of any revenue that Sangamo may realize from sublicensing agreements. The license granted to Sangamo is exclusive for the treatment or prevention of disease in humans using a combination of the zetakine and disruption of the expression or function of an endogenous gene.

"We are pleased to enter into these agreements with Sangamo. This is another example of how City of Hope's unique mix of innovative technology, translational infrastructure and our ability to forge partnerships with companies can help advance the frontiers of medical science," said Larry A Couture, Ph.D., Senior Vice President and Founding Director, Center for Applied Technology Development, City of Hope. "Sangamo has a powerful technology that may provide an elegant solution to the issues that Dr. Jensen has encountered. One of City of Hope's important missions is to translate scientific developments from the bench to the patient as efficiently as possible. We look forward to working collaboratively to accomplish this."

About Gliomas

Gliomas are the most common type of primary brain tumors; 20,000 cases are diagnosed and 14,000 glioma-related deaths occur annually in the United States. Glioblastoma multiforme, a type of glioma, is rapidly progressive and nearly uniformly lethal. Currently, malignant glioma is managed through surgery and radiation that often exacerbates the already severe symptoms caused by the location of the tumor. With modern surgical and radiotherapeutic techniques the mean duration of survival has increased to 82 weeks, although 5-year survival rates have only increased from 3 to 6%. Resections of >90% of bulky tumors are usually attempted provided that vital functional anatomy is spared. The addition of chemotherapy to resection and radiation provides only marginal survival advantage to patients. Approximately 80% of recurrent tumors arise from remnants of the original incompletely resected tumor. The median survival of recurrent glioblastoma multiforme patients treated with re- resection is 36 weeks.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2 clinical trial for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are on-going to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X- linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

About City of Hope

City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a Comprehensive Cancer Center, the highest honor bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network, City of Hope's research and treatment protocols impact care throughout the nation. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics and shares its scientific knowledge with medical centers locally and globally, helping patients battling serious diseases. For more information, visit www.cityofhope.org.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the development of a novel cell therapy for the treatment of glioblastoma multiforme, research and development of other novel ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., [phone], ext. 271, or [e-mail]; or media, Justin Jackson of Burns McClellan, Inc., [phone], for Sangamo BioSciences, Inc.; or Shawn Le of City of Hope, 1-800-888-5323, or [e-mail] http://www.sangamo.com

Copyright (C) 2006 PR Newswire. All rights reserved

[aktianer]

KAPITALERHÖHUNG um ca. 15% dürfte heutigen Kursrückgang ausgelöst haben:

Alnylam to offer and sell about 4.7 mln shares
Mon Dec 11, 2006 4:42pm ET147
Dec 11 (Reuters) - Alnylam Pharmaceuticals Inc. (ALNY.O: Quote, Profile , Research) said it will offer and sell about 4.7 million common shares in a public offering.

The biopharmaceutical company said it intends to grant the underwriter a thirty-day option to purchase up to about 705,000 additional shares. (Reporting by Neetha Mahadevan in Bangalore)

© Reuters 2006. All Rights Reserved.

[aktianer]

Antwort auf Beitrag Nr.: 26.128.839 von aktianer am 12.12.06 16:53:02

Sorry - Falscher Thread - Kapitalerhöhung betrifft Alnylam!

[tokajo]

Sangamo Receives Michael J. Fox Foundation Funding to Develop Novel ZFP Therapeutic for the Treatment of Parkinson's Disease
RICHMOND, Calif., Jan 23, 2007 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has been awarded funding by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support the development of a ZFP Therapeutic(TM) to treat Parkinson's disease (PD). The $950,000 award will be paid over a period of two years.
Sangamo will develop zinc-finger DNA-binding protein transcription factors (ZFP TFs(TM)) to activate the expression of glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophic factor that has shown promise in preclinical testing to slow or stop the progression of Parkinson's disease.

"We are enthusiastic about Sangamo's novel approach to GDNF as it fits squarely within our desire to promote alternative therapeutic strategies for this and other promising molecules," said Brian Fiske, PhD, associate director of research programs for MJFF. "The work is of particular interest given that Sangamo already has similar technology in clinical trials for diabetic neuropathy and peripheral artery disease and, with a positive result, could proceed rapidly into clinical trials for PD."

Sangamo's technology platform permits the development of highly specific ZFP TFs that can be used to regulate or modify genes at the DNA level. Using a ZFP TF, a gene can be activated in a patient's own cells in its natural cellular context. Use of a ZFP TF to activate the GDNF gene in the brain -- as compared to addition of a GDNF cDNA or the recombinant protein -- may allow the delivery of a more physiologically relevant dose of the growth factor. This may be of particular significance when targeting potent natural growth factors such as GDNF, where sufficient but not super-physiological levels of the therapeutic protein are required to achieve potency with safety.

"We are very pleased that The Michael J. Fox Foundation is recognizing and supporting the potential of Sangamo's unique technology with this award," said Edward Lanphier, Sangamo's President and CEO. "We believe that our approach to therapeutic gene regulation, which mimics the natural regulation of the gene in the body, has advantages over other approaches that add GDNF as either the gene or the recombinant protein. Success in this project would establish the validity of the use of ZFP TFs in the brain and set the stage for the application of this powerful technology to other genes that may have a therapeutic benefit in PD."

About Parkinson's Disease

Parkinson's disease is a chronic, progressive disorder of the central nervous system and results from the loss of cells in a section of the brain called the substantia nigra. These cells produce dopamine, a chemical messenger responsible for transmitting signals within the brain. Loss of dopamine causes critical nerve cells in the brain, or neurons, to fire out of control, leaving patients unable to direct or control their movement in a normal manner. The symptoms of Parkinson's may include tremors difficulty maintaining balance and gait; rigidity or stiffness of the limbs and trunk; and general slowness of movement (also called bradykinesia). Patients may also eventually have difficulty walking, talking, or completing other simple tasks. Symptoms often appear gradually yet with increasing severity and the progression of the disease may vary widely from patient to patient. There is no cure for Parkinson's disease. Drugs have been developed that can help patients manage many of the symptoms; however they do not prevent disease progression.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $90 million in research to date, either directly or through partnerships.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2 clinical trial for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/" target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/ .

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., [phone], ext. 271, or
[e-mail], or Justin Jackson (media) of Burns McClellan, Inc.,
212-213-0006, or [e-mail]

http://www.sangamo.com

[tokajo]

Neue Empfehlung mit Kurzsziel 11 $

Zacks Bull and Bear of the Day Highlights: Sangamo Biosciences, LeapFrog Enterprises, Allianz and Crown Castle

CHICAGO, Feb 01, 2007 (BUSINESS WIRE) --

Bull of the Day:

Our Bull of the Day recommendation is for Sangamo Biosciences, Inc. (Nasdaq:SGMO). Sangamo uses a proprietary gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer, and immune diseases such as sickle cell anemia and HIV. We are optimistic about this novel technology and are encouraged to hear that the company intends to bring more drugs into the clinic by the end of this year. We maintain our Buy rating on shares of Sangamo based on the platform technology and the progress the company has made for both its clinical and preclinical programs. Our target price is $11.00.

[cyberhai]

Die 8 Dollar sind sind unter relativ großem Volumen geknackt:



Gruß Cyberhai

[aktianer]

Sangamo BioSciences Earnings Conference Call (Q4 2006)
Scheduled to start Thu, Feb 8, 2007, 5:00 pm Eastern

[tokajo]

Antwort auf Beitrag Nr.: 27.438.828 von aktianer am 05.02.07 10:33:02

Sangamo BioSciences to Present at the Cowen and Company 27th Annual Health Care Conference

RICHMOND, Calif., March 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at the Cowen and Company 27th Annual Health Care Conference in Boston on Tuesday, March 13, 2007 at 1:45 pm (ET).

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview" http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IR… The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2 clinical trial for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFTM) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNTM) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D, of Sangamo BioSciences, Inc., [phone], ext. 271, or [e-mail]; or media, Justin Jackson of Burns McClellan, Inc., [phone], for Sangamo BioSciences, Inc.

http://www.sangamo.com/

Copyright (C) 2007 PR Newswire. All rights reserved

[mortem]

gibt es was neues aus dieser Front? oder wie sind die kursabschläge zu erklären?

[tokajo]

Antwort auf Beitrag Nr.: 28.332.442 von mortem am 16.03.07 18:35:57

Nach meinen Infos ist der Kurs nicht durch irgendwelche Infos und Rücknahme der Tests begründet. Im Langfristchart sieht man deutlich mehrere Peaks die von Hoffnung geschürt werden und der Kurs dann auf die Uptrendlinie wieder zurückfällt.

Schau dir doch bitte mal den kostenlosen Rohstoffdaily Brief vom 15.03.07 an. Dort wird Werbung für den kostenpflichtigen Brief gemacht. Wenn dort nicht Sangama gemeint ist )

[mortem]

Antwort auf Beitrag Nr.: 28.371.795 von tokajo am 19.03.07 15:09:39

naja, war mir nicht sicher, ob das webcast vom letzten mittwoch irgendwelche Aktionäre enttäuscht haben könnte, denn seit diesen Webcast ging es bergab. heute allerdings wieder leicht in grün

[aktianer]

Antwort auf Beitrag Nr.: 28.371.795 von tokajo am 19.03.07 15:09:39

@tokajo,
Du schreibst "Rücknahme der Tests" - was heißt das?

Danke für die Aufklärung!

Gruß
aktianer

[tokajo]

Antwort auf Beitrag Nr.: 28.385.403 von aktianer am 20.03.07 11:13:22

Hi aktianer,

ich meinte mit dem Satz nur, daß die klinischen Tests der Phase 1 oder 2 nicht ! abgebrochen wurden.
In der Regel brechen Biotechfirmen die Versuche ab, nachdem festgestellt wird, daß die Aussicht auf Erfolg gering ist.
Im Anschluß unten die aktuellen Bereiche von Sangamo, an denen geforscht wird.
---

We are currently developing ZFP TFs for the treatment of the following human diseases:

Diabetic Neuropathy
Diabetic peripheral sensory and motor neuropathy is one of the most frequent complications of diabetes. Apart from rigorous control of blood glucose, the only therapies approved by the FDA for the treatment of diabetic neuropathy are analgesics and antidepressants that address only the symptoms and do not retard or reverse the progression of the disease. Sangamo has ongoing Phase 2 and Phase 1 clinical trials to test a ZFP Therapeutic SB-509, which is designed to up-regulate the endogenous VEGF-A gene. VEGF-A has been demonstrated to have direct neuroproliferative, neuroregenerative and neuroprotective properties.

Sangamo also intends to initiate a Phase 2 repeat-dosing trial in the first half of 2007 in subjects that have a so-called “blocked nerve” or no measurable NCV in their lower limb.

back to top



Cardiovascular Disease and Peripheral Vascular Disease.
There is increasing interest in the development of therapeutic approaches to ischemic heart disease (IHD) and peripheral artery disease (PAD) that might stimulate the human body's natural ability to form new blood vessels, a process called angiogenesis. For this purpose we have developed ZFP TFs designed to activate the expression of angiogenic factors called vascular endothelial growth factors (VEGFs), specifically VEGF A.

We believe that a critical advantage of our ZFP TF technology is the ability to activate the endogenous VEGF A gene resulting in the production of all of the normal splice variants and thus the natural protein isoforms in the ratios normally observed in nature. VEGF A, in its natural state, has multiple splice variants that are involved in the normal physiologic response and appear to be required for the generation of normal, functional vasculature.

In December, 2002 we published initial pre-clinical data in the journal Nature Medicine demonstrating that our ZFP TFs can induce the growth of new blood vessels in rodent models. Our ZFP TFs can stimulate the production of all the major VEGF splice variants in the same proportion normally observed when tissues are oxygen-deprived.

In October, 2004 preclinical animal efficacy studies in the rabbit ischemic hind limb model were published in the American Heart Association Journal Circulation.

Sangamo acquired this clinical stage program in December 2006 from Edwards Lifesciences. Edwards filed an IND application for the ZFP TF, EW-A-401, in February 2004 and initiated a Phase 1clinical trial in August 2004 for the treatment of intermittent claudication. An additional Phase 1study began in June 2005 for the treatment of the more severe form of PAD, critical limb ischemia. The accrual and treatment phase of this trial is complete.
back to top



Congestive Heart Failure.
We are developing a ZFP-Therapeutic for the down regulation of Phospholamban, a well-characterized gene target that has a key role in calcium flux in heart muscle and is believed to be directly involved in congestive heart failure.

back to top


Cancer (Glioblastoma)
Gliomas are the most common type of primary brain tumors; 20,000 cases are diagnosed and 14,000 glioma-related deaths occur annually in the United States. Glioblastoma multiforme, a type of glioma, is rapidly progressive and nearly uniformly lethal. In collaboration with researchers at City of Hope who have developed a "zetakine" engineered T-cell therapy for this cancer, Sangamo is developing a ZFP Therapeutic that uses our ZFN technology to disrupt the expression of the gene encoding the glucocorticoid receptor in these T-cells. Sangamo anticipates filing an IND for this therapeutic in late 2007.

Cancer Immunotherapy.
Sangamo scientists are engineering replication incompetent adenoviral vectors to deliver ZFP TFs that up-regulate granulocyte macrophage colony stimulating factor (GM-CSF) and pigment epithelial derived factor (PEDF). GM-CSF is a powerful immunostimulator and has been shown to augment anti-tumor immune responses. PEDF is a potent antiangiogenic factor that blocks the angiogenic function of VEGF. We believe that this approach may be used to treat cancer both at the tumor site and systemically.

back to top


Intractable Neuropathic Pain.
Intractable neuropathic pain is only partially treatable by current medical and non-medical therapies and many small molecule drugs have significant undesirable side effects. We are evaluating the use of ZFP TFs to repress the expression of the specific genes encoding proteins in nerve cell membranes.

back to top


We are engineering ZFNs for Therapeutic Gene Modification:
Gene Correction and Gene Disruption.
The ZFP DNA binding domain may also be coupled to the cleavage domain of a restriction endonuclease—an enzyme that cuts DNA—creating a zinc finger nuclease or ZFN™.

We can design a ZFN to facilitate either :

ZFN-mediated gene correction: the replacement of a disease-causing mutation with a "normal" or "corrected" DNA sequence, (e.g. for mongenic diseases such as X-linked SCID, sickle cell anemia, beta-thalassemia) or
ZFN-mediated gene-disruption: disruption of a disease-related gene resulting in the expression of a truncated or non-functional protein (e.g. for HIV/AIDS treatment)
Our ZFN technology allows us to facilitate modification of a DNA sequence at a very specific point in the genome without the need for integration of foreign DNA sequences into the genome of cells. ZFN-mediated gene correction will allow the corrected gene to be expressed in its natural chromosomal context and may provide a safe and effective approach to the precise repair of DNA sequence mutations. In April 2005, in Nature, Sangamo scientists published data demonstrating highly efficient permanent ZFN-mediated gene correction in primary human cells (Urnov, F.D. et al., April 4, 2005, Nature Advance Online Publication doi: 10.1038/nature 03556).

back to top


We are developing ZFNs for therapeutic gene correction of the following monogenic diseases:

Sickle Cell Anemia (SCA).
SCA is caused by a mutation in the human β-globin gene. According to the National Heart, Lung and Blood Institute of the NIH, approximately 72,000 people in the U.S. have sickle cell disease. Moreover, approximately 2.5 million Americans carry the sickle cell trait. Sangamo scientists and collaborators are developing methods for ZFN-mediated correction of the β-globin gene mutation that causes sickle cell anemia. We are collaborating on this program with the Children’s Hospital of Oakland Research Institute.

back to top


Beta-Thalassemia.
Beta-Thalassemia is an inherited blood disorder that causes mild or severe anemia due to reduced hemoglobin and fewer red blood cells than normal. Sangamo scientists and collaborators are developing methods for ZFN-mediated correction of the β-globin gene mutation that causes β-Thalassemia.

back to top


X-linked Severe Combined Immunodeficiency (X-linked SCID)
Mutations in the gene encoding the IL2Rγ protein invariably cause X-linked SCID (X-linked Severe Combined Immunodeficiency Disease) or so-called Bubble–boy disease. Patients with such mutations do not produce a functional IL2Rγ protein; never develop a functional immune system and die of severe infections within 12-18 months of birth. Sangamo scientists have used ZFN-mediated gene correction in model cells and primary cells to correct this genetic lesion. This work was published in Nature magazine in April, 2005. We are developing these ZFNs for use in hematopoietic stem cells as a potential therapeutic.



back to top

We are developing ZFNs for therapeutic gene disruption as a potential therapy for:

Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS)
HIV infection results in the death of immune system cells and thus leads to AIDS, a condition in which the body’s immune system is depleted to such a degree that the patient is unable to fight off common infections and ultimately succumbs to opportunistic infections or cancers. CCR5 is the co-receptor for HIV entry into T-cells and without CCR5 expressed on their surface, HIV cannot infect these cells. A population of individuals has been identified that is immune to HIV infection, despite multiple exposures to the virus. They have a natural mutation, CCRΔ532, that results in the expression of a shortened, non-functional CCR5 protein. This mutation appears to have no observable deleterious effect on the growth or survival or these individuals. We are using our ZFN-mediated gene disruption technology to disrupt the CCR5 gene in cells of a patient’s immune system to make these cells permanently resistant to HIV infection. The aim is to provide a population of HIV-resistant cells that can fight opportunistic infections. In collaboration with scientists at the University of Pennsylvania and the University of Los Angeles California, UCLA, we are pursuing both ex- and in vivo approaches in T-cells and hematopoietic. Sangamo anticipates filing an IND for this therapeutic in late 2007.

back to top


Commercialization of ZFP Therapeutics.
We plan to develop and commercialize ZFP-Therapeutics in partnership with pharmaceutical and biotechnology companies. For certain ZFP-Therapeutics we intend to negotiate partnerships with terms that will provide partners with exclusive rights to the regulation of specific genes for certain clinical indications and geographic areas covered under the agreement. For other ZFP-Therapeutics, we intend to retain certain commercial product rights or negotiate partnerships for such products after substantial internal development.

[aktianer]

Antwort auf Beitrag Nr.: 28.388.190 von tokajo am 20.03.07 13:53:59

@Tokajo,

danke für die Klarstellung.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.394.763 von aktianer am 20.03.07 18:30:07

Im Taipan Börsenbrief wird meiner Meinung nach Sangamo als die nächste medizinische Revolution angepriesen mit "Verzehnfachungspotzenzial"!

[tokajo]

Antwort auf Beitrag Nr.: 28.436.947 von Magnetfeldfredy am 22.03.07 17:48:18

Hi Magnetfeldfredy

http://www.heise.de/tr/result.xhtml?url=/tr/artikel/71061&wo…

Zieh dir doch bitte mal den Artikel von Technology Review rein. Dort wird der ganze Zusammenhang über die technischen Möglichkeiten recht ausführlich beschrieben. Schade nur daß Sangamo nicht im der Doku über das Leben im Jahr 2057 vorgestellt wurde.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.437.422 von tokajo am 22.03.07 18:09:32

Guten Morgen Tokajo,

super Bericht, sehr informativ!

Glaubst Du, daß sich die Technologie durchsetzt?

Wenn ja wird Sangamo wirklich zum Global-Gen-Player!

Servus

Magnetfeldfredy

[tokajo]

Antwort auf Beitrag Nr.: 28.444.292 von Magnetfeldfredy am 23.03.07 07:44:59

Wenn die Technologie fertig entwickelt ist wird Sie sich sicher durchsetzen. Überleg doch nur mal die Kostenersparnisse für das marode Krankenkassensystem. Die großen Player interessieren sich auch für das Thema (s. Homepage Sangiamo). Der aktuelle Stand wird auf der Biotech Conference am 29.März vorgestellt.


Sangamo BioSciences to Present at the Future Leaders in the Biotech Industry Conference

RICHMOND, Calif., March 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at the Future Leaders in the Biotech Industry Conference in New York on Thursday, March 29, 2007 at 10:00 am (ET).

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview" http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IR… The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2 clinical trial for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Justin Jackson of Burns McClellan, Inc., [phone], for Sangamo BioSciences, Inc.; or Elizabeth Wolffe, Ph.D of Sangamo BioSciences, Inc., [phone], ext. 271, or [e-mail]

http://www.sangamo.com/

Copyright (C) 2007 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 28.444.659 von tokajo am 23.03.07 08:28:52

Hier noch der Link zur Conference
http://www.biocentury.com/html/conferences/fl/2007/presenter…

Inhalt der Präsentation:
Sangamop plans to complete enrollment in Phase II trial in diabetic neuropathy by year end. Also looking for Phase I data in critical limb ischemia this year, plus preclinical data in neurodegeneration, cancer pain, AMD and congestive heart failure.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.444.752 von tokajo am 23.03.07 08:37:09

Bis wann glaubst Du kann die Therapie für die Patienten zugänglich sein?

[aktianer]

Antwort auf Beitrag Nr.: 28.444.292 von Magnetfeldfredy am 23.03.07 07:44:59

Eine Menge Schaubilder (42 Stück) von der Konferenz vom 13.03.2007 kannst du (nach Registrierung) unter folgender Adresse abrufen:

http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-ne…

Zusätzlich kannst du den Vortrag von Lanphier abhören (konnte allerdings kaum etwas von dem Gesprochenen verstehen - aber die Schaubilder informieren auch schon ganz gut).

Zu deiner Frage, wann mit der Marktreife des ersten Produktes zu rechnen ist, ist wohl kaum eine Aussage möglich. In der Bio- und Gentech-Branche gehören Verzögerungen, aber auch ein Scheitern zu den normalen Ereignissen. Was mich bei Sangamo etwas stört, ist die Vielzahl der Projekte; da Sangamo nur 75 Angestellte zählt, habe ich etwas Angst, daß man sich zu sehr verzettelt. Auf der anderen Seite erhöht gerade die Vielzahl der Projekte die Chance, daß das eine oder andere Projekt zum Erfolg geführt werden kann.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.460.204 von aktianer am 23.03.07 19:54:14

Vielen Dank, Ihr seid alles sehr hilfreiche Sangamo Aktionäre!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.472.105 von Magnetfeldfredy am 24.03.07 10:58:41

Was ist denn heute los, minus 5 % ohne News mit relativ hohen Umsatz, weiß da jemand mehr?

[cyberhai]

Antwort auf Beitrag Nr.: 28.518.519 von Magnetfeldfredy am 27.03.07 14:31:36

Der Kurs in Deutschland ist nicht relevant bzw. erst dann, wenn die Börse in den USA geöffnet hat und da ist die Aktie im Plus:

Last Trade: 6.71
Trade Time: 10:39AM ET
Change: Up 0.02 (0.30%)
Prev Close: 6.69
Open: 6.64
Bid: 6.72 x 100
Ask: 6.73 x 400

Gruß Cyberhai

[tokajo]

Hi Magnetfeldfredy,

nur die Ruhe. Ist halt Biotec. Sangamo und andere sind vor der Veröffentlichung von Forschungsergebnisse sehr stark von der allgemeinen Situation an der Nasdaq abhängig. Die Umsätze dort sind normal zwischen 1 und 1.5 Millionen USD.

Bei so einer Aktie (meine Meinung! ) glaubt man an den Erfolg. Zum Zocken gibt es Papiere die weit höhere Volatilitäten aufweisen.

Heute doch übrigens recht stabil.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.521.889 von tokajo am 27.03.07 16:49:38

Schaut gut aus!

[tokajo]

Antwort auf Beitrag Nr.: 28.531.638 von Magnetfeldfredy am 27.03.07 23:18:46

Nicht vergessen !
Heute

Sangamo BioSciences at Future Leaders in the Biotech Industry
Date: Thursday, March 29, 2007
Event Time: 10:00 a.m. ET
Duration: 1 hour
Location: New York, NY

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.563.081 von tokajo am 29.03.07 15:34:48

Hast Du schon Ergebnisse von Sangoma zu der Tagung bzw. Reaktionen darauf?

[aktianer]

Antwort auf Beitrag Nr.: 28.577.503 von Magnetfeldfredy am 30.03.07 09:16:02

QMagnetfeldfredy,

bisher nichts Neues an der Westfront. Habe gerade nochmals die Homepage aufgrufen und auch kurz mal reingehört - scheint immer noch der Text von vor einingen Tagen zu sein - obwohl das gestrige Datum angegeben ist. Das Verfahren, einfach nur die Präsentation aufzuzeichnen und dann auf der Homepage so wiederzugeben, ärgert mich schon die ganze Zeit. Habe deshalb das Unternehmen angemailt und angeregt, daß man die Prsäentationen auch als Text veröffentlichen sollte. Würde mich allerdings wundern, wenn dies tatsächlich geschähe.
Orientiert man sich nach der heutigen Kursentwicklung, dürfte allerdings Positives an die Investoren vermittelt worden sein; wollte eigentlich noch etwas nachlegen, werde jetzt aber abwarten, vielleicht kommt man ein einigen Wochen doch noch etwas günstiger rein.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.589.365 von aktianer am 30.03.07 18:04:13

Merci, ich habe auf www.sangamo.com gelesen, daß 14 Tage nach der Tagung der Text dazu kommt, ganz schön spät oder?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 28.589.365 von aktianer am 30.03.07 18:04:13

Die Q1 Zahlen am 1.5.07 werden anscheinend sehr gut, der Kurs zieht deutlich an!

[aktianer]

Antwort auf Beitrag Nr.: 29.018.885 von Magnetfeldfredy am 26.04.07 18:37:04

der augenblickliche Anstieg verwundert mich etwas - Gewinnausweise sind sicherlich noch in weiter Ferne und klinische Daten sind eigentlich erst für das Ende des 1.Halbjahrs angekündigt. Trotzdem erfreulich, wenns mal wieder etwas nach oben geht.

Der von Sangamo angegebene Zeitrahmen, den ich mir zwecks besserer Übersicht zusammengestellt habe, sieht bei mir so aus (ohne Gewähr):

Juno 2007: Daten zu Phase Ib zu SB-509 sollen vorliegen
Jahresende 2007: Plans to complete enrollment in Phase II trial in
diabetic neuropathy by year end. Also looking for
Phase I data in critical limb ischemia this year,
plus preclinical data in neurodegeneration, cancer
pain, AMD and congestive heart failure.
2.Halbjahr 2008: Ergebnisse zu Phase II zu SB-509 sollen vorliegen
2.Halbjahr 2008: nerve conduction regeneration Phase II-Ergebnisse
sollen kommen

Im Zeitschema nicht enthaltene (hochspekulative) Möglichkeiten, die für den Kursanstieg ursächlich sein könnten:
a) gestiegene Aussichten auf weitere Meilensteinzahlung von Dow AgroSciences
b) Positive Überraschung aus der von Edwards zurückgeholten Entwicklung zu Gefäßerkrankungen.

[cyberhai]

Antwort auf Beitrag Nr.: 29.019.766 von aktianer am 26.04.07 19:33:58

Es wird eine weitere Phase II-Studie gestartet:

http://biz.yahoo.com/prnews/070426/sfth112.html?.v=1

Gruß Cyberhai

[benefactor [KommA]]

Sangamo BioSciences Announces Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
Monday April 30, 7:00 am ET

RICHMOND, Calif., April 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced that it had entered into a Research and License Agreement with Genentech, Inc. Under this agreement, Sangamo will provide Genentech with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology and will design and engineer ZFP nucleases (ZFN(TM)) for Genentech to evaluate and potentially use to generate cell lines with novel characteristics for protein pharmaceutical production purposes. Financial terms of the agreement were not disclosed.

"We are very pleased to be able to provide Genentech, a leader in the discovery, development, commercialization and manufacturing of biotherapeutics, with a non-exclusive, research and commercial license to certain aspects of our ZFP technology," said Edward Lanphier, Sangamo's president and chief executive officer. "We have engineered ZFNs to facilitate the efficient generation of production cell lines with altered traits. Our technology has the potential to change the speed and efficiency of cell engineering to meet the increased demand for proteins in a variety of industries including pharmaceutical protein manufacturing."

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.

http://biz.yahoo.com/prnews/070430/sfm042.html

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 29.072.248 von benefactor am 30.04.07 14:44:12

Schade daß die tolle Nachricht so verpufft, ich denke Sangamo wird noch für viele Furore sorgen, Zeit muß man schon mitbringen!

[tokajo]

Antwort auf Beitrag Nr.: 29.077.106 von Magnetfeldfredy am 30.04.07 20:01:07

Neue Präsentation über den Ergebnisfortschritt am 21.Mai

Gruß Tokajo

Sangamo BioSciences to Present at the Sixth Annual JMP Securities Research Conference
RICHMOND, Calif., May 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at the Sixth Annual JMP Securities Research Conference in San Francisco on Monday, May 21, 2007 at 3:00 pm (PT).

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Company Overview" http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IR… The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

[tokajo]

Sangamo BioSciences Added to NASDAQ Biotechnology Index
RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a world-leader in the development and commercialization of zinc finger DNA-binding proteins (ZFPs) as novel therapeutics, announced today that it was added to the NASDAQ Biotechnology Index(R) (Nasdaq: NBI) effective with the market open today, Monday, May 21, 2007.

[tokajo]

Antwort auf Beitrag Nr.: 29.525.121 von tokajo am 29.05.07 15:36:17

Neues Kursziel 13 Dollar ( + 100 %)

Gruß Tokajo
Zacks Analyst Interview Highlights: MedImmune, Genzyme and Sangamo Biosciences.

CHICAGO, May 30, 2007 (BUSINESS WIRE) --
Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses MedImmune (Nasdaq: MEDI), Genzyme (Nasdaq: GENZ) and Sangamo Biosciences, Inc. (Nasdaq: SGMO).

A synopsis of today's Analyst Interview is presented below. The full article can be read at http://at.zacks.com/?id=2678.

With another earnings season in the books, did you have any major surprises among the companies in your coverage?

Most of the biotech companies I cover are small-cap biotech. Earnings releases are usually non-events for them. Investors are most concerned about the clinical developments and cash-burn rate for these small-cap, development-stage biotech companies.

Among the companies with product sales, actual sales in the first quarter were generally in-line with our estimates. Two companies are exceptions. MedImmune's (Nasdaq: MEDI) Synagis sales were $507 million in the first quarter, which was $22 million over our estimate of $485 million. As a result, EPS for the first quarter was $0.66 per share versus our $0.50 per share estimate. Genzyme's (Nasdaq: GENZ) product sales in the first quarter were $847 million, $24 million over our estimate of $850 million, though EPS was in line with our estimate due to higher operating expenses offsetting the higher revenue.

What names do you like in particular, currently? And why?

I am very optimistic on Sangamo Biosciences, Inc. (Nasdaq: SGMO). I have a Buy rating on Sangamo based on its unique platform technology and promising pipeline. SGMO developed Zinc Finger DNA-binding protein technology (ZFP), and has a decent pipeline targeting unmet medical needs. The company has a few drug candidates in phase I and phase II clinical trials targeting diabetes, cardiovascular diseases, HIV and brain cancer. SGMO's unique proprietary technology distinguishes itself from the average struggling pharmaceutical companies developing "me too" drugs. This technology has attracted some big pharmaceutical companies for collaboration and makes it an ideal buyout target for acquirers. Our target price is $13.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros by going to http://at.zacks.com/?id=2648.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a)The Zacks Performance Rank performance is the total return of equal weighted simulated portfolios consisting of those stocks with the indicated Zacks Rank net of fees. Results reflect the reinvestment of dividends and other earnings. Simulated results do not represent actual trading and may not reflect the impact that economic and market factors might have had on decision-making if an adviser were actually managing a client's money.

(b)The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 29.539.383 von tokajo am 30.05.07 13:51:07

Das wär doch was 13 US Dollar!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 29.564.006 von Magnetfeldfredy am 31.05.07 21:12:16

Super News zu Sangamo:

Sangamo BioSciences Presents First ZFP Therapeutic Data Demonstrating in Vivo Protection Against HIV
Wednesday June 6, 4:10 pm ET
Preclinical animal model shows ZFN-modified T-cells engraft and are protected from HIV infection


RICHMOND, Calif., June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced the presentation of data from its program to develop a zinc finger DNA-binding protein (ZFP) Therapeutic(TM) for HIV/AIDS that demonstrate that ZFN-modified human T-cells are protected from HIV infection and have a selective survival advantage in a mouse model of HIV challenge. In the second half of 2007, Sangamo expects to initiate a Phase 1 clinical trial to test this HIV ZFP Therapeutic, working with Dr. Carl June, Director of Translational Research at the Abramson Family Cancer Research Institute and collaborators at the University of Pennsylvania.
ADVERTISEMENT


Sangamo's ZFP nuclease (ZFN(TM)) technology can be used to make human primary T-cells resistant to HIV infection by permanently modifying the DNA sequence encoding CCR5, an essential co-receptor for the entry of HIV into immune cells. Individuals have been identified who carry a natural mutation of the CCR5 gene, CCR5-delta32, which confers resistance to HIV infection. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections resulting in AIDS (Acquired Immune Deficiency Syndrome). Individuals diagnosed with AIDS are susceptible to life-threatening diseases or opportunistic infections, which are caused by microbes that usually do not cause illness in people with healthy immune systems. Sangamo's initial approach is to modify the CCR5 gene in T-cells to provide patients with a reservoir of ZFN-modified HIV-resistant immune cells that can fight opportunistic infections and the virus itself.

"Scientists from Sangamo Biosciences approached me with an extraordinary proposition," stated Dr. June. "They told me that they had the means to create CD4+ T-cells with permanent modification of the CCR5 gene and a robust resistance to HIV infection. This exciting collaboration, involving my colleagues at the University of Pennsylvania and the team of scientists at Sangamo has rapidly progressed from that idea to data demonstrating that ZFN modified cells are HIV resistant and have a selective survival advantage when reintroduced into an animal. This is consistent with our aim of reconstituting a functional HIV-resistant immune system in patients infected with the virus.

"This is the first presentation of in vivo data from our program to develop a ZFP Therapeutic for the treatment of HIV, and it is significant that these animal data confirm our earlier observations in isolated cells," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Previously, we had shown that ZFN-modified primary human T-cells are resistant to HIV infection not only surviving continuous exposure to HIV but selectively expanding in cell culture to the point that they represented the vast majority of cells in the population at the end of the experiment. In these more recent data we show that that observation holds true when these HIV-resistant cells are tested in a mouse model of HIV infection and demonstrate that after ZFN-modification the cells are stable and have a selective advantage in the presence of HIV."

In the experiments presented by Dr. June and Sangamo scientist, Michael Holmes, Ph.D., isolated human T-cells were treated with ZFNs specific for CCR5. The modified cells were infused into a mouse model, the NOG mouse, with or without a source of HIV. The NOG mouse lacks an immune system and thus does not reject the human cells. After 33 days, the mice were sacrificed and their blood analyzed for the presence of ZFN-modified cells. Researchers determined that ZFN-modified cells engrafted normally in the mouse and that the proportion of modified cells present at the end of the experiment was statistically significantly higher in mice in the presence of HIV infection (p=0.008). These data suggest that, in the presence of HIV, the ZFN-modified cells have a selective advantage and evade HIV infection and destruction.

"These animal data are very encouraging as we prepare to initiate a Phase 1 clinical trial in HIV/AIDS with this ZFP Therapeutic in the second half of 2007," stated Edward Lanphier, Sangamo's president and CEO. "By administering ZFNs to patients' T-cells, the goal is to provide HIV-infected individuals with a reservoir of healthy and uninfectable immune cells that would be available to combat opportunistic infections and HIV itself. We believe that using ZFNs to permanently modify the CCR5 gene in T-cells and thus directly block HIV from entering cells may have a number of advantages over the systemic effects of CCR5 antagonists in development."

The data were presented on June 1, 2007 at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT), which was held in Seattle, Washington. In addition to Dr. Holmes' presentation, which was selected for the prestigious Presidential Symposium, Sangamo scientists and collaborators presented data in six oral presentations and three posters describing preclinical data from Sangamo's ZFP Therapeutic programs. These included programs in pain, nerve crush and spinal cord injury, macular degeneration and glioblastoma. In addition, Sangamo sponsored a Symposium chaired by Donald Kohn, M.D., Director, Gene, Immune and Stem Cell Therapy Program at Children's Hospital Los Angeles, which featured the following presentations:


-- ZFPs as Therapeutics - Applications and Advantages of the Technology
-- Philip Gregory, D. Phil., Vice President, Research, Sangamo
BioSciences, Inc.
-- Therapeutic Applications of a ZFP TF activator of VEGF-A
-- Dale Ando, M.D., CMO and Vice President, Therapeutic Development,
Sangamo BioSciences, Inc.
-- ZFN Mediated Disruption of CCR5 to Create CCR5 deficient CD4 Cells for
HIV Therapy
-- Carl June, M.D., Director, Translational Research, Abramson Family
Cancer Research Institute, University of Pennsylvania School of
Medicine
-- Gene Editing & Site-Specific Gene Addition in Human Stem Cells Using
ZFN and Integrase-Defective Lentiviral Vectors
-- Luigi Naldini, M.D., Ph.D., Professor of Cell and Tissue Biology,
School of Medicine, Scientific Co director, The San Raffaele
Telethon Institute for Gene Therapy (HSR-TIGET)
-- Engineering Cellular Scalpels for Excising Invasive Tumor Cells of
Malignant Glioma
-- Michael Jensen, M.D., Associate Chairman, Division of Cancer
Immunotherapeutics and Tumor Immunology, Beckman Research Institute,
City of Hope

A replay of the Symposium is available on Sangamo's website in the Investor section under Events and Presentations and can be accessed via the following link http://w.on24.com/r.htm?e=52463&s=1&k=A279AD2E58B632D476492D…

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 29.674.886 von Magnetfeldfredy am 06.06.07 22:46:38

Diese Company könnte die Medizin mit Ihrer patentierten Gentechnick revolutionieren, auch im Agrarbereich:

Dow AgroSciences Highlights Partnership With Sangamo in Wall Street Presentation
Tuesday June 5, 4:13 pm ET
Dow AgroSciences describes Sangamo technology as part of its 'Game Changing' innovation strategy


RICHMOND, Calif., June 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced that its partner, Dow AgroSciences, LLC highlighted the successful collaboration between the two companies in a recent presentation to investors on Wall Street. The presentation made by Daniel R. Kittle, Ph.D., Dow AgroSciences vice president of Research and Development, was part of the Merrill Lynch Agricultural Chemicals Conference in New York.
ADVERTISEMENT


"We continue to be very impressed with our partnership with Sangamo and with the overall progress of our collaboration," said Kittle. "The scientific milestones that we have achieved mark key events in the application of the ZFP technology toward trait generation and trait stacking, and importantly were achieved across different crop plants core to our healthy oils and crop protection businesses. The ZFN(TM) technology platform has significant potential for the development of precision traits."

In a press release distributed earlier today, Dow AgroSciences said that "Cutting-edge techniques, such as the ability to precisely target and regulate gene function in plants through an agreement with Sangamo BioSciences, are enabling the company to reach key discovery milestones. Dow AgroSciences has been able to target native genes in canola using engineered ZFN(TM) technology to affect specific gene sites with exceptional precision. In addition, ZFNs(TM), designed to specifically cleave a native corn gene sequence, were used to target a pre-selected site and enable site-specific transgene integration. This represents the first successful targeted integration of DNA into a pre-selected native corn sequence."

The three-year agreement between Dow AgroSciences and Sangamo BioSciences was initiated in October 2005 and it provides Dow AgroSciences with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. The ability to selectively control specific genes is emerging as a critical tool in modern biotechnology. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP TFs(TM) that can control gene expression and consequently, cell function. For example, Sangamo has demonstrated that plant oils can be improved using ZFP TFs.

Sangamo has also developed sequence-specific ZFNs(TM) for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

[aktianer]

Antwort auf Beitrag Nr.: 29.675.016 von Magnetfeldfredy am 06.06.07 22:55:04

@Magnetfeldfreddy,

sind ja erfreuliche Nachrichten, vor allem der Beginn der HIV-Test-Phase I im 2.Halbjahr 07. Kurs hat gestern auch entgegen dem Markttrend deutlich im Plus geschlossen, nachbörslich lag er sogar bei 7,70 U$.

Trotzdem, man sollte die Erwartungen kurzfristig nicht zu hoch spannen. In diesem Bereich liegen Hochs und Tiefs sehr nahe beieinander.

Schönen Feiertag
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 29.675.016 von Magnetfeldfredy am 06.06.07 22:55:04

Es geht weiter up!

[tokajo]

Antwort auf Beitrag Nr.: 29.949.172 von Magnetfeldfredy am 15.06.07 22:53:46

Hi zusammen,

die letzten 2 Tage gings schön bergauf.
Interessant in diesem Zusammenhang auch ein Artikel der aktuellen Technology Reviev http://www.heise.de/tr/artikel/90211

Die größten Vertreter der Pharma-Branche zehren von den Forschungserfolgen vergangener Zeiten, scheuen das Risiko von kompletten Neuentwicklungen und suchen stattdessen ihr Heil in Fusionen unter ihresgleichen – oder im Aufkauf von Biotech-Unternehmen, die viel versprechende Medikamente in der Entwicklung haben. Bereits jetzt stammt mehr als die Hälfte der Produkte von Big Pharma nicht aus ihrer eigenen Forschung, sondern wurde entweder von kleineren Pharma-Unternehmen oder Biotech-Unternehmen einlizenziert.

Die Zurückhaltung ist verständlich: Die Suche nach neuen Medikamenten gleicht der nach einer Nadel im Heuhaufen. Von 10000 potenziellen Wirkstoffen schafft es am Ende nur einer als Medikament auf den Markt und die Entwicklungskosten beziffert die Industrie auf gut 800 Millionen Dollar oder mehr. Richtig lohnenswert ist die intensive Forschung deshalb nur, wenn am Ende ein echter Umsatzbringer herauskommt – ein „Blockbuster.

Drei Entwicklungen lassen das Verlangen danach immer größer werden: Erstens läuft in den kommenden Jahren der Patentschutz für viele umsatzstarke Medikamente aus; zweitens werden die Generika-Hersteller immer aggressiver; und drittens kommt zunehmend Kostenbewusstsein ins Gesundheitswesen. Innovativer Nachschub tut also Not – doch nach einem Hoch mit 40 bis 50 neuen Wirkstoffe pro Jahr vor zehn Jahren ist die Zahl solcher Zulassungen bei der US-Behörde Food and Drug Administration (FDA) auf etwa 20 pro Jahr gesunken; die europäische Zulassungsbehörde EMEA hat einen ähnlichen Trend registriert.

Zur Schließung der Innovationslücke, die Experten zwischen den frühen und späten Phasen der klinischen Entwicklung ausgemacht haben, führt der Weg von Big Pharma immer häufiger über die Biotech-Industrie. Der Grund: Für die medikamentös einfach zu behandelnden Krankheiten gibt bereits chemische Wirkstoffe, aber bei den komplexeren Krankheiten wie AIDS, Krebs oder Alzheimer muss man viel spezifischer in das fein austarierte biologische System eingreifen. Dafür sind spezialisierte Proteine, Impfstoffe oder Hormone notwendig.

Doch all das ändert nichts am prinzipiellen Problem der teurer und seltener werdenden Blockbuster: je größer ein Unternehmen wird, desto schwerer wird es, Wachstum und erfolgreichere Medikamente zu generieren. Viele Experten rufen bereits die Ablösung des „One drug fits all“-Prinzips aus: Statt einem Medikament für alle zeigen immer genauere Kenntnisse der genetischen Grundlagen von Krankheiten und Wirkmechanismen in die Richtung einer auf die Besonderheiten von Patientengruppen abgestimmten Medizin.

Die mit Abstand radikalste Entwicklung hat Matthew Bell, Manager bei Arthur D. Little, vor diesem Hintergrund schon im Jahr 2003 vorgezeichnet: Wie in der Ölindustrie in den 1970er-Jahren werde sich auch bei Pharma die klassische Wertschöpfungskette auflösen – einzelne Unternehmen würden künftig nicht mehr alle Aufgaben von der Forschung bis hin zur Produktion abdecken, sondern sich spezialisieren – auf Forschung, Entwicklung und klinische Tests oder auf Herstellung, Vermarktung und Verkauf.

Vielleicht der Grund für den starken Anstieg.

Gruß Tokajo

[getshorty]

Hohe Umsätze, steigende Kurse, good News!

Just out from JMP. SGMO - "DN Data at ADA Could Exceed Expectations due to Novel Mechanism - Positive upcoming data from SB-509 study; reiterate Strong Buy rating & $15 price target. "

[getshorty]

Frisch auf finanznachrichten.de


Sangamo Biosciences "buy"

Tuesday, June 19, 2007 6:55:35 AM ET
Cantor Fitzgerald

NEW YORK, June 19 (newratings.com) - In a research note published yesterday, analyst Pamela Bassett of Cantor Fitzgerald reiterates her "buy" rating on Sangamo Biosciences Inc (SGMO.NAS). The target price is set to $17.

[tokajo]

Antwort auf Beitrag Nr.: 30.017.646 von getshorty am 19.06.07 13:28:30

Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration

Successful Application of Sangamo's ZFP Technology to Two Crop Species

INDIANAPOLIS, Ind. and RICHMOND, Calif., June 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of research milestones as part of their joint Research and Commercial License Agreement. These milestones represent the successful application of Sangamo's zinc finger DNA-binding protein (ZFP) technology to the generation of specific traits in two major crop species -- maize and canola.

"Our collaboration with Sangamo has been extremely positive, and we continue to be very excited by the precision and promise of this technology," said Dan Kittle, vice president, Research and Development for Dow AgroSciences. "These milestones demonstrate the ability of ZFP Nucleases (ZFNs(TM)) to act precisely at their intended target in canola and corn, crops of commercial importance, not model systems, and represent the first demonstration of the precise placement of a gene of interest into a specific native gene in maize. This is a development that has potentially significant impact on the cost and timelines of generating crop products with new and improved traits. In addition, Sangamo's technology holds the potential to enable gene editing of native traits and up- and down-regulation of genes to influence metabolic profiles of plants. Everything that we have seen and everything that we have done only reinforces our enthusiasm and commitment to this technology."

"Our ZFP technology can be used to specifically regulate and modify genes," said Philip Gregory, D. Phil., Sangamo's vice president of research. "We have already demonstrated the utility of our ZFN 'genome editing' technology in human cells. Moreover, this technology has the unique advantage of generating the desired trait outcomes without needing to be permanently present in the modified cells. In applying engineered ZFNs to crop plants, Dow AgroSciences scientists have built upon our experience in developing ZFP technology for human therapeutics and accomplished a series of 'scientific firsts.'"

These milestones include the first demonstration of ZFN-mediated targeted integration of DNA into a native gene in maize and the first demonstration of targeting a native gene in canola with ZFNs.

Sangamo scientists recently published data [in Proceedings of the National Academy (PNAS (2007) 104: 3055)] demonstrating the introduction of a "gene-sized fragment" of DNA into a specific location in the human genome via ZFN-mediated targeted gene addition. Dow AgroSciences scientists have similarly used Sangamo-designed ZFNs to successfully target native genes in crops with extraordinary molecular precision.

"Dow AgroSciences has had the foresight to recognize the power of our ZFP technology and the expertise to implement it successfully into its precision trait development program," said Edward Lanphier, Sangamo's president and chief executive officer. "In our research partnership we are rapidly developing innovative applications in plant biotechnology."

The three-year agreement initiated October 2005, provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. The ability to selectively control specific genes is emerging as a critical tool in modern biotechnology. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs(TM)) that can control gene expression and consequently, cell function. For example, Sangamo has demonstrated that plant oils can be improved using ZFP TFs.

Sangamo has also developed sequence-specific ZFNs(TM) for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top tier agricultural company providing innovative crop protection, seeds, and biotechnology solutions to serve the world's growing population. A wholly owned subsidiary of The Dow Chemical Company, global sales for Dow AgroSciences are $3.4 billion. Visit http://www.dowagro.com for more information.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement and the application of Sangamo's ZFP TFs and ZFNs in plant agriculture. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

(TM) Trademark of Sangamo Biosciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Robyn Heine of Dow AgroSciences LLC, [phone], [e-mail]; or Elizabeth Wolffe, Ph.D., of Sangamo BioSciences, Inc., [phone], ext. 271, [e-mail]; or Justin Jackson of Burns McClellan, Inc., [phone], [e-mail], for Sangamo BioSciences, Inc. http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[getshorty]

In der Schlussauktion über 1.000.000 shares gehandelt,
nachbörslich nochmals 1.100.000 shares!

Sind da vielleicht gute Nachrichen im Anmarsch!!!!!

Sangamo BioSciences: Positive results from SB-509 trial

By Katherine Hunt
Last Update: 5:14 PM ET Jun 22, 2007


SAN FRANCISCO (MarketWatch) -- Sangamo BioSciences Inc. (SGMO : sangamo biosciences inc com
News , chart , profile , more
Last: 8.49-0.05-0.59%

5:12pm 06/22/2007

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
SGMO8.49, -0.05, -0.6%) late Friday said that Phase I clinical data from its ZFP Therapeutic program of SB-509 demonstrated "statistically significant" improvements in subjects with diabetic neuropathy, a complication of diabetes. SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor designed to up-regulate the expression of the gene encoding vascular endothelial growth factor, the biotechnology company said. Sangamo said it's currently evaluating SB-509 in two ongoing Phase II clinical trials for the treatment of diabetic neuropathy. "We are very excited by the significant improvements that we observed in several measurements of nerve health in subjects with mild-to-moderate diabetic neuropathy over six months after a single administration of SB-509," said Mark Kipnes, lead investigator on the Phase I trial, in a statement.

[getshorty]

nachbörslich:

SANGAMO BIOSCIENCE (NasdaqGM:SGMO)

After Hours: 8.90 0.43 (5.08%) as of 5:07PM ET on 06/22/07

Quelle: http://www.marketwatch.com/quotes/sgmo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.157.530 von getshorty am 22.06.07 23:37:46

Das ist der freudige Grund:

Press Release Source: Sangamo BioSciences, Inc.


Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
Friday June 22, 4:54 pm ET
Presentation Details Statistically Significant Clinical Results for SB-509 in Development for Treatment of Diabetic Neuropathy
Sangamo Also Announces Two ZFN Pre-Clinical Programs Unanimously Approved by RAC


CHICAGO, June 22 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of encouraging Phase 1 clinical data from its ZFP Therapeutic(TM) program at the 67th Scientific Sessions of the American Diabetes Association (ADA). As disclosed in an oral presentation entitled, "Improved Neurologic Exam and Nerve Conduction Velocities in Diabetic Neuropathy Patients Treated with Vascular Endothelial Growth Factor (VEGF) Zinc Finger Protein Activator (SB-509)," results of Sangamo's Phase 1b clinical trial demonstrated statistically significant improvements in subjects with diabetic neuropathy. SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating SB-509 in two ongoing Phase 2 clinical trials for the treatment of diabetic neuropathy.
ADVERTISEMENT


"We are very excited by the significant improvements that we observed in several measurements of nerve health in subjects with mild to moderate diabetic neuropathy over six months after a single administration of SB-509," commented the presenter, Mark Kipnes, M.D., lead investigator on the Phase 1 trial and an endocrinologist at the Diabetes and Glandular Disease Clinic, San Antonio, Texas. "The data obtained in this clinical trial demonstrate that SB-509 appears to have not only a neuroprotective but possibly also a neuroregenerative effect. Currently, the only treatment options are analgesics and antidepressants to control pain symptoms. In contrast, SB-509 is designed to address the actual nerve damage and therefore could have a profound impact on the lives of patients suffering with diabetic neuropathy."

In addition, Sangamo announced today that two zinc finger nuclease (ZFN) pre-clinical therapeutic programs -- modification of the CCR5 gene in human primary T-cells for the treatment of HIV/AIDS and a novel therapy for the treatment of glioblastoma -- were reviewed and unanimously approved by the National Institutes of Health Recombinant DNA Advisory Committee (RAC) earlier this week. Sangamo filed applications for both programs with the RAC earlier this year, and a unanimous decision was made during the RAC's public review process which took place from June 19-21.

"This is an important step toward our goal of initiating Phase 1 clinical trials of both ZFP Therapeutic programs by the end of this year," said Edward Lanphier, president and CEO of Sangamo. "The fact that the RAC unanimously approved both programs is very gratifying and a testimony to the hard work and tireless preparation by the research and development groups at Sangamo."

Clinical Results Presented at ADA Conference

The data presented at ADA were collected from subjects with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509. Subjects received a single treatment in both legs of either placebo (6 subjects) or SB-509 (6 subjects who received 60 mg total dose or 30 mg per leg). All of the subjects completed 6-month follow-up testing. Clinicians observed statistically significant clinical improvements in quantitative sensory testing (QST) which quantifies perception of vibration and in nerve conduction velocity (NCV), a measure of the ability of a nerve to transmit an applied electrical signal. Specifically, mean QST testing compared to baseline in SB-509 treated patients showed a 42% improvement compared to 13% worsening in the placebo group (a delta in QST of 55%, p<0.0077) and the mean sum of improvement of all lower extremity motor NCVs was 1.9 Meters/sec with SB-509 treatment compared to -2.3 Meters/sec with placebo (a delta in NCV of 4.2 Meters/sec, p<0.047). Clinicians also observed a trend for improvement in SB-509 treated patients in a composite measure of nerve health, the Total Neuropathy Score or TNS. The TNS is a comprehensive approach to evaluating changes in nerve health and includes assessment of several factors, including neurologic exam, QST, electrophysiologic studies and neurologic symptoms.

In addition, data were presented from a subject with a "blocked nerve" in the leg. "Blocked nerves" are nerves, that in response to electrical stimulus, have no measurable induced nerve conduction velocity or NCV but are still functional. Typically, diabetics with blocked nerves have more severe symptoms of neuropathy. Following a single treatment with SB-509, recovered and improved NCV were observed in this subject over a six-month follow-up period.

Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer, stated, "In addition to improvement in TNS and QST, three subjects in our Phase 1b study with 'blocked nerves' showed recovered and improved NCV during a six-month follow-up period after a single treatment with SB-509. This suggests that SB-509 may have a role in nerve regeneration, which is consistent with preclinical observations in a spinal cord paralysis model of statistically significant improvement in hind limb function. To further investigate and confirm this finding of a potential nerve regeneration activity of SB-509 in DN we have initiated a repeat-dosing, single-blind Phase 2 trial in subjects with moderate to severe DN."

From a safety perspective, the Phase 1b data were consistent with previous observations that a single treatment of SB-509 was well tolerated and that no severe adverse events were observed. Importantly, subjects in the study were treated within the pharmacologically effective dose range that was demonstrated to be efficacious in preclinical animal studies. Injection site reactions were the most common adverse events reported and were mild and reversible.

"We are pleased that our SB-509 diabetic neuropathy program Phase 1 update was selected for an oral presentation at the most significant US diabetes meeting of the year," said Edward Lanphier, Sangamo's president and CEO. "We believe that SB-509 represents a new therapeutic approach for diabetic neuropathy, designed to directly protect and possibly restore nerve function, in contrast to the current standard of care designed to address the pain associated with this condition. We expect to provide an additional update on the progress of this trial later in the year. We are encouraged by the data so far and are swiftly moving forward to the next stage of clinical development with our two ongoing Phase 2 clinical trials."

About the SB-509 Clinical Program

SB-509 is an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene.

Phase 1

Phase 1b study to assess the safety and clinical effects of a single administration of SB-509 to subjects is ongoing. Subjects were randomized and administered either SB-509 or placebo in both legs by intramuscular injection. Two dose levels of SB-509 have been tested. At the first dose level, three subjects were administered placebo and three subjects were treated with a total of 30 mg of SB-509, 15 mg per leg. Accrual of these subjects is complete. A further twenty-two subjects have been treated at the second dose level with either placebo or a total dose of 60 mg of SB-509, administered as 30 mg per leg. Subjects in this Phase 1b study will be monitored for both the safety and tolerability of SB-509 treatment as well as evaluation of pain and clinical effects on lower limb diabetic neuropathy at one, two, three and six months post-treatment.

Phase 2

Sangamo has two ongoing Phase 2 studies in diabetics with sensory/motor neuropathy:

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. The trial will be conducted at multiple sites.

Approximately 100 subjects will be enrolled into the trial. Subjects will be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 66 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group (approximately 33 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Specifically, investigators will use the following tests: the visual analog scale for pain intensity (VASPI), total neuropathy score (TNS) to assess signs and symptoms of the condition. A composite scoring system is widely regarded by neurologists as the most comprehensive approach to evaluating changes in nerve health. In addition to qualitative assessment of symptoms, the TNS includes electrophysiological testing using nerve conduction velocity (NCV) to assess the rate at which a nerve can conduct an electrical signal, and quantitative sensory testing (QST) with the Vibratron II instrument, to assess the threshold of detection of vibration. In addition, skin biopsies will be taken to evaluate the direct therapeutic effect of SB-509 on nerve regrowth. This test is a very sensitive marker of DN severity and may provide an important mechanistic marker for efficacy.

The trial is expected to take approximately 12 months to screen and enroll subjects, four months for subject treatment and a further 8 months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or the Sangamo website at http://www.sangamo.com/.

Phase 2 study of SB-509 for moderate to severe DN

The clinical trial is a single-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with moderate to severe diabetic peripheral sensory motor neuropathy in the legs. The trial will be conducted at multiple sites.

Approximately 45 subjects will be enrolled in the trial. Subjects will be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 3 months. The remaining group (approximately 15 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of two treatments (Day 0 and 90). Subjects will receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Specifically, investigators will use the following tests: the visual analog scale for pain intensity (VASPI), total neuropathy score (TNS) to assess signs and symptoms of the condition.

For each subject the trial is expected to take approximately fourteen months: two months for screening, three months for subject treatment and a further nine months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or the Sangamo website at http://www.sangamo.com/.

About SB-509

SB-509 is administered as an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene. VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

[mortem]

Antwort auf Beitrag Nr.: 30.198.282 von Magnetfeldfredy am 23.06.07 09:07:06

Ich bin nicht richtig bei der Sache (Erkältung) und kann mich daher nicht richtig in diesen Veröffentlichungen hineindenken. Kann mir jemand die Kurzfassung auf Deutsch geben? Was bedeutet das Ganze?

Besten Dank!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.203.501 von mortem am 23.06.07 17:45:29

Erkältung, eine ziemlich lächerliche Entschuldigung für das Nicht-Übersetzen-Wollen!
Und dann auch noch alles erklären, was bist denn Du für einer?

[mortem]

Antwort auf Beitrag Nr.: 30.204.875 von Magnetfeldfredy am 23.06.07 18:26:35

Naja, Erkältung in dem Sinne ist es in der Tat nicht, eher gewaltige Kopfschmerzen und Schlappheit. Aber egal, dann werde ich mich mal selber mühsam an die Auswertung machen, wenn ich hier nur ausgelacht werde,...

PS:hätte ja sein können, dass ein Hilfsbereiter hier mit wenigen Worten, ohne erneuten Aufwand, dies hätte zusammenfassen können,...

schönes WE noch

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.215.539 von mortem am 23.06.07 23:02:08

Nach dem Motto, "jeden Tag steht ein Depp auf, man muß Ihn nur finden", nein im Ernst, übersetzte alles und mach Dir ein eigenes Bild von Sangamo dann bist Du auch von Deinem Investment überzeugt und handelst nicht wie Lemminge!

Nur soviel, Sangamo kann und wird die Pharmazie revolutionieren, auch im Agrarbereich! Vielleicht ein 1000%-er im Zeitraum von 5 Jahren!

[tokajo]

Antwort auf Beitrag Nr.: 30.203.501 von mortem am 23.06.07 17:45:29

Hi mortem,

schau dir am besten die Präsentation bei www.sangamo.com an und lies mal den deutschen Artikel von der Zeitschrift technology Review über Sangamo.

Sangamo präsentiert auf der Diabetes Tagung den aktuellen Stand Ihrer Entwicklung.

So wie Magnetfeldfredy schreibt, kann die Technik von Sangamo die Medizin und Agrartechnik wirklich revolutionieren. M.E können mehr als 1000 % drin sein - (falls Sangamo selbstständig bleibt).

Gruß Tokajo

[getshorty]

Antwort auf Beitrag Nr.: 30.301.781 von tokajo am 25.06.07 09:45:06

Schade, hätte mir aufgrund der tollen Nachrichten von Freitag und des hohen Volumens (vorallem nachbörslich), für heute etwas mehr erwartet.

@mortem
tokajo hat völlig Recht, der Artikel erklärt einiges :

http://www.heise.de/tr/artikel/print/71061

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 20.467.356 von fire.fox am 02.03.06 16:25:05

Bis die großen Erfolge bei Sangamo kommen müssen wir noch durchs "Blutbad der Börse"!

[tokajo]

Antwort auf Beitrag Nr.: 30.215.539 von mortem am 23.06.07 23:02:08

Heute Abend findet wieder eine Onlinepräsentation von Sangamo über den aktuell Stand Ihrer Forschung statt.

In der Vergangenheit war dies immer für ein paar Prozente gut.

Gruß Tokajo

Sangamo BioSciences to Present at the Jefferies Healthcare Conference

RICHMOND, Calif., June 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at the Jefferies Healthcare Conference in New York on Thursday, June 28, 2007 at 3:40 pm (ET).

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF (TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN (TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.367.392 von tokajo am 28.06.07 14:27:25

Bis jetzt gehts leider in die falsche Richtung!

[aktianer]

neue Partnerschaft:

Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents
Tuesday July 10, 4:00 pm ET
Companies Combine Proprietary Technologies to Create High Value Research Products

ST. LOUIS, and RICHMOND, Calif., July 10 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL - News), a leading Life Science and High Technology company with 2006 revenues of $1.8 billion, and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News), a world leader in the research and development of zinc finger DNA-binding proteins (ZFPs) announced today a significant alliance focused on the development of high value laboratory research reagents based upon Sangamo's ZFP technology. The alliance combines Sigma's global marketing capabilities and significant reputation as a provider of high quality products and kits for scientific research with Sangamo's substantial expertise in the field of ZFPs.

ADVERTISEMENT
ZFPs are the dominant class of naturally occurring proteins known as transcription factors and are found in the nucleus of every cell. They bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that can recognize a specific DNA sequence, Sangamo scientists have created ZFP nucleases or ZFNs(TM) that facilitate efficient and highly specific gene modification and ZFP transcription factors or ZFP TFs(TM) that specifically control gene expression and consequently, cell function. Scientists at Sigma-Aldrich and Sangamo will use ZFNs like precision "surgical instruments" to modify genes in cells and to develop and market ZFP products for broad use in numerous laboratory research reagent applications. Among the anticipated applications are cell lines with enhanced protein production performance, panels of knock-out cell lines for drug discovery, as well as novel stem cell and transgenic animal models.

"ZFPs are another great example of the leading-edge platform technologies we are adding to our expanding collection of "customer first" products and services," said Jai Nagarkatti, President and CEO of Sigma-Aldrich. "This alliance bolsters our ongoing commitment to enable science globally through innovation. We believe that Sangamo's ZFP technology could fundamentally alter the way in which research on living cells and organisms is conducted. By vastly improving the precision and efficiency with which genomes of living organisms can be modified and regulated, ZFPs provide significant potential for both research and development. Our alliance with Sangamo will enable us to create even more novel research products and services to accelerate the success of our customers while continuing to deliver exceptional value for our shareholders."

"We are extremely pleased to partner with Sigma-Aldrich, a group globally recognized as a world leader in the development and sales of innovative laboratory research reagents," said Edward Lanphier, Sangamo's president and chief executive officer. "Our business strategy is to work with partners to maximize the commercial potential of our technology platform across all fields of use. In addition, a long-term goal at Sangamo has been to increase the accessibility and appreciation of the power and broad applicability of ZFPs for a variety of DNA-based research applications. We believe that the combination of our novel ZFP platform with Sigma's proven experience in development and marketing of research products will not only aid us in this goal but will create high value products from our core technology. Sigma is at the nexus of the most profound innovations occurring in cell and molecular biology, and this gives them incredible perspective with respect to the diverse applications to which this technology can be applied. We look forward to a very exciting and rewarding relationship."

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.623.508 von aktianer am 10.07.07 22:40:49

Diese Firma wird Ihren Weg gehen, Kooperationen mit den großen der Branchen!

[aktianer]

Antwort auf Beitrag Nr.: 30.623.757 von Magnetfeldfredy am 10.07.07 22:57:21

ja, sieht nicht schlecht aus; vor allem ist man nun noch breiter aufgestellt als andere Biotechs.
Im nachfolgenden Artikel werden ergänzend zur gestern eingestellten
Sangamo-Mitteilung Zahlen benannt:

Sigma-Aldrich joins forces with Sangamo
Tuesday July 10, 6:09 pm ET

Sigma-Aldrich Corp. said Tuesday it formed an alliance with Sangamo BioSciences Inc. that will focus on the development of high value laboratory research reagents based upon Sangamo's zinc finger DNA-binding proteins (ZFPs) technology.

ADVERTISEMENT
Under the deal, Sigma-Aldrich will pay $13.75 million to Sangamo as a license fee and payment for 1 million shares of Sangamo's stock, which it will buy at about $7.75 a share. Sangamo stands to get up to $22 million in further payments depending on the success of the program.

ZFPs are the dominant class of naturally occurring proteins known as transcription factors and are found in the nucleus of every cell. They bind to DNA to regulate gene expression.

Among the anticipated applications are cell lines with enhanced protein production performance, panels of knock-out cell lines for drug discovery, as well as novel stem cell and transgenic animal models.

Sangamo BioSciences Inc. (Nasdaq: SGMO - News), based in Richmond, Calif., is involved in the research and development of zinc finger DNA-binding proteins.

St. Louis-based Sigma-Aldrich Corp. (Nasdaq: SIAL - News) produces biochemical and organic chemical products used in research, biotechnology, pharmaceutical development and chemical manufacturing.

Published July 10, 2007 by the St. Louis Business Journal

http://biz.yahoo.com/bizj/070710/1488987.html?.v=2

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.626.793 von aktianer am 11.07.07 10:11:17

Danke für die Infos, ich habe gestern noch per Live-Stream die Pressekonferenz angehört und die Zahlen mitbekommen, da wächst ein Gigant, habe recherchiert, Taipan empfahl Sangamo schon vor einem Jahr mit Kursziel 22 US Dollar, jetzt die Kooperationen mit Genentech, Sigma, .... da wächst was heran!

[getshorty]

Der Newsflow bei Sangamo ist Spitze!
Vielleicht können wir sogar bald das 52 Wochenhoch von USD 8,89 knacken!

Wir werden sehen!

gruß shorty

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.629.067 von getshorty am 11.07.07 12:13:46

Kursziel von 17 US Dollar bestätigt, Deal mit Sigma 60 US Millionen Dollar wert, mehr:

Ahead of the Bell: Sangamo Shares Up
Wednesday July 11, 9:12 am ET
Sangamo BioSciences Rises on Sigma Protein Development Pact


NEW YORK (AP) -- Sangamo BioSciences Inc. shares rose in premarket trading Wednesday, on pace to open at a five-year high after the company said it will work with Sigma-Aldrich Corp. to create laboratory research chemicals using technology Sangamo has developed.
ADVERTISEMENT


Sangamo said it has modified zinc finger DNA-binding proteins, which are found in every cell, to modify genes and cell function. The companies will develop reagents, or chemicals used to start chain reactions.

Sigma-Aldrich will pay $13.5 million initially, including a purchase of 1 million shares of Sangamo stock. Sangamo could receive up to $22 million more depending on development and commercial progress.

Cantor Fitzgerald analyst Pamela Basset reiterated a "Buy" rating on Sangamo shares, and expects the stock price nearly double over the next year, rising to $17. She said the deal will be worth $60 million, not including royalties Sangamo could receive, if development is successful.

Basset said the deal shows that ZFP technology has a great deal of commercial potential, as pharmaceutical companies will want to use it in testing their products.

"We expect the Sigma-Aldrich collaboration to focus on creating cell lines for the entire 'druggable' universe all genetic targets which would enable pharma and biopharma companies to test drug candidates in a very rapid and specific manner," she said.

Shares gained 46 cents, or 5.4 percent, to $9.01 in premarket electronic trading, and were on pace to open at a five-year high. The stock closed at $8.55 Tuesday, and has traded between $4.26 and $8.89 in the last year.

Shares of Sigma-Aldrich finished at $42.83 Tuesday.

Questions or comments about this story should be directed to the Financial News desk of The Associated Press at [phone].

[tokajo]

Antwort auf Beitrag Nr.: 30.632.730 von Magnetfeldfredy am 11.07.07 15:45:28

ATH erreicht.


Gruß Tokajo

[getshorty]

Antwort auf Beitrag Nr.: 30.632.952 von tokajo am 11.07.07 15:55:16

Na also!

[aktianer]

Antwort auf Beitrag Nr.: 30.633.160 von getshorty am 11.07.07 16:06:37

Wahnsinn, wie die heute weiterläuft; eigentlich habe ich erwartet, daß heute eine kleine Konsolidierung kommt - und jetzt übersprang sie gerade die 9,50 U$.

[getshorty]

Antwort auf Beitrag Nr.: 30.634.162 von aktianer am 11.07.07 16:53:13

Jetzt wird mir aber langsam schwindlig!
Auch die USD 10 sind geknackt - wohin soll das führen?

[tokajo]

Antwort auf Beitrag Nr.: 30.637.455 von getshorty am 11.07.07 19:13:45

Warte erst mal ab wo wir nach der ersten Zulassung stehen werden.
Für mich steht fest - Sangamo wird ein Tenbagger - .

Gruß Tokajo

[getshorty]

Antwort auf Beitrag Nr.: 30.637.741 von tokajo am 11.07.07 19:25:54

Dein Wort in Gottes Ohr!

Gruß shorty

[tokajo]

Antwort auf Beitrag Nr.: 30.637.940 von getshorty am 11.07.07 19:35:02

Die Elf sind Vergangenheit.

Gruß Tokajo

[aktianer]

Antwort auf Beitrag Nr.: 30.638.089 von tokajo am 11.07.07 19:41:01

volatiler Handel i.d. letzten halben Stunde - vielleicht Eindeckungen der Shorties? lt. Yahoo dürften ca. 10% short gewesen zu sein.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.637.741 von tokajo am 11.07.07 19:25:54

Servus Tokajo,

bis wann erwartest Du die erste Zulassung denn?

Auf alle Fälle hab ich heute noch 1000 Stück in Frankfurt zu 6,42 gekauft, war kein Fehler!

Stay long and strong!

Gruß

[tokajo]

Antwort auf Beitrag Nr.: 30.640.808 von Magnetfeldfredy am 11.07.07 21:20:26

Das kann dir derzeit keiner beantworten. Das Diabetesprogramm befindet sich in der Vorbereitung zur Phase 2. Diese dauert mindestens ein halbes Jahr.
Aber es gibt ja auch noch die Agrarprojekte mit Dow und andere Cooperationen.
Wie früher mehrfach schon erwähnt wurde, falls die neue Technik funktioniert (und bisher sieht es so aus) kann die Medizintechnik revolutioniert werden.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.648.204 von tokajo am 12.07.07 08:49:26

Danke!

[tokajo]

Sangamo Announces Sale of $30 Million of Common Stock to Institutional Investors

RICHMOND, Calif., July 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has obtained commitments from a select group of institutional investors to purchase an aggregate of 3,278,689 shares of common stock, at a price of $9.15 per share, for gross proceeds of approximately $30.0 million, before fees and expenses. The closing is expected to take place on Friday, July 20, 2007, subject to the satisfaction of customary closing conditions. JMP Securities and Piper Jaffray & Co. acted as joint lead placement agents, with Leerink Swann & Company and Janney Montgomery Scott acting as co-placement agents for this offering.

The shares are being offered pursuant to the Company's registration statement on Form S-3 declared effective by the Securities and Exchange Commission on May 9, 2007. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sales of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to amount of proceeds expected to be received from the closing of the offering, the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Form 10-Q and Form 8-K. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D., of Sangamo BioSciences, Inc., [phone], ext. 271,
[e-mail]
http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX

[aktianer]

Antwort auf Beitrag Nr.: 30.727.709 von tokajo am 17.07.07 15:32:58

Bisherige Kursentwicklung deutet darauf hin, daß man die Kapitalerhöhung vor allem als Vertrauensbeweis in die Sangamo-Technik interpretiert.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.728.324 von aktianer am 17.07.07 16:03:05

Seh ich genau so, kann aber auch wie bei Arqule so kommen, daß erst Tage später der Kurs deutlich nachgibt, wie eben bei Arqule!

Jedoch bin ich von Sangamos Technik überzeugt und langfristig spielt daß dann sowieso keine Rolle!

Warum aber Kapitalerhöhung wenn durch den Sigma Deal 13,75 Dollar sofort reinkommen?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.734.025 von Magnetfeldfredy am 17.07.07 21:05:15

Sorry 13.75 Millionen Dollar anstatt 13,75 Dollar!

[benefactor [KommA]]

Antwort auf Beitrag Nr.: 30.734.025 von Magnetfeldfredy am 17.07.07 21:05:15

Also ich finde das PP ist eine gelungene Sache. Es gibt fast nichts Schlimmeres als ein Biotech-Unternehmen, das ständig Ebbe in der Kasse hat.

[aktianer]

Antwort auf Beitrag Nr.: 30.734.025 von Magnetfeldfredy am 17.07.07 21:05:15

Ich glaube, die Kosten für die Durchführung klinischer Studien sind in den letzten Jahren stark angestiegen. Deshalb ist es richtig, bei guten Kursen deren Finanzierung sicherzustellen Übrigens kommen am 24.July die Zahlen für das 2.Quartal, vieleicht erfahren wird ja dann weitere Details.

Gruß
akianer

[aktianer]

Sangamo CEO Sells 25,000 Shares
Thursday July 19, 10:24 am ET
Sangamo Biosciences Chief Executive Edward Lanphier II Sells 25,000 Shares

NEW YORK (AP) -- The president and chief executive of drug developer Sangamo Biosciences Inc. sold 25,000 shares of common stock under a prearranged trading plan, according to a Securities and Exchange Commission filing Wednesday.

In a Form 4 filed with the SEC, Edward O. Lanphier II reported he sold the shares Monday for $10.05 apiece.

The stock sale was conducted under a prearranged 10b5-1 trading plan which allows a company insider to set up a program in advance for such transactions and proceed with them even if he or she comes into possession of material nonpublic information.

Insiders file Form 4s with the SEC to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.

Sangamo Biosciences is based in Richmond, Calif.

[getshorty]

@tokajo, fredy und aktianer
vielleicht weiß jemand, warum es nachbörslich so raufgeht??

After Hours: 11.03 1.22 (12.44%) as of 4:01PM ET on 07/23/07
Last Trade: 9.81
Trade Time: 4:00PM ET
Change: 0.04 (0.41%)
Prev Close: 9.77
Open: 9.66
Bid: 9.88 x 500
Ask: 11.05 x 500
1y Target Est: 13.12

[getshorty]

Hat sich erledigt!
After Hours: 9.80 0.01 (0.13%) as of 4:12PM ET on 07/23/07

Last Trade: 9.81
Trade Time: 4:00PM ET
Change: 0.04 (0.41%)
Prev Close: 9.77
Open: 9.66
Bid: 9.86 x 100
Ask: 10.15 x 400
1y Target Est: 13.12

Day's Range: 9.66 - 9.96
52wk Range: 4.61 - 11.40
Volume: 255,035
Avg Vol (3m): 514,443
Market Cap: 343.99M
P/E (ttm): N/A
EPS (ttm): -0.61
Div & Yield: N/A (N/A)

[tokajo]

Die Zahlen sind da. M. E. wie erwartet.

Gruß Tokajo
Sangamo BioSciences Reports Second Quarter 2007 Financial Results
7/24/2007

RICHMOND, Calif., July 24, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $2.6 million as compared to second quarter 2006 revenues of $1.8 million. Second quarter 2007 revenues were from Sangamo's partnerships in the areas of plant agriculture, private foundation and federal government research grants and enabling technologies.

The consolidated net loss for the quarter ended June 30, 2007 was $5.2 million, or $0.15 per share, as compared to a net loss of $3.3 million, or $0.11 per share, in the same period of 2006. At June 30, 2007, the company had cash, cash equivalents, investments and interest receivable of $44.6 million.

Total second quarter 2007 operating expenses were $8.4 million as compared to $5.8 million in the prior year period. Research and development expenses were $6.3 million for the three months ended June 30, 2007 as compared to $4.0 million for the second quarter of 2006. The increase in research and development expenses for the second quarter of 2007 compared with the same period in 2006 is principally due to increased expenses associated with our clinical program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and for glioblastoma. General and administrative expenses were $2.1 million for the second quarter of 2007 as compared to $1.8 million for the same period in 2006.

Net interest and other income for the second quarter of 2007 was $657,000 as compared to $745,000 in the comparable period of 2006.


Recent Highlights

-- Sangamo raised $30 million in a registered direct offering to
institutional investors. On July 17, Sangamo announced that it had sold
an aggregate of 3,278,689 shares of common stock, at a price of $9.15
per share, for gross proceeds of approximately $30.0 million, before
fees and expenses.
-- Sangamo and Sigma-Aldrich Corporation established a major alliance to
develop and commercialize high value laboratory research reagents based
upon zinc finger DNA-binding protein (ZFP) technology. Pursuant to the
agreement announced on July 10, Sangamo received an upfront payment of
$13.5 million which included license fees and sale of one million
shares of Sangamo stock. Sangamo is also eligible to receive
development and commercial milestone payments and royalties on product
sales.
-- Positive data from the Phase 1b clinical trial of ZFP Therapeutic(TM),
SB-509, for diabetic neuropathy presented at the American Diabetes
Association Meeting. Clinical investigator, Mark Kipnes, M.D.,
presented data from this study that demonstrate statistically
significant improvements in nerve conduction velocity and quantitative
sensory testing in subjects with mild to moderate diabetic neuropathy
over a six month period after a single administration of SB-509.
-- Sangamo received unanimous approval from the National Institutes of
Health Recombinant DNA Advisory Committee (RAC) for two ZFN Therapeutic
programs. Two ZFP nuclease (ZFN) pre-IND therapeutic programs --
modification of the CCR5 gene in human primary T-cells for the
treatment of HIV/AIDS and a novel therapy for the treatment of
glioblastoma -- were reviewed and unanimously approved by the RAC on
June 19.
-- Continued progress in achievement of milestones in collaboration with
Dow AgroSciences. Sangamo and Dow AgroSciences jointly announced the
successful achievement of research milestones as part of our joint
Research and Commercial License Agreement. The milestones represent the
successful application of Sangamo's ZFP technology for the generation
of specific traits in two major crop species -- maize and canola.
-- Sangamo entered into a Research and License Agreement with Genentech in
the area of protein pharmaceutical production. Under the agreement
announced on April 30, Sangamo will develop ZFNs(TM) designed to make
targeted modifications to the genome of Genentech cell lines for use in
mammalian cell-based protein pharmaceutical production. Genentech has
paid Sangamo an upfront fee, and will pay an ongoing technology access
fee and certain payments upon achievement of specified milestones
relating to the research of ZFNs and the development and
commercialization of products manufactured using a modified cell line
created by ZFN technology.
-- Initiation of Phase 2 clinical trial of SB-509 in subjects with
moderate to severe diabetic neuropathy (DN) or "blocked nerves".
Sangamo announced the initiation of a second Phase 2 clinical trial; a
randomized, single-blind, placebo-controlled, repeat-dosing study
designed to evaluate the clinical safety and clinical effects of repeat
administration of SB-509 in diabetic subjects that have "blocked
nerves," or unmeasurable nerve conduction velocity (NCV), in at least
one of the nerves in the leg.



Six-Month Results

For the six-month period ended June 30, 2007 the consolidated net loss was $10.5 million, or $0.30 per share, compared with a consolidated net loss of $6.1 million, or $0.20 per share, in the comparable period in 2006. Revenues for the first six months of 2007 were $4.0 million as compared to $3.9 million in the same period of 2006. Total operating expenses for the six months ended June 30, 2007 and 2006 were $15.9 million and $11.2 million, respectively.

Conference Call and Webcast

Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 888-802-2278 for domestic callers and 913-312-1264 for international callers. The passcode for the call is 1436008. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations". For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8.00 p.m. ET on July 24, 2007 to July 31, 2007. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820, respectively. The conference ID number for the replay is 1436008. The webcast will be available on the Sangamo website for two weeks after the call.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effects in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Research at Sangamo is partially funded by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology (NIST). Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Form 10-Q and Form 8-K. Sangamo assumes no obligation to update the forward-looking information contained in this press release.



SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
Consolidated Statement of Operations
Data

Revenues $2,584 $1,777 $4,006 $3,913
Operating expenses:
Research and development 6,309 4,028 11,739 7,617
General and administrative 2,113 1,821 4,112 3,576
Total operating expenses 8,422 5,849 15,851 11,193
Loss from operations (5,838) (4,072) (11,845) (7,280)
Interest income, net 657 745 1,305 1,209
Net loss $(5,181) $(3,327) $(10,540) $(6,071)

Basic and diluted net loss per common
share $(0.15) $(0.11) $(0.30) $(0.20)

Shares used in computing basic and
diluted net loss per common share 35,136 31,312 35,097 30,959



CONDENSED BALANCE SHEET DATA June 30, Dec. 31,
2007 2006
Cash, cash equivalents, and
investments $44,585 $53,975
Total assets $46,936 $55,780
Total stockholders' equity $39,934 $48,705



SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc., [phone], x271, [e-mail] http://www.sangamo.com

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.819.162 von getshorty am 23.07.07 22:21:59

Sangamo wird`s trotz der guten Aussichten sicher nich leicht haben wenn man sieht was aus aussichtsreichen Aktien wie GPC geworden ist, auch wird der Gesamtmarkt runter gehen, abwarten?

[tokajo]

Antwort auf Beitrag Nr.: 30.847.008 von Magnetfeldfredy am 25.07.07 17:19:24

Bei der Meldung ist es kein Wunder, das GPC abschmiert.

Gruß Tokajo

Die Münchner Biotechfirma GPC Biotech hat in den USA einen herben Rückschlag erlitten. Berater der US-Gesundheitsbehörde FDA votierten gegen die Zulassung des Hoffnungsträgers Orplanta. Das Schicksal des Medikaments ist von besonderer Bedeutung.
Dem Krebsmittel wurden bislang weltweite Spitzenumsätze von 500 Mio. $ pro Jahr zugetraut. Die Chance, dass das Mittel noch zugelassen wird, beziffern Experten auf nur noch 50 Prozent. Ausschlaggebend sind weitere Studiendaten, die in rund sechs Monaten vorliegen sollen. Der Kurs der GPC-Aktie brach daraufhin am Mittwoch um bis zu 42 Prozent ein; sie schloss bei minus 33 Prozent bei 9,82 Euro.

[getshorty]

Antwort auf Beitrag Nr.: 30.853.835 von tokajo am 26.07.07 09:03:34

Der Kurs ist ja momentan ein Trauerspiel!

31.07.2007 22:09
Sangamo BioSciences to Present at the Canaccord Adams 27th Global Growth Conference

RICHMOND, Calif., July 31 /PRNewswire-FirstCall/ -- Sangamo BioSciences, (Nachrichten) Inc. announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:30 am (ET) on Tuesday, August 7, 2007 at the 27th Annual Canaccord Adams Global Growth Conference in Boston.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

So long,
shorty

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 30.959.277 von getshorty am 31.07.07 22:35:31

Der Kurs ist heute entgegen des "sauschwachen" Gesamtmarkts super gelaufen, + 5 Prozent, zeitweise fast 10 %!
Sangamo wird uns noch viel Freude machen, wenn auch volatile Freude!

[aktianer]

Antwort auf Beitrag Nr.: 31.014.906 von Magnetfeldfredy am 03.08.07 22:26:32

Präsentation dürfte vorüber sein: Kurs zieht nämlich kräftig
auf 9,78 U$ an.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.085.115 von aktianer am 08.08.07 19:25:37

Sangamo kann die Medizin revolutionieren, daß dürfen wir nie vergessen!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.087.881 von Magnetfeldfredy am 08.08.07 22:25:10

Wieder über 10 US Dollar bei dem "Gemetzel", Hut ab!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.116.442 von Magnetfeldfredy am 10.08.07 16:19:05

Heute in USA über 11 US Dollar, wow, ich glaube da kommen bald good news......

[getshorty]

Antwort auf Beitrag Nr.: 31.243.716 von Magnetfeldfredy am 21.08.07 18:10:13

By: Rob Cos (Rob posted on IV board link below)

http://www1.investorvillage.com/smbd.asp...

Look @ 57 SGMO partners listed in rpt. Last thing I want is an early takeover, but its tough to believe SGMO can remain independent with partners like Amgen, Genentech, Pfizer, Bristol Myers, Merck, AstraZeneca, Smithkline Beecham, Pharmacia & J&J....


Unfortunately we may one day wake up to a double overnight like RNAI did after the Merck takeover announcement. Wouldn't be a bad quick score but my gut tells me this is a multibagger if it remains independent.


List of Partners (57):

Amgen Inc.
ARTEMIS Pharmaceuticals GmbH
AstraZeneca plc
Avigen Inc.
Baxter InternationalInc.
Bayer AG
Bayer Corporation
Bayer ScheringPharma AG
Bristol-MyersSquibb Co.
California Institute ofTechnology(Caltech)
Charles River Laboratories International Inc.
City of Hope
National MedicalCenter
Cystic Fibrosis Foundation
Dow AgroSciences LLC
Dow Chemical Co.
DuPont Pharmaceuticals Company
Edwards Lifesciences Corp.
Exelixis Inc.
Genentech Inc.
Genset SA
Glaxosmithkline plc
ICAgen Inc.
Immunex Corporation
Isogenica Limited
Japan Tobacco Inc.
Johnson &Johnson
Juvenile Diabetes Research Foundation (JDRF)
LifeScan, Inc.
Massachusetts Institute of Technology
MaxCyte, Inc
Medarex Inc.
Merck & Co. Inc.
MERCK KGAA
Merck Serono S.A.
MGI Pharma Inc.
Millennium Pharmaceuticals Inc.
National Institute of Standards and Technology
National Institutes of Health (NIH)
Novo Nordisk A
OnyxPharmaceuticals Inc.
Pfizer Inc.
Pharmacia & Upjohn, Inc.
Pharmacia Corporation
Procter & Gamble Co.
Purdue Pharma L.P
Renessen LLC
Roche Holding AG
Rosetta Inpharmatics, Inc
Sigma-Aldrich Corp.
SmithKline Beecham Plc
Targeted Genetics Corp.
The Johns Hopkins University
The National Heart, Lung, and Blood Institute (NHLBI)
The Scripps Research Institute
The U.S.Department of Health and Human Services
Wyeth
Zycos Inc.


Sentiment : Strong Buy

[tokajo]

Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference

RICHMOND, Calif., Sept 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 1:30 pm (PT) on Monday, September 17, 2007 at the ThinkEquity Partners' 5th Annual Growth Conference in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.519.335 von tokajo am 11.09.07 07:11:32

Bleibst Du long Tokajo oder tradest Du Sangamo?

[tokajo]

Antwort auf Beitrag Nr.: 31.542.481 von Magnetfeldfredy am 12.09.07 09:41:54

Ich bin hier very long investiert. Obwohl der Kursverlauf sich zum Traden eignet. Dafür sind mir aber hier die Umsätze und der Spread zu gering.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.548.817 von tokajo am 12.09.07 16:58:35

Servus Tokajo,

ich bleibe auch mit meinen 1000 Stück long, könnte ein Teenbagger werden!

[getshorty]

Antwort auf Beitrag Nr.: 31.553.075 von Magnetfeldfredy am 12.09.07 21:35:26

Neues 52-Wochenhoch geknackt. Weiter so!

Here's the link to the Dow/Monsanto call on the corn deal that I understand mentions SGMO a couple times including the last analyst question I think. -

http://phx.corporate-ir.net/phoenix.zhtm...

Gruß shorty

[getshorty]

Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
Successful Application of Sangamo's ZFP Technology to Two Crop Species

INDIANAPOLIS, Ind. and RICHMOND, Calif., June 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the successful completion of research milestones as part of their joint Research and Commercial License Agreement. These milestones represent the successful application of Sangamo's zinc finger DNA-binding protein (ZFP) technology to the generation of specific traits in two major crop species -- maize and canola.

"Our collaboration with Sangamo has been extremely positive, and we continue to be very excited by the precision and promise of this technology," said Dan Kittle, vice president, Research and Development for Dow AgroSciences. "These milestones demonstrate the ability of ZFP Nucleases (ZFNs(TM)) to act precisely at their intended target in canola and corn, crops of commercial importance, not model systems, and represent the first demonstration of the precise placement of a gene of interest into a specific native gene in maize. This is a development that has potentially significant impact on the cost and timelines of generating crop products with new and improved traits. In addition, Sangamo's technology holds the potential to enable gene editing of native traits and up- and down-regulation of genes to influence metabolic profiles of plants. Everything that we have seen and everything that we have done only reinforces our enthusiasm and commitment to this technology."

"Our ZFP technology can be used to specifically regulate and modify genes," said Philip Gregory, D. Phil., Sangamo's vice president of research. "We have already demonstrated the utility of our ZFN 'genome editing' technology in human cells. Moreover, this technology has the unique advantage of generating the desired trait outcomes without needing to be permanently present in the modified cells. In applying engineered ZFNs to crop plants, Dow AgroSciences scientists have built upon our experience in developing ZFP technology for human therapeutics and accomplished a series of 'scientific firsts.'"

These milestones include the first demonstration of ZFN-mediated targeted integration of DNA into a native gene in maize and the first demonstration of targeting a native gene in canola with ZFNs.

Sangamo scientists recently published data [in Proceedings of the National Academy (PNAS (2007) 104: 3055)] demonstrating the introduction of a "gene-sized fragment" of DNA into a specific location in the human genome via ZFN-mediated targeted gene addition. Dow AgroSciences scientists have similarly used Sangamo-designed ZFNs to successfully target native genes in crops with extraordinary molecular precision.

"Dow AgroSciences has had the foresight to recognize the power of our ZFP technology and the expertise to implement it successfully into its precision trait development program," said Edward Lanphier, Sangamo's president and chief executive officer. "In our research partnership we are rapidly developing innovative applications in plant biotechnology."

The three-year agreement initiated October 2005, provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. The ability to selectively control specific genes is emerging as a critical tool in modern biotechnology. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs(TM)) that can control gene expression and consequently, cell function. For example, Sangamo has demonstrated that plant oils can be improved using ZFP TFs.

Sangamo has also developed sequence-specific ZFNs(TM) for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top tier agricultural company providing innovative crop protection, seeds, and biotechnology solutions to serve the world's growing population. A wholly owned subsidiary of The Dow Chemical Company, global sales for Dow AgroSciences are $3.4 billion. Visit http://www.dowagro.com for more information.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement and the application of Sangamo's ZFP TFs and ZFNs in plant agriculture. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

(TM) Trademark of Sangamo Biosciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Robyn Heine of Dow AgroSciences LLC, [phone], [e-mail]; or Elizabeth
Wolffe, Ph.D., of Sangamo BioSciences, Inc., [phone], ext. 271,
[e-mail]; or Justin Jackson of Burns McClellan, Inc., [phone],
[e-mail], for Sangamo BioSciences, Inc.
http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[tokajo]

Schon aufgefallen ?
Neues ATH bei 12,73 $
Letztes ATH ohne Widerstände dynamisch überschritten.

Gruß Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 31.647.152 von tokajo am 18.09.07 17:31:51

Sorry 12,87

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.647.172 von tokajo am 18.09.07 17:33:20

So kanns weitergehen!

[aktianer]

Antwort auf Beitrag Nr.: 31.647.152 von tokajo am 18.09.07 17:31:51

Anstieg dürfte der gestrigen Präsentation zu verdanken sein. Kurs mittlerweile bereits bei 13,03 $ (13,10 war beim letzten kräftigen Kursanstieg das intra-day-high). Mal sehen, ob wir heute darüber schließen können.

Gruß
aktianer

[benefactor [KommA]]

Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Tuesday September 18, 1:15 pm ET
Preclinical Animal Data Demonstrates Selective Survival Advantage of ZFN-Treated Immune Cells after HIV Infection

RICHMOND, Calif., Sept. 18 /PRNewswire-FirstCall/ - Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of data demonstrating that human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)) and preferentially survive and expand in an animal after HIV infection. The presentation, entitled, "Establishment of HIV Resistant CD4 T-Cells by Engineered Zinc Finger Protein Nucleases" is taking place today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago.

"The positive results being presented at ICAAC continue to strengthen our belief that CCR5-ZFNs are an important and promising class of anti-HIV compounds and may represent a "next generation" of HIV-entry blocking agents," said Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, and a co-author of the study. "I look forward to working with Sangamo to bring this program into the clinic as quickly as possible."

Sangamo's ZFNs are designed to permanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect cells of the immune system. Individuals carrying a naturally occurring mutation of their CCR5 gene, a variant known as CCR5-delta32, have been shown to be resistant to HIV infection.

"The data presented today are very significant," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Most importantly, we have demonstrated that a single treatment with our CCR5-specific ZFNs generates a population of HIV-resistant T-cells similar to the situation in individuals carrying the natural CCR5-delta32 mutation. We have shown that these ZFN-modified cells are made permanently resistant to HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections and HIV itself. In addition, we have reported on the successful ZFN-modification of clinical-scale quantities of human CD4 T-cells. The modified cells exhibited the expected properties of normal CD4 T-cells minus a functional CCR5 receptor. This demonstrates that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic which is our immediate goal for this ZFP Therapeutic."

Several major pharmaceutical companies have initiated programs to develop small molecule or antibody approaches to block the binding of HIV to CCR5. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. One such drug was recently approved by the US Food and Drug Administration with a "black box" warning, the strongest for prescription drugs, concerning the risk of liver toxicity and the possibility of heart attacks.

Sangamo's ZFN technology represents a means of potentially circumventing these limitations or risks by specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs. This results in permanent modification of the CCR5 protein so that HIV cannot enter and infect the cells. This approach could potentially enable the generation of a reservoir of protected CD4 T-cells that are available to fight the opportunistic infections that are characteristic of AIDS as well as the AIDS virus itself.

Data Reported in the ICAAC Presentation

The reported results demonstrate that a one-time exposure to CCR5-specific ZFNs resulted in the generation of an HIV-resistant population of human primary T-cells that permanently expressed disrupted CCR5 proteins. These ZFN-modified CD4 T-cells expanded stably in HIV-infected cultures for several weeks and appeared to behave identically to untreated T-cells except that they were resistant to infection by HIV. ZFN treated primary CD4 T-cells and transformed CD4 cell lines resisted infection with R5-tropic HIV, resulting in enrichment of ZFN-generated CCR5-disrupted cells in the population upon long-term exposure to virus (>70 days). Importantly, in the presence of HIV, ZFN-modified CD4 T-cells also preferentially expanded in a mouse model. The modified cells were infused into mice that lack a normal immune system and thus do not reject human cells. After 33 days, the mice were sacrificed and analyzed for the presence of ZFN-modified cells. Researchers determined that ZFN-modified cells engrafted normally in the mouse and that the proportion of modified cells present at the end of the experiment was greater than two to three fold higher in mice in the presence of HIV infection (which was statistically significant p=0.008). These data suggest that, in the presence of HIV, the ZFN-modified cells have a selective advantage and evade HIV infection and destruction.

In addition, researchers demonstrated successful ZFN-modification of clinical-scale quantities of human CD4 T-cells and that these modified cells exhibited the expected properties of normal T-cells. This demonstrates that ZFN-modified human CD4 T-cells could be produced in quantities required for the translation of this program into the clinic.

About HIV/AIDS and CCR5

HIV stands for Human Immunodeficiency Virus. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers resulting in AIDS (Acquired Immune Deficiency Syndrome). Individuals diagnosed with AIDS are susceptible to life-threatening diseases called opportunistic infections, which are caused by microbes that usually do not cause illness in healthy people. According to Worldaidsday.org, over 3 million people were infected with HIV in 2005. There are now over 40 million people living with HIV and AIDS worldwide.

CCR5 is the chemokine receptor that HIV uses as a co-receptor to gain entry into immune cells. CCR5 is perhaps the most important of the known co-receptors for HIV, since the most commonly transmitted strains of HIV are strains that bind to CCR5 -- so-called "R5" strains. A small fraction of the population carries a mutation in their CCR5 gene, called the delta32 mutation. This mutated version of the gene produces malformed CCR5 proteins, which cannot be used by HIV as a co-receptor. Individuals that have mutant delta32 versions of both of their CCR5 genes are resistant to infection by R5 HIV strains.

[getshorty]

Antwort auf Beitrag Nr.: 31.648.732 von benefactor am 18.09.07 19:29:32

Gehe davon aus, dass in den nächsten Tagen neu überarbeitete
Kursziele veröffentlicht werden!

Warten wir mal ab,
Gruß shorty

[tokajo]

Mal was älteres zum Nachdenken - Sirna war ein kleines
Biotec Unternehmen in der RNA Forschung mit ähnlichen Aufgabenziele wie unsere Sangamo.

Gruß Tokajo

Merck & Co. will Sirna Therapeutics für 1,1 Milliarden Dollar kaufen
01.11.2006 - (dpa-AFX) Merck & Co. will für 1,1 Milliarden US-Dollar das Biotechunternehmen Sirna Therapeutics kaufen. Merck biete 13 Dollar in bar je Aktie und wolle Sirna zu 100 Prozent übernehmen, teilte der Konzern in New York mit. Sirna-Aktien hatten den Handel am Montag mit einem Abschlag von 0,69 Prozent auf 6,45 Dollar beendet. Im nachbörslichen Handel schossen die Papiere um 92,71 Prozent auf 12,43 Dollar in die Höhe.

[tokajo]

Und die nächste Präsentation erfolgt am Mittwoch.

Gruß Tokajo

RICHMOND, Calif., Sept 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 3:00 pm (ET) on Wednesday, September 26, 2007 at the UBS 2007 Global Life Sciences Conference in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.667.226 von tokajo am 19.09.07 21:01:05

Hätte nichts dagegen wenns bei Sangamo auch so laufen würde!

[aktianer]

Antwort auf Beitrag Nr.: 31.670.621 von Magnetfeldfredy am 20.09.07 09:34:12

die Zusammensetzung des Aktionariats sieht lt. Yahoo folgendermaßen aus:

Major Holders

% of Shares Held by All Insider and 5% Owners: 11%
% of Shares Held by Institutional & Mutual Fund Owners: 30%
% of Float Held by Institutional & Mutual Fund Owners: 34%
Number of Institutions Holding Shares: 62

Lanphier selber hält indirekt ca. 1,74 Mio.Stück, also um die 4,3% rum.

http://finance.yahoo.com/q/mh?s=SGMO

[aktianer]

schöne Kursentwicklung kurz vor der Präsentation am 26.09.07.

Kurs hat mittlerweile die 14-Dollarmarke übersprungen.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.726.652 von aktianer am 24.09.07 18:31:53

Sangamo steigt auf neue Hochs, die Präsentation war anscheindend sehr gut!

[tokajo]

Antwort auf Beitrag Nr.: 31.751.965 von Magnetfeldfredy am 26.09.07 17:28:40

Warte erst mal ab. Die Präsentatin ist erst um 15 Uhr Ortzeit dort.
Schau dir vorab das aktuelle Factsheet auf der www.sangamo.com Seite an. Für Ende diesen Jahres sind mehrere Beantragung auf die PHase 1 geplant.
Im Vergleich zu den derzeitigen Explorerwahns sind wir hier erst ganz am Anfang.

PS. Schaut euch mal Global Green Inc (GGRN) an. War in meiner liebsten "Börsenzeitung" Technology Review ein interessanter Bericht über die Ölgewinnung aus Algen. Das Verfahren soll, bezogen auf die Fläche 100 x mehr Öl produzieren können, als die bisherigen Biodieselpflanzen.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.752.870 von tokajo am 26.09.07 18:23:45

Danke Tokajo!

Was hast Du ein persönliches Kurzziel für Sangamo?

Gruß

Magnetfeldfredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.753.339 von Magnetfeldfredy am 26.09.07 18:58:40

Muß natürlich heißen: Was hast Du für ein persönliches Kursziel? Sorry!

Klappt daß wirklich mit der Ölgewinnung aus Algen?

Gruß

[tokajo]

Antwort auf Beitrag Nr.: 31.753.372 von Magnetfeldfredy am 26.09.07 19:01:01

Ein Kursziel zu definieren ist m.E bei Sangamo schwer einzustufen. Hängt alles vom Erfolg ihrer Technologie ab. Wenn man daran glaubt und alles funktioniert halte ich Kursziele für Ende 2008 von 45 $ für durchaus realistisch.

zu Global Green findest du auf der www.heise.de/tr bald Infos, oder gehe doch mal in den Bahnhofszeitschriftenladen.
Auf der Homepage von http://www.globalgreensolutionsinc.com/s/Home.asp ist ebenfalls das Verfahren beschrieben.

Gruß Tokajo

[tokajo]

Habt ihr die Präsenation bereits angehört. Edward Lanphier spricht hier mit einer solchen Begeisterung für seine Forschungsprojekte und verspricht Ende Oktober weitere bahnbrechende News.

25 Minuten die jeder Investor für Sangamo übrig haben sollte.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.774.891 von tokajo am 28.09.07 12:23:26

Servus Tokajo,

ist das auf www.sangamo.com zu hören, oder wo hast Du das her?

Danke, super Infos von Dir, danke!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.776.932 von Magnetfeldfredy am 28.09.07 14:49:03

Na auf www.sangamo.com habe ich nur gefunden, daß die PRÄSENTATION ca. 14 Tage später auf der Homepage abzurufen ist.
Hast Du einen anderen Link?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.777.039 von Magnetfeldfredy am 28.09.07 14:55:02

Juhu, ich habs selber gefunden, auf dem Link Investor unter Presentation!
Sehr interessant, da steckt viel Potenzial drin, aber von bahnbrechenden News habe ich nichts gehört, was soll das sein, oder ist mein Buissens Englisch zu schlecht?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.774.891 von tokajo am 28.09.07 12:23:26

Die Präsentation hat auch die Analysten begeistert, Kursziel US DollarRating-Update: Vancouver (aktiencheck.de AG) - Die Analysten von Canaccord Adams stufen die Aktie von Sangamo BioSciences (ISIN US8006771062/ WKN 936386) unverändert mit "buy" ein. Das Kursziel werde von 13,10 auf 20 USD angehoben. (27.09.2007/ac/a/u) 20!

[aktianer]

Antwort auf Beitrag Nr.: 31.778.324 von Magnetfeldfredy am 28.09.07 16:05:10

hab gerade den gesamten Text zu deinem vorher geposteten Kursziel gefunden, ineresssant sind auch die Termine für das Restjahr:

For FULL easier to read version of this Canaccord Adams report see this link:

http://www1.investorvillage.com/smbd.asp...

Can Adams-"SGMO LOOKING TO QUICKLY MOVE UP VALUE CHAIN; RAISING $13.10 TARGET TO $20.. increasingly strong fundamentals&positive data&collaborative news flow, which we expect to continue over the next year. 6 key upcoming events. Analyst Day Dec 5 in NY"

26 September 2007-Canaccord Adams-Sangamo BioSciences

Target: US$20.00 ­

LOOKING TO QUICKLY MOVE UP VALUE CHAIN; RAISING TARGET

Event

Sangamo’s shares have seen considerable strength as of late after several positive news events. We are raising our 12-month price target from US$13.10 to US $20.00.

Impact

Our upward revision of our target is based on what we perceive to be increasingly strong fundamentals and positive data and collaborative news flow, which we expect to continue over the next year. Primary focus of our valuation remains on the SB-509 program for diabetic neuropathy (DN); however, we expect the clinical pipeline to quickly grow into multiple therapeutic indication opportunities. We expect continued progress for the lead clinical program in diabetic neuropathy, with added Phase 1b data in early November 2007 and completion of enrollment of both Phase 2 trials expected by YE/07. In addition, we expect the impending start of two Phase 1 studies for HIV and glioblastoma.

We also believe that the company’s news flow surrounding nontherapeutic alliances, such as Dow AgroSciences, Sigma Aldrich, and Genentech engineering alliance, should continue to bear both fundamental and financial fruit.

Valuation

We reiterate our BUY rating. We use our probability-weighted NPV model to obtain our new US$20.00 price target. With the potential for both clinical development and business development news flow in the next 12 months, we believe Sangamo’s shares warrant a higher valuation.

EXPECT CONTINUED STRENGTH ON UPCOMING CATALYSTS

Sangamo’s shares have seen considerable strength as of late after several positive news events. We are raising our 12-month price target from US$13.10 to US$20.00. Our upward revision of our target is based on what we perceive to be increasingly strong fundamentals and positive data and collaborative news flow, which we expect to continue over the next year. Primary focus of our valuation remains on the SB-509 program for diabetic neuropathy (DN); however, we expect the clinical pipeline to quickly grow into multiple therapeutic indication opportunities. We expect continued progress for the lead clinical program in diabetic neuropathy, with added Phase 1b data in early November 2007 and completion of enrollment of both Phase 2 trials expected by YE/07. In addition, we expect the impending start of two Phase 1 studies for HIV and glioblastoma.

We also believe that the company’s news flow surrounding non-therapeutic alliances, such as Dow AgroSciences, Sigma Aldrich and Genentech engineering alliance, should continue to bear both fundamental and financial fruit.

Upcoming events

1. Updated Phase 1b DN data at the Society for Neuroscience meeting in San Diego (November 3-7). Incremental data will be presented on additional patients in the study as well as three other preclinical presentations;

2. In late October during the company’s quarterly conference call, we expect to receive a comprehensive update on the company’s clinical plans across the pipeline;

3. On December 5, Sangamo will host an Analyst Day in New York;
4. In H2/07, we expect the completion of enrollment of both ongoing Phase 2 studies using SB-509 for DN;

5. We expect the impending initiations of two Phase 1 programs for HIV and glioblastoma relatively shortly;

6. Once SB-509 Phase 2 data is released in 2008, we fully expect Sangamo to partner with a major pharmaceutical firm with an existing sales force in the diabetic arena.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.779.712 von aktianer am 28.09.07 17:29:23

Super recherchiert!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.781.993 von Magnetfeldfredy am 28.09.07 20:01:01

Neuer positiver Artikel:

Welcome back to the Mailbag, which unfortunately was closed most of the week because I was in New York at the UBS Global Life Sciences Conference.
I'll return to your emails next week, but in the meantime, here are some reports and updates from the conference. This week:


Sangamo BioSciences (SGMO - Cramer's Take - Stockpickr - Rating)

Medarex (MEDX - Cramer's Take - Stockpickr - Rating)

Dendreon (DNDN - Cramer's Take - Stockpickr - Rating)

Telik (TELK - Cramer's Take - Stockpickr)

Encysive Pharmaceuticals (ENCY - Cramer's Take - Stockpickr - Rating)


--------------------------------------------------------------------------------

Two institutional investor friends of mine brought up Sangamo this week in separate conversations. On the same day, my BlackBerry buzzed with an email from a retail investor and InvestorVillage.com message board poster informing me that he had "upgraded" Sangamo to "possibly the next Celgene (CELG - Cramer's Take - Stockpickr - Rating), but definitely the next Alnylam (ALNY - Cramer's Take - Stockpickr - Rating)."

I haven't thought much about Sangamo since writing about the company in early August, so I looked at the chart and was surprised to see the stock's move from $10 to $14.

Memo to James Altucher: Sangamo is a rocket stock!

All kidding aside, Sangamo does have an interesting story to tell. As I described back in August, the company is engineering protein "switches" called zinc fingers that can turn genes on or off. It's similar to the work being done with RNA interference, or RNAi, with one big difference: RNAi can only turn genes off while zinc finger proteins have the ability to turn genes on and off.

[tokajo]

Antwort auf Beitrag Nr.: 31.832.602 von Magnetfeldfredy am 03.10.07 17:22:23

Neue Präsentation beim Bio Investorforum http://investorforum.bio.org/opencms/bif/2007/companyInfo/pr…

Gruß Tokajo

Sangamo BioSciences to Present at the 2007 BIO InvestorForum

RICHMOND, Calif., Oct 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Philip Gregory, D.Phil., Sangamo's vice president of research, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:45pm (PT) on Wednesday, October 10, 2007 at the BIO InvestorForum in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.842.213 von tokajo am 04.10.07 14:42:34

Servus Tokajo,

auf zu neuen Höhen, und sollte die Zulassung wirklich klappen könnte es ein Vervielfacher werden, aber nicht zu euphorisch werden, oder?

Gruß

Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.847.064 von Magnetfeldfredy am 04.10.07 20:06:35

Sangamo steigt stark an, Bericht über Nobelpreis für Forscher die gezielt Gene ausschalten können, das kann auch Sangamo!

[toynet]

Antwort auf Beitrag Nr.: 31.903.677 von Magnetfeldfredy am 08.10.07 20:57:00

Wo arbeiten die beiden denn? Habe nichts finden können? Und wer kann das denn noch außer Sangamo?

TN

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.904.338 von toynet am 08.10.07 22:07:28

Keine Ahnung wo die arbeiten, bei mir nicht! Spaß beiseite, Sangamo ist mit der Zink-Finger-Methode schon führend, aber Tokajo ist Experte, der kann Dir besser helfen als ich, ich halte Sangamo für eine potentiellen Vervielfacher!

[toynet]

Antwort auf Beitrag Nr.: 31.904.620 von Magnetfeldfredy am 08.10.07 22:44:23

wenn sie nicht vorher einkassiert werden. Die Frage ist wer käme dafür in Frage?

TN

[tokajo]

Antwort auf Beitrag Nr.: 31.904.620 von Magnetfeldfredy am 08.10.07 22:44:23

Mario Capecci arbeitet an der University of Utahhttp://capecchi.genetics.utah.edu/

Der große Unterschied zu Sangamo ist, einfach gesagt, das Sangamo die Gene auch wieder einschalten kann.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.909.697 von tokajo am 09.10.07 13:41:31

Servus Tokajo,

glaubst Du auch an eine evtl. Übernahme wie von anderen Boardteilnehmern angesprochen?
Morgen ist wieder eine Präsentation, gute News könnten den Kurs meiner Meinung nach bis auf 20 US Dollar hieven, oder?

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 31.913.163 von Magnetfeldfredy am 09.10.07 16:48:31

Hi Fredy,

hatte ich kürzlich bereits schon mal angedeutet.
s. nochmals mein Posting vom 19.09 weiter unten.


Sangamo ist derzeit nur mit 600 Mio Dollar bewertet. Das Potential schätze ich auf ein Vielfaches der derzeitigen Marktkapitalierung ein. Große Entwicklungspartner sind bereits an Bord.
In der Regel übernehmen die grossen Konzerne kleine innovative Unternehmen. Wird auch erwünscht, da den kleinen oftmals die Gelder nicht reichen. Wann der Zeitpunkt einer Übernahme erfolgt kann ich nicht beurteilen


Gruß Tokajo

Mal was älteres zum Nachdenken - Sirna war ein kleines
Biotec Unternehmen in der RNA Forschung mit ähnlichen Aufgabenziele wie unsere Sangamo.

Gruß Tokajo

Merck & Co. will Sirna Therapeutics für 1,1 Milliarden Dollar kaufen
01.11.2006 - (dpa-AFX) Merck & Co. will für 1,1 Milliarden US-Dollar das Biotechunternehmen Sirna Therapeutics kaufen. Merck biete 13 Dollar in bar je Aktie und wolle Sirna zu 100 Prozent übernehmen, teilte der Konzern in New York mit. Sirna-Aktien hatten den Handel am Montag mit einem Abschlag von 0,69 Prozent auf 6,45 Dollar beendet. Im nachbörslichen Handel schossen die Papiere um 92,71 Prozent auf 12,43 Dollar in die Höhe.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.913.388 von tokajo am 09.10.07 17:00:28

Danke, die Zukunft schaut auf alle Fälle sehr rosig aus!

[toynet]

Antwort auf Beitrag Nr.: 31.913.388 von tokajo am 09.10.07 17:00:28

Hallo tokajo,

war Sirna auch so breit aufgestellt bzgl. Partner, wie ich das aus der Liste aus Investorvillage von Anfang September sehe, da ist ja alles dabei was Rang und Namen hat.

Wer wird denn dann der Glückliche, bei dem die ganzen Mitbewerber dann ihr Geld reinstecken dürfen?

Gruß

TN

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.913.388 von tokajo am 09.10.07 17:00:28

Servus Tokajo,

hast Du schon was von der heutigen Präsentation in San Francisco mitbekommen, mein Live-Stream funktioniert leider nicht!

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 31.931.873 von Magnetfeldfredy am 10.10.07 21:31:25

Sorry, hatte noch nicht reingehört.

Ab Morgen oder übermorgen wird die Präsentation aber auf der Webseite zum nachhören sein. Im Vergleich zur letzten Präsentation, die erst vor kurzem stattfand, dürfte jedoch nichts neues drin stehen.

Gruß Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 31.934.111 von tokajo am 11.10.07 07:58:45

Habe mir soeben die aktuelle Präsentation auf der Sangamo Homepage angesehen.

Ich muß mich korrigieren. Dort sind doch viele Neuigkeiten aufgeführt.
U.a Vergleich zum Wettbewerb mir RNAi Technology.
Update zur aktuellen Forschung insbesondere Aids
Vorstellung der aktuellen Partnerprogramme mit Dow, Pfizer, Sigma Aldrich, Genentech und anderen.

Lohnt sich

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.944.031 von tokajo am 11.10.07 18:51:40

Sangamo erklimmt neue Hochs, 16 US Dollar, trozt eines schwächelnden DOW Jones!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.944.031 von tokajo am 11.10.07 18:51:40

Sangamo wurde heute von Pacific Growth Equities erstmals gecoverd, mit Rating "buy"!
Jedoch kann ich das angegebene Kursziel nicht finden?
Weißt Du mehr?
Gruß Fredy

[tokajo]

Antwort auf Beitrag Nr.: 32.050.064 von Magnetfeldfredy am 17.10.07 16:55:02

Hi Magnetfeldfredy,

habe auch nur die Info vom Wallstreetreporter. Für ein neues ATH 15,70 $ hat es auf alle Fälle gereicht. So macht Börse Spass.

Gruß Tokajo.

[tokajo]

Antwort auf Beitrag Nr.: 32.050.393 von tokajo am 17.10.07 17:06:01

Sorry Tippfehler,

meinte 16,70. Entschuldigung an alle 20 Investierten.

Gruß Tokajo

[cultom4president]

21 Investierte!

Pacific Growth Starts Sangamo Biosciences (SGMO) at Buy
10/17/2007 08:54EDT by StreetInsider.com
Pacific Growth initiates coverage on Sangamo Biosciences, Inc. (NASDAQ: SGMO) with a Buy rating.

Sangamo BioSciences is engaged in the research, development and commercialization of deoxyribonucleic acid (DNA)-binding proteins for the therapeutic regulation and modification of disease-related genes.

Ein Kursziel wurde noch nicht genannt, denke aber das die 20USD noch in diesem Jahr erreicht werden!

cultom

[tokajo]

Sangamo BioSciences Announces Third Quarter 2007 Conference Call

RICHMOND, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. SGMO today announced that the company will release its third quarter 2007 financial results on Wednesday, October 24, 2007 after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters. The conference call dial-in numbers are 877-440-5788 for domestic callers and 719-325-4887 for international callers. The passcode for the call is 4209173. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under 'Events and Presentations'. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8.00 p.m. ET on October 24, 2007 to October 31, 2007. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820, respectively. The conference ID number for the replay is 4209173. The webcast will be available on the Sangamo website for two weeks after the call. About Sangamo Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com. This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, clinical trials, therapeutic applications of Sangamo's ZFP technology platform and use of proceeds. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.060.136 von tokajo am 18.10.07 08:25:13

Servus Tokajo,

Sangamo ist "in", steigt und steigt, kommt nochmals ein Rückschlag?

Gruß Fredy

[cultom4president]

Welche Erwartungen stellt ihr an den CC am 24.10.?

cultom

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.060.136 von tokajo am 18.10.07 08:25:13

Servus Tokajo,

der Taipan empfiehlt in seiner neuesten Ausgabe Sangamo zum spekulativen Kauf mit 2 Jahreskursziel von US Dollar 50!!!!!!

Gruß

Fredy

[tokajo]

Hallo zusammen, die Zahlen zum 3.Quartal sind da. Einen Kommentar hierzu spare ich mir. Erstens bin ich in der Materie zu wenig drin und zweitens sind die Zahlen im derzeitigen Ausbaustadium wenig aussagekräftig. Steigende Kurse werden es zeigen.

Gruß Tokajo

Sangamo BioSciences Reports Third Quarter 2007 Financial Results

RICHMOND, Calif., Oct 24, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported financial results for the third quarter ended September 30, 2007. Revenues for the third quarter of 2007 were $2.3 million as compared to third quarter 2006 revenues of $1.8 million. Third quarter 2007 revenues were primarily from Sangamo's agreements with Dow AgroSciences (DAS), Sigma-Aldrich Corporation, private foundation research grants, and enabling technology agreements in protein production.

The consolidated net loss for the quarter ended September 30, 2007 was $4.3 million, or $0.11 per share, as compared to a net loss of $2.8 million, or $0.08 per share, in the same period of 2006. At September 30, 2007, the Company had cash, cash equivalents and investments of $84.2 million.

Total third quarter 2007 operating expenses were $7.6 million as compared to $5.4 million in the prior year period. Research and development expenses were $5.9 million for the three months ended September 30, 2007 as compared to $3.9 million for the third quarter of 2006. General and administrative expenses were $1.7 million for the three months ended September 30, 2007 and $1.6 million for the third quarter of 2006. The increase in expenses for the third quarter of 2007 was primarily associated with the Company's clinical program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased personnel and lab supply expenses due to increased headcount in the Research and Development departments.

During the third quarter of 2007, Sangamo entered into a license agreement with Sigma-Aldrich under which Sangamo received $13.5 million, which was comprised of an equity investment by Sigma of Sangamo's common stock valued at $8.55 million, a $3.95 million license fee and $1.0 million of research funding. Sangamo plans to recognize the $1.0 million of research funding over a 12 month period and the $3.95 million license fee over the entire 36 month research period of the agreement.

Net interest and other income for the third quarter of 2007 was $1.1 million as compared to $798,000 in the comparable period of 2006.

Recent Highlights -- Establishment of major alliance with Sigma-Aldrich Corporation to develop and commercialize high value laboratory research reagents based upon Sangamo's zinc finger DNA binding protein technology. In July 2007, as part of the agreement, Sangamo received an upfront payment of $13.5 million which included license fees and the purchase of one million shares of Sangamo stock. Sangamo is also eligible to receive development and commercial milestone payments of up to $24 million and royalties on product sales. -- Sangamo closed a registered direct offering to institutional investors. In July 2007, Sangamo sold an aggregate of 3,278,689 shares of common stock to a group of institutional investors in a registered direct offering, resulting in gross proceeds to the company of approximately $30.0 million before fees and expenses. -- Presentation of in vivo protection data from ZFN HIV Program at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Sangamo scientists presented data demonstrating that human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)) and preferentially survive and expand in an animal after HIV infection. In addition, they reported on the successful ZFN-modification of clinical-scale quantities of human CD4 T-cells. -- Dow Chemical Company highlights Sangamo technology. In a September teleconference hosted by the Dow Chemical Company (Dow), the CEOs of both Dow and Dow AgroSciences described their enthusiasm for Dow's successful partnership with Sangamo, the power of Sangamo's ZFP technology and its potential role in Dow's future.
Nine-Month Results

For the nine-month period ended September 30, 2007 the consolidated net loss was $14.8 million, or $0.41 per share, compared with a consolidated net loss of $8.9 million, or $0.28 per share, in the comparable period in 2006. Revenues for the nine months ended September 30, 2007 were $6.3 million as compared to $5.7 million in the same period of 2006. Total expenses for the nine months ended September 30, 2007 and 2006 were $23.5 million and $16.6 million, respectively. The increase in total expenses for the nine month period ended September 30, 2007 was primarily associated with our clinical program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased personnel headcount and lab supply expenses in the Research and Development departments.

Conference Call and Webcast

Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-440-5788 for domestic callers and 719-325-4887 for international callers. The passcode for the call is 4209173. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations". For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 24, 2007 to October 31, 2007. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820, respectively. The conference ID number for the replay is 4209173. The webcast will be available on the Sangamo website for two weeks after the call.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, eligibility to receive development, milestone and royalty payments, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SELECTED FINANCIAL DATA (in thousands, except per share data) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2007 2006 2007 2006 Consolidated Statement of Operations Data: Revenues $2,325 $1,779 $6,331 $5,692 Operating expenses: Research and development 5,916 3,853 17,655 11,470 General and administrative 1,728 1,569 5,840 5,145 Total operating expenses 7,644 5,422 23,495 16,615 Loss from operations (5,319) (3,643) (17,164) (10,923) Interest income, net 1,051 798 2,356 2,007 Net loss $(4,268) $(2,845) $(14,808) $(8,916) Basic and diluted net loss per common share $(0.11) $(0.08) $(0.41) $(0.28) Shares used in computing basic and diluted net loss per common share 38,925 33,939 36,387 31,960 CONSOLIDATED CONDENSED BALANCE SHEET DATA September 30, December 31, 2007 2006 Cash, cash equivalents, and investments $84,156 $53,975 Total assets 86,344 55,780 Total stockholders' equity 75,824 48,705
SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.142.436 von tokajo am 25.10.07 08:29:38

Guten Morgen Tokajo,

die Zahlen sind ok, etwas weniger Verlust als geschätzt, dafür etwas weniger Umsatz, jedoch die Phantasie in Sangamo ist meiner Meinung nach gigantisch, jedoch auch das Risiko!
Der Taipan-Aktienbrief empfiehlt ja Sangamo mit Kursziel US Dollar 50!! auf 2-3 Jahressicht!
Schönen Tag!

[tokajo]

Antwort auf Beitrag Nr.: 32.142.528 von Magnetfeldfredy am 25.10.07 08:40:07

Hi Fredy,

hast du das Webcast bereits angehört. Insbesondere die Vorstellung der neuen Clinical Trials und die Terminvorschau zur Ergebnispräsentation lassen gutes erahnen. Für einen Biotec-Wert fühle ich mich dort gut aufgehoben.

Gruß Tokajo.

Bin leider erst mal 4 Tage auf Messe in Düsseldorf.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.146.453 von tokajo am 25.10.07 13:11:55

Was machst Du denn beruflich? Ich bin Fußballakrobat, im ernst, mehr unter: www.fussballshow.de
Jetzt höre ich mir mal die Webcast an und morgen habe ich eine Show in Stuttgart!

Gruß

Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.146.453 von tokajo am 25.10.07 13:11:55

Sangamo erklimmt neue Jahreshochs, suuuuuuuuuuuuuuuuuuuuuuuuper!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.152.067 von Magnetfeldfredy am 25.10.07 18:35:50

Sangamo auch in der Stammzellenforschung mit großen "Ambitionen"!
Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Monday October 29, 7:00 am ET
Application of ZFN Technology in Stem Cells has Potential to Yield High Value Research Reagents and Therapeutic Products


ST. LOUIS and RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL - News) and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the publication of data demonstrating the use of Sangamo's ZFP Nucleases (ZFNs) for "gene-editing" in human stem cells. This work represents a significant advance in the ability to specifically and efficiently modify the human genome in stem cells potentially enabling the efficient generation of stem cell lines for use as models of human disease for medical research and for drug testing. In addition to its use in the generation of valuable research reagents, the technology has potential in the therapeutic application of stem cells.
ADVERTISEMENT


The work, which was carried out in the laboratory of Luigi Naldini, M.D., Ph.D. at the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy, in collaboration with Sangamo scientists, was published in Nature Biotechnology as an advance online publication (http://www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt1353.…

"This is a significant advance for both research and the potential therapeutic use of stem cells," stated Dr. Naldini, a senior author of the study. "Stem cells are the body's natural resource for regeneration and repair and the ability to efficiently add a therapeutic gene into the genome of a cell at a predetermined location or to correct a mutated gene in a patient's stem cells may enable us to provide a long term solution for many genetic diseases. The powerful combination of our highly efficient delivery platform and Sangamo's ZFN technology made possible unprecedented gene modification efficiency in these therapeutically important cells".

The data published in the Nature Biotechnology paper demonstrate that ZFN-mediated gene modification can be used to correct both mutations in the IL-2R gamma gene, the defective gene in X-linked severe combined immunodeficiency (X-linked SCID), and to add a therapeutic gene to a pre-determined 'safe-harbor' site in the genome of both human hematopoietic stem cells and human embryonic stem (ES) cells. This putative 'safe-harbor site' was selected by the investigators for its capacity to allow efficient expression of the therapeutic gene and to tolerate an insertion event without adverse effects.

"These data open new avenues for experimental biology, biotechnology and medicine," said Philip Gregory, D.Phil., Sangamo's vice president of research. "This year's Nobel Prize for Medicine recognized the importance of gene targeting, or the site specific manipulation of the mouse genome, which has revolutionized biology and enabled the generation of mouse cell-lines and transgenic mouse models of human disease. However, until now and the development of our ZFN technology, genomes of other species such as humans and plants could not be efficiently modified in a site specific manner. Our ZFN technology enables the specific and targeted modification of any genome of potentially any species and may enable the development not only of potential therapeutics but also human cell lines and transgenic animals bedsides the mouse that may be valuable models of human disease for medical research and drug development."

"This publication represents ground-breaking research in the use of ZFNs and stem cells. Sigma's aim is to enable this kind of cutting-edge science by making innovative technologies available to scientists throughout the world," stated David Smoller, Ph.D., President of Sigma-Aldrich's Research Biotech Unit. "This work demonstrates the specificity and efficiency with which Sangamo's ZFN technology platform can be used to correct and add DNA sequences into the genomes of living cells and is further proof of its power and broad applicability. The ZFN technology has potential applications in the rapid generation of both modified stem cells and somatic cell lines that can be used at multiple stages of disease research and drug development. We expect to have ZFN research reagents similar those used in this publication available to all research scientists in the very near future."

About ZFPs

ZFPs are the dominant class of naturally occurring proteins known as transcription factors and are found in the nucleus of every cell. They bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that can recognize a specific DNA sequence, Sangamo scientists have created ZFP nucleases or ZFNs(TM) that facilitate efficient and highly specific gene modification and ZFP transcription factors or ZFP TFs(TM) that specifically control gene expression and consequently, cell function. Scientists at Sigma-Aldrich and Sangamo will use ZFNs like precision "surgical instruments" to modify genes in cells and to develop and market ZFP products for broad use in numerous laboratory research reagent applications. Among the anticipated applications are cell lines with enhanced protein production performance, panels of knock-out cell lines for drug discovery, as well as novel stem cell and transgenic animal models.

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,800 employees providing excellent service worldwide. We are committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more

information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sigma-Aldrich's and Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFNs, and potential therapeutic, medical research and drug development uses of the ZFN technology. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and Sigma-Aldrich to develop commercially viable products and technological developments by our competitors. See the SEC filings, and in particular, the risk factors described in the Annual Report on Form 10-K and its most recent 10-Q of each of Sangamo and Sigma-Aldrich. Neither Sigma-Aldrich nor Sangamo assumes any obligation to update the forward-looking information contained in this press release.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.186.216 von Magnetfeldfredy am 29.10.07 12:14:12

Sangamo Shares Rise on Study Data
Monday October 29, 12:37 pm ET
Sangamo Biosciences Shares Rise to 52-Week High on Positive DNA Technology Study


NEW YORK (AP) -- Shares of Sangamo Biosciences Inc. rose to a new 52-week high Monday after the company cited study data showing its DNA technology could be used for gene modification.
The stock rose $1.91, or 11 percent, to $19.34 in midday trading. Shares reached a 52-week high of $19.82 earlier in the trading session, topping a previous 52-week peak of $17.46.

ADVERTISEMENT


Data from a study published in the journal Nature Biotechnology indicated the company's ZFN-mediated gene modification can be used to correct genetic mutations linked to immunodeficiency, and as an addition to the genome of stem cells. The data holds the possibility for the creation of new lines of stem cells that can be used as models for human disease and for medical research and drug testing, according to the company.

Sangamo is working to modify zinc finger DNA-binding proteins in order to modify genes and cell function. The company is partnering with Sigma-Aldrich Corp. in developing the technology.

Pacific Growth Equities analyst Liana Moussatos said the company's technology, combined with stem cell technology, has the potential to regenerate damaged organs and spinal tissue.

The company has the potential for peak annual royalties of over $150 million, she said.

Shares of Sigma-Aldrich rose 22 cents to $50.54.

[toynet]

Antwort auf Beitrag Nr.: 32.114.546 von Magnetfeldfredy am 22.10.07 22:24:43

Den Wert hatten sie vor einem 3/4 Jahr schon mal empfohlen, der ist aber dann im März durch den SL rausgefallen. Sie sind wenigstens ehrlich und schreiben das auch.

Wer nicht verkauft hat kann sich heute doppelt freuen.

Ich sehe in dem Was sie entwickeln eine zukunftsweisende Technologie, den Nobelpreis gibt es ja nicht für Kleinigkeiten. Das sieht man ja an den Weiterentwicklungen für den Nobelpreis für die Forscher im Forschungszentrum in Jülich, die Weiterentwicklung der Ergebnisse ist dort schon umgesetzt und jeder findet es in seinem PC wenn es nicht ´ne ganz alte Gurke ist. Bei den Festplatten war es jedenfalls eine. Das sehe ich alles noch nicht zu Ende gedacht, was damit möglich wird.

Ich meine wir werden noch viel Freude hier haben, und vielleicht mag der eine oder andere auch noch mal davon profitieren, und das nicht nur auf dem Konto. Ich hoffe nur sie werden nicht zu früh geschluckt.

Nur meine ganz persönliche Meinung.

TN

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.196.769 von toynet am 29.10.07 22:26:41

Ja mit Sangamo kann man zur Zeit gut Geld verdienen, ich rechne aber nach dem steilen Anstieg auch mit einer baldigen Konsolidierung und vor einer Übernahme müßen die Phase II Studien voll überzeugen, oder?

[aktianer]

Antwort auf Beitrag Nr.: 32.221.483 von Magnetfeldfredy am 31.10.07 17:32:35

interessanter Biotech-Blog von Dr.Josef Strohmeier, u.a. auch mit Beiträgen zu Sangamo:

http://www.mastertraders.de/biotech/?cat=22

[toynet]

Antwort auf Beitrag Nr.: 32.221.483 von Magnetfeldfredy am 31.10.07 17:32:35

Laß uns mal die nächsten Zahlen abwarten, eine Konsi sehe ich auch als als nötig an.

Sie haben viele Partner, wieviel Umsatz auf wen entfällt kann ich nicht ermessen. Im Agrarbereich haben sie ja wohl schon etwas bewirkt. Es bleibt abzuwarten wie weit sich das auf anderes auch noch umsetzen läßt. Ich sehe sie im Trend, es sollte also noch eine Zeit gut weiterlaufen, aber auch mit Zwischenstopps.

Bis jemand einfällt etwas noch ganz anderes zu versuchen.

Also erst mal die nächsten Zahlen, und dann schauen wir weiter.

TN

[toynet]

Antwort auf Beitrag Nr.: 32.223.937 von aktianer am 31.10.07 20:00:54

Danke für den blog

TN

[tokajo]

Antwort auf Beitrag Nr.: 32.148.061 von Magnetfeldfredy am 25.10.07 14:56:42

Hi Fredy,

bin zurück. Wie ich sehe hat sich Sangamo in der Zeit schön weiterentwickelt.

Beruflich bin ich im Vertrieb für eine Hamburger Firma in Baden Württemberg in Sachen Kunststoff unterwegs.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.252.182 von tokajo am 02.11.07 11:48:28

Servus Tokajo,

dann wär ja mein "Geheimtipp" Lumera auch interessant für Dich, die stellen auf Nano-Polymer-Basis die schnellsten drahtlosen Modulatoren her und haben einen Proteomic-Prozessor entwickelt der "revolutinär" sein wird, wär auch was für unsere Sangamo Proteine, oder?

[tokajo]

Eine neue Studie zur Verringerung der Schmerzen bei Krebspatienten wurde positiv vorgestellt. Es kann nur weiter aufwärts gehen.

Gruß Tokajo

Sangamo BioSciences Presents Postive Data Showing Pain Reduction by Novel ZFP Therapeutic at Society for Neuroscience Meeting

SAN DIEGO, Calif., Nov 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data demonstrating that treatment with a zinc finger DNA-binding protein (ZFP) Therapeutic targeting TrkA, a validated pain receptor, significantly reduced the perception of pain in a mouse model of bone cancer pain. The presentation of in vivo data from this novel therapeutic program was made at Neuroscience 2007, the 37th annual meeting of the Society for Neuroscience in San Diego.

"These positive, proof of principle data highlight the potential for our ZFP technology in the treatment of chronic pain," commented Philip Gregory, D. Phil. Sangamo's vice president of research. "The TrkA-NGF pathway is a well- validated pain target which is the focus of intense effort for the development of new pain therapeutics. Our approach of targeting TrkA at the DNA level using a ZFP repressor delivered directly into the relevant tissue, the affected nerve, derives specificity at two levels and thus avoids possible non-specific effects of a systemic treatment."

Sangamo has developed a ZFP transcription factor (ZFP TF) that represses the expression of the TrkA receptor (neurotrophic tyrosine kinase receptor type 1). TrkA is a high affinity receptor for nerve growth factor (NGF) and has been demonstrated to have a role in pain perception. Mutations in the TrkA gene have been shown to be responsible for congenital insensitivity to pain with anhidrosis (CIPA), a rare genetic disorder characterized by a lack of pain sensation.

"Persistent pain, particularly pain associated with certain cancers, remains an unmet medical need," stated Edward Lanphier, Sangamo's president and chief executive officer. "Approved analgesic approaches have drawbacks. For example, opioids, which are widely prescribed to treat cancer pain, have side-effects that significantly affect a patient's quality of life. There is an urgent need to develop more specifically efficacious drugs directed against new molecular targets, which has thus far proven difficult. We believe that by 'turning off' the expression of pain receptors directly in the affected tissue, our ZFP Therapeutics potentially have significant advantages over approaches that are currently available and under development."

Data Reported in the Neuroscience 2007 Presentation

The reported results demonstrate that Sangamo's ZFP TF represses expression of TrkA in cells in culture. ZFP TF treated cells no longer respond to nerve growth factor stimulation demonstrating that the expression of the TrkA receptor has been turned off. To test whether ZFP-mediated TrkA repression can block pain signaling in a mouse model of bone cancer pain, scientists delivered a gene encoding the ZFP TF using a modified, non-replicating vector derived from the herpes virus (HSV). HSV enables specific and efficient delivery to local nerves (specifically the dorsal root ganglia) through skin injection.

Mice with experimental bone cancer in the right limb were subcutaneously injected in the right foot pad with ZFP TF TrkA-repressor, or positive or negative control vectors and pain behavior assessed one and two weeks later. Pain was assessed in two ways; using a subjective spontaneous ambulatory pain score (SAPS) and via measurement of mechanical allodynia (MA). Tumor-bearing mice inoculated with the ZFP vector had statistically significantly reduced SAPS and MA at both the 1- and 2-week time points compared to tumor-bearing control animals.

Abstract # 904.23/AA27: "An Engineered Zinc Finger Protein Transcriptional Repressor of TrkA Reduces Nociception in a Mouse Model of Bone Cancer Pain"

*H. S. Zhang(1), D. Krisky(2), A. R. McNamara(1), Y. Jouvenot(1), S. Tan(1), S. Huang(3), D. Wolfe(2), J. B. Wechuck(2), S. K. Spratt(1), J. C. Glorioso(3), P. D. Gregory(1), J. R. Goss(3)

(1) Sangamo BioSciences Inc., Richmond, CA; (2) Diamyd Inc., Pittsburgh, PA (a wholly-owned subsidiary of Diamyd Medical, Stockholm, Sweden); (3) Dept. of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA.

About Chronic Pain

As many as 90 million people in the United States suffer from pain with as many as 8 million suffering from severe chronic pain and a further 3 million suffering from severe cancer-related pain. Studies have shown that 90% of patients with advanced cancer experience severe pain, and that pain occurs in 30% of all cancer patients regardless of the stage of the disease. The most common cancer pain is from tumors that metastasize to the bone, the second most common cancer pain is caused by tumors infiltrating nerves. Effective management of such pain remains inadequate. The few drugs currently being used can have very significant side effects and severely affect a patient's quality of life. Chronic pain is a major and underserved market opportunity. The discovery of several new pain-related pathways and drug targets has increased the pharmaceutical industry's focus on this area.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com/

Copyright (C) 2007 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.290.368 von tokajo am 05.11.07 13:44:26

Wollte ich auch gerade reinstellen, hört sich super an, jedoch wie lange dauert es bis man die Technologie an Menschen erfolgreich anwenden kann?
Viele Grüße

Fredy

[getshorty]

Melde mich nach längerer Zeit wieder mal-
mit guten Neuigkeiten!

Gruß shorty

JMP Securities ....Biotechnology–Update....November 5,2007
Sangamo BioSciences, Inc. (1)

SB509 Market Potential in Diabetic Neuropathy — Give Me a “B”! Reiterate STRONG BUY raising price target from $20 to $30

INVESTMENT HIGHLIGHTS

• We find that Sangamo’s diabetic neuropathy program represents a billion-dollar opportunity; reiterating Strong Buy and raising price target from $20 to $30.

With clinical data anticipated to provide further proof of concept (Phase 1b this week, Phase II in late 1H08), we conducted a thorough analysis of the diabetic neuropathy (DN) market. As a result of evaluating the competitive environment and unmet medical need, we now believe SB-509, with its novel mechanism of action and potential disease-m odifying activity, could achieve blockbuster revenues for Sangamo. While we view SB-509 as a platform unto itself, with clinical and preclinical programs in several vascular and neurodegenerative indications (i.e., spinal cord injury, amylotrophic lateral syndrome, critical limb ischemia, peripheral arterial disease), our current valuation is based only on the leading indication in DN. In addition, we excluded from our assumptions potential revenue derived from the DowAgra Sciences agriculture collaboration, the Sigma-Aldrich cell line engineering partnership, and the Genentech (DNA, $74.83, Not Rated) protein production deal, as well as commercial opportunities from Sangamo’s earlier-stage drug candidates, including ZFN CCR5 for the treatment of HIV, the IL-13 zetakine for glioblastoma, and ZFP TrkA repressor for cancer bone pain. Employing an NPV analysis based on US SB-509 revenue (discounted at 30%), we derive a $30 price target, up from our previous price target of $20, which was based on a comparable analysis of platform-enabled technology companies.

• Sharpening our pencils on diabetic neuropathy market opportunity. Type 2 diabetes mellitus is one of the fastest-growing diseases among Western cultures. In the US, it is estimated that 16 million people are living with diabetes, although only about 7.2 million have actually been diagnosed (source: National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]). DN is a common side-effect of diabetes that affects almost all diabetic patients within 10 years of diagnosis. While medications are available for diabetic neuropathy, such as pregabalin (Lyrica, from Pfizer [PFE], $23.67, Not Rated), a GABA receptor agonist, and non-steroidal anti-inflammatory drugs (NSAIDs), these treatments are only symptomatic and do not address the underlying cause of the pain. However, 2007-2011 consensus estimates project Lyrica revenues of $1.7 billion, $2.3 billion, $2.7 billion, $3.1 billion, and $3.4 billion, which in our view reflects a very large market opportunity for drugs with novel approaches to treating DN. Given SB-509’s neuroprotective and neuroregenerative effects, we believe SB-509 could become the first disease-modifying drug marketed for DN and would be entitled to this large commercial indication.

• SB-509 DN NPV analysis: RAISING PRICE TARGET TO $30. In our SB-509 DN revenue model, we are assuming product launch in late 2010, and only in the US market. Based on other novel biotechnology therapeutics (i.e., monoclonal antibodies) and the disease-modifying attributes of SB-509, we assign a $30,000 annual cost, which we believe could be a conservative estimate. We assume a peak penetration rate of 10% by 2015 and peak sales of $6.5-7.0 billion, with a gross margin of 40%. Based on some patent protection surrounding the ZFP technology expiring around 2017-2018, our NPV is composed of net revenues from SB-509 sales through 2017, discounted back at 30% to our FY08 shares outstanding estimate, from which we derive a 12-month price target of $30.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.295.940 von getshorty am 05.11.07 18:13:27

Super News, danke, aber auch schon der Taipan Börsenbrief hat Sangamo schon vor Wochen auf eine 2-Jahreskursziel von US Dollar 50 gestellt!
Wenn SGMO nicht zuvor übernommen wird!

[tokajo]

Antwort auf Beitrag Nr.: 32.295.940 von getshorty am 05.11.07 18:13:27

Hi shorty,

so macht Börse Spass. Das Schöne dabei: Die genannten 30 $ sind das 12 Monatsziel von JMP ohne das mit SB 509 jemals Gewinne eingefahren worden sind.
Ab 2009 geht es dann wahrscheinlich erst richtig ab (Hoffe ich zumindest)

Gruß Tokajo

[tokajo]

Und die nächste Phase 2 ab 2008

Gruß Tokajo

Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at Society for Neuroscience Meeting

SAN DIEGO, Nov 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of additional Phase 1b clinical data from its ZFP Therapeutic(TM) program at Neuroscience 2007, the 37th annual meeting of the Society for Neuroscience. The data demonstrate statistically significant improvements in quantitative measurements of neurological health in subjects with diabetic neuropathy (DN), suggesting an alteration of disease progression.

Additional data were presented suggesting that a single treatment with SB- 509 may increase the mobilization of stem cells into a subject's blood. These circulating stem cells may have implications for the nerve regeneration and nerve and blood vessel growth that have been reported from SB-509 treatment. Sangamo plans to further investigate this observation and evaluate the kinetics of mobilization in a new Phase 2 trial that the Company expects to initiate in the first quarter of 2008 in subjects with mild to moderate DN.

"The data obtained in this clinical trial demonstrate that, six months after a single treatment, SB-509 appears to have not only a neuroprotective but also possibly a neuroregenerative effect," commented the presenter, Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "We are very pleased with these data. We are also excited by the observation of mobilization of aldehyde bright stem cell into the blood stream of subjects with diabetic neuropathy after a single treatment with SB-509. VEGF ZFP TF(TM) treatment appears to mobilize between 100 and 1000-fold more stem cells than are typically being introduced into patients in many of the stem cell therapeutic approaches that are currently being tested.

We believe that exploring this observation of natural mobilization of stem cells in a new Phase 2 trial in subjects with diabetic neuropathy may provide us with valuable mechanistic data that could aid in the ultimate development of this product for a number of neurological and vascular indications. In addition, this may provide us with a pharmacodynamic surrogate biomarker that enables easy monitoring of the response of subjects to SB-509."

SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating SB-509 in two ongoing Phase 2 clinical trials for the treatment of diabetic neuropathy.

"We continue to be very pleased and impressed by the disease-altering improvements that we have observed in several measurements of nerve health in subjects with mild to moderate diabetic neuropathy treated with SB-509," said Edward Lanphier, President and CEO of Sangamo BioSciences. "We are also very excited to be evaluating SB-509 in models of spinal cord injury, traumatic brain injury, and in a major new initiative, a Phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). We will provide more details about trial design and timing for both our stem cell mobilization and ALS Phase 2 trials at our Analyst Briefing in early December."

Clinical Results Presented at Neuroscience 2007

The data presented at the Society for Neuroscience meeting were collected from subjects with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509. Subjects received a single treatment in both legs of either placebo (10 subjects) or SB-509 (10 subjects who received 60 mg total dose or 30 mg per leg). All of the subjects completed six-month follow-up testing. Clinicians observed statistically significant clinical improvements in quantitative sensory testing (QST) which quantifies perception of vibration. Specifically, mean QST testing compared to baseline in SB-509 treated patients showed a 25.9% improvement compared to 5.4% worsening in the placebo group (a delta in QST of 31.3%, p<0.02) and the mean sum of improvement of all lower extremity motor NCVs was 1.02 Meters/sec with SB-509 treatment compared to -0.81 Meters/sec with placebo (a delta in NCV of 1.83 Meters/sec). Notably, NCV measurements of the tibial nerves in SB-509 treated subjects showed consistent trends for improvement in both velocity of conduction of an applied electrical signal as well as the measured amplitude of the signal at two points on the nerve. Specifically, the mean sum of NCVs in treated subjects was 2.3 Meters/sec compared to a worsening of 0.9 Meters/sec in placebo treated subject (a delta in NCV of 3.2 Meters/sec). Clinicians also observed a trend for improvement in SB-509 treated patients in a composite measure of nerve health, the modified Total Neuropathy Score or TNS.

In addition, preliminary data were presented demonstrating a four-fold increase in "aldehyde bright" stem cells in the bloodstream of subjects at 30 days post a single intramuscular treatment with SB-509. This represents an increase of 0.05%-0.1% of circulating blood mononuclear cells corresponding to approximately one billion stem cells in vivo. VEGF ZFP TF treatment appears to mobilize 100-1000-fold more stem cells than are typically being introduced into patients in many of the stem cell therapeutic approaches that are currently being tested. Aldehyde bright stem cells can be identified in the subject's blood by staining with a substrate of aldehyde dehydrogenase, an enzyme that is highly expressed in stem cells. Stem cells can self-renew through cell division giving rise to more stem cells and, under certain conditions, can be induced to become cells with a special function in the body such as nerves and blood vessels. It is believed that in response to long-range signals, stem cells are able to migrate from the blood circulation into areas of injury or degeneration and participate in the repair response. Aldehyde bright stem cell populations of human bone marrow have been shown to be highly enriched in cell types thought to mediate tissue repair, including endothelial, mesenchymal, neural and hematopoietic progenitor cells. Sangamo expects to initiate a Phase 2 clinical trial to further investigate this observation in the first half of 2008.

Preclinical Results from Sangamo's DN program Presented at

Neuroscience 2007

In addition, preclinical animal data will be presented by Sangamo's collaborators in the laboratory of Professor David Tomlinson, Ph.D., Faculty of Life Sciences, University of Manchester, U.K., on Wednesday, November 7, 2007 in a presentation entitled "Effect of Engineered VEGF-A Zinc Finger DNA-Binding Transcription Factor on Diabetic Neuropathy Molecular Markers (MAP kinases). A role for Gp38/Podoplanin?"

About the SB-509 Clinical Program

About SB-509

SB-509 is administered as an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene. VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

Phase 1

The Phase 1b study to assess the safety and clinical effects of a single administration of SB-509 to subjects is ongoing. Subjects were randomized and administered either SB-509 or placebo in both legs by intramuscular injection. Two dose levels of SB-509 have been tested. At the first dose level, three subjects were administered placebo and three subjects were treated with a total of 30 mg of SB-509, 15 mg per leg. Accrual of these subjects is complete. A further twenty-two subjects have been treated at the second dose level with either placebo or a total dose of 60 mg of SB-509, administered as 30 mg per leg. Subjects in this Phase 1b study will be monitored for both the safety and tolerability of SB-509 treatment as well as evaluation of pain and clinical effects on lower limb diabetic neuropathy at one, two, three and six months post-treatment.

Phase 2

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. The trial is being conducted at 19 sites.

Approximately 100 subjects will be enrolled into the trial. Subjects will be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 66 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group (approximately 33 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a distribution pattern that targets the skeletal muscle adjacent to the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Investigators will primarily use the total neuropathy score (TNS) to assess signs and symptoms of the condition. A composite scoring system such as the TNS, is widely regarded by neurologists as the most comprehensive approach to evaluating changes in nerve health. In addition to qualitative assessment of symptoms, the TNS includes electrophysiological testing using nerve conduction velocity (NCV) to assess the rate at which a nerve can conduct an electrical signal, and quantitative sensory testing (QST) with the Vibratron II instrument, to assess the threshold of detection of vibration. In addition, skin biopsies will be taken to evaluate the direct therapeutic effect of SB-509 on nerve regrowth. This test is a very sensitive marker of DN severity and may provide an important mechanistic marker for efficacy. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or the Sangamo website at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/.

The Juvenile Diabetes Research Foundation, or JDRF, the major charitable funding organization of research leading to a cure for type 1 diabetes and its complications, is providing up to $3 million of funding towards this Phase 2 clinical trial pursuant to a research agreement between Sangamo and JDRF.

Sangamo has stated that it expects to complete accrual of this trial by the end of 2007 and to have data in the second half of 2008.

Phase 2 study of SB-509 for moderate to severe DN

The clinical trial is a single-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with moderate to severe diabetic peripheral sensory motor neuropathy in the legs, so-called "blocked nerves". The trial is being conducted at multiple sites.

Approximately 45 subjects will be enrolled in the trial. Subjects will be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 3 months. The remaining group (approximately 15 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of two treatments (Day 0 and 90). Subjects will receive injections in a distribution pattern that targets the skeletal muscle adjacent to the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Specifically, investigators will use the total neuropathy score (TNS) to assess signs and symptoms of the condition.

Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or the Sangamo website at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/. Sangamo expects to have data from this trial by the end of 2008.

About SB-509

SB-509 is administered as an injectable formulation of plasmid DNA that encodes a ZFP TF, designed to upregulate the VEGF-A gene. VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease-induced nerve damage.

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com/

Copyright (C) 2007 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 32.312.686 von tokajo am 06.11.07 18:24:48

Nach den letzten 3 Meldungen zu den verschiedenen Therapieformen gibt es wieder eine Übersicht vom CEO am 13.11. Die JMP Conferencen richten sich teilweise auch an Investoren und wirkt sich kurstechnisch daher wahrscheinlich stärker aus.

Gruß Tokajo

Sangamo BioSciences to Present at the JMP Securities Healthcare Focus Conference

RICHMOND, Calif., Nov 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:30 pm (ET) on Tuesday, November 13, 2007 at the JMP Securities Healthcare Conference in Boston.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.344.919 von tokajo am 08.11.07 17:36:30

Ganz schön heftig heute der Abschlag, teilweise bis zu 4 US Dollar!
Wenns mal einen richtigen Crash gibt wo stehen wir wohl dann?

Hilft nur ohne Stop Loss zu arbeiten und Sangamo very long zu sehen, oder?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.344.919 von tokajo am 08.11.07 17:36:30

Ganz schön heftig heute der Abschlag, teilweise bis zu 4 US Dollar!
Wenns mal einen richtigen Crash gibt wo stehen wir wohl dann?

Hilft nur ohne Stop Loss zu arbeiten und Sangamo very long zu sehen, oder?

[toynet]

Antwort auf Beitrag Nr.: 32.350.817 von Magnetfeldfredy am 08.11.07 22:14:28

very long, auf jeden Fall, und ohne SL.

Ich sehe da einen neuen Behandlungsansatz für viele Erkrankungen. Es ist bisher nur beschränkt auf einzelne Erkrankungen. Das ist imho aber nur ein Start, irgendwo wird hier etwas Grundlegendes studiert derzeit. Wie viele Formen der Nervenschädigungen gibt es denn wo es bisher noch heißt unheilbar? Sehr viele. Ein Beispiel nur: Multiple Sklerose, ein riesiger Markt von Betaferonproduzenten; neben dem wo sie derzeit Studien durchführen.

Nachzulesen auch auf Yahoo. Wie ich schon mal geschrieben hatte, Nobelpreise gibt es für Grundlegendes. Imho gibt es hier etwas Grundlegendes, also dabeibleiben. Irgendwann wird sie einer einkaufen, ich hoffe es dauert noch, und wenn dann zu einem guten Preis für uns.

TN

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.344.919 von tokajo am 08.11.07 17:36:30

Sangamo "schmiert weiter ab", wie blöd sind eigentlich die Amis?
Erst hui und jetzt Alles pfui, was hat Sangamo mit der Suprime-Krise zu tun, nichts!

Na ja sollte der Markt noch crashen bekommen wir die Sangamo wahrscheinlich für 10 US Dollar!

[aktianer]

Antwort auf Beitrag Nr.: 32.394.667 von Magnetfeldfredy am 12.11.07 16:07:01

falls es nur Gewinnmitnahmen sind, ist es positiv für die Aktie, denn die Neueinsteiger haben sicherlich andere Kursziele im Visier als jene, die bei 4 $ eingestiegen sind.

Andererseits könnten aber auch negative Testergebnisse Insider veranlaßt haben, in größerem Maße zu verkaufen (am Freitag gingen immerhin 3% des GK über den Thresen). Ich denke da vor allem an Auswertungsergebnisse für die morgige Präsentation!

Aber auch die erste Variante hat einiges für sich, neigen doch Anleger in Krisenzeiten dazu, Gewinne zu realisieren.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.396.326 von aktianer am 12.11.07 17:49:58

Ein Investor hat seinen Anteil von ca. 9% auf 7 % reduziert, mehr hier:
AP
Sangamo Biosciences Investor Cuts Stake
Monday November 12, 11:48 am ET
Sangamo Biosciences Holder Kopp Investment Advisors Cuts Stake to 7.2 Percent; Shares Fall


NEW YORK (AP) -- Investment adviser Kopp Investment Advisors LLC reduced its stake in DNA technology company Sangamo Biosciences Inc. to 7.2 percent, according to a Securities and Exchange Commission filing Friday.
In morning trading, Sangamo shares dropped $1.47, or 8.8 percent, to $15.21. The stock reached a 52-week high of $19.82 in late October, when the company reported study data showing its DNA technology could be used for gene modification.

According to the filing, Kopp Investment now owns 2.9 million Sangamo shares. In mid-September, Kopp owned about 3.3 million Sangamo shares, representing an 8.3 percent stake in the Richmond, Calif.-based company.

Ich glaube nicht, daß der Investor Studienergebnisse vorab erhalten darf! Der braucht halt Geld für die Verluste aus der Suprime-Krise, hoffe ich zumindest!

[aktianer]

Antwort auf Beitrag Nr.: 32.396.414 von Magnetfeldfredy am 12.11.07 17:56:02

Auch der Vize-Präsident hat 12500 Stück verkauft - offenbar noch zu recht hohen Kursen!
http://biz.yahoo.com/ap/071114/sangamo_biosciences_vp_inside…" target="_blank" rel="nofollow ugc noopener">http://biz.yahoo.com/ap/071114/sangamo_biosciences_vp_inside…
Sangamo BioSciences VP Exercises Options
Wednesday November 14, 4:08 pm ET
Sangamo BioSciences VP Greg Zante Exercises Options for 11,858 Shares

NEW YORK (AP) -- The vice president of finance and administration at biotechnology company Sangamo BioSciences Inc. exercised options for 11,858 shares of common stock, according to a Securities and Exchange Commission filing.

In a Form 4 filed with the SEC Thursday, Greg Zante reported he exercised options for the shares Thursday for $3 to $4.11 apiece and then sold 12,500 the same day for $18.03 apiece.

Insiders file Form 4s with the SEC to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.

Sangamo is based in Richmond, Calif.

[tokajo]

Antwort auf Beitrag Nr.: 32.439.392 von aktianer am 15.11.07 15:58:44

Hallo zusammen,

die Verkäufe würde ich nicht negativ betrachten. Kopp Investment ist eine Fondgesellschaft, die selbstverständlich auch Regelungen zur Risikostreuung aufweist. Der Kurs ist in der letzten Zeit schön gestiegen, daß dann der Anteil reduziert wird ist doch verständlich.

Und Greg Zante hat seine Optionen eingelöst. Mach ich auch bei meinen Optionen (nicht Sangamo) und freue mich auf das Geld.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.441.773 von tokajo am 15.11.07 18:09:43

Guten Morgen Tokajo,

hast Du Sangamo noch, oder hast Du verkauft?

Ich habe noch meine 1000 Stück, bin aber beunruhigt da wir brutal abstürzen, ich halte trotzdem!

Viele Grüße mit der Hoffnung daß es bald wieder aufwärts geht!

Fredy

News
Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
Tuesday November 20, 4:00 pm ET


RICHMOND, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:00 am (ET) on Wednesday, November 28, 2007 at the Piper Jaffray 19th Annual Health Care Conference in New York.
ADVERTISEMENT


The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release

[tokajo]

Antwort auf Beitrag Nr.: 32.504.486 von Magnetfeldfredy am 21.11.07 07:31:40

Hi Fredy,

ich bin auch noch mit allen und ein paar Stück mehr investiert. Das Börsenumfeld hier ist derzeit nicht gerade berauschend. Da hat auch unsere Sangamo darunter zu leiden. Für mich gilt SGMO weiterhin als Langfristinvest.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.504.713 von tokajo am 21.11.07 08:24:48

Na dann stehen wir Beide das Debakel durch!

[tokajo]

Antwort auf Beitrag Nr.: 32.505.116 von Magnetfeldfredy am 21.11.07 09:10:42

Offensichtlich hat der Rückgang mit den neuen Ergebnissen zur Stammzellenforschung zu tun. Gestern Abend kam ein Bericht in den Nachrichten über den Nutzen der Forschung. Wissenschaftler glauben vereinfacht ausgedrückt, die Stammzellen in kranke Organe einpflanzen zu können, die dann die betroffenen Gene austauschen.

Offensichtlich glauben einige Investoren, daß die Beschaffung von Geldern für Sangamo dadurch schwieriger werden kann und ein neuer potentieller Wettbewerber entstanden ist.

Bei näherer Betrachtung hat Sangamo einen Vorsprung von einigen Jahren. Immerhin befindet man sich bereits bei einigen Produkten in der Phase 2. Bin gespannt ob in der neuen Präsentation auf die Thematik eingegangen wird.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.520.808 von tokajo am 22.11.07 09:35:52

Servus Tokajo,

den erwähnten Bericht hab ich auch gesehen, jedoch arbeiten "die" doch mit Viren und Sangamo eben nicht! Ein Experte erwähnte auch daß alles in vitro, also im Reagenzglas und bei Mäusen klappt, jedoch beim Menschen noch nicht erprobt wurde.

Sangamo ist ja für Diabetes schon in Phase 2 und hat diese Stufen schon lange hinter sich und es scheint zu funktionieren.

Jedoch hilfts dem Aktienkurs bei dem katastrophalen Umfeld nicht und ich denke es wird noch schlimmer an den Aktienmärkten!

[cultom4president]

Servus Miteinander,

Sangamo hat es im Sog der Aktienmärkte ziemlich erwischt. Nun, meine erste Position war nicht so optimal vom Timing, aber ich denke das ich bei Kursen um die 8€ erfolgreicher agieren werde. Mittelfristig bleibt dieser Wert sicher sehr spannend. Auf eine marktbreite Jahresendralley setze ich weiterhin.

cultom

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.521.746 von cultom4president am 22.11.07 10:43:29

Aus welchen Gründen setzt Du auf eine Ralley, Suprime-Krise weitet sich aus, Verbrauchervertrauen schlecht wie nie, Dollar wird immer "weicher", Zinssekungsphantasie sinkt......

Es gibt eine Ralley aber nach unten.......

[cultom4president]

Antwort auf Beitrag Nr.: 32.521.854 von Magnetfeldfredy am 22.11.07 10:50:16

Du lieferst doch schon die Begründung dafür!

Wir hatten die Subprimekrise im August gehabt, nun kamen die Banken endlich mit ihren faulen Krediten hinter dem Ofen hervor. Andere Bereiche wie die Technologiemärkte wurden zu unrecht bestraft. Von dort sehe ich auch eine Ralley für die Gesamtmärkte starten.

Es wurde meiner Meinung fast alles zur Suprime gesagt und ein gehöriger Batzen ist eingepreist. Druck gibt es nur noch seitens Öl und Euro/Dollar.

cultom

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.523.502 von cultom4president am 22.11.07 12:38:13

Zur Suprimkrise: Die Banken haben bis jetzt ca. 48 Milliarden US Dollar abgeschrieben, laut n-tv Telebörse hat die Bank of England 400 Milliarden genannt die aufgrund der Suprime Krise abgeschrieben werden müssen!
Die Technologiewerte sind Zykliker und auch Cisco hat gemeldet daß die Nachfrage aufgraund der Suprimekrise nachläßt, wenns eine Rezzession in den USA gibt leiden die Zykliker am meisten und leider auch unsere Sangamo, ich halte trotzdem denn ich machte schon große Fehler wie z.B. mit Eurofins-Aktien die ich in der 2000-er Börsenkrise für EUR 5 verkaufte, heute stehen sie bei 70-80 EUR, das kann uns mit Sangamo auch passieren!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.520.808 von tokajo am 22.11.07 09:35:52

Servus Tokajo,

heute war Präsentation der Updates von Sangamo, gibts irgendwelche News?
Gruß
Fredy

[tokajo]

Antwort auf Beitrag Nr.: 32.602.907 von Magnetfeldfredy am 28.11.07 18:40:18

Hi Fredy,
habe mir die Geschichte heute morgen kurz mal angehört. Findest alles auf der Homepage unter events.
Es werden zwei neue Phase 1 Projekte Cancer(Glioblastoma) und HIV initiert, nachdem die preclinical Phase kurz vorm Abschluß steht. Desweiteren findet nächste Woche in New York ein Analystenbriefing wieder statt.

Läuft alles super.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.608.823 von tokajo am 29.11.07 08:57:57

Servus Tokajo,

vielen Dank für die Infos, ich hör auch mal rein!

Gruß

Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.608.823 von tokajo am 29.11.07 08:57:57

So jetzt geht`s wieder up! Hab mir die Präsentation angehört, wie Du sagst, Alles im Plan!
Auf zu neuen Höhen!

[tokajo]

Antwort auf Beitrag Nr.: 32.617.223 von Magnetfeldfredy am 29.11.07 18:33:03

Hallo zusammen,

die erste Phase 2 und das New Yorker Analystentreffen werden heute wahrscheinlich ein paar Prozente bewirken.

Gruß Tokajo

Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy

Milestone Triggers Payment to Sangamo from JDRF

RICHMOND, Calif., Dec 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center Phase 2 clinical trial evaluating SB-509, a ZFP Therapeutic(TM) for the treatment of mild to moderate diabetic neuropathy (DN). The company expects to have data from this trial in the second half of 2008.

"The completion of enrollment of our first Phase 2 clinical trial represents a significant milestone for Sangamo and I am pleased that we achieved this major clinical goal as planned, before the end of 2007," commented Edward Lanphier, Sangamo's president and CEO. "We have been very encouraged by the disease-altering improvements that we observed in our preclinical studies and in the Phase 1b trial and look forward to presenting the data from this current study by the end of 2008."

This Phase 2 trial followed a positive Phase 1 study that demonstrated clinical safety of a single treatment with SB-509 as well as statistically significant improvements in Quantitative Sensory Testing (QST), clinically relevant improvements in motor and sensory nerve conduction velocities (NCV) and a trend towards improvement in Total Neuropathy Score (TNS), suggesting an alteration of disease progression in subjects with DN. The Phase 2 study was designed to confirm and expand these findings and to evaluate repeat dosing with SB-509.

The trial has been partially funded by a $3.0 million commitment from the Juvenile Diabetes Research Foundation International (JDRF) pursuant to a research agreement between Sangamo and JDRF. Completion of enrollment of the trial triggers a milestone payment from JDRF under this agreement.

About SB-509

SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). Sangamo is currently evaluating this ZFP Therapeutic in a second ongoing Phase 2 clinical trial for the treatment of moderate to severe DN; plans to initiate a third Phase 2 trial to evaluate the effect of SB-509 on the mobilization of stem cells in subjects with DN; and has a preclinical program targeting spinal cord injury. Sangamo has also announced a new clinical program, the initiation of a Phase 2 clinical trial in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) in the first half of 2008.

Phase 2 study of SB-509 for mild to moderate DN

The clinical trial is a double-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.

A total of 102 subjects have been enrolled into the trial. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group is being treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group is receiving an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a distribution pattern that targets the skeletal muscle adjacent to the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Investigators will use quantitative sensory testing (QST) with the Vibratron II instrument to assess the threshold of detection of vibration, electrophysiological testing using nerve conduction velocity (NCV) to assess the rate at which a nerve can conduct an electrical signal, and a composite scoring system, the total neuropathy score (TNS) to assess signs and symptoms of the condition. In addition, skin biopsies will be taken to evaluate the direct therapeutic effect of SB-509 on nerve regrowth. This test may provide an important mechanistic marker for efficacy. Subjects will be assessed for seven months following the last dosing.

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on Amyotrophic Lateral Sclerosis (ALS), cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs, therapeutic applications of Sangamo's ZFP technology platform and payments upon achievement of research milestones. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.659.220 von tokajo am 04.12.07 14:38:16

Ganz schön volatil unsere Sangamo!

[tokajo]

Antwort auf Beitrag Nr.: 32.662.180 von Magnetfeldfredy am 04.12.07 17:43:46

Hat offensichtlich dieses Mal etwas länger gedauert, bis die Leute verstehen um was es geht. ) Ende 2008 erwartet man die Ergebnisse. Ich bin gespannt wo wir dann stehen - dreistellig ?? (in Dollar)

Gruß Tokajo

[tokajo]

Schaut sich heute jemand die Konferenz an ? Ich bin die nächste paar Tage leider unterwegs.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.675.776 von tokajo am 05.12.07 19:01:05

Mach ich und sag Dir Bescheid!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.675.776 von tokajo am 05.12.07 19:01:05

News!

Sangamo BioSciences Provides Update on Company's Accomplishments in 2007 and 2008 Objectives
Wednesday December 5, 4:05 pm ET
Company Updates on Four Phase 2 Clinical Trials
Dow AgroSciences CEO Discusses Future Opportunities with Sangamo Technology


NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced that the company will provide an update on milestones achieved in 2007 and preview objectives for 2008 during its annual Investor and Analyst Briefing held in New York City today.
ADVERTISEMENT


Jerome Peribere, President and CEO of Dow AgroSciences will discuss the success of the two companies' collaboration to develop zinc finger DNA-binding protein (ZFP) technology for use in plant agriculture and Dow AgroSciences' future plans to commercialize the technology. Mr. Peribere will be joined by Edward Lanphier, Sangamo's President and CEO and other members of Sangamo's senior management team.

"We have been very pleased with the progress of our collaboration with Sangamo and by the success that we have had together to confirm our conviction that the ZFP platform has the ability to truly transform the field of plant genetics," commented Mr. Peribere. "We have established that Sangamo's ZFP technology can be used to regulate and modify genes in plants with great specificity and reliability. This enables significant savings in both the rate and cost of development of new crop products with improved traits, characteristics and regulatory designation. We envision that the application of ZFP-mediated gene modification and regulation will become a major component of our plant biotechnology process and, as we enter commercialization and sublicensing, will have a 'game-changing' role in the future of plant breeding."

"The past year has been an exciting and transformational period for Sangamo in which we have successfully achieved several major goals," said Edward Lanphier, president and CEO of Sangamo. "The progress that we have made this year in both clinical and business development activities put us in a very strong position to continue to advance and commercialize our ZFP technology in therapeutics, plant agriculture, laboratory reagents and enhanced cell-lines for pharmaceutical protein manufacturing. We expect 2008 to be another year of significant accomplishments for Sangamo as we achieve a number of major value-creating events."

Mr. Lanphier continued, "We presented positive top-line clinical data from our Phase 1b trial of our lead ZFP Therapeutic(TM), SB-509, an activator of vascular endothelial growth factor (VEGF) for the treatment of diabetic neuropathy (DN). Sangamo is building on this positive data by initiating further clinical trials as we continue our efforts to develop this technology as a novel platform for therapeutic development. This year we also achieved our goal of successfully completing the accrual of subjects to the Phase 2 trial of SB-509 for DN which will give us data in the second half of 2008. In addition to our two Phase 2 clinical trials in DN, we have announced our plans to initiate further Phase 2 studies of SB-509 in stem cell mobilization and amyotrophic lateral sclerosis (ALS) and to initiate two Phase 1 clinical trials in ZFP-mediated gene modification for glioblastoma and HIV/AIDS. We have also advanced and expanded our preclinical pipeline and presented data from several programs at major scientific and medical meetings.

"We also continued to monetize our technology outside of the human therapeutic space. This year we established a major relationship with Sigma-Aldrich Corporation to develop and commercialize ZFP-based laboratory research reagents. We also entered into several cell-line engineering collaborations including a commercial license agreement with Genenetech. The research phase of our collaboration with Dow AgroSciences to apply our ZFP technology for plant agriculture applications is going very well as demonstrated by the achievement of multiple milestones and we look forward to moving into the commercial phase by the fourth quarter of 2008.

"By the second half of 2008, we expect to have data from two Phase 2 trials in patients with diabetic neuropathy, to have initiated two new trials of SB-509 in stem cell mobilization and ALS, and two new Phase 1 trials in patients with HIV infection and glioblastoma. Achievement of these objectives, as well as commercial progress in our collaboration with Sigma and entry into the commercial phase of our collaboration with Dow AgroSciences, will be key to further enhancing the market-leading presence for our technology. As has become increasingly evident, an innovation gap exists in the pharmaceutical sector, and we believe that our progress in advancing our technology platform, which is unique in its generation of novel, highly differentiated therapies and products, will create interest among potential partners for our ZFP Therapeutic programs."

Sangamo Accomplishments in 2007

During the briefing several of the company's achievements will be highlighted including:


-- Sangamo presented "top-line" clinical data from its ZFP Therapeutic
program to develop SB-509, a ZFP activator of VEGF for the treatment of
diabetic neuropathy at both the Annual Scientific Sessions of the
American Diabetes Association in June and the Society for Neuroscience
Annual Meeting in November. The data showed statistically significant
improvements in several measurements of neurologic health in subjects
with mild to moderate diabetic neuropathy over a six-month period after
treatment with a single administration of SB-509.
-- Sangamo completed accrual for its repeat-dosing Phase 2 trial of SB-509
in patients with mild to moderate DN, and anticipates having data from
this trial in the second half of 2008.
-- Successful prosecution of Sangamo's collaboration with Dow AgroSciences
has resulted in the achievement of several research milestones
including the first demonstration of ZFN-mediated targeted integration
of DNA into a native gene in maize and the first demonstration of
targeting a native gene in canola with ZFNs.
-- Sangamo established a major alliance with Sigma-Aldrich Corporation to
develop and commercialize high value laboratory research reagents based
upon Sangamo's zinc finger DNA binding protein technology. In July
2007, as part of the agreement, Sangamo received an upfront payment of
$13.5 million which included license fees and the purchase of one
million shares of Sangamo stock. Sangamo is also eligible to receive
development and commercial milestone payments of up to $24 million,
sublicense payments and royalties on product sales.
-- Further strengthening its balance sheet, Sangamo completed a registered
direct offering of its common stock. In July 2007, Sangamo sold an
aggregate of 3,278,689 shares of common stock to a group of
institutional investors in a registered direct offering, resulting in
gross proceeds to the company of approximately $30.0 million before
fees and expenses. The company estimates that it will end 2007 with
approximately $80M in cash and cash equivalents.


Select 2008 Objectives

During the briefing Sangamo will also discuss the following anticipated objectives for 2008:


-- In the second half of 2008, Sangamo expects to have data from its
repeat-dosing Phase 2 trial of SB-509 in patients with mild to moderate
DN and anticipates completing accrual and having data from a second
Phase 2 trial of the same drug in patients with moderate to severe DN.
-- Dow AgroSciences has the option to exercise a commercial license for
the use of our ZFP technology in plant agriculture in the second half
of 2008.
-- The Phase 2 trial that Sangamo plans to initiate in the first quarter
of 2008 evaluating the mobilization of aldehyde bright stem cells in
subjects with diabetic neuropathy after treatment with the SB-509.
-- Plans for a Phase 2 trial of SB-509 for the treatment of ALS will also
be outlined at the briefing. Sangamo expects to initiate this trial in
the first half of 2008.
-- Plans to initiate a Phase 1 trial of a ZFP Therapeutic to treat
glioblastoma in the first half of 2008 and a Phase 1 trial for a ZFP
Therapeutic to treat HIV infection in the second half of 2008.
-- Sangamo expects to report data from the Phase 1 clinical programs in
critical limb ischemia, the severe form of peripheral artery disease in
2008.
-- Sangamo estimates that it expects to end 2008 with approximately $55M
in cash and cash equivalents, based on current expense projections and
expected progress in existing corporate relationships.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.675.776 von tokajo am 05.12.07 19:01:05

Kurs nachbörslich auf 16,26 US Dollar gestiegen!

Die Zusammenarbeit mit DowAgroSciences wird noch viel Kohle bringen!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.679.005 von Magnetfeldfredy am 06.12.07 06:21:53

Neues Kursziel nach Analystenkonferenz:

Rating-Update: New York (aktiencheck.de AG) - Die Analysten von Cantor Fitzgerald stufen die Aktie von Sangamo BioSciences (ISIN US8006771062/ WKN 936386) unverändert mit "buy" ein. Das Kursziel werde von 17 auf 27 USD angehoben. (06.12.2007/ac/a/u)

[aktianer]

Antwort auf Beitrag Nr.: 32.679.526 von Magnetfeldfredy am 06.12.07 08:47:48

nachbörslich deshalb wohl bereits bei 16,25 U$. Vielleicht ist die heftige Konsolidierung damit bereits abgeschlossen.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.679.571 von aktianer am 06.12.07 08:52:31

Hoffen wir`s!

Sangamo wird eine Cash-Cow, mit DowAgroScience werden neue Projekte realisiert die regelmäßig Kohle reinbringen und mit Sigma Aldrich ist man in der Stammzellenforschung obenauf, ganz zu Schweigen wenn die Diabetis Behandlung mit dem eingenem Produkt klappt!
Jedoch glaube ich, daß sich Sangamo stark volatil nach oben bewegen wird!

[tokajo]

Antwort auf Beitrag Nr.: 32.680.677 von Magnetfeldfredy am 06.12.07 10:31:32

Hallo zusammen, habe mir soeben die Präsentation angesehen und heruntergeladen. War sehr beeindruckend, vor allem dann, wenn man nur die Hälfte versteht. 2 Stunden und 156 Folien. Bin weiterhin sehr optimistisch und stocke meinen Anteil auf.


Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.695.371 von tokajo am 07.12.07 12:23:44

Servus Tokajo,

habe auch nochmal 1000 Stück gekauft, jetzt zum Durchschnittspreis von 11 EUR pro Aktie.

Glaubst Du wirklich daß Sangamo dreistellig wird?
Schön wärs!

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 32.698.958 von Magnetfeldfredy am 07.12.07 17:32:37

Warum nicht, vielleicht noch nicht in 2008. Sangamo hat jetzt ein MK von 600 Mio $. Wenn ein paar der Entwicklungen marktreif werden, sind 6 Millarden $ sicherlich nicht hochgegriffen. Gut finde ich die Combi mit Dow Agro Sciences. Hier wird schneller verdient als mit Medikamenten und die Zulassungen sind einfacher.

Gruß Tokajo

[tokajo]

Sangamo BioSciences Announces Presentation of Data for ZFP Therapeutic for Glioblastoma at American Society for Hematology Meeting

ZFN Modified Cells Show Glioblastoma Killing in the Presence of Dexamethasone in Mouse Tumor Model

RICHMOND, Calif., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of positive data in a mouse tumor model from its program to develop a novel cell therapy using its zinc finger DNA-binding protein nuclease (ZFN(TM)) technology for treatment of glioblastoma multiforme (GBM), a progressive and usually fatal brain cancer. The data were presented at the 49th Annual Meeting of the American Society of Hematology (ASH) by Sangamo's collaborator Michael C.V. Jensen, M.D., Associate Chair, Division of Cancer Immunotherapeutics & Tumor Immunology, City of Hope.

"Working with Sangamo, we have succeeded in generating ZFN-modified engineered T-cells that can destroy glioblastoma cells in vivo in the presence of dexamethasone," said Dr. Jensen. "This is an important result in the progress of our efforts to create a cell-based product which can be used in combination with glucocorticoids such as dexamethasone to treat patients with GBM. The ZFN-modification of GR in these T-cells does not alter their cytolytic or 'killing' properties and enables them to function in the presence of glucocorticoids, which would normally inhibit T-cell function."

Dr. Jensen has developed novel chimeric immunoreceptors called zetakines that can be engineered into human immune cells to generate a population of cells that can specifically recognize and destroy cancer cells. Dr. Jensen has already used these engineered cells in clinical trials for malignant gliomas and lymphoma. In his current clinical protocol, T-cells are removed from a patient with GBM and modified to express the zetakine. These modified cells are infused into the brain following surgery for the targeted elimination of residual tumor cells. Frequently, however, glucocorticoids, such as dexamethasone, must be administered to patients pre- and post-surgery to stop the brain swelling caused by the tumor and surgery. Glucocorticoids inactivate or kill the desirable T-cells through a protein known as the glucocorticoid receptor (GR) limiting the benefit of this novel therapy. Currently, this approach is also patient-specific or autologous, which makes it time and labor-intensive. Cells without a functional GR are drug-resistant and should therefore be available to destroy tumor cells. The aim of the collaboration is to use Sangamo's ZFN gene modification technology to delete the GR in T-cells engineered to express the zetakine. The specific deletion of GR in the zetakine expressing anti-glioma T-cells allows them to be used in the presence of glucocorticoids and to be developed as an "off the shelf" or allogeneic cell product that can be used rapidly in all GBM patients. Sangamo expects to file an Investigative New Drug (IND) application for this cell therapy in the first half of 2008.

"These data represent another important step forward in this program and we are committed to moving into the clinic as soon as possible," said Edward Lanphier, Sangamo's president and CEO. "We are very pleased to be working with City of Hope and Mike Jensen and his team who have developed this novel approach to the treatment of GBM. We believe that, in combination with our proprietary ZFN technology, we have the opportunity to significantly broaden the patient population that could benefit from these advances."

Data Presented at ASH

Sangamo scientists have engineered ZFNs specifically targeted to the glucocorticoid receptor gene. Data were presented yesterday at the ASH annual meeting held in Atlanta, Georgia, that demonstrate that these ZFNs cleave their intended target sequences with high specificity and efficiency resulting in the knockout of GR and the creation of glucocorticoid resistant cells. These zetakine-positive, GR-negative T-cells were demonstrated to kill glioblastoma cells in the presence of dexamethasone in vitro and in vivo in a mouse model of GBM.

About Gliomas

Gliomas are the most common type of primary brain tumors; 20,000 cases are diagnosed and 14,000 glioma-related deaths occur annually in the United States. Glioblastoma multiforme (GBM), a type of glioma, is rapidly progressive and nearly uniformly lethal. Currently, malignant glioma is managed through a combination of chemotherapy, surgery and radiation that often exacerbates the already severe symptoms caused by the location of the tumor. With modern combination therapy (surgical and radiotherapeutic techniques) the mean duration of survival has increased to 82 weeks, although 5-year survival rates have only increased from 3 to 6%. Resections of >90% of bulky tumors are usually attempted provided that vital functional anatomy is spared. The addition of chemotherapy to resection and radiation provides only marginal survival advantage to patients. Approximately 80% of recurrent tumors arise from remnants of the original incompletely resected tumor. The median survival of recurrent glioblastoma multiforme patients that are eligible to be treated with re-resection is 36 weeks.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ALS, cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

About City of Hope

City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a Comprehensive Cancer Center, the highest honor bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network, City of Hope's research and treatment protocols advance care throughout the nation. City of Hope is located in Duarte, Calif., just northeast of Los Angeles, and is ranked as one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit http://www.cityofhope.org.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the development of a novel cell therapy for the treatment of glioblastoma multiforme, research and development of other novel ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

Copyright (C) 2007 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.713.639 von tokajo am 10.12.07 13:16:50

Wollt ich auch gerade reinstellen! Das unglaubliche an der "Zinkfingertechnologie" ist für mich, daß sie in allen Bereichen in den Sangamo forscht erfolgreich eingesetzt werden kann.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.713.639 von tokajo am 10.12.07 13:16:50

Schon erstaunlich, gute News und Sangamo fällt stark trozt gutem Dow?

[aktianer]

Antwort auf Beitrag Nr.: 32.717.356 von Magnetfeldfredy am 10.12.07 18:01:36

vom Gefühl her würde ich sagen, daß die vielen Präsentationen in letzter Zeit eher schaden als nützen: es tritt ein Abstumpfungsprozeß ein und in der Folge wird man vielleicht dann gar nicht mehr ernstgenommen; denn wie soll es möglich sein, alle paar Tage wichtige News über Entwicklungsfortschritte auf Konferenzen zu präsentieren? Grundsätzlich freue ich mich, wenn ich als Aktionär auf dem Laufenden gehalten werde - andererseits würden auch einfach Meldungen in Fachmagazinen/Börsenmagazinen reichen. Na ja, vielleicht trügt mich mein Gefühl und die vielen Auftritte entfalten langfristig gesehen doch noch Wirkung.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.713.639 von tokajo am 10.12.07 13:16:50

Frohe Weihnachten und auf steigende Kurse bei Sangamo!!

[eloesch]

Gutes neues nachträglich, mit Steigen is nix http://img.wallstreet-online.de/smilies/frown.gif
Hat jemand was neues gehört?

[tokajo]

Antwort auf Beitrag Nr.: 32.940.168 von eloesch am 04.01.08 15:56:25

Euch kann man im Urlaub keine 3 Wochen alleine lassen.

Das einzig negative derzeit war, daß Kopp Investment sich von seinen restlichen Anteilen getrennt hat. Siehe die SEC News auf der Sangamo Website.
Drückt natürlich stark auf den Kurs. Kopp Investment hatte bereit früher einene Anteil verkauft. Bin mal gespannt wie die Präsentation heute aufgenommen wird.

Gruß Tokajo
Sangamo BioSciences to Present at the 26th Annual JPMorgan Healthcare Conference

RICHMOND, Calif., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 3:00 pm (PT) on Monday, January 7, 2008 at the JPMorgan Healthcare Conference in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

Copyright (C) 2008 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.965.171 von tokajo am 07.01.08 11:56:47

Servus Tokajo,

Die Frage ist warum hat er sich von allen Anteilen getrennt, wenn er an die Sangamo Technik glaubt warum verkauft er dann Alles oder vielleicht muß er verkaufen?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 32.965.171 von tokajo am 07.01.08 11:56:47

Am 5.2.2008 kommen Quartals-und Jahresendzahlen mit Pipeline-Updates, vielleicht gibts ja dann wieder mal einen UP-Move?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.247.934 von Magnetfeldfredy am 02.02.08 14:54:46

Bin wohl der letzte Sangamoianer, hier die Zahlen, nicht schlecht aber z.Zt. hilft sowieso Nichts!
Sangamo 4Q Loss Narrows on Lower Costs
Tuesday February 5, 5:06 pm ET
Sangamo Biosciences' 4th-Quarter Loss Narrows on Mix of Lower Costs and Revenue Boost


RICHMOND, Calif. (AP) -- Sangamo Biosciences Inc. said Tuesday its fourth-quarter loss narrowed as research and development costs fell and partnerships produced higher revenue.
The company lost $6.7 million, or 17 cents per share, compared with a loss of $8.9 million, or 26 cents per share, during the same period a year prior. Revenue rose 26 percent to $2.8 million from $2.2 million.

ADVERTISEMENT


Analysts polled by Thomson Financial expected a loss of 13 cents per share on revenue of $2.8 million.

The revenue boost came from partnerships with Dow Agrosciences, Sigma-Aldrich Corp., research grants, and technology agreements, the company said. Development costs fell 21 percent to $7.9 million. The same period a year prior included costs from the buyout of Edwards Lifesciences' ZFP program.

For the full year, the company lost $21.5 million, or 58 cents per share, compared with a loss of $17.9 million, or 55 cents per share. Revenue rose to $9.1 million from $7.9 million.

Shares of Sangamo rose 18 cents to $12.05 in after-hours trading after falling 28 cents, or 2.3 percent to close at $11.87 during regular trading.

[aktianer]

Antwort auf Beitrag Nr.: 33.288.533 von Magnetfeldfredy am 06.02.08 20:13:41

@Magnetfeldfreddy,
ich denke, wir sind alle noch an Bord - trotz der enttäuschenden Kursentwicklung. Aber so ist es nun mal bei den Biotechs; hier braucht man einfach viel Geduld und für die Nerven ist es dann besser, nicht zu oft auf die Kurse zu schauen.
Die Zahlen lagen wohl im Rahmen der Erwartungen und deshalb auch kaum eine Reaktion; wichtiger ist sowieso der Fortgang der Entwicklungen und hier stehen im 2.Halbjahr 2008 die Ergebnisse aus der
klin.Phase II zu SB-509 an. Fallen diese positiv aus, dann dürfte es wieder deutlich aufwärts gehen.

Gruß
aktianer

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.291.427 von aktianer am 07.02.08 08:02:34

Du hast Recht! Hier die aktuelle Analysteneinstufung, komisch weiter strong buy, jedoch Kursziel von 30 US Dollar auf US Dollar 18 gesenkt, das sollten mir die Analysten mal erklären !

Rating-Update: San Francisco (aktiencheck.de AG) - Die Analysten von JMP Securities stufen die Aktie von Sangamo BioSciences (ISIN US8006771062/ WKN 936386) unverändert mit "strong buy" ein. Das Kursziel werde von 30 auf 18 USD gesenkt. (07.02.2008/ac/a/u)

[tokajo]

Antwort auf Beitrag Nr.: 33.292.236 von Magnetfeldfredy am 07.02.08 09:48:50

Hi Fredy,

ich bin nach wie vor überzeugt von Sangamo. Im hiesigen Umfeld bringt eine positive Pressemeldung oder Präsentation keinen Kursgewinn. Biotechs sind fast alle Gefallen, da im Umfeld der Suprime Krise die Gelder bei den Banken etwas tiefer in den Taschen sitzen. Aufgrund der langsam steigenenden Lizenzeinnahmen braucht hier nach m.M. Sangamo keine Angst haben.
Entscheidend wird sein, wie aktianer schon schrieb, die kommenenden Studien

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.298.649 von tokajo am 07.02.08 17:23:17

Servus Tokajo,

schön mal wieder was von Dir zu hören, ja ich halte meine 1000 Stück eisern!
Irgendwann wird diese "scheiß" Suprime-Krise auch vorbei sein!

Gruß Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.298.649 von tokajo am 07.02.08 17:23:17

News:


Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
Tuesday February 12, 3:00 pm ET
CEO of Dow AgroSciences Announces Milestone in Wall Street Presentation


INDIANAPOLIS, and RICHMOND, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced the successful completion of a key research milestone as part of their joint Research and Commercial License Agreement. This milestone represents the successful application of Sangamo's zinc finger DNA-binding protein nuclease (ZFN(TM)) technology in precision genome editing of a native plant gene with the aim of improving a valuable trait in canola, a crop central to Dow AgroSciences' business.
ADVERTISEMENT


"It is my pleasure to announce we have achieved another significant milestone in the validation of zinc finger protein capabilities in plants," stated Jerome Peribere, the president and CEO of Dow AgroSciences, during his presentation at the Goldman Sachs Twelfth Annual Agricultural Biotech Forum. "We have demonstrated the robust utility and flexibility of the Sangamo technology in precision editing of a native plant gene, confirming the power of zinc finger proteins to accomplish specific and targeted modifications of the plant's own genetic sequence. The technology shows potential to enable the delivery of 'designer' crops into new and existing markets."

The milestone is the first demonstration of the precise modification of the DNA sequence of an existing gene in canola designed to generate an improved trait. This further demonstrates the ability of ZFNs to act at their intended target in crops of commercial importance.

"Sangamo's technology is revolutionizing scientists' ability to modify genes in cells. The power of the ZFP platform is being harnessed by Sangamo in therapeutics, our partner Sigma-Aldrich in research reagents, and, as we heard today, by Dow AgroSciences in plant agriculture to positively effect changes in plant genomes at a speed, efficiency, and specificity which heretofore was only considered a dream," said Edward Lanphier, Sangamo's president and CEO. "Dow AgroSciences has the expertise to implement our technology successfully into its precision trait development program."

The three-year agreement initiated October 2005 provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals.

Sangamo has also developed sequence-specific ZFNs for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand.

About Dow AgroSciences LLC

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $3.8 billion. Learn more at http://www.dowagro.com.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement, the anticipated execution of commercial and collaborative agreement with Dow AgroSciences, the application of Sangamo's ZFP TFs and ZFNs in plant agriculture, and the impact of milestone achievements on regulatory process and commercialization of new crop products. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Dow AgroSciences ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly report on Form 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

(TM)Trademark of Sangamo Biosciences, Inc.




--------------------------------------------------------------------------------

[tokajo]

Antwort auf Beitrag Nr.: 33.347.629 von Magnetfeldfredy am 12.02.08 21:52:22

Hi Fredy,

hier noch die zugehörige Pressemitteilung von Dow AgroSciences.
Die Technik von Sangamo wird in Zukunft einer der Schlüsselfaktoren für die Zukunft von Dow Agro sein.

Sollte bald wieder in die gewohnten Kursregionen kommen.

Gruß Tokajo

Dow AgroSciences Success Highlighted on Wall Street

Source: Dow AgroScience news release Dow AgroSciences' growing technology share was the focus of a recent presentation to investors made by Jerome Peribere, president and CEO of Dow AgroSciences. Peribere spoke to investors at the Goldman Sachs Agricultural Chemicals Conference in New York City. At the conference, Peribere reinforced the Dow AgroSciences' technology-based strategy of growing its agrichemicals business while developing new biotechnology products and platforms. 'We believe the company with the best technology will ultimately generate the most value,' said Peribere. 'We are building our capabilities to do exactly that and provide our customers with revolutionary solutions.' He cited numerous examples of the company's innovation. Chemical solutions highlighted include aminopyralid herbicide, which is rapidly becoming the standard in the range and pasture segment with use in other crops such as cereals and oilseed rape being explored. The company is launching its new insecticide spinetoram in 2008 as well as its new broad-spectrum cereal herbicide pyroxsulam, which was recently registered in Canada under the brand name SIMPLICITY™ herbicide. A new sap-feeding insecticide continues to advance rapidly through the company's pipeline. Dow AgroSciences made a great deal of progress enhancing its seeds business in 2007, and Peribere cited examples from the Americas which show the company is strengthening its corn, cotton, sunflower, and canola product portfolio. A key move in 2007 was the company's announcement of its SmartStax™ agreement with Monsanto, creating the industry's first eight-gene stack of traits in corn. As a result of this scientific breakthrough, Peribere expects Dow's HERCULEX™ insect protection technology to be on approximately 40 percent of U.S. corn acres in the SmartStax launch year of 2010 and on about 60 percent of acres by 2012. This technology package will be further enhanced when Dow AgroSciences launches its Dow Herbicide Tolerance technology in 2012 for corn, and in 2013 for cotton and soybeans. 'Glyphosate resistance is a growing reality in key crops, and our family of herbicide tolerance traits as part of an overall technology offering will help growers address both grass and weed issues with multiple classes of herbicides,' said Peribere. To continue bringing innovation to market, the company is using cutting-edge science such as Sangamo BioSciences' zinc finger protein technology. Peribere announced Dow AgroSciences has confirmed the power of zinc finger proteins, working in combination with a plant's natural DNA repair mechanisms, to accomplish specific and targeted modifications of the plant's own genetic sequence. This capability, unique to zinc finger proteins, will be a key component of the company's future, enabling delivery of 'designer' crops into new and existing markets. Peribere concluded that growth for Dow AgroSciences will continue as it develops technology leadership, builds a billion-dollar corn business and continues to advance its ag chemical pipeline. AgriMarketing note: The presentation included a slide which reported the following market shares: U.S.: Corn: 4%...7% of seed for silage Sunflower: 37% Cotton: 3% in '06; 6% in '07 Argentina: Corn: 2% Sunflower: 50% Brazil: Corn: 16% (#3) Mexico: Corn: 0% in '04; 1% in '07; goal of 4% in '09

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.369.606 von tokajo am 14.02.08 16:52:16

Servus Tokajo,

super recherchiert! Auf geht`s Sangamo zu alten oder auch neuen Höhen!

[tokajo]

Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production

RICHMOND, Calif., Feb 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that it has entered into a second Research and License Agreement with Genentech, Inc. expanding on the original agreement to include additional targets for potential improvement of production cell lines using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.

"We are pleased to expand our relationship with Genentech, a company that has always operated at the cutting edge of innovative development," said Edward Lanphier, Sangamo's president and chief executive officer. "Under this second non-exclusive, research and commercial license agreement, Sangamo will design and engineer additional ZFNs that target genes identified by Genentech to potentially improve protein pharmaceutical production in mammalian cells. This further agreement strengthens our belief that there is a growing appreciation of the value of our technology which provides a rapid, reliable and highly specific method to efficiently alter genes in eukaryotic cells."

Sangamo announced a strategic relationship with Sigma-Aldrich in July 2007 aimed at commercializing the research aspects of the ZFP technology in several areas, including the field of protein production. "As a Sangamo partner, Sigma is fully committed to bringing this powerful new technology to the scientific research community in the form of future products and services, which we believe will lead to a new era of scientific endeavor," said David Smoller, Ph.D., President of Sigma-Aldrich's Research Biotech Unit.

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, strategic relationship with collaborators, clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and its collaborators to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2008 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.491.128 von tokajo am 27.02.08 14:31:20

Serfus Tokajo,

wollt ich auch gerade reinstellen, super Info, oder was meinst Du?

Bei der Börsenkirse wird uns diese News nach unten absichern und später wenn die Suprimekrise endet geht`s up mit Sangamo!

Schönen Tag nocb!

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 33.491.410 von Magnetfeldfredy am 27.02.08 14:51:07

Hi Fredy, sehe ich ähnlich. Sangamo hatte in der letzten Zeit etwas Schwierigkeiten, nachdem ein Investor ausgestiegen ist.
Seitens der weiteren Entwicklung muß und kann man nur abwarten, wie die Produktpipeline weiter entwickelt wird.
Hier bin ich allerdings äußerst positiv gestimmt. Bis jetzt musste Sangamo noch keinen Rückschlag verkraften. Ab der ersten Zulassung wird es m.A. sehr steil bergauf gehen, da Sangamo ein völlig neues System entwickelt. Und die benötigten Gelder hierfür erhält das Unternehmen durch die Partnerschaften mit Dow Agrio Sciences, Genentech uvm.

Ich find es immer wieder schön wenn vorbörslich ein Ask von 2000 angezeigt wird. (Weiss hat nichts zu sagen, aber trotzdem ... )

Gruß Tokajo

[tokajo]

Nicht schlecht heute, ging anfangs rasant auf 17,25 Dollar hoch. ?
Warum auch immer. War nur die Meldung mit der naked short liste

Gruß Tokajo

[substance]

Antwort auf Beitrag Nr.: 33.493.762 von tokajo am 27.02.08 17:10:03

Hallo Tokajo,

welcher Investor ist wann ausgestiegen? Könntest Du mir da eine Quelle nennen?

[tokajo]

Antwort auf Beitrag Nr.: 33.509.431 von substance am 28.02.08 21:44:54

Ich meinte die alte Geschichte vom November 2007 - Kopp Investment. Ist mittlerweile verdaut.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.511.457 von tokajo am 29.02.08 08:47:26

Toller Chef, in der Börsenkrise Aktienoptionen in solch einem Ausmaß auszuüben! Der denkt ja toll an seine Shareholder!

AP
Sangamo CEO Lanphier Exercises Options
Monday March 10, 2:12 pm ET
Sangamo Biosciences CEO Edward O. Lanphier II Exercises Options for 400,000 Shares


NEW YORK (AP) -- The president and chief executive of Sangamo Biosciences Inc. exercised options for 400,000 shares of common stock and then sold 75,000 shares, according to a Securities and Exchange Commission filing Friday.
In a Form 4 filed with the SEC, Edward O. Lanphier II reported he exercised the options for 17 cents apiece Wednesday and sold shares for $12.40 to $12.77 apiece Wednesday and Thursday.

Insiders file Form 4s with the SEC to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.

Sangamo is based in Richmond, Calif.

[tokajo]

Antwort auf Beitrag Nr.: 33.602.961 von Magnetfeldfredy am 10.03.08 22:17:18

Da gebe ich dir vollkommen recht.

Übrigens der Annual Report 2007 ist auch da. Hoffentlich werden 2008 die angestrebten Ziele erreicht. HIV Phase 1 usw.

Gruß Tokajo

[mortem]

Antwort auf Beitrag Nr.: 33.602.961 von Magnetfeldfredy am 10.03.08 22:17:18

heißt das, dass der Verkaufserlös in private Taschen geflossen ist und nicht etwa als KE verstanden werden kann?

Danke,...

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.607.568 von mortem am 11.03.08 13:35:21

So sehe ich das zumindest, aber er hat uns Aktionären einen Bärendienst erwiesen, er scheint nicht überzeugt zu sein, daß der Kurs bald höher steht, sonst hätte er nicht verkauft, oder hat er verkaufen müssen da sonst seine Yacht, Privatjet.... nicht refinanziert werden kann, Suprime läßt grüßen und uns gruseln...

[mortem]

Antwort auf Beitrag Nr.: 33.612.498 von Magnetfeldfredy am 11.03.08 19:19:49

hab mal gerechnet, nach den Zahlen nach müsste er beinahe eine Mille $ eigenommen haben. Ist natürlich eine Menge Holz und zeugt in der Tat nicht von Eigenüberzeugtheit, zumindest auf kurzer bis mittlere Sicht. Wer weiß wozu er das Geld gebraucht hat, immerhin sind jetzt Immo's spot billig, vll konnte er ein Objekt nicht wiederstehen,...
wer weiß,...

[tokajo]

Antwort auf Beitrag Nr.: 33.614.224 von mortem am 11.03.08 21:44:27

was heisst in der SEC Pflichtmeldung eigentlich:
7. Nature of Indirect Beneficial Ownership (Instr. 4') By Trust

These shares are held in the Edward O. Lanphier II and Cameron M. Lanphier Trust U/T/A August 30, 2002, Edward O Lanphier II and Cameron M. Lanphier Trustees (the "Trust").

Laut Übersetzung ist es eigentlich eine Art Stiftung

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.621.393 von tokajo am 12.03.08 16:28:54

Vielleicht ist das eine Stiftung "aller Zumwinkel" wie in Lichtenstein
Mir egal wieviel er verdient wenn wir alle durch Sangamo reich werden!
Zur Zeit eher arm!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.633.664 von Magnetfeldfredy am 13.03.08 18:04:34

Sehr arm!!!

[tokajo]

Antwort auf Beitrag Nr.: 33.666.796 von Magnetfeldfredy am 17.03.08 22:30:40

Hi Fredy,

derzeit steht im Ask der zukünftige Wert 260 $ von Sangamo.

Bin jetzt auch aufgrund eines Nachkauf ins Minus gerutscht. Bin gespannt was uns das Jahr 2008 an Highlights bringt. In der letzten Präsentation war doch einiges in der Pipeline.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.668.176 von tokajo am 18.03.08 09:09:12

Servus Tokajo,

ich glaube die Amis verkaufen jetzt viele kleine Nebenwerte wie Sangamo, ohne Rücksicht auf Pipline etc. die brauchen cash...
Shit!!!
Aber ich bleib dabei, bin jetzt mit 6.000 EUR im roten Bereich allein mit SGMO!
Was mich sehr negativ stimmt ist die Tatsache,daß bei Erholungen des DOW Sangamo überhaupt nicht mitmacht!

[tokajo]

Antwort auf Beitrag Nr.: 33.675.258 von Magnetfeldfredy am 18.03.08 17:41:22

Zinc-finger proteins promise new treatment for HIV/AIDS

LONDON -- A kind of protein called zinc-finger proteins which can turn genes on and off permanently may transform treatment of HIV/AIDS, heart disease and diabetes, British newspaper The Times reported on Tuesday. Sangamo BioSciences, a company in California, has already developed several drugs based on the zinc-finger proteins discovered and named in 1985 by Aaron Klug of the Laboratory of Molecular Biology in Cambridge, England, The Times said. 'We can use this technique to change the function of a single gene permanently. The beauty of zinc-finger nuclease lies in their simplicity. Where other methods are long, arduous and often messy, it is relatively easy to switch off genes using this method,' Klug was quoted as saying. The first Sangamo drugs designed to target genes have begun clinical trials in the United States on patients with arterial disease and diabetes-induced nerve damage. The most advanced of the drugs uses a zinc-finger nuclease - an enzyme - to treat diabetic neuropathy, a common complication of diabetes that causes nerve damage and pain. The drug binds to a gene called VEGF-A, known to protect the nervous system, and switches it on to prevent nerve damage. Phase 2 trials of the drug are underway. The same gene is also being targeted to treat peripheral arterial disease, which causes blocked arteries in the limbs. A zinc-finger drug that has started safety trials aims to stimulate VEGF-A activity, which can promote the growth of new arteries. According to the report, a third trial for HIV is due to begin within months. If the trial is successful, scientists predict that the technique could change the way many diseases are treated, making genetic therapies a routine part of medicine for the first time. Klug said that in the longer term, a similar approach might be used to grow new blood vessels in the heart.

[tokajo]

Antwort auf Beitrag Nr.: 33.675.537 von tokajo am 18.03.08 17:59:34

Hier ist noch der Link zur "The Times"
http://www.timesonline.co.uk/tol/news/uk/science/article3571…

Der Artikel ist etwas ausführlicher.

Das wird schon.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.676.195 von tokajo am 18.03.08 18:43:11

Ich hoffe auch!
Aber während der Suprime-Krise verpuffen alle good news!
Danke für die News!
Gruß Fredy

[mortem]

+0,77
+8,72%

fürs erste mal nicht schlecht, dennoch weit von dem wo wir herkommen. Ich hoffe, dass die Richtung beibehalten wird,...

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.678.758 von mortem am 18.03.08 21:44:40

Wenigstens wieder zweistellig!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.691.600 von Magnetfeldfredy am 19.03.08 22:02:09

Good News, it works!

Press Release Source: Sangamo BioSciences, Inc.


Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines
Monday March 24, 7:00 am ET
ZFN Technology has Broad Applications in Research, Drug Development and Therapeutics


ST. LOUIS and RICHMOND, Calif., March 24 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL - News) and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the publication of data demonstrating the use of Sangamo's zinc finger DNA-binding protein nucleases (ZFNs(TM)) in a new approach for rapid generation of "knock-out" cell lines, important tools in research and therapeutic product development.
ADVERTISEMENT


This work, which was carried out in collaboration with scientists from Pfizer Inc, represents a significant advance in the specificity and efficiency of the generation of cell lines in which an individual gene has been "knocked-out" or deleted. Such cell lines are powerful tools that are widely used in research to identify a gene's function, in drug development to screen potential drug candidates and for production of recombinant proteins. In addition, Sangamo is using this technology to develop ZFP Therapeutics(TM) for the treatment of HIV/AIDS and brain cancer. Sigma-Aldrich is Sangamo's exclusive licensee for this technology in the laboratory research reagent field.

"These data have broad implications for experimental and translational biology, biotechnology and medicine," said Philip Gregory, D.Phil., Sangamo's vice president of research. "The generation of knockouts in basic research and industrial cell line engineering has been severely limited by the absence of efficient methods for the specific, targeted disruption of any gene. Our ZFN technology facilitates this in a rapid, single-step process. Importantly, the process enables the simultaneous disruption of both cellular copies of the gene of interest with an efficiency that obviates the need for selection markers and other complicated strategies to identify knockout cells -- a dramatic improvement over existing methodologies."

The work, co-authored by scientists at Sangamo and Pfizer Inc, was published online on March 21, 2008, http://www.pnas.org/cgi/content/abstract/0800940105v1 in the Early Edition of the Proceedings of the National Academy of Sciences ("Targeted Gene Knockout in Mammalian Cells Using Engineered Zinc Finger Nucleases").

The data demonstrate that ZFN technology can be used to significantly speed up the process of generating cell lines in which a single gene is specifically knocked out. ZFNs were used to place a double strand break in the DNA sequence precisely within the gene to be eliminated. The process then takes advantage of the cell's DNA repair system which repairs the break in the sequence. This natural process often results in a small amount of DNA being deleted at the site of the break and the consequent disruption of the expression of the gene and the protein that it encodes. Sangamo and Pfizer scientists demonstrated that the disruption process occurred with sufficiently high frequency that selection markers were not required to identify multiple independent knockout cell lines with minimal screening effort.

"This publication represents ground-breaking work in the use of ZFNs and highlights an application of this powerful technology that is expected to revolutionize research, drug development, and protein production. Sigma's aim is to make the technology widely available to scientists throughout the world," stated David Smoller, Ph.D., President of Sigma-Aldrich's Research Biotech Unit. "In addition to reagents for knocking out an investigator's 'favorite gene' in a particular cell type, the ZFN platform can be used to generate panels of cell lines for small molecule drug screening in which the 'druggable universe' of gene targets have been individually knocked out. We expect to have ZFN research reagents similar to those used in this publication available to all research scientists in the very near future."

"The applications of this technology are of significant commercial value," said Edward Lanphier, Sangamo's president and CEO. "While the current publication focuses on research and biotechnology applications, we have used these same techniques for knocking out genes in multiple crop plants and to develop ZFP Therapeutics(TM). We are developing potential treatments for HIV/AIDS by knocking-out the CCR5 gene in T-cells and for brain cancer (glioblastoma) by disrupting the glucocorticoid receptor (GR) in engineered killer T-cells. We expect to file Investigative New Drug Applications (INDs) for both of these programs to enter the clinic later this year."

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. We are committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sigma-Aldrich's and Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFNs, and potential therapeutic, medical research and drug development uses of the ZFN technology and the timing of initiation of clinical trials by Sangamo. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and Sigma-Aldrich to develop commercially viable products and technological developments by our competitors. See the SEC filings, and in particular, the risk factors described in the Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q of each of Sangamo and Sigma-Aldrich. Neither Sigma-Aldrich nor Sangamo assumes any obligation to update the forward-looking information contained in this press release.

[mortem]

Antwort auf Beitrag Nr.: 33.713.913 von Magnetfeldfredy am 24.03.08 18:45:19

This publication represents ground-breaking work in the use of ZFNs and highlights an application of this powerful technology that is expected to revolutionize research, drug development, and protein production.




Die Frage, die ich mir stelle, warum wurde vor 2 Wochen eine Aktienoptionen ausgeführt, mit der hätte man doch warten können (bei den denkbaren Aussichten)?
Und warum wirkt sich die News aktuell nicht sonderlich auf den Kurs aus?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.714.385 von mortem am 24.03.08 20:02:10

Ich denke der CEO hat genug Aktien von seiner Firma um auch bei deutlich steigenden Kursen, die ich aber erst in 1-2 Jahren erwarte, zu partizieren!
Und die Aktienoptionen hat er eben ausgeübt um seinen akutellen Lebensstandard zu sicher!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.718.950 von Magnetfeldfredy am 25.03.08 13:35:10

News, die Technik von Sangamo greift auch bei Tieren und bringt Revenues!
Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Monday April 7, 7:00 am ET


RICHMOND, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced that it had entered into a License Agreement with Open Monoclonal Technologies (OMT), a private company based in Palo Alto, California. Under this agreement, Sangamo will provide a non-exclusive, worldwide license to OMT for the commercial use of transgenic animals generated using Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. OMT will pay Sangamo an upfront license fee, payments upon the achievement of certain clinical development milestones, a share of payments received by OMT from sublicensees, and royalties on sales of any products developed using Sangamo's ZFP technology. For any given OMT Product, OMT has the right to buy out its future royalty payment obligations under the Agreement by paying a lump sum fee to Sangamo.
ADVERTISEMENT


"Our ZFP Nuclease (ZFN) platform addresses a major problem that has long hampered the development of transgenic models in species other than mice," said Philip Gregory, Sangamo's vice president of research. "Site-specific manipulation of the mouse genome via gene targeting revolutionized biology and enabled the generation of mouse cell-lines and transgenic mouse models of human disease. However, until now, and the application of ZFNs, genomes of other species could not be efficiently modified in a site-specific manner. The frequency and precision of ZFN-mediated genome editing, in combination with the ability to design ZFNs against potentially any gene, opens up the potential to more easily generate transgenic animals of any species."

"We are pleased to provide OMT with a non-exclusive, commercial license to use transgenic animals generated using our ZFN technology," said Edward Lanphier, Sangamo's president and chief executive officer. "There is growing appreciation of the value of our technology as a rapid, reliable and highly specific tool to modify genes in eukaryotic cells and even whole organisms. As this increases we believe that there will be numerous applications of the technology in the generation of a variety of transgenic species as models of human disease and for drug development. "

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X- linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the payment of fees and royalties under the license agreement, development of transgenic species, and the application of Sangamo's ZFP technology in the development of transgenic animals as models of human disease and for drug development. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.




--------------------------------------------------------------------------------
Source: Sangamo BioSciences, Inc.

[tokajo]

Antwort auf Beitrag Nr.: 33.825.398 von Magnetfeldfredy am 07.04.08 13:21:03

Sangamo hat bis jetzt einen guten Lauf. + 6 %.
Am 30 Mai findet das wichtige Asco Meeting statt http://www.asco.org/portal/site/ASCO/

Forschungsergebnisse hierzu werden diesmal bereits ab 15.Mai veröffentlicht. Ich nehme an das Sangamo hier auch über Neuigkeiten berichten werden.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.858.797 von tokajo am 10.04.08 17:13:41

Oder es keimt wieder Übernahmefantasie auf?

[tokajo]

Antwort auf Beitrag Nr.: 33.860.906 von Magnetfeldfredy am 10.04.08 20:31:05

Hi Fredy,
Millenium ist gestern übernommen worden. Aufschlag von 53 % auf den aktuellen Kurs.

10.04.2008 09:33:00

Takeda übernimmt Millennium Pharmaceuticals für 8,8 Mrd. Dollar

Osaka (aktiencheck.de AG) - Die Takeda Pharmaceutical Co. Ltd. (ISIN JP3463000004 / WKN 853849), der größte Pharmakonzern in Japan, übernimmt den amerikanischen Biotechnologiekonzern Millennium Pharmaceuticals Inc. (ISIN US5999021034 / WKN 900625) für rund 8,8 Mrd. Dollar.

Wie aus einer gemeinsamen Pressemitteilung vom Donnerstag hervorgeht, erhalten die Aktionäre von Millennium Pharmaceuticals im Rahmen der Offerte 25,00 Dollar in bar für jeden Anteilsschein. Dies entspricht einer Prämie von 53 Prozent auf den Schlusskurs der Aktie vom Mittwoch. Die Boards beider Unternehmen haben der Transaktion bereits zugestimmt.

Im Geschäftsjahr 2007 beliefen sich die Erlöse von Millennium Pharmaceuticals auf rund 528 Mio. Dollar.

Die Aktie von Takeda Pharmaceutical schloss heute in Tokio bei 5.410 Japanischen Yen (-2,52 Prozent), die von Millennium Pharmaceuticals gestern in New York bei 16,35 Dollar. (10.04.2008/ac/n/a)

Quelle: Finanzen.net / Aktiencheck.de AG

© Aktiencheck.de AG


Quelle: AKTIENCHECK.DE

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.864.924 von tokajo am 11.04.08 11:44:02

Servus Tokajo,

ja, daß könnte uns auch passieren aber mir wäre ca. 12 EUR für eine Sangamo Aktie viel zu billig, wir sind ja auch im Agrarbereich mit Monsanto gut dabei und ich kann mich erinnern, daß im Herbst der Taipan Börsenbrief Sangamo mit "Strong buy" und Kursziel 50 US Dollar aufgenommen hat, daß wäre schon eher in meinem Sinn und auch in Deinem, oder?

[tokajo]

Antwort auf Beitrag Nr.: 33.869.315 von Magnetfeldfredy am 11.04.08 18:38:58

Hallo zusammen, kann man eigentlich im nachhinein den Diskussionstitel ändern, oder besteht hier eine Art Urheberrecht.?

Weitere Präsentation von Sangamo zum Thema Gehirntumor.

Gruß Tokajo

Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

SAN DIEGO, April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of positive data in a mouse tumor model from its ZFP Therapeutic(TM) program for the treatment of glioblastoma multiforme (GBM), a progressive and usually fatal brain cancer. The data were presented in the New Approaches to Biological Therapy Session at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) by Sangamo's collaborator Michael C.V. Jensen, M.D., Associate Chair, Division of Cancer Immunotherapeutics & Tumor Immunology, City of Hope.

"In collaboration with Sangamo, we have successfully generated engineered T-cells that can destroy glioblastoma tumor cells in animals in the presence of glucocorticoids," said Dr. Jensen. "Treatment of recurrent GBM with modified T-cells, an otherwise promising approach for this cancer, is rendered ineffective by the use of glucocorticoids to control inflammation of the brain due to the tumor and surgery. These data show that we have solved that problem and are making significant progress in our efforts to create an 'off-the-shelf' cell-based product for the treatment of GBM. The ZFN(TM)-modification of the glucocorticoid receptor (GR) in our engineered T-cells protects the cells from the effects of glucocorticoids which would normally inhibit T-cell function, and in addition, does not alter their cytolytic or tumor-killing properties."

Dr. Jensen has developed novel chimeric immunoreceptors called "zetakines" that can be engineered into human immune cells to generate a population of cells that can specifically recognize and destroy cancer cells. He has already used these engineered cells in clinical trials for malignant gliomas. In his current clinical protocol, T-cells are removed from a patient with GBM and modified to express the zetakine. These modified cells are infused into the brain following surgery for the targeted elimination of residual tumor cells. Frequently however, glucocorticoids, such as dexamethasone, must be administered to patients pre- and post-surgery to stop the brain-swelling caused by the tumor and surgery. Glucocorticoids inactivate or kill the T-cells through a protein known as the glucocorticoid receptor (GR), limiting the benefit of this novel therapy. Currently, this approach is also patient-specific or autologous, which makes it time and labor-intensive. Cells without a functional GR are drug-resistant and should therefore be available to destroy tumor cells.

The aim of the collaboration is to use Sangamo's zinc finger DNA-binding protein nuclease (ZFN) gene modification technology to delete the GR in T-cells engineered to express the zetakine. The specific deletion of GR in the zetakine-expressing, anti-glioma T-cells allows them to be used in the presence of glucocorticoids and to be developed as an "off the shelf" or allogeneic cell product immediately available to GBM patients. The data presented at AACR suggest that this strategy is effective in animal models of the disease. Sangamo expects to file an Investigative New Drug (IND) application for this cell therapy in 2008.

"These data demonstrate an important direct therapeutic application of our ZFN technology for the optimization of cell-based pharmaceuticals," said Edward Lanphier, Sangamo's president and CEO. "We are very pleased to be working with City of Hope and Mike Jensen and his team who have developed this novel approach to the treatment of GBM. We believe that, in combination with our proprietary ZFN technology, we have the opportunity to significantly broaden the patient population that could benefit from these advances."

Data Presented at AACR

Sangamo scientists have engineered ZFNs specifically targeted to the glucocorticoid receptor (GR) gene. Data were presented demonstrating that treatment of T-cells engineered to kill glioblastoma cells with these ZFNs results in the knockout of the GR gene creating glucocorticoid-resistant T-cells. These zetakine-positive, GR-negative T-cells killed glioblastoma cells in vitro. In addition, data were presented from a mouse model of GBM demonstrating that the T-cells were capable of killing tumor cells in the presence of the glucocorticoid dexamethasone.

About Gliomas

Gliomas are the most common type of primary brain tumors; 20,000 cases are diagnosed and 14,000 glioma-related deaths occur annually in the United States. Glioblastoma multiforme (GBM), a type of glioma, is rapidly progressive and nearly uniformly lethal. Currently, malignant glioma is managed through a combination of chemotherapy, surgery and radiation. With modern combination therapy, the mean duration of survival has increased to 82 weeks, although 5-year survival rates have only increased from 3% to 6%. Approximately 80% of recurrent tumors arise from remnants of the original incompletely resected tumor. The median survival of recurrent glioblastoma multiforme patients that are eligible to be treated with re-resection is 36 weeks.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com .

About City of Hope

City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a Comprehensive Cancer Center, the highest honor bestowed by the National Cancer Institute, and a founding member of the National Comprehensive Cancer Network, City of Hope's research and treatment protocols advance care throughout the nation. City of Hope is located in Duarte, Calif., just northeast of Los Angeles, and is ranked as one of "America's Best Hospitals" in cancer and urology by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit http://www.cityofhope.org.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the development of a novel cell therapy for the treatment of glioblastoma multiforme, research and development of other novel ZFP TFs and ZFNs, the initiation and results of clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2008 PR Newswire. All rights reserved

[Magnetfeldfredy]

Servus Tokajo,

in unseren kleinen aber feinen "Runde"!
Gute News, jedoch dauert`s Jahre bis was draus wird, oder?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.890.900 von Magnetfeldfredy am 15.04.08 18:30:15

5000 Stück mit Bid 7,40 in Frankfurt!
Kommt was Großes?

[tokajo]

Antwort auf Beitrag Nr.: 33.917.664 von Magnetfeldfredy am 18.04.08 12:51:44

Servus Fredy,

mir ist nichts bekannt. Die kleinen Anleger erfahren sind jedoch meist hintendran.

Zur Erinnerung: Sangamo ist weiterhin strong Buy.
http://www.nasdaq.com/earnings/analyst_recommendations.asp?s…

Gruß Tokajo

[Magnetfeldfredy]

Servus Tokajo,

na ja, Hauptsache Sangamo steigt!

Servus Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.918.507 von Magnetfeldfredy am 18.04.08 14:01:04

Unser Chef verkauft wieder Aktien, man der braucht aber viel Kohle!
AP
Sangamo Biosciences president and CEO sells 25,000 shares
Friday April 18, 3:57 pm ET
Sangamo Biosciences President and CEO Edward Lanphier sells 25,000 shares of common stock


NEW YORK (AP) -- The president and chief executive of Sangamo Biosciences Inc., which researches and develops DNA-binding proteins, sold 25,000 shares of common stock under a prearranged trading plan, according to filings with the Securities and Exchange Commission.
In Form 4s filed with the SEC Thursday, Edward O. Lanphier II reported selling the shares Tuesday for $11.27 to $11.66 apiece.

Lanphier owned the shares indirectly through a trust.

The stock sale was conducted under a prearranged 10b5-1 trading plan, which allows a company insider to set up a program in advance for such transactions and proceed with them even if he or she comes into possession of material nonpublic information.

Insiders file Form 4s with the SEC to report transactions in their companies' shares. Open market purchases and sales must be reported within two business days of the transaction.

Sangamo is based in Richmond, Calif.

[tokajo]

Antwort auf Beitrag Nr.: 33.924.447 von Magnetfeldfredy am 19.04.08 08:03:26

Am 30.04 gibt´s die Quartalszahlen. Bin gespannt wie sich die Lizenzeinnahmen und Milestone Zahlungen entwickelt haben.

Gruß Tokajo

Sangamo BioSciences Announces First Quarter Conference Call and Webcast

RICHMOND, Calif., April 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2008 financial results on Wednesday, April 30, 2008, after the market closes. The press release will be followed by a conference call at 2:00 p.m. PT, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-675-4749 for domestic callers and 719-325-4940 for international callers. The passcode for the call is 6274211. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 5:00 p.m. PT on April 30, 2008 to 8:59 p.m. PT on May 7, 2008. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 6274211.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFTM) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNTM) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2008 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.972.296 von tokajo am 25.04.08 13:39:38

Servus Tokajo,

dem steigendem Kurs von Sangamo zu urteilen müßten die Zahlen gut sein, hast Du konkrete Schätzungen?

Schönes Wochenende!

Gruß Fredy

[tokajo]

Antwort auf Beitrag Nr.: 33.977.927 von Magnetfeldfredy am 26.04.08 13:47:38

Hi Fredy,

leider nein. So weit stecke ich bei Sangamo nicht drin.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 33.982.105 von tokajo am 28.04.08 08:41:49

Ich habe recherchiert -0,16 EUR/Share ist die Analystenschätzung!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.002.567 von Magnetfeldfredy am 30.04.08 15:16:53

Ergebnis pro Aktie: -0,20 aber der Ausblick stimmt!

Sangamo BioSciences Reports First Quarter 2008 Financial Results

RICHMOND, Calif., April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2008 financial results and accomplishments.

For the first quarter ended March 31, 2008, Sangamo reported a consolidated net loss of $8.0 million, or $0.20 per share, compared to a net loss of $5.4 million, or $0.15 per share, for the same period in 2007. As of March 31, 2008, the company had cash, cash equivalents and short-term investments of $73.6 million.

Revenues for the first quarter of 2008 were $2.8 million, compared to $1.4 million for the same period in 2007. First quarter 2008 revenues were primarily from Sangamo's agreements with Dow AgroSciences and Sigma-Aldrich Corporation, research grants and enabling technology agreements in protein production.

Research and development expenses were $8.6 million for the first quarter of 2008, compared to $5.4 million for the same period in 2007. The increase in R&D expenses is primarily related to advancing Sangamo's ZFP Therapeutic(TM) clinical program in diabetic neuropathy and costs related to pre-IND programs in HIV/AIDS and glioblastoma, as well as increased personnel and laboratory supply expenses. Non-cash employee stock-based compensation included in research and development expenses totaled $0.9 million and $0.3 million in the 2008 and 2007 periods, respectively.

General and administrative expenses were $2.9 million for the first quarter of 2008, compared to $2.0 million for the corresponding 2007 period. The increase in general and administrative expenses was primarily due to increased personnel costs. Non-cash employee stock-based compensation included in general and administrative expenses totaled $0.9 million and $0.2 million in the 2008 and 2007 periods, respectively.

Total operating expenses for the first quarter of 2008 were $11.6 million, compared to $7.4 million for the same period in 2007.

Net interest and other income was $0.8 million for the first quarter of 2008, compared to $0.6 million for the same period in 2007, primarily due to higher average cash and investment balances.

First Quarter 2008 Highlights
-- Initiation of a Phase 2 stem cell mobilization clinical trial. The
study is a randomized, single-blind, placebo-controlled, multi-
center Phase 2 clinical trial of SB-509 (SB-509-703) in subjects
with mild to moderate diabetic neuropathy (DN) and is designed to
evaluate the pharmacokinetics of stem cell mobilization into the
bloodstream after treatment. Circulating stem cells observed post
treatment with SB-509 are highly enriched in cell types that mediate
tissue repair. In addition, early data suggests that SB-509
treatment may mobilize between 100 to 1000-fold more cells than are
typically being introduced into subjects in many of the ex vivo stem
cell therapeutic approaches that are currently being tested.
Ultimately, this phenomenon may also serve as a pharmacodynamic
surrogate biomarker enabling a physician to easily monitor progress
of this therapy for DN after SB-509 administration.
-- Entry into a second Research and License Agreement with Genentech,
Inc. and a new License Agreement with Open Monoclonal Technologies
(OMT). Sangamo's second agreement with Genentech is an expansion of
an earlier agreement and includes modification of additional targets
for potential improvement of production cell lines using our
proprietary zinc finger DNA-binding protein nuclease (ZFN)
technology. Sangamo also agreed to provide a non-exclusive,
worldwide license to OMT for the commercial use of transgenic
animals generated using our proprietary ZFN technology. OMT is
paying Sangamo an upfront license fee, payments upon the achievement
of certain clinical development and commercial milestones, a share
of payments received by OMT from sublicensees, and royalties on
sales of any products developed using Sangamo's ZFP technology.
-- Successful completion of a key research milestone as part of the
joint Research and Commercial License Agreement between Dow
AgroSciences LLC and Sangamo This milestone represents the
successful application of Sangamo's ZFN technology in precision
genome editing of a native plant gene with the aim of improving a
valuable trait in canola, a crop central to Dow AgroSciences'
business.
-- Presentation of positive preclinical animal data from Sangamo's ZFP
Therapeutic program for the treatment of glioblastoma multiforme
(GBM). Data were presented in the New Approaches to Biological
Therapy Session at the 2008 Annual Meeting of the American
Association for Cancer Research (AACR) by Sangamo's collaborator
Michael C.V. Jensen, M.D., Associate Chair, Division of Cancer
Immunotherapeutics & Tumor Immunology, City of Hope. The data
demonstrated that treatment of T-cells, engineered to kill
glioblastoma cells, with ZFNs specifically targeted to the
glucocorticoid receptor (GR) gene results in the knockout of the GR
gene creating glucocorticoid-resistant T-cells. These zetakine-
positive, GR-negative T-cells kill glioblastoma cells in vitro. In
addition, data were presented from a mouse model of GBM
demonstrating that these T-cells were capable of killing tumor cells
in the animal in the presence of the glucocorticoid dexamethasone.
-- Publication of data demonstrating the use of Sangamo's ZFN
technology in a new approach for rapid generation of "knock-out"
cell lines. Sigma-Aldrich Corporation and Sangamo announced the
publication of work which was carried out in collaboration with
scientists from Pfizer Inc and represents a significant advance in
the specificity and efficiency of the production of "knock-out" cell
lines. Such cell lines are powerful tools that are widely used in
research to identify a gene's function, in drug development to
screen potential drug candidates and for production of recombinant
proteins. The data were published in the Proceedings of the
National Academy of Sciences Early Edition online on March 21, 2008,
http://www.pnas.org/cgi/content/abstract/0800940105v1 ("Targeted
Gene Knockout in Mammalian Cells Using Engineered Zinc Finger
Nucleases") and in the print edition of the journal. Sigma-Aldrich
is Sangamo's exclusive licensee for this technology in the
laboratory research reagent field.
-- Nomination of Thomas G. Wiggans for election to Sangamo's Board of
Directors. Mr. Wiggans was most recently the Chief Executive Officer
of Connetics Corporation from 1994, and Chairman of the Board from
January 2006, until December 2006 when Connetics Corporation was
acquired by Stiefel Laboratories, Inc. He has extensive senior
management experience in the biotechnology industry in executive and
board positions with a number of life sciences companies. He will
stand for election by shareholders, along with other board members
standing for re-election, at Sangamo's Annual Meeting which will be
held at 9:00 a.m. (PT) on Wednesday, June 4, 2008 at Sangamo's
headquarters in Richmond, California.



Conference Call

Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. The webcast replay will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide forward-looking guidance.

The conference call dial-in numbers are 877-675-4749 for domestic callers and 719-325-4940 for international callers. The passcode for the call is 6274211. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on April 30, 2008 to 11:59 p.m. ET on May 7, 2008. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 6274211.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership with collaborators and anticipated amount of cash and cash equivalents. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.



SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)
Quarter Ended March 31,
2008 2007
Consolidated Statement of Operations Data:
Total revenues $2,765 $1,422
Operating expenses:
Research and development 8,646 5,430
General and administrative 2,927 1,999
Total operating expenses 11,573 7,429
Loss from operations (8,808) (6,007)
Interest and other income, net 836 648
Net loss $(7,972) $(5,359)
Basic and diluted net loss per common share $(0.20) $(0.15)
Shares used in computing basic and diluted net
loss per common share 40,489 35,057


March 31, December 31,
2008 2007
(Unaudited)
CONSOLIDATED CONDENSED BALANCE SHEET DATA

Cash, cash equivalents and short-term
investments $73,579 $81,412
Total assets 76,742 83,900
Total stockholders' equity 66,457 72,122


SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com


Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX


Close window | Back to top

[tokajo]

Antwort auf Beitrag Nr.: 34.008.324 von Magnetfeldfredy am 01.05.08 10:44:23

Hi Fredy,

ich finde die Zahlen sehr gut. Inbesondere die ums doppelte gestiegenen Einnahmen von 2.8 Mio für das 1.Quartal.
So wird die Basis für die weitere Entwicklung geschaffen. Je weiter die Fortschritte, desto höher die Kosten.
Einen wirklichen Rückschlag hatten wir bis jetzt noch nie.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.028.555 von tokajo am 05.05.08 14:36:36

Servus Tokajo,

die Zahlen sind gut, aber Sangamo wird ja mit ca. 500 Millionen US Dollar an der Börse bewertet, da müssen die Projekte wirklich erfolgreich werden um das zu rechtfertigen, oder?

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 34.029.959 von Magnetfeldfredy am 05.05.08 17:00:05

Morgen ist wieder eine richtungsweisende Konferenz.

Gruß Tokajo

Sangamo BioSciences to Present at the 7th Annual JMP Securities Research Conference

RICHMOND, Calif., May 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 12:00 p.m. (ET) on Tuesday, May 20, 2008 at the 7th Annual JMP Securities Conference in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

[tokajo]

Antwort auf Beitrag Nr.: 34.122.037 von tokajo am 19.05.08 09:40:08

Und am 22.05 ist die Nächste.

Gruß Tokajo

Sangamo BioSciences to Present at the Citi Investment Research Global Healthcare Conference

RICHMOND, Calif., May 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 11:30 a.m. (ET) on Thursday, May 22, 2008, at the 2008 Citi Investment Research Global Healthcare Conference in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.122.650 von tokajo am 19.05.08 10:43:51

Servus Tokajo,

Neue Daten!



Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
Monday May 19, 7:00 am ET
Progenitor Cell Mobilization Observed in Subjects with Critical Limb Ischemia Treated with ZFP Therapeutic


MIAMI, May 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of data from a Phase 1 clinical trial of a zinc finger DNA-binding protein activator of vascular endothelial growth factor (ZFP-VEGF) in subjects with critical limb ischemia (CLI). The data demonstrate that administration of ZFP-VEGF resulted in a statistically significant increase in circulating progenitor or stem cells in the peripheral blood. In addition, within a subgroup in which bone marrow cells were examined before and after treatment, the data suggests that subjects who showed the most marked clinical improvements, as judged by limb salvage, ulcer healing, reduction in pain and increased oxygen concentrations in the tissues, also showed the greatest increase in bone marrow stem cells. The trial was conducted by principal investigator Brian Annex, M.D., Director, Vascular Medicine and his colleagues at Duke University Medical Center.
ADVERTISEMENT


"The data obtained in this clinical trial are very interesting and may have important implications for assessing biological activity and efficacy of this therapeutic strategy," commented the presenter, Robert Mitchell, M.D., of the department of medicine at Duke University Medical Center. "Several of the subjects in this trial were already scheduled for amputation but chose to enroll in this important trial. Within a subgroup analysis, the data demonstrate that the best clinical responders had the largest fold increase in bone marrow stem cells twelve days after dosing. Increased mobilization of stem cells, which may be involved in tissue regeneration and repair, may provide an early indication of a biological response to this therapy."

"These data, and other clinical and preclinical observations of natural mobilization of stem cells in a response to our ZFP activator of VEGF, are very interesting and form the basis of our most recently initiated Phase 2 study (SB-509-703)," commented Dale Ando, M.D. Sangamo's vice president of therapeutic development and CMO. "In this Phase 2 clinical trial we are monitoring changes in the numbers of stem cells in the circulation of subjects with mild to moderate diabetic neuropathy after treatment with our ZFP Therapeutic. We believe that the study may provide us with valuable pharmacodynamic data on the relationship between stem cell mobilization and treatment."

Clinical Results Presented at the ISCT Meeting

The data presented at the ISCT meeting on Sunday, May 18, 2008, were collected from a single arm, open-label, Phase 1 clinical trial in subjects (n=20) with critical limb ischemia (Rutherford Grade 4/5). Qualifying subjects were assigned to receive dose-escalating, intra-muscular injections of ZFP-VEGF in the ischemic leg (index leg). Subjects were clinically classified as significant responders, minimal responders or non-responders based on their tissue oximetry readings. Circulating progenitor cells were measured and quantitated by FACS analysis based on aldehyde dehydrogenase activity (ALDH+) and expression of CD34 in 11 subjects. These measures were subsequently compared with clinical outcomes. Additionally, bone marrow samples from 8 patients were evaluated for ALDH+ cells on Day 0 and Day 12 post treatment to determine the effects of ZFP-VEGF on progenitor cell mobilization.

Clinicians observed a mean increase in circulating CD34+/ ALDH + cells of 1.3 fold from Day 0 to Day 30 post-treatment and 1.9 fold from Day 0 to Day 90 post-treatment. In addition, subjects with 7 to 9 fold increases in bone marrow stem cells were also the best clinical responders as assessed by increased tissue oxygen perfusion, improved pain scores, ulcer healing and amputation rates.

Aldehyde bright stem cells can be identified in the subject's blood or bone marrow by staining with a substrate of aldehyde dehydrogenase, an enzyme that is highly expressed in stem cells. Stem cells can self-renew through cell division giving rise to more stem cells and, under certain conditions, can be induced to become cells with a special function in the body such as nerves and blood vessels. It is believed that in response to long-range signals, stem cells are able to migrate from the blood circulation into areas of injury or degeneration and participate in the repair response. Aldehyde bright stem cell populations of human bone marrow have been shown to be highly enriched in cell types thought to mediate tissue repair, including endothelial, mesenchymal, neural and hematopoietic progenitor cells.

"We are pleased to have an opportunity to highlight several of our ZFP Therapeutic programs at this meeting focused on development of novel cell therapies," said Edward Lanphier, Sangamo's president and CEO. "The stem cell data that Dr. Mitchell presented align well with observations that we and our collaborators have made in both preclinical animal models of angiogenesis and in our early clinical studies of our ZFP activator of VEGF, SB-509. We look forward to the data from our ongoing Phase 2 clinical trial, SB-509-703 which is designed to investigate this potentially useful effect of our ZFP Therapeutic as a means of mobilizing cells that have a function in tissue repair and regeneration."

Other Presentations of Data from Sangamo Programs at the ISCT Meeting

In addition, preclinical data is being presented from Sangamo's ZFP Therapeutics programs in glioblastoma and HIV/AIDS.


-- Sunday, May 18: Oral Session: Immunotherapy and Dendritic Cells;
"Zinc Finger Nucleases Targeting the Glucocorticoid Receptor Allow
IL-13 Zetakine Transgenic CTLs to Kill Glioblastoma Cells in vivo in
the Presence of Immunosuppressing Glucocorticoids" Philip Gregory, D.
Phil., Vice President, Research, Sangamo BioSciences, Inc.

-- Monday, May 19:
-- Workshop: "Emerging Technologies" Bruce Levine, Ph.D., Department
of Pathology and Laboratory Medicine, University of Pennsylvania
School of Medicine.
-- Poster Session: "Controlling HIV in vivo - Establishment of HIV
Resistant CD4 T Cells by Engineered Zinc Finger Protein
Nucleases."

It works very well!!!!

[tokajo]

Antwort auf Beitrag Nr.: 34.124.379 von Magnetfeldfredy am 19.05.08 14:08:53

http://www.forbes.com/global/2008/0602/050_2.html

Sehr interessanter Bericht über die Zusammenarbeit und Zukunft zwischen Dow Agro Sience und Sangamo.

Zukunft der Nahrungsmittelproduktion usw.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.170.339 von tokajo am 26.05.08 10:52:15

Servus Tokajo,

hab ich auch schon gelesen, sehr interessant!
Aber zum Durchbruch werden noch several years vergehen, leider!
Ich bleib dabei!
Viele Grüße

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 34.170.403 von Magnetfeldfredy am 26.05.08 11:01:08

Hoffen wir mal dass der Analyst von der Materie keine Ahnung hat.

Gruss Tokajo


AP
Sangamo skids as analyst doubts ZPF success
Thursday May 29, 11:21 am ET
Sangamo Biosciences declines as analyst says SB-509 trials will fail and stock will tumble


NEW YORK (AP) -- Shares of Sangamo Biosciences Inc. sank Thursday after an analyst said two trials of a key drug candidate are going to fail.
Brean Murray Carret & Co analyst Jonathan Aschoff began coverage of the stock with a "Sell" rating and a target price of $5 per share, suggesting shares will fall almost 60 percent over the next year. He thinks two trials of SB-509 as a treatment for diabetic neuropathy will fail, and as a result, investors will expect less from the company's zinc finger protein technology.


The Richmond, Calif., company did not immediately return calls seeking comment.

Drugs using zinc finger protein technology are designed to turn parts of genes on or off. SB-509 is being tested as a treatment for diabetes-related nerve pain, which it is expected to treat by increasing the production of a protein called VEGF. Sangamo says that may improve the structure and function of nerves.

Sangamo is also developing products for vascular disease, heart failure and cancer.

Aschoff said ZFPs can be used to change gene expressions in laboratory settings, but that does not mean the drugs will be useful in treating diseases. He said the company will report results from two trials of SB-509 in the fourth quarter, and he does not think the drug will be more effective than a placebo.

Because all of Sangamo's product candidates are based on the same technology, those failures will decrease investor optimism about its remaining products, he said.

Shares fell $1.33, or 11 percent, to $11 in heavy trading.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.198.312 von tokajo am 29.05.08 17:38:25

Servus Tokajo,

na ja ein bisschen Ahnung wird der schon haben oder sogar Insiderwissen?
Was mich stutzig macht ist das Sangamo nicht sofort dementiert und auch der CEO hat ja ca. 50.000 Stück Sangamo Aktien verkauft!
Ich bin erstmal raus, sollte der Trial scheitern gehts wirklich stark bergab, falls nicht kann ich ja wieder zukaufen!

Ich hab schon schwere Schlappen mit GPC Biotech, Spectrum Pharma etc. erlebt und viel Geld verloren und Gott sei Dank daraus gelernt!
Schade schade schade, na ja die Hoffnung stirbt zuletzt.....

[tokajo]

Antwort auf Beitrag Nr.: 34.199.324 von Magnetfeldfredy am 29.05.08 19:40:52

Hallo Fredy,
scheint wir kommen jetzt in die heisse Phase. Firmen, die sofort dementieren sind mir wieder eher suspekt. Meist ist dann doch ein Fünkchen Wahrheit dahinter. Die Ergebnisse werden erst im 4 Quartal erwartet. Jetzt von einem Analyst von einem Scheitern auszugehen, ist schon etwas vermessen. Die Methode von Sangamo ist neu und könnte, wenn Sie funktioniert, das System revolutionieren.
Ich bin daher immer voller Hoffnung, irgendwann 3 stellig zu sein.
Aber Optimist bin schon immer gewesen. Sollte es nicht eintreffen, bleibt das genannte Kurzziel von 6$ für die Saatgutbehandlung.

Gruss Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 34.201.942 von tokajo am 30.05.08 09:01:35

Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Thursday May 29, 4:12 pm ET


RICHMOND, Calif., May 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on Sangamo's diabetic neuropathy programs at 1:40 p.m. (ET) on Friday, June 6, 2008, at the Canaccord Adams Diabetes and Obesity Conference in San Francisco.
ADVERTISEMENT


The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.




--------------------------------------------------------------------------------
Source: Sangamo BioSciences, Inc.

[Magnetfeldfredy]

Servus Tokajo,

danke für die Infos, am 6. Juni werden wir wohl schlauer sein, bis dahin bleibe ich an der Seitenlinie!

Gruß

Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.203.207 von Magnetfeldfredy am 30.05.08 11:18:21

Oh, oh.... letzter Trade in USA mit 220.000 Stück zu Tagestief, ich befürchte schlechte News...

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.231.381 von Magnetfeldfredy am 03.06.08 22:31:50

Also im Agrarbereich funktionierts die Technololgie von Sangamo!

Bist Du noch investiert Tokajo?

News:

Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
Thursday June 5, 7:00 am ET
ZFP Technology Accelerates Precision Gene Control, Trait Stacking in Commercial Crop Species


INDIANAPOLIS and RICHMOND, Calif., June 5 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the successful completion of research milestones as part of their joint Research and Commercial License Agreement. These milestones represent the successful application of Sangamo's zinc finger DNA-binding protein (ZFP) technology to the generation of specific traits in two major crop species -- maize and canola.
ADVERTISEMENT


"Our collaboration with Sangamo continues to be spectacularly successful," said Jerome Peribere, president and chief executive officer of Dow AgroSciences. "These milestones build on our earlier achievements and demonstrate the versatility and broad applicability of the ZFP platform to both regulate and modify genes in commercially important plant species. We have now proven that the ZFP technology can accelerate the process of 'trait stacking', which will result in a shorter path to commercialization of crops containing new traits. We believe ZFP technology has the power to truly transform our industry."

Peribere points out that the technology also allows control of the expression of existing genes. Many genes have already been identified in crop species that control the development of major traits relevant to agriculture such as seed quality, yield, and resistance to environmental stresses. Yet until now there has not been a technology that allows precise control of the activity of these genes. ZFP technology provides such an approach and its unique advantage, in addition to its efficiency, is its demonstrated flexibility. The technology can be used to regulate or modify any gene in any species.

Scientists at Dow AgroSciences, in collaboration with Sangamo scientists, used ZFP Nucleases (ZFNs(TM)) to place a herbicide resistance gene into a specified location of the maize genome in a rapid, single-step process. The precise insertion of the gene into the targeted location significantly advances the ability to stack a trait with other commercially valuable traits and accelerate the breeding process to deliver a launch-ready variety. This achievement demonstrates the potential value and versatility of targeted transgene insertion into crops.

Sangamo's ZFP transcription factor (ZFP TF(TM)) technology was used to achieve the second milestone, the control of the expression of a native gene in canola, a major food oil crop species in North America and in Asia. The ZFP TF was engineered at Sangamo to enable scientists at Dow AgroSciences to regulate a gene involved in a key step of oil biosynthesis and to change the metabolic profile of plant tissue.

"It has been both exciting and gratifying to witness the successful application of our ZFP technology in plants in collaboration with the Dow AgroSciences team," said Edward Lanphier, Sangamo's president and chief executive officer. "Dow AgroSciences has had the foresight to recognize the power and potential of our technology and the expertise to rapidly implement it successfully into its precision trait development program in commercially relevant crop species. They are leading the way in the development of innovative applications in plant biotechnology."

The three-year agreement initiated October 2005 provides Dow AgroSciences with access to Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures. During the initial three-year research term, Dow AgroSciences has the option to obtain a commercial license that will allow them to sell products incorporating or derived from plant cells generated using Sangamo's ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals, and to grant sublicenses to other companies in the industry.

ZFPs are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. The ability to selectively control specific genes is emerging as a critical tool in modern biotechnology. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting to a particular gene or genes of interest. By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs) that can control gene expression and consequently, cell function.

Sangamo has also developed sequence-specific ZFNs for precision gene modification and targeted gene insertion. These technologies have the potential to play a major role in bringing new discoveries in genomics forward to the marketplace. The use of Sangamo's ZFP technology to enable the efficient and reproducible generation of combinations or stacks of multiple traits and the insertion of new traits could address increasing demand for crops for food and fuel.

About Dow AgroSciences LLC

Dow AgroSciences LLC (NYSE: DOW - News), based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $3.8 billion. Learn more at http://www.dowagro.com.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Dow AgroSciences LLC and Sangamo BioScience, Inc.'s current expectations. These forward-looking statements include, without limitation, references to the achievement of additional milestones under the Research and Commercial License Agreement, the application of Sangamo's ZFP TFs and ZFNs in plant agriculture and the potential of Sangamo's ZFP technology to create new products in the marketplace. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Dow AgroSciences to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the its Annual Report on Form 10-K and its most recent report on Form 10-Q. Dow AgroSciences and Sangamo BioSciences, Inc. assume no obligation to update the forward-looking information contained in this press release.

(TM)Trademark of Sangamo Biosciences, Inc.




--------------------------------------------------------------------------------
Source: Sangamo BioSciences, Inc.


Email Story
Set News Alert
Print Story
Yahoo! Buzz






Related Quotes
DOW
SGMO 39.34
10.17 0.00
0.00 News
News
View Detailed Quotes
Delayed 20 mins
Providers - Disclaimer


Related News Stories
· [$$] Firms Weigh Climate Bill's Cost - at The Wall Street Journal Online (Wed Jun 4)
· In Pictures: The Least-Reputable Industries - at Forbes.com (Wed Jun 4)
· Paper or pricey plastic? - at Reuters (Wed Jun 4)
· Manufacturers say passing on rising costs - Reuters (Wed Jun 4)
More...

--------------------------------------------------------------------------------

· By industry: Biotechnology, Chemicals - Major Diversified



ADVERTISEMENT






Top Stories
· Fr. Telecom says it would pay $42B for TeliaSonera - AP (6:13 am)
· Stocks head for higher open ahead of jobs reports - AP (7:20 am)
· No rate movement expected from ECB, BoE Thursday - AP (6:30 am)
· As Icahn grumbles, Yahoo sets plans for ad growth - AP (5:48 am)
More...

--------------------------------------------------------------------------------

· Most-viewed articles




RSS Feeds
Add headlines to your
personalized My Yahoo! Page
( About My Yahoo! and RSS )

DOW Headlines
My Yahoo RSS SGMO Headlines
My Yahoo RSS Chemicals - Major Diversified Headlines
My Yahoo RSS Biotechnology Headlines
My Yahoo RSS More Finance RSS Feeds




--------------------------------------------------------------------------------

[tokajo]

Antwort auf Beitrag Nr.: 34.244.539 von Magnetfeldfredy am 05.06.08 13:35:09

Hi Fredy,

ja ich bin noch drin. Bist zur Verlustphase bräuchte es auch noch etwas. Wenn die Verunsicherung hier draussen wäre, hätte der Markt sicherlich ganz anders reagiert.

Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.246.134 von tokajo am 05.06.08 16:05:08

Servus Tokajo,

hier die News zum Diabetic Programm daß der Anlalyst anzweifelt!
Ich sehe hier weder good noch bad News!
Aber der Verunsicherung zeigt sich schon am vorbörslichen Kurs in den USA!

Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Friday June 6, 7:00 am ET
Sangamo Announces Completion of Accrual and Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic Neuropathy


SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the completion of patient enrollment into its Phase 2 clinical trial (SB-509-701) in subjects with moderate to severe diabetic neuropathy. Additionally, based upon positive initial data, the company plans to expand this study and enroll additional subjects to obtain more information for the design of a potential Phase 3 trial.
ADVERTISEMENT


"Our initial review of data from SB-509-701, while preliminary, was quite encouraging," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "As such, we plan to double the number of subjects in this study and evaluate an additional treatment schedule. Because of the definitive nature of the endpoint in this trial -- recovery of nerve conduction velocity or NCV -- these additional data may provide important information which could potentially expedite a Phase 3 study."

SB-509-701 is a randomized, single-blind, placebo-controlled, repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN). The study is designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetic subjects that have unmeasurable nerve conduction velocity (NCV) in at least one of the nerves in the leg.

In the initial trial, 45 subjects have completed enrollment. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) was treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb and will be treated every 3 months. The remaining group (approximately 15 subjects) received an equal volume of placebo on the same schedule. Each subject will receive a total of two treatments (Day 0 and 90). Subjects receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

The expansion protocol will enroll approximately 45 additional subjects in the trial. Subjects will again be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group (approximately 15 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in a similar pattern to that used in the initial part of the trial.

"In our Phase 1 studies we noted interesting clinical improvements in a number of subjects," said Edward Lanphier, Sangamo's president and CEO. "In addition to improvement in quantitative sensory testing (QST), three subjects with so-called "blocked nerves" or unmeasurable nerve conduction velocity measurements in the leg showed recovered and improved NCV after a single treatment with SB-509 and two of the three subjects showed recovery and improvement past a six-month follow-up period. As these observations were made in the Phase 1 trial, which studied only a small number of subjects, we initiated a Phase 2 trial, SB-509-701, to further investigate this finding. Our primary review of data from the SB-509-701 study continued to show a marked neurophysiologic improvement in severe diabetic neuropathy patients with unmeasurable nerve conduction velocities treated with SB-509. Based upon these observations we plan to expand this trial to provide additional data that could help support a future pivotal study."

Data from SB-509-701 will be presented at appropriate clinical meetings

[mortem]

oh, ohoh,...

minus 18%?

Ich hoffe es ist nur eine Übertreibung, und dass die wieder kommt,...

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.256.977 von mortem am 06.06.08 18:22:09

Na ja, so schnell kommt Sangamo nicht zurück, die Studie für Diabetic wird ausgeweitet, die Dosis verdoppelt...
Ich vermute der Analyst hat leider Recht!

[tokajo]

Antwort auf Beitrag Nr.: 34.259.708 von Magnetfeldfredy am 07.06.08 10:12:06

Sangamo BioSciences reveals Phase 1b clinical trial data of SB-509-401 administered for diabetic neuropathy - Quick Facts

(RTTNews) - Sunday, Sangamo BioSciences Inc. (SGMO: News, Chart, Quote ) presented encouraging Phase 1b clinical data from its ZFP Therapeutic program at the American Diabetes Association meeing. A Chronic Degenerative Polyneuropathy, results of Sangamo's Phase 1b clinical trial of SB-509-401 demonstrated statistically significant improvements in measurements of nerve health and function in subjects with diabetic neuropathy. While the primary end-point of Sangamo's Phase 1b study was safety, data were also collected that were designed to measure changes in neurological health. Quantitative sensory testing using the Vibratron II is used as a method of assessing a subject's change in vibration sensitivity. The data presented were collected from subjects with mild to moderate diabetic peripheral neuropathy. Twelve subjects each received a single treatment in both legs of either placebo or SB-509 as 60 mg total dose, 30 mg per leg. All of the subjects completed six-month follow-up testing. SB-509 was well tolerated. From a safety perspective, the Phase 1b data were consistent with previous observations that a single treatment of SB-509 was well tolerated and that no drug-related severe adverse events were observed. For comments and feedback: contact [e-mail]

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.264.783 von tokajo am 09.06.08 08:47:50

Guten Morgen Tokajo,

wie bewertest Du diese Meldung, doch kein Scheitern oder was nun..

Danke für Deine Meinung!

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 34.265.093 von Magnetfeldfredy am 09.06.08 09:33:42

Hi Fredy, sind Meldungen zu zwei verschiedenen Medikamenten. SB 509-401 und die 701. Die 401 Version ist erst in Phase 1 b. Die 701 in Phase 2.
Ob positiv oder negativ kann ich nicht beurteilen. Da es sich grundsätzlich um ein komplett neues Verfahren handelt, kann ich mir ganz gut vorstellen, dass man auf der sicheren Seite ist. Was ich glaube ist ein zeitliche Verzögerung der Ergebnisse, gepaart mit dem aktuellen Umfeld, aber zum Trading habe ich meine Sangamo nicht.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.265.840 von tokajo am 09.06.08 11:36:07

Danke für Deine Einschätzung, ich lasse SGMO auf meiner Watchlist, vorerst!

[liebgeld]

Antwort auf Beitrag Nr.: 34.265.840 von tokajo am 09.06.08 11:36:07

Lieber tokajo,

du scheinst sangamo ja ins Herz geschlossen zu haben. Ich irre erst sehr kurz durch den Aktienwald und geh deshalb noch leicht verloren.
Ich bin auf sangamo durch den aktienbrief taipan aufmerksam geworden (probeabo), die Zinkfingeridee hatte mir gut gefallen. beidenen ist die aktie aber ausgestoppt worden. Jetzt werben die aber schon wieder sogar im Aufreißer mit der,als gott-weiß-welche Jahrhundert-chance,
bleiben natürlich nebulös. Ich weiß nur, daß sie von der Aktie sprechen,
weil ich ihre Börsenbriefbeschreibung eben schon gelesen habe.
Wie siehst du denn die chancen und in welchem Zeitrahmen?
Ist das jetzt ein Einsteigerkurs, wenn man interessiert ist?
Und mit welchen Stückzahlen? Mein Zeithorizont könnte schon ein paar Jahre sein?
Danke für deine Antwort.
liebgeld

[tokajo]

Antwort auf Beitrag Nr.: 34.267.013 von liebgeld am 09.06.08 14:38:08

Hallo liebgeld,

eigentlich sollte man sich in keine Aktien verlieben. Falls es berechtigt abwärts geht fliegt bei mir alles raus.

Aber hier bei Sangamo verstehe ich auch nicht alles. Ein totaler Flop wie im Rohstoffbereich oder Internetbuden glaube ich kann es nicht geben, da nach unten über die Crop Sciences einiges abgefangen werden kann. Medizintechnisch betrachtet ist die Methode sowas von revolutionär. Aufmerksam bin ich durch den Artikel in der Technology review. www.heise.de/tr. Lohnt sich zu lesen.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.268.702 von tokajo am 09.06.08 18:13:19

Servus Tokajo,

Du hast Recht Sangamos Technologie ist absolut revolutionär, aber das Wichtigste dabei ist daß die Zinkfingertechnoligie wirkt und daß wird bezweifelt, hier helfen nur erfolgreiche Studien!

Ich glaube es geht noch viel tiefer mit dem Kurs da die Bewertung allein für den Agrarbereich noch zu hoch ist, leider!

[aktianer]

Antwort auf Beitrag Nr.: 34.278.546 von Magnetfeldfredy am 11.06.08 08:20:19

@freddy,

bin am selben Tag wie Du ausgestiegen. Der Grund hierfür lag in der Erfahrung, die ich mit Alnylam Wochen vorher bereits machen mußte. Auch dort sind zwei Analysten, offenbar mit hohem Ansehen in der Branche ausgestattet, die die Wirksamkeit der Alny-Technologie bezweifeln. In der Folge fiel der Kurs und konnte sich seither nur mühsam etwas erholen, aber die alten Kurshöhen sind wohl i.d. nächsten Monaten illusionär. Da können die Alny-Haus-Analysten so oft positive Kommentare abgeben, wie sie wollen, das hilft dem Kurs leider kaum. Hier, wie bei Sangamo, müßen vermutlich eindeutige Ergebnisse her um den Kurs mal wieder richtig anzuschieben. Fraglich ist aber, ob dies in den nächsten Jahren überhaupt zu erwarten ist.
Als zweiter Punkt für meinen Verkauf möchte ich noch die Aktienverkäufe von CEO Lamphier anführen (neben dem sowieso laufenden verkaufsprogramm), die mich etwas mißtrauisch gemacht haben. Und der dritte Punkt waren die niedrigen Milestonezahlungen durch Dow Agro. Auch dies unterminierte mein Vertrauen in den Wert der Technologie.

Auf der der anderen Seite war und ist posititv, daß Institutionelle mit einem sehr hohen Anteil investiert sind, und bei denen kann man voraussetzen, daß diese ihr Investment über Gutachten abgesichert haben. Ein weiteres Pro-Argument ist die Anwendungsbreite der Zincfinger-Technologie.

Eigentlich wollte ich diese Aktie auf Jahre hin halten, aber wie gesagt, die Erfahrungen mit Alnylam, führten letztendlich doch zum Ausstieg. Bleibe, wie Du, mal an der Seitenlinie und warte in Ruhe die Entwicklung ab.

Viel Glück allen Investierten!

[aktianer]

@Freddy,
sehe gerade, daß mein dritter und fünfter Satz etwas kurios geraten ist. Deshalb hier die lesbare Version:

Auch dort bezweifeln (zwei) Analysten, offenbar mit hohem Ansehen in der Branche ausgestattet, die Wirksamkeit der Alny-Technologie. In der Folge fiel der Kurs und konnte sich seither nur mühsam ein wenig erholen - die alten Kurshöhen sind wohl i.d. nächsten Monaten illusionär. Da können die Alny-Haus-Analysten noch so oft positive Kommentare abgeben, dem Kurs hilft es leider kaum.

[liebgeld]

Antwort auf Beitrag Nr.: 34.268.702 von tokajo am 09.06.08 18:13:19

Guten Abend Tokajo,

hab den Artikel auch gelesen, wenn beweisbar wird, daß die Methode
an einer Stelle was reparieren kann, ohne an einer anderen was
u zerstören,.....ja dann wäre das ein unglaublicher Fortschritt....
Bist du denn noch investiert? Ich werde den Wert auf jeden Fall
beobachten.

Bis dann
liebgeld

[aktianer]

Ein weiterer interessanter Kommentar zu der jüngsten Präsentation als auch zur Einschätzung der Person Aschoff:

Biotech-Stock Mailbag: Sangamo

06/13/08 - 06:59 AM EDT

By Adam Feuerstein
Senior Writer

This week's Biotech Mailbag kicks off with an email from David V., who asks:

Would you comment on Sangamo BioSciences' (SGMO - commentary - Cramer's Take) recent downturn, which was spurred by Brean Murray Carret analyst Jonathan Aschoff saying that the midstage trial to treat diabetic neuropathy is expected to fail?

I first wrote about Sangamo last August because the company had an interesting story to tell, even if there were scant clinical data to back it up. Sangamo is engineering protein "switches," called zinc fingers, that can turn genes on or off. It's similar to the work being conducted with RNA interference, or RNAi, with one big difference: RNAi can only turn genes off, while zinc finger proteins have the ability to switch genes off and on.

Sangamo's lead pipeline drug, SB-509, is being developed as a way to turn on a gene that will regenerate nerves in patients with diabetic neuropathy.

The stock was at $10 when I penned that piece last August. It then ran all the way to $19 in November before retreating to around $9 in March. Another surge pushed the stock back above $13 recently, but then Brean Murray's Aschoff initiated coverage of the stock with a sell rating in late May, and the stock is now back under $9. (Biotech: a beta lover's dream.)

I've read Aschoff's notes and believe he raises some important questions and concerns about the clinical data presented on SB-509 to date.

The only data we have on the drug come from a phase Ib study in 24 mild-to-moderate diabetic neuropathy patients. Updated results were presented at this week's American Diabetes Association meeting. Sangamo reported a statistically significant clinical benefit favoring SB-509 on two measures of nerve health -- the neuropathy impairment score in the lower limbs (NIS-LL) and quantitative sensory testing, or QST.

Aschoff points out that SB-509 failed to show a statistically significant benefit on two other important tests of nerve health, most significantly the nerve conduction velocity (NVC) test, which measures a nerve's ability to conduct electrical impulses.

Moreover, there is no data yet to show that SB-509 has any significant ability to reduce or eliminate severe nerve pain in diabetic neuropathy patients, Aschoff writes. This is important because pain is the primary physical complaint of these patients.

Sangamo is running several larger, phase II studies of SB-509 right now, with results ready for release starting in the fourth quarter. Perhaps these studies will provide more definitive evidence of the drug's efficacy. Aschoff thinks the more likely scenario is that the phase II studies will be negative, based on the weak data presented so far. That's why he has a sell rating and a $5 price target on the stock. Let's also note that Sangamo rejiggered one of these phase II studies by doubling the number of patients enrolled and upping the frequency of dosing -- not necessarily a bullish sign.

It should be noted that other analysts are more optimistic about SB-509's chances, including Cantor Fitzgerald's Pamela Bassett. She has a buy rating and a $27 price target on the stock, and in particular, believes Sangamo is a prime candidate for a big-money development partner.

My take on all of this hews very close to where I was last August: I'm not ready to believe in zinc finger proteins, or SB-509 in particular, until there are some convincing data from phase II studies. Aschoff raises enough questions to make me want to withhold judgment for the next slug of data.

One more thing on Aschoff: Yes, I know he got in trouble a few years ago for impersonating a doctor to get information about a clinical trial. He was wrong, got caught and was punished. I don't believe that transgression tarnishes his reputation for life.

Since then, Aschoff has made some really good stock calls; he's also made some bad ones. In other words, he's just like everyone else in this industry. I choose to evaluate Aschoff's work not on a mistake he made a long time ago, but on his ability to make profitable stock calls today.


http://www.thestreet.com/story/10421051/1/feuersteins-biotec…

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.305.878 von aktianer am 15.06.08 18:58:03

Also im Agrarbereich funktioniert die Zinkfingertechnologie anscheinend super:
Dow AgroSciences inks biotech deal with Sangamo
Wed Jun 18, 2008 6:04pm EDT Email | Print | Share| Reprints | Single Page| Recommend (0) [-] Text [+]

Related News
Dow falls 394.64 points on jobless rate, record oil
06 Jun 2008
Unemployment data, oil’s record drive sell-off
06 Jun 2008

powered by Sphere
Market News
Oil slips below $136 ahead of Jeddah | Video
Futures point flat; financials on the radar | Video
Dollar rallies at Swissie's expense and sterling boosted
More Business & Investing News... Featured Broker sponsored link
#1 FX Broker - Shares Mag 2007 By Carey Gillam

SAN DIEGO, JUNE 18 (Reuters) - Dow AgroSciences, a unit of Dow Chemical Co (DOW.N: Quote, Profile, Research, Stock Buzz). said on Wednesday it had exercised its option to obtain a commercial license for "zinc finger" technology from Sangamo BioSciences (SGMO.O: Quote, Profile, Research, Stock Buzz) .

Dow AgroSciences is paying $6 million for the license, which will allow it to commercialize products incorporating or developed from plant cells using zinc-finger, DNA-binding protein technology (ZFP), in agricultural crops, industrial products and plant-derived biopharmaceuticals.

Sangamo and Dow AgroSciences have been collaborating to apply ZFP technology to plants under a three-year research and commercial license option agreement initiated in October 2005. Dow AgroSciences had until October to exercise its option.

Jerome Peribere, president and CEO of Indianapolis-based Dow AgroSciences, cited "tremendous success" in the research as prompting the early decision to cement the licensing deal.

"The next generation of plant genetic improvement will successfully bring new products to market by reducing complexity and cutting the development time by one to two years," said Peribere in a statement.

Dow said the ZFP technology has "the potential to revolutionize agricultural biotechnology" using precision gene modification and targeted gene insertion to give plants very specific traits more quickly than using conventional means.

Dow AgroSciences said it will sublicense the technology to third parties for development of particular products under the trademark name of EXZACT Precision Traits.

The technology should speed development of healthier cooking oils, resistance to a broad range of insect pests and diseases; enhanced photosynthetic efficiency and higher yields, company officials said. (Reporting by Carey Gillam; Editing by Marguerita Choy)

[aktianer]

Sangomo erhält 6 Mio.U$ an Lizenzgebühren von Dow AgroSciences

"Dow AgroSciences inks biotech deal with Sangamo
Wed Jun 18, 2008 6:04pm EDT

By Carey Gillam

SAN DIEGO, JUNE 18 (Reuters) - Dow AgroSciences, a unit of Dow Chemical Co (DOW.N: Quote, Profile, Research, Stock Buzz). said on Wednesday it had exercised its option to obtain a commercial license for "zinc finger" technology from Sangamo BioSciences (SGMO.O: Quote, Profile, Research, Stock Buzz) .

Dow AgroSciences is paying $6 million for the license, which will allow it to commercialize products incorporating or developed from plant cells using zinc-finger, DNA-binding protein technology (ZFP), in agricultural crops, industrial products and plant-derived biopharmaceuticals................"

Gesamter Text:
http://www.reuters.com/article/marketsNews/idINN183895792008…

[aktianer]

Antwort auf Beitrag Nr.: 34.333.895 von aktianer am 19.06.08 15:48:12

@Freddy,
die 6 Mios. scheinen den Kurs auch nicht zu beflügeln. Könnte sein, daß die Höhe der Summe die Erwartungen der Investoren enttäuscht hat!

[Magnetfeldfredy]

Servus,

scheint so, jedoch darf man nicht vergessen, daß neben der Zahlung von 6 Millionen US Dollar sicher Tantiemen anfallen werden und auch mit Monsanto hat ja SGMO ein Joint Venture!
Was ich nicht verstehe, die Zinkfinger Technologie wird die Agrarbiotechnologie revolutionieren, so der Chef on DOW Agrar..., aber davon hat der "blöde" Analyst nichts geschrieben, nur daß die Zinkfingertechnologie beim Diabetic Programm scheitern wird, was er selber auch nicht wissen kann!
Na ja abwarten und Tee oder besser Bier trinken!

[Magnetfeldfredy]

Wie ich schon sagte der Anal-Yst der SGMO abstrafte hat keine Ahnung!
News:
AP
Analysts: Sangamo's Dow deal could be key driver
Thursday June 19, 3:35 pm ET
Sangamo's deal with Dow AgroSciences could be lucrative in the long term, analysts say


NEW YORK (AP) -- Dow AgroSciences' move to license genetic-based therapies from Sangamo Biosciences Inc. could mean a large infusion of cash with little loss of product rights for the biotechnology company, according to several analysts.
ADVERTISEMENT


On Thursday, Richmond, Calif.-based Sangamo said the Dow Chemical Co. subsidiary exercised an option to license Sangamo technology called finger DNA-binding proteins. The technology has the potential to produce healthier cooking oils, disease-resistant plants and better crop yields.

The companies have been partners for three years, and several analysts expect the move to be a lucrative long-term situation for Sangamo. Dow's exercising of the commercial license results in a $6 million payment pus an additional $4 million in potential milestone payments.

"We believe the Dow alliance represents an important monetization of ZFP technology that has the potential to bring in substantial cash without giving up any of the therapeutic rights core to Sangamo's business," Piper Jaffray analyst Edward A. Tenthoff said in a note to investors.

The partnership has been highly successful so far, he said, reaffirming a "Buy" rating wit a $20 price target.

Meanwhile, Leerink Swann & Co. analyst John Sullivan reaffirmed a "Outperform" rating on the stock, saying Sangamo's financial flexibility is improved by the Dow deal. He reaffirmed a $18 price target.

Sangamo shares, meanwhile, fell 32 cents, or 3.5 percent, to $8.93 on average trading volume during the afternoon session. The stock has traded between $7.61 and $19.82 over the past 52 weeks.

[tokajo]

Antwort auf Beitrag Nr.: 34.337.199 von Magnetfeldfredy am 19.06.08 22:53:12

Morgen Freddy,
und bist du noch auf der Seitenlinie ?.
Scheint ein spannendes zweites Halbjahr zu geben. Nach meiner Einschätzung dürften jetzt erneute Analystenschätzungen eintreffen.

Bin gespannt wie es weitergeht.

Gruss Tokajo

[Magnetfeldfredy]

Servus Tokajo,

ich habe wieder eine kleine Position von 600 Stück aufgebaut, will auch evtl. bei erneuter Kursschwäche aufstocken, was meinst Du wohin geht der Kurs?

Viele Grüße

Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.339.735 von Magnetfeldfredy am 20.06.08 11:36:02

News:

AP
Sangamo technology shows promise in treating HIV
Monday June 30, 9:23 am ET
Sangamo technology demonstrates ability to make genes resistant to HIV virus


RICHMOND, Calif. (AP) -- Sangamo BioSciences Inc., which develops genetic-based therapies, said Monday data shows the company's technology can make certain cells in the immune system resistant to the HIV virus.
ADVERTISEMENT


The technology, known as zinc finger DNA-binding proteins, acts on the CCR5 gene (a co-receptor that enables HIV to enter and infect cells of the immune system), essentially "knocking-out" the gene.

The results were published online Sunday in the journal Nature Biotechnology.

Sangamo said that while drugs exist that block the binding of HIV to the CCR5 gene, they require a constant high concentration of the drug in the system and have side effects, while its technology requires only a one-time exposure.

Sangamo's ZFNs are designed to permanently modify the DNA sequence covering CCR5. Individuals carrying a naturally occurring mutation of their CCR5 gene have been shown to be resistant to HIV infection.

"The modified cells preferentially survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells," said Dale Ando, M.D., Sangamo's chief medical officer, in a statement.

Sangamo expects to initiate a clinical trial to evaluate this approach by the end of the year.

[tokajo]

Antwort auf Beitrag Nr.: 34.404.602 von Magnetfeldfredy am 30.06.08 15:43:30

Hi Fredy,
hier ist noch der Artikel in verkürzter Form zu finden.

http://medgadget.com/archives/2008/06/zinc_finger_dnabinding…

Wäre schön gewesen, wenn vor der Meldung Sangamo nicht von ein paar Analysten schlecht geredet wurde. Hätte damals sicherlich für neue Höchststände ausgereicht.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.408.972 von tokajo am 01.07.08 08:50:20

Good News:

Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
Wednesday July 9, 7:00 am ET
Transgenic Animals to be Developed for Therapeutic and Diagnostic Applications


ST. LOUIS and RICHMOND, Calif., July 9 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL - News) and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced a research and license agreement to provide Roche (SWX: ROG - News) with non-exclusive, worldwide rights for the use of its proprietary zinc finger nuclease (ZFN) technology to develop cell-lines and transgenic animals that have targeted modifications in a specified gene in a specified species. Roche also has an option to obtain an exclusive, worldwide license for the commercial use of such ZFN-generated transgenic animals in the production of therapeutic and diagnostic products.
ADVERTISEMENT


The research phase of the agreement will be conducted in collaboration with both Sangamo and Sigma-Aldrich, Sangamo's exclusive licensee of ZFN technology for high-value research reagents.

"There is growing appreciation of the value of ZFN technology as a rapid, reliable and highly specific tool for modifying genes in eukaryotic cells and whole organisms," said David Smoller, Ph.D., President of Sigma-Aldrich's Research Biotech Business Unit. "We are excited to be working with Sangamo to provide Roche with high-value ZFN reagents for the generation of transgenic animals. ZFN technology promises to enable the generation of a variety of transgenic models of human disease, expediting drug development and production."

"Roche is a leading global healthcare company with an established reputation of innovation. We are pleased to provide them with our ZFN technology which provides a cutting-edge approach for disease research," said Edward Lanphier, Sangamo's President and Chief Executive Officer. "The frequency and precision of ZFN-mediated genome editing, in combination with the ability to design ZFNs against potentially any gene, opens up the possibility of more easily generated transgenic animals of any species."

Zinc finger DNA-binding proteins (ZFPs) are the dominant class of naturally occurring transcription factors in organisms from yeast to humans. Transcription factors, which are found in the nucleus of every cell, bind to DNA to regulate gene expression. Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting of a particular gene or genes of interest. ZFNs are engineered forms of ZFPs that also contain a nuclease component which can facilitate modification of a target gene of interest.

"The power of ZFN technology was recently demonstrated in a study published in Nature Biotechnology," said Philip Gregory, D.Phil., Sangamo's Vice President for Research. "Using ZFNs in zebrafish, a widely recognized system for human disease modeling and in vivo drug discovery, resulted in the generation of fish in which the ZFN-targeted gene has been eliminated or 'knocked out'. Apart from the mouse, the majority of other animals including zebrafish have historically lacked methods for precision targeted mutagenesis. This publication demonstrates that ZFNs present a powerful solution to this problem with application across virtually any species for any gene."

Terms of the Agreement

Under this agreement, Sangamo will provide a non-exclusive, worldwide research license for the use of its proprietary ZFN technology in the development of transgenic animals. In this phase Roche will pay research fees, including research maintenance fees and research event payments. If Roche elects to exercise its option for an exclusive commercial license it will owe Sangamo an option license fee, additional payments upon the achievement of certain clinical development events and royalties on sales of therapeutic and diagnostic products developed by Roche using the ZFN-modified animals.

About the Nature Biotechnology Publication

The work entitled, "Heritable Targeted Gene Disruption in Zebrafish Using Designed Zinc Finger Nucleases" was carried out in collaboration with the laboratory of Sharon Amacher, Ph.D., Associate Professor of Genetics, Genomics and Development at the University of California, Berkeley. The paper and an accompanying commentary appear in the June 2008 print issue of the magazine, Nature Biotechnology, June 2008, vol 26, 6, pp702-708. http://www.nature.com/nbt/journal/v26/n6/abs/nbt1398.html

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. We are committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at http://www.sigma-aldrich.com

About Sangamo BioSciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on HIV/AIDS, neuropathic pain, cancer, nerve regeneration and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X- linked SKID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the payment of fees and royalties under the license agreement, development of transgenic species, and the application of Sangamo's ZFP technology in the development of transgenic animals as models of human disease and for drug development. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

[tokajo]

Antwort auf Beitrag Nr.: 34.469.587 von Magnetfeldfredy am 09.07.08 13:08:49

Und noch eine.
Neuer Lizenzpartner ist Roche.

Roche licenses zinc finger tech to aid its discovery programmes

10-Jul-2008 - Sangamo Biosciences and Sigma-Aldrich have licensed their zinc finger nuclease (ZFN) technology to Roche to enable the pharma giant to develop cell lines and transgenic animals. The deal includes the non-exclusive worldwide rights for the commercial use of ZFN-generated transgenic animals in the production of therapeutic and diagnostic products as well as a research agreement that will see all three firms collaborating to develop new cell lines and transgenic animals using the technology. The transgenic animals and cell lines will be used as disease models in Roche's discovery programmes as well as potentially being used to generate vaccines and therapeutic biological drugs. ZFNs are modified zinc finger proteins (ZFPs) that can be used to modify target genes in a variety of organisms. 'There is growing appreciation of the value of ZFN technology as a rapid, reliable and highly specific tool for modifying genes in eukaryotic cells and whole organisms,' said Dr David Smoller, president of Sigma-Aldrich's Research Biotech Business Unit. 'We are excited to be working with Sangamo to provide Roche with high-value ZFN reagents for the generation of transgenic animals. ZFN technology promises to enable the generation of a variety of transgenic models of human disease, expediting drug development and production.' Last year, [http://www.labtechnologist.com/news/ng.asp?id=78091] Sigma-Aldrich licensed the technology for use as research reagents in a deal that could be worth up to $35m (22m). ZFPs are naturally occurring transcription factors that bind to DNA to regulate gene expression and occur in a range of organisms from yeast to humans. They can be engineered to target specific gene sequences as well as to incorporate a nuclease component and form ZFNs that can modify the target gene. This modification can lead to the target gene being eliminated or 'knocked out' of a species which can then be used to generate in vivo disease models. A recent study published in Nature Biotechnology showed that ZFNs could be used to generate zebrafish disease models in which the ZFN-targeted gene was eliminated. 'Using ZFNs in zebrafish, a widely recognized system for human disease modeling and in vivo drug discovery, resulted in the generation of fish in which the ZFN-targeted gene has been eliminated or 'knocked out',' said Dr Philip Gregory. 'Apart from the mouse, the majority of other animals including zebrafish have historically lacked methods for precision targeted mutagenesis. This publication demonstrates that ZFNs present a powerful solution to this problem with application across virtually any species for any gene.' In an article in the following issue of Nature Biotechnology, Sangamo's ZFN technology was shown to induce HIV-1 resistance in human immune CD4 T-cells by modifying the CCR5 gene which plays a key role in HIV T cell attachment and penetration. 'We have demonstrated that a single treatment with our CCR5-specific ZFNs generates a population of HIV-resistant human T-cells similar to the situation in individuals carrying the natural CCR5-delta32 mutation,' said Dr Dale Ando, Sangamo's vice president of therapeutic development. 'ZFN-modification of these cells is permanent and makes them resistant to HIV. The modified cells preferentially survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. In an HIV-infected patient, such modified cells could be available as a protected reservoir within the immune system to fight both opportunistic infections and HIV itself.' The firm expects to initiate clinical trials to evaluate the approach by the end of the year.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.522.487 von tokajo am 16.07.08 18:13:18

Q 2 Zahlen:

Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Wednesday July 23, 4:00 pm ET


RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today reported second quarter 2008 financial results and accomplishments.
ADVERTISEMENT


For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss of $7.4 million, or $0.18 per share, compared to a net loss of $5.2 million, or $0.15 per share, for the same period in 2007. As of June 30, 2008, the company had cash, cash equivalents and investments of $64.3 million.

Revenues for the second quarter of 2008 were $2.8 million, compared to $2.6 million for the second quarter of 2007. Second quarter 2008 revenues were primarily comprised of revenue recognition from the Company's collaboration agreements with Dow AgroSciences (DAS) and Sigma-Aldrich, enabling technology agreements in protein production and research grants. The revenue recognized for the second quarter of 2008 consisted of $2.4 million in collaboration agreements and $464,000 in research grants.

Research and development expenses were $8.3 million for the second quarter of 2008, compared to $6.3 million for the same period in 2007. The increase in research and development expenses for the second quarter of 2008 was primarily due to advancing the Company's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs. Non-cash employee stock-based compensation included in research and development expenses totaled $0.7 million and $0.3 million in the second quarter of 2008 and 2007, respectively.

General and administrative expenses were $2.5 million for the second quarter of 2008, compared to $2.1 million for the same period in 2007. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation which totaled $0.6 million in the second quarter of 2008 compared to $0.2 million in the same period in 2007.

Total operating expenses for the second quarter of 2008 were $10.8 million, compared to $8.4 million for the same period in 2007.

Net interest and other income was $570,000 for the second quarter of 2008, compared to $657,000 for the same period in 2007.

Six Month Results

For the six months ended June 30, 2008, the consolidated net loss was $15.4 million, or $0.38 per share, compared to a net loss of $10.5 million, or $0.30 per share, for the period ended June 30, 2007. Revenues were $5.6 million for the first half of 2008, compared to $4.0 million in the same period in 2007. Total operating expenses were $22.4 million for the first half of 2008 and $15.9 million in the first half of 2007. The increase in operating expenses for 2008 was primarily associated with Sangamo's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs and lab supply expenses.

Recent Highlights

-- Dow AgroSciences announces early exercise of commercial license for ZFP technology. Four months earlier than expected Dow AgroSciences (DAS) announced during the BIO International Convention in June that they had exercised their option, under and existing agreement with Sangamo, for a commercial license to Sangamo's zinc finger DNA-binding protein (ZFP) technology for use in plant agriculture. DAS will use the technology to generate products itself and plans to sublicense the technology to other companies under the trademark of ExZact Precision Traits(TM). As part of the agreement, Sangamo will receive a license fee payment of $6.0 million and the balance of the outstanding milestone payments of approximately $2.3 million. In addition, Sangamo is eligible to receive development and commercial milestone payments and royalties on product sales for any product that DAS develops, as well as 25% of any cash consideration received by DAS under such sublicenses. A webcast replay of the press conference that DAS hosted is available on Sangamo's website on the Investor page under Events and Presentations.

-- Presentation of complete 180 day follow-up data from Phase 1b study of SB-509 in subjects with diabetic neuropathy (DN). Data from the Phase 1b clinical trial were presented at the American Diabetes Association Meeting in June. The data demonstrate statistically significant improvement in quantitative sensory testing and Neuropathy Impairment Score-Lower Limbs (NIS-LL), a quantitative measure of the neurologic exam, as well as clinically relevant trends toward improvement in nerve conduction velocities. The trial was conducted in subjects with mild to moderate diabetic neuropathy over a six month period after a single administration of SB-509. SB-509 is an injectable formulation of plasmid DNA that encodes a ZFP transcription factor (ZFP TF(TM)), designed to upregulate the vascular endothelial growth factor-A (VEGF-A) gene.

-- Phase 2 clinical trial, SB-509-701 fully enrolled and expanded. A Phase 2 study of SB-509 is being undertaken in subjects with moderate to severe diabetic neuropathy with at least one "blocked nerve". In addition to the announcement of the completion of accrual of the first part of the trial, Sangamo announced plans to expand and broaden the trial to test an additional dosing regimen.

-- Data from critical limb ischemia Phase 1 trial presented at the International Society for Cellular Therapy Meeting. Sangamo's collaborators from Duke University presented data from the completed Phase 1 trial of the company's ZFP TF activator of VEGF-A for the treatment of critical limb ischemia. The data from this trial demonstrated that administration of the ZFP transcription factor resulted in a statistically significant increase in circulating stem cells in the peripheral blood. In addition, within a subgroup in which bone marrow cells were examined before and after treatment, the data suggests that subjects who showed the most marked clinical improvements, as judged by limb salvage, ulcer healing, reduction in pain and increased oxygen concentrations in the tissues of the lower limbs, also showed the greatest increase in bone marrow stem cells. This observation of stem cell mobilization after treatment with Sangamo's ZFP TF activator of VEGF-A, is being further investigated in an ongoing Phase 2 trial of SB-509, SB-509-703.

-- Announcement of research and license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) for the use of ZFP technology to develop transgenic animals. In July, Sangamo and Sigma-Aldrich Corporation jointly announced a research and license agreement to provide Roche with non-exclusive, worldwide rights for the use of Sangamo's ZFP nuclease (ZFN(TM)) technology to develop cell-lines and transgenic animals with targeted modifications in a specified gene in a specified species. Roche also has an option for an exclusive, worldwide license from Sangamo for the commercial use of such ZFN-generated transgenic animals in the production of therapeutic and diagnostic products.

-- Publication of preclinical data in Nature Biotechnology. Papers highlighting therapeutic and research applications of Sangamo's ZFN technology were published in the scientific journal, Nature Biotechnology. The first paper demonstrated the use of ZFNs to efficiently generate transgenic animals, in this case zebrafish, a widely recognized system for human disease modeling and in vivo drug discovery. A second publication described the successful ZFN-mediated disruption of the CCR5 gene in human T-cells and the positive effects on HIV resistance and reduction in viral load in an animal model of HIV infection.

Na, alles im Rahmen, was schön wäre wenn die Partnerschaften mehr Kohle einbringen würden als die Peanuts der Agrarriesen oder was meinst Du Tokajo?

[tokajo]

Antwort auf Beitrag Nr.: 34.591.084 von Magnetfeldfredy am 26.07.08 07:54:35

Hi Fredy, scheint alles normal zu sein.
Wichtig im jetztigen Stadium ist, dass ihnen das Geld nicht ausgeht um die Entwicklungen weiter voranzutreiben. Aber derzeit mit 64,3 Millionen sind sie hier ganz gut versorgt.

Das wird schon.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.596.413 von tokajo am 28.07.08 10:27:53

Na ja jetzt bleib ich mal dabei und schau mir die Geschichte weiter an!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.596.413 von tokajo am 28.07.08 10:27:53

Neues Kursziel:
Rating-Update: Boston (aktiencheck.de AG) - Die Analysten von Leerink Swann & Co. stufen die Aktie von Sangamo BioSciences (ISIN US8006771062/ WKN 936386) unverändert mit "outperform" ein. Das Kursziel werde von 18 auf 17 USD gesenkt. (26.08.2008/ac/a/u)

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.865.880 von Magnetfeldfredy am 26.08.08 16:15:29

Hier erfreuliche Daten:
Sangamo rises on early SB-509 trial data
Tuesday August 26, 3:32 pm ET
Sangamo rises as trial show SB-509 improved function for patients with damaged nerves


NEW YORK (AP) -- Shares of Sangamo BioSciences Inc. rose Tuesday after the company released preliminary results from a mid stage trial of its drug candidate SB-509, which showed the drug helped improve nerve function in diabetes patients.
ADVERTISEMENT


In September, the company will present preliminary results from the study of SB-509, which is designed to treat severe diabetic neuropathy, or nerve damage caused by diabetes. On Tuesday, an overview of early results from the trial showed that five of eight patients treated with SB-509 had better nerve potential after 180 days of treatment.

Only one of the four patients who were given a placebo had the same improvement.

The results were published on the Web site of the American Neurological Association.

"Such early improvement in severely affected population has never been reported and suggests that SB-509 has novel regenerative potential for the reversal of nerve damage in severe (diabetic peripheral neuropathy)," the company said.

In afternoon trading, shares of Richmond, Calif.-based Sangamo rose 38 cents, or 4 percent, to $9.81.

Piper Jaffray analyst Edward Tenthoff said the results may bode well for a larger study of SB-509. Data from that 110-patient study is due in the fourth quarter. He maintained a "Buy" rating on the stock, with a price target of $20. That implies the stock will more than double in value over the next year.

Tuesday's data was from a study including 45 patients. In the trial, 17 patients were given a 60-milligram injection of SB-509 at the start of the trial, and another injection 90 days later. Results were taken 180 days after the first injection.

[tokajo]

Antwort auf Beitrag Nr.: 34.871.244 von Magnetfeldfredy am 26.08.08 22:08:34

Hi Fredy,

das wird schon.
20 $ fürs erste sind ja auch nicht schlecht.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 34.873.910 von tokajo am 27.08.08 08:13:02

Servus Tokajo,

wär schon zufrieden für den Anfang!

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 34.884.109 von Magnetfeldfredy am 27.08.08 21:59:49

Damit es hier nicht untergeht.
Gruss Tokajo

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS

RICHMOND, Calif., Sept 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure.

Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.

In ALS, the motor nerves comprised of nerve cells in the brain and spinal cord that control the body's voluntary muscles, gradually degenerate. As the nerve cells begin to die, the muscles weaken and shrink. As the disease progresses, patients gradually lose the use of their limb and neck muscles, ultimately becoming paralyzed and unable to breathe without assistance. Fifty percent of patients with ALS die within three to five years of diagnosis. Currently, there is only one approved drug for ALS; Riluzole has been demonstrated to slow the progression of this debilitating disease with only modest clinical benefit, extending the survival of ALS patients by approximately three months.

"Initiation of a Phase 2 clinical study of SB-509 in subjects with a motor neuron and muscle disease such as ALS is an obvious next step in the evaluation of this novel therapeutic," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "The drug is designed to activate the expression of the subject's own VEGF-A gene. There is mounting pre-clinical and clinical evidence to support a correlation between reduced VEGF-A levels and progression of this life-threatening disease. Our Phase 1 clinical studies of SB-509 in diabetic neuropathy have shown that the drug is well tolerated. Data from this clinical study and pre-clinical studies in animal models of nerve damage reveal positive effects of SB-509 on motor nerve function and muscle composition. Similar effects on motor nerves and muscles in these patients may slow the progression of ALS by preserving nerve function and improving muscle fiber composition and strength."

The Phase 2 trial (SB-509-801) is a randomized repeat-dosing, open-label, multi-center study designed to evaluate the effect of intramuscular administration of SB-509 on the progression of the disease in subjects with ALS, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) a validated rating instrument for monitoring the progression of disability in patients with ALS. Efficacy of SB-509 will be evaluated by comparing the rate of ALS disease progression in subjects treated with SB-509 in this study to historical placebo controls. In addition to gathering data on safety and tolerability of SB-509 in subjects with ALS, data will be collected to evaluate the effect of SB-509 on additional clinical measures. These measures include Forced Vital Capacity (FVC), a test of lung function; Neurophysiologic Index (NI), a measure of neurologic impairment; Manual Muscle Test (MMT), a test of muscle strength; and survival. Finally, the study will also evaluate stem cell mobilization in subjects with ALS receiving SB-509.

"We are pleased to meet our goal of beginning a Phase 2 clinical trial in ALS this year and are very excited to begin these proof of principle studies," said Edward Lanphier, Sangamo's president and CEO. "VEGF has been demonstrated to have a fundamental role in the growth and health of blood vessels, nerves and muscle and we believe that our approach of using a ZFP TF to stimulate the expression of all of the natural forms of a subject's own VEGF-A gene may have potential therapeutic benefit for a variety of neurodegenerative conditions including ALS."

About the Study, SB-509-801

A total of 40 subjects with ALS will be enrolled in this trial and randomized into one of two treatment cohorts. The first cohort of 35 subjects will receive 60 mg of SB-509 in a divided dose into muscles in the arm, leg, and along the spine on both sides of the body. A second cohort of 5 subjects will receive 60 mg of SB-509 in a divided dose into the muscles in the lower limb in both legs. Each subject will receive a total of two treatments of 60 mg of SB-509 intramuscularly three months apart on Day 0 and Day 90. The study will be carried out over 11 months, including 2 months for screening, 3 months for two study treatments, and 6 months of follow-up after administration of the final dose. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or http://www.alsa.org

About Amyotrophic Lateral Sclerosis (ALS)

More than 30,000 Americans have ALS, according to the ALS Association, a nonprofit organization that supports ALS research and public and patient education about the disease. 3,000 to 5,000 new cases of the disease are diagnosed every year. Men and women of all ethnic and racial groups are equally affected, usually between the ages of 40 and 70. The disease attacks the motor nerves, nerve cells in the brain and spinal cord that control the body's voluntary muscles. As the motor nerves begin to die, the muscles weaken and shrink. Early symptoms of ALS may include unusual tiredness and clumsiness, muscle weakness, slurred speech, and difficulty swallowing. As the disease progresses, patients gradually lose the use of their hands, arms, legs, and neck muscles, ultimately becoming paralyzed. They can speak and swallow only with great difficulty. About half of people with ALS die within three to five years of diagnosis.

[tokajo]

Antwort auf Beitrag Nr.: 35.050.829 von tokajo am 10.09.08 16:54:02

http://de.wikipedia.org/wiki/Amyotrophe_Lateralsklerose

Link zu Wikipedia.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.050.863 von tokajo am 10.09.08 16:56:41

Trotz Allem sind wir auf All-time-Low in diesem Jahr und es schaut nicht nach Besserung aus!
Gruß
Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.076.885 von Magnetfeldfredy am 12.09.08 14:29:37

Totalabsturz heute! Es ist zum Heulen, es kamen ja neue Daten die wie`s ausschaut nicht überzeugen!
Was meinst Du Tokajo, raus oder Augen zu und durch?
Hier die News:
Sangamo BioSciences Announces Presentation of Data From Diabetic Neuropathy Clinical Trials
Monday September 15, 10:00 am ET
Positive Interim Data from Ongoing SB-509-701 Study in Subjects with Moderate to Severe Diabetic Neuropathy and Additional Data from Phase 1b Clinical Trial SB-509-401


RICHMOND, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of positive interim Phase 2 clinical data from its ZFP Therapeutic(TM) program (SB-509-701) at the International Society for Cellular Therapy (ISCT) Europe Regional Meeting in Antwerp, Belgium. The data presented demonstrate an improvement in nerve conduction velocity (NCV) in SB-509 treated subjects with moderate to severe diabetic neuropathy (DN), a patient population that until now has been considered impossible to treat.
ADVERTISEMENT


Sangamo management will host a conference call at 11:00 a.m. ET today to discuss these data.

In addition, on September 8, 2008, new data were presented from Sangamo's Phase 1b study (SB-509-401) at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) demonstrating a statistically significant (p= 0.0016) positive correlation of 2 or more response endpoints in the SB-509 treated group compared with placebo treated subjects at day 180 post-treatment. Response endpoints were defined as greater than a 14% improvement in quantitative sensory testing (QST), greater than 0.8 meters/second (m/sec) improvement in NCV and greater than a 3 point improvement as judged by the Neuropathy Impairment Scale -- Lower Limbs (NIS-LL). Data have previously been presented from this trial demonstrating a statistically significant improvement in NIS-LL and QST and trends for improvement in NCV. Sangamo has a larger, repeat-dosing clinical trial (SB-509-601) in this population of subjects with mild to moderate DN.

Data presented today at ISCT from the study SB-509-701 were collected from subjects with moderate to severe diabetic peripheral neuropathy. All subjects entered the trial with between one and six nerves in the lower limb that were "blocked" or for which no NCV could be measured. The majority of the subjects had at least one blocked sural nerve, the most relevant in DN. Subjects received two treatments in both legs of either placebo (n=10 subjects) or SB-509 (n=17) (60 mg total dose, 30 mg per leg) one at Day 0 and one at Day 90. Recovery of NCV during 180 days post treatment in subjects who entered the trial with blocked sural nerves was observed in 75% of the SB-509-treated subjects compared to 25% of the placebo-treated group. SB-509 was well tolerated and no drug-related severe adverse events were observed.

"While these are interim data, we are very pleased and excited by the return of NCV in such a high percentage of these subjects," commented Dale Ando, M.D., Sangamo's vice president, therapeutic development and CMO. "This is a patient population for which historically there have been absolutely no treatment options. This sural nerve recovery data in subjects in the Phase 2 study reinforces our preliminary and surprising data in 3 subjects in the Phase 1 trial.

The sural nerve on the foot is a sensory nerve and one of the first nerves to be affected as diabetic neuropathy progresses. However, some of the subjects enrolled in this study had quite severe neuropathy with all six nerves of the nerves that we are monitoring blocked. Not surprisingly, we found that subjects entering the study with fewer blocked nerves showed the highest rates of response to these two treatments with SB-509.

When we began this trial we chose a more conservative two dose regimen as this is a sicker population than that originally tested in the Phase 1b study. The data suggest that two doses are well tolerated and that our observations from the Phase 1 trial were worth pursuing. We have expanded the trial to include a third treatment with SB-509 and believe that the increased dose and increased subject numbers will provide us with valuable information in determining how well more severely affected DN patients will respond."

A total of 45 subjects have been enrolled in the trial (SB-509-701) who were randomized to one of two groups in a 2:1 ratio and received 2 treatments at (Day 0 and Day 90). The trial has also been expanded to include a further 45 subjects randomized in the same ratio who will receive three treatments (Day 0, Day 60 and Day 120), the same dosing schedule as that used in Sangamo's Phase 2 trial of SB-509 in subjects with mild to moderate DN (SB-509-601).

"While these data are from a relatively small number of subjects, we are very encouraged by the safety of SB-509 in a repeat dosing situation and the greater evidence for clear improvements that are unprecedented in this moderate to severe DN population," said Edward Lanphier, Sangamo's president and CEO. "SB-509 is designed to address nerve damage and these data demonstrate that SB-509 may have both a neuroprotective and a neuroregenerative effect and confirm earlier analyses which showed similar trends. Based on these data and data from our Phase 1b study we expanded the SB-509-701 trial. Additional data from this expanded trial may provide important information which could expedite the design of a Phase 3 study. We also look forward to presenting data from our double blind Phase 2 clinical trial (SB-509-601) later this year."

[Bachalor]

was ist nur in letzter zeit mit den al so hochgelobteb biotechs

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.135.649 von Bachalor am 16.09.08 19:46:39

Ich glaub die Amis verscherlben eben zur Zeit alles um "Kohle" zu machen, oder ist das der Grund:
Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
Tuesday September 16, 4:00 pm ET
CompoZr(TM) Zinc Finger Nuclease Platform enables Precise, Permanent, and Heritable Modification of the Genome


ST. LOUIS, Sept. 16 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL - News) today launched its CompoZr(TM) platform of zinc finger nuclease (ZFN) reagents. The CompoZr ZFN platform of reagents is expected to provide researchers with the ability to target and precisely manipulate the genome of living cells, resulting in cell lines or whole organisms with defined gene deletions, insertions, or corrections. Initially offered as a customized service for developing ZFNs for specific gene targets, the CompoZr ZFN platform will eventually include ZFN-based kits for targeted transgene insertion and a catalog of off-the-shelf reagents for commonly studied gene targets, gene families, and pathways. Applications for Sigma's new platform technology include creation of knockout and knock-in cell lines, cell lines that yield significantly greater amounts of protein, and novel transgenic animal models.
ADVERTISEMENT


ZFN reagents are a class of engineered DNA-binding proteins that facilitate targeted editing of the genome within a living cell by creating double-strand breaks in DNA at user-specified locations. Double-strand breaks stimulate the cell's natural DNA-repair processes, namely homologous recombination and non-homologous end joining, to induce site-specific mutagenesis. Using CompoZr reagents, researchers can, for the first time, generate precisely targeted genomic edits using a rapid, single-step procedure, resulting in cell lines with permanent and heritable gene deletions, insertions, or modifications. Additionally, Sigma-Aldrich is collaborating with leading academic researchers to demonstrate the effectiveness of ZFNs in the creation of whole animal knockout models in mice and other species, including rats and rabbits.

"Zinc Finger Nuclease technology has held significant promise for more than a decade and is now mature enough to fundamentally alter the way in which research on living cells and organisms is conducted," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "By refining ZFN production methods and utilizing our established distribution capabilities, Sigma-Aldrich is making this exciting technology available to life science researchers worldwide."

By facilitating the creation of complete gene knockout and knock-in somatic, embryonic and primary cell lines, ZFNs allow researchers to precisely determine the biological function of a gene in more relevant backgrounds. It is anticipated that ZFN-mediated genome editing could be used to generate novel animal models of disease that more closely mimic human disease, as well as providing more realistic data on the potential toxicity of new drug compounds. For biopharmaceutical manufacturers, ZFNs will enable the creation of cell lines with improved growth characteristics, altered glycosylation properties, and other traits resulting in higher yields.

Through its exclusive partnership with Sangamo BioSciences, Inc. (Nasdaq: SGMO - News), the pioneer in zinc finger nuclease research, Sigma Life Science is the sole source of validated research reagents incorporating ZFN technology. Sigma Life Science employs high-throughput production methods to create customized ZFN reagents for user-specified gene targets in just six to eight weeks. All CompoZr reagents are functionally validated in a cell line appropriate for the intended organism of interest, and customers are provided with full protocols for use of their reagents and troubleshooting support from Sigma Life Science's experienced technical team.

Sigma-Aldrich has invested over $60 million in its Life Science and High Technology Center in St. Louis, where over 200 scientists work to transform cutting-edge research into first-to-market products that are key to researchers' work in the fields of functional genomics, proteomics and cell biology using its market-leading RNA interference tools, whole genome amplification technology and comprehensive Prestige Antibody(TM) portfolio.

For more information on Sigma-Aldrich's CompoZr zinc finger nuclease technology platform, visit http://www.compozrzfn.com or contact a sales representative at [e-mail].

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-

[tokajo]

Antwort auf Beitrag Nr.: 35.139.192 von Magnetfeldfredy am 16.09.08 23:12:24

Hi Fredy,
momentan handeln doch die wenigsten Menschen rational. Beide Infos sind doch super Neuigkeiten. Mit dem Lizenzpartner Sigam Aldrich werden unsere Sangamo Produkte erstmals kommerziell eingesetzt. Die Lizenzeinnahmen sollten langsam fliessen. Die kurzzeitigen - 20 % in Deutschland sind sicherlich durch Privatverkäufe im engen Markt erfolgt und haben nichts mit der Realität zu tun. Kaufen wenn, die Kanonen donnern.
Das Sangamo kein kurzfristiges Investment ist, sollte eigentlich jedem klar sein.
Gruß Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.144.154 von tokajo am 17.09.08 09:27:53

Servus Tokajo,

hast ja Recht, aber ins Grübeln kann man schon kommen!

Gruß Fredy

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.144.242 von Magnetfeldfredy am 17.09.08 09:33:28

Die Amis spinnen, und Sangamo wird zum Spielball der Zocker!

[benefactor [KommA]]

Im Moment gibt es einfach zu viele Panikverkäufe, Margin Calls und Short Sales.

[tokajo]

Antwort auf Beitrag Nr.: 35.177.360 von benefactor am 18.09.08 22:51:44

http://files.shareholder.com/downloads/SGMO/424990751x0x2365…

Für alle die es interessiert. Aktuelle Präsentation zur UBS Healthcare Konferenz und Ausblick für 2008 und 2009.
Ohne Wertung, da momentan sowieso alle nur spinnen

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.291.795 von tokajo am 26.09.08 14:11:21

Habs gesehen, schaut gut aus, obs derzeit was bringt ist das andere!
Long and strong"
Gruß Fredy

[tokajo]

Antwort auf Beitrag Nr.: 35.295.872 von Magnetfeldfredy am 26.09.08 17:31:16

Zacks Equity research

Gruss Tokajo


Sangamo Biotech a Strong Buy

Sangamo Biosciences, Inc. (Nasdaq: SGMO) is a biopharmaceutical company engaging in designing and developing engineered transcription factors for gene regulation. The company uses a proprietary gene regulation technology to discover and develop a new class of therapeutic candidates for cardiovascular disease, cancer, neuropathic pain and immune diseases, such as sickle cell anemia and HIV.

Sangamo uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases. We are optimistic about this novel technology and are encouraged to hear that the company intends to bring more drug candidates into the clinic in 2008.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.549.829 von tokajo am 13.10.08 15:55:12

Servus Tokajo,

und noch ein buy, auch wenns zur Zeit nichts bringt!

Merriman Curhan Ford & Co stuft SANGAMO BIOSCIENES auf buy



Rating-Update:

San Francisco (aktiencheck.de AG) - Die Analysten von Merriman Curhan Ford & Co stufen die Aktie von Sangamo BioSciences (ISIN US8006771062/ WKN 936386) in einer Ersteinschätzung mit "buy" ein. (16.10.2008/ac/a/u)
Analyse-Datum: 16.10.2008

Rating: buy
Analyst: Merriman Curhan Ford & Co
SANGAMO BIOSCIENES

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.549.829 von tokajo am 13.10.08 15:55:12

Good News, aber eigentlich dasselbe wie schon 2005 oder?

Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Tuesday October 28, 4:05 pm ET
Preclinical Animal Data Demonstrates Selective Survival Advantage of ZFN-Treated Immune Cells after HIV Infection and Reduced Viral Loads


WASHINGTON and RICHMOND, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of data demonstrating that human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)) resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection. The presentation, entitled, "Establishment of HIV Resistant CD4 T-cells Using Engineered Zinc Finger Protein Nucleases (ZFNs)" is taking place today at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC.
ADVERTISEMENT


"We are very excited about these data and our collaboration with Sangamo to develop an HIV/AIDS therapeutic," said Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, and a co-author of the study. "The ability to prevent immune cells from becoming infected by HIV has the potential to provide long term control of both the opportunistic infections characteristic of AIDS as well as the virus itself. We look forward to bringing this program into the clinic."

Sangamo's ZFNs are designed to permanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect cells of the immune system. Individuals carrying a naturally occurring mutation of their CCR5 gene, a variant known as CCR5-delta32, have been shown to be resistant to HIV infection.

"These data provide good support for the evaluation of our first ZFN-based ZFP Therapeutic in man," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "It was observed more than ten years ago that individuals carrying the natural CCR5-delta32 mutation were highly resistant to infection by HIV. Consequently, a variety of small molecule and antibody approaches have been tested as potential therapeutics. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. We believe that our ZFN technology provides an approach that circumvents the dosing and potential toxicity issues of a systemic therapy. By specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs, we can generate a population of R5-tropic HIV-resistant T-cells.

We have shown that these ZFN-modified human cells are made permanently resistant to infection by HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections characteristic of AIDS and HIV itself. The modified cells exhibited the expected properties of normal CD4 T-cells. These data also demonstrate that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic. We intend to file an investigational new drug (IND) application for this ZFP Therapeutic this year and begin a clinical trial as soon as possible."

Data Reported in the ICAAC/IDSA Presentation

The reported results demonstrate that a one-time exposure to CCR5-specific ZFNs resulted in the generation of an HIV-resistant population of primary human T-cells by the permanent genetic modification of the CCR5 gene. These ZFN-modified CD4 T-cells expanded stably in HIV-infected cultures for several weeks and appeared to behave identically to untreated T-cells except that they were resistant to infection by HIV. ZFN treated primary CD4 T-cells and transformed CD4 cell lines resisted infection with R5-tropic HIV (virus that uses the CCR5 co-receptor to enter cells), resulting in enrichment of ZFN-generated CCR5-disrupted cells in the population upon exposure to virus. Importantly, in the presence of HIV, ZFN-modified CD4 T-cells also preferentially expanded in a mouse model. The modified cells were infused into mice that lack a normal immune system and thus do not reject human cells. After 33 days, the mice were sacrificed and analyzed for the presence of ZFN-modified cells. Researchers determined that ZFN-modified cells engrafted normally in the mouse and that the proportion of modified cells present at the end of the experiment was greater than two to three fold higher in mice in the presence of HIV infection (p=0.008). It was also determined that 50 days after infection, mice given the ZFN-modified cells had increased numbers of CD4 cells and a statistically significant seven-fold reduction in viral load in their peripheral blood (P<0.001) compared to mice given control cells. A high level of specificity of the CCR5-ZFNs for their target site was demonstrated by immunochemistry and direct genomic sequence analysis of ZFN-treated human CD4 T-cells. These data suggest that, in the presence of HIV, the ZFN-modified cells have a selective advantage allowing them to evade infection and destruction leaving them able fight opportunistic infections and HIV itself.

In addition, Sangamo and its collaborators have demonstrated successful ZFN-modification of clinical-scale quantities of human CD4 T-cells and that these modified cells exhibited the expected properties of normal T-cells. This demonstrates that ZFN-modified human CD4 T-cells could be produced in quantities required for the translation of this program into the clinic.

About HIV/AIDS and CCR5

HIV stands for Human Immunodeficiency Virus. HIV infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers resulting in AIDS (Acquired Immune Deficiency Syndrome). Individuals diagnosed with AIDS are susceptible to life-threatening diseases called opportunistic infections, which are caused by microbes that usually do not cause illness in healthy individuals. According to UNAIDS/WHO, over 2.7 million people were infected with HIV in 2007. There are now over 33 million people living with HIV and AIDS worldwide.

CCR5 is the chemokine receptor that HIV uses as a co-receptor to gain entry into immune cells. CCR5 is perhaps the most important of the known co-receptors for HIV, since the most commonly transmitted strains of HIV are strains that bind to CCR5 -- so-called "R5" strains. A small fraction of the population carries a mutation in their CCR5 gene, called the delta32 mutation. This mutated version of the gene produces malformed CCR5 proteins, which cannot be used by HIV as a co-receptor. Individuals that have two copies of this mutant form of CCR5 (delta32) are resistant to infection by R5 HIV strains.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including but not limited to, technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials for Sangamo's HIV/AIDS therapeutic development program, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in Sangamo's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.549.829 von tokajo am 13.10.08 15:55:12

Hier diez Zahlen zum Q3, alles in line! Ich habe dem CC gelauscht, sind alle sehr zuversichtlich!
Sangamo BioSciences Reports Third Quarter 2008 Financial Results
Wednesday October 29, 4:05 pm ET


RICHMOND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today reported third quarter 2008 financial results and accomplishments.
ADVERTISEMENT


For the third quarter ended September 30, 2008, Sangamo reported a consolidated net loss of $6.3 million, or $0.15 per share, compared to a net loss of $4.3 million, or $0.11 per share, for the same period in 2007. As of September 30, 2008, the company had cash, cash equivalents and investments of $59.5 million. Subsequent to the end of the quarter, the company received $8.5 million in scheduled payments from collaborators.

Revenues for the third quarter of 2008 were $3.7 million, compared to $2.3 million for the third quarter of 2007. Third quarter 2008 revenues were primarily comprised of revenue recognition from the company's collaboration agreements with Dow AgroSciences (DAS) and Sigma-Aldrich, enabling technology agreements in protein production and research grants. The revenue recognized for the third quarter of 2008 consisted of $3.2 million from collaboration agreements and $549,000 from research grants.

Research and development expenses were $7.6 million for the third quarter of 2008, compared to $5.9 million for the same period in 2007. The increase in research and development expenses for the third quarter of 2008 was primarily due to advancing the company's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs. Non-cash stock-based compensation included in research and development expenses totaled $580,000 and $364,000 in the third quarter of 2008 and 2007, respectively.

General and administrative expenses were $2.6 million for the third quarter of 2008, compared to $1.7 million for the same period in 2007. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash stock-based compensation which totaled $709,000 in the third quarter of 2008 compared to $202,000 in the same period in 2007.

Total operating expenses for the third quarter of 2008 were $10.1 million, compared to $7.6 million for the same period in 2007.

Net interest and other income was $42,000 for the third quarter of 2008, compared to $1.1 million for the same period in 2007. The decrease is due to lower average investment balances and lower interest rates as well as a foreign currency translation loss during the quarter.

Nine Month Results

For the nine months ended September 30, 2008, the consolidated net loss was $21.7 million, or $0.53 per share, compared to a net loss of $14.8 million, or $0.41 per share, for the nine-month period ended September 30, 2007. Revenues were $9.4 million for the first nine months of 2008, compared to $6.3 million in the same period in 2007. Total operating expenses were $32.5 million for the first nine months of 2008 and $23.5 million for the same period of 2007. The increase in operating expenses for 2008 was primarily associated with Sangamo's clinical development programs in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and glioblastoma, as well as increased research and development personnel costs and lab supply expenses.


Recent Highlights
* Initiation of a Phase 2 clinical trial (SB-509-801) to evaluate SB-509
in subjects with Amyotrophic Lateral Sclerosis (ALS). ALS is a
progressive, degenerative motor-neuron disease for which there are
limited treatment options and no cure. The Phase 2 trial is a
randomized repeat-dosing, open-label, multi-center study designed to
evaluate the effect of intramuscular administration of SB-509 on the
progression of the disease in subjects with ALS. In addition to
gathering data on safety and tolerability of SB-509, the study will
also evaluate stem cell mobilization in subjects with ALS receiving
SB-509.
* Presentation of additional data from Phase 1b study of SB-509
(SB-509-401) and interim data from Phase 2 study (SB-509-701) in
subjects with diabetic neuropathy (DN). Additional data from the
Phase 1b clinical trial (SB-509-401) were presented at the 44th Annual
Meeting of the European Association for the Study of Diabetes (EASD),
demonstrating a statistically significant (p=0.0016) positive
correlation of 2 or more response endpoints in the SB-509 treated group
compared with placebo treated subjects at day 180 post-treatment.
Response endpoints were defined as greater than a 14% improvement in
quantitative sensory testing (QST), greater than 0.8 meters/second
(m/sec) improvement in NCV and greater than a 3 point improvement as
judged by the Neuropathy Impairment Scale - Lower Limbs (NIS-LL). The
trial was conducted in subjects with mild to moderate diabetic
neuropathy over a six month period after a single administration of
SB-509. Positive interim clinical data were also presented at the
International Society for Cellular Therapy (ISCT) Europe Regional
Meeting in Antwerp, Belgium from the Phase 2 trial of SB-509
(SB-509-701) conducted in subjects with moderate to severe DN who
entered the trial with at least one "blocked nerve". The data
demonstrate recovery of sensory nerve conduction velocity (NCV) in 75%
of SB-509 treated subjects compared to 25% of placebo treated subjects.
SB-509 is an injectable formulation of plasmid DNA that encodes a ZFP
transcription factor (ZFP TF(TM)), designed to upregulate the vascular
endothelial growth factor-A (VEGF-A) gene.
* Official launch of Sigma-Aldrich CompoZr(TM) platform of zinc finger
nuclease (ZFN) reagents for gene-editing. In September, Sangamo's
partner, Sigma-Aldrich Corporation (Nasdaq: SIAL - News), the exclusive
distributor of ZFP products for research applications, launched sales
of CompoZr ZFN reagents. The CompoZr ZFN platform of reagents is
expected to provide researchers with the ability to target and
precisely manipulate the genome of living cells, resulting in cell
lines or whole organisms with defined gene deletions, insertions, or
corrections. Initially offered as a customized service for developing
ZFNs for specific gene targets, the CompoZr ZFN platform will
eventually include ZFN-based kits for targeted transgene insertion and
a catalog of off-the-shelf reagents for commonly studied gene targets,
gene families, and pathways. For more information on Sigma-Aldrich's
CompoZr zinc finger nuclease technology platform, visit
http://www.compozrzfn.com or contact a sales representative at
[e-mail] .

[tokajo]

Antwort auf Beitrag Nr.: 35.744.773 von Magnetfeldfredy am 29.10.08 11:50:37

Hallo Fredy, meinst du diese Meldung von 2005.
Ist für mich allerdings eine Riesenunterschied zur aktuellen Meldung. Immerhin wurde diesmal die Wirksamkeit an Tierversuchen bestätigt. Desweiteren ist mittlerweile auch das Abramson Family Cancer Research Institute als Treiber mitdabei. Früher wäre Sangamo hier 2 stellig gestiegen. Aber was solls. In zwei Jahren sieht die Welt wieder anders aus.
Gruss Tokajo

RICHMOND, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that data from its program to develop a ZFP Therapeutic(TM) for HIV/AIDS were presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. The study represents the first demonstration that cells can be made resistant to HIV infection by treatment with Sangamo's proprietary zinc finger DNA-binding protein nucleases (ZFN(TM)) designed to specifically disrupt the CCR5 gene.

In its anti-HIV preclinical research program, Sangamo has designed ZFNs that can be used to disrupt the CCR5 gene, a receptor required for HIV entry into immune cells. The researchers found that ZFN-modified cells were resistant to HIV infection whereas control cells were infected when challenged with the virus. Furthermore, when CCR5 expression was experimentally restored in the ZFN-modified cells, HIV was once again able to infect these cells. Sangamo has shown disruption of the CCR5 gene in a number of different cell types including T-cells, the target cell for this therapeutic approach.

"CCR5 is an important target in the fight against HIV/AIDS," stated Edward Lanphier, Sangamo's president and CEO. "Individuals with a natural mutation of their CCR5 gene have been shown to be resistant to HIV infection. Several major pharmaceutical companies have initiated programs to develop small molecule drugs to block HIV binding to CCR5, but in recent months two trials have been halted, one due to reports of liver toxicity of the candidate drug. We believe that using ZFNs to permanently modify the CCR5 gene specifically in T-cells and thus directly block the expression of the protein on the surface of these cells may have several advantages over the systemic effects of other drugs in development."

Small molecule or antibody approaches require the constant presence of antagonist in high enough concentrations to block therapeutically relevant numbers of the CCR5 protein, of which there are approximately 10,000 copies on the surface of each T-cell. In contrast, brief exposure of T-cells to Sangamo's ZFNs has been shown to result in permanent modification of the CCR5 gene and consequent alteration of the CCR5 protein.

"We believe that the data presented at ICAAC provide another important validation of our novel approach to HIV," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "By administering ZFNs to patients, we could potentially provide HIV-infected individuals with a reservoir of healthy and uninfectable T-cells that would be available to fight both opportunistic infections and HIV itself. In this program, we have been working in close collaboration with Dr. Carl June at the University of Pennsylvania with the goal of initiating a Phase 1 clinical trial to test our ZFP Therapeutic in 2006."

Dr. Carl June, Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, is a leader in the field of research testing T-cell therapies for cancer and HIV infection. Dr. June stated, "After the recent negative news regarding trials with pharmacologic blockade of CCR5, it is very important that we focus on positive results involving this well-validated disease target. I am encouraged by Sangamo's findings and look forward to collaborating with the Company further to bring this promising approach into the clinic."

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.823.728 von tokajo am 04.11.08 14:50:52

Du hast Recht,aber SGMO "kackt" heute wieder sauber ab!
Ich muß, wie Du schon sagst, 2 Jahre halten!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.823.728 von tokajo am 04.11.08 14:50:52

Bad News:
Press Release Source: Sangamo BioSciences, Inc.


Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Monday November 10, 4:02 pm ET
Company Will Host a Conference Call Today To Discuss the Data and Ongoing Clinical Development Programs


RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in a number of measures of nerve function and health at the primary analysis point, day 180 post-treatment.
ADVERTISEMENT



Sangamo management will host a conference call at 5:00 p.m. ET today to review these data and the ongoing clinical studies supporting the development of SB-509.

"Our first Phase 2 study, SB-509-601, had three goals," stated Dale Ando, M.D., Sangamo's vice president, therapeutic development and CMO. "First, we wanted to determine the safety of repeat dosing. Second, we evaluated dose schedule, specifically whether a regimen of three administrations of the maximum dose given at two month intervals would be more effective than a single administration. Finally, we hoped to gain clarity around clinical endpoints for use in the design of future studies. While this study has not added to our data around the most suitable end-points or dosing schedule for a Phase 3 trial, it has demonstrated that the drug continues to have an excellent safety profile. This is valuable information for our future development efforts."

"We also know that SB-509 is an active agent. We have positive preclinical data in several animal models of angiogenesis and nerve injury. We also have impressive data from our prior Phase 1 clinical study, SB-509-401, with a single treatment in the same patient population. In addition, we have encouraging positive interim data in our SB-509-701A study in which we are assessing recovery of nerve conduction velocity (NCV) in subjects with moderate to severe DN after two treatments with SB-509. Recovery of NCV in this more severe population that presents with "blocked" nerves or nerves with unmeasurable NCVs provides a binary outcome. The SB-509-701A trial is nearly complete and we expect to have more data from this study in the first quarter of 2009."

"The results from the SB-509-601 study are certainly unexpected," stated Edward Lanphier, Sangamo's president and CEO. "The data that we obtained on measures of nerve health and function are quite different than what we observed in our Phase 1b study. However, the 601 trial is only one part of our broad clinical development program to evaluate SB-509 which we will continue to prosecute. Based on our positive Phase 1b clinical data and encouraging interim data from our Phase 2 repeat-dosing study (SB-509-701A) in subjects with moderate to severe DN, we continue to have a high degree of confidence in this drug."

Conference Call

Sangamo will host a conference call today, November 10, 2008 at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm . The webcast replay will also be available for two weeks after the call. During the conference call, the company will review the data presented today.

The conference call dial-in numbers are 888-690-2875 for domestic callers and 913-981-5543 for international callers. The passcode for the call is 2585543. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on November 10, 2008 to midnight, Monday November 17, 2008. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820, respectively. The conference ID number for the replay is 2585543.

About SB-509

SB-509 is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF- A). VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease- induced nerve damage.

Phase 2 Study of SB-509 for Mild to Moderate DN (SB-509-601)

The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.

110 subjects were enrolled into the trial. Subjects were randomized to one of two groups. The larger group was treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every two months. The remaining group received an equal volume of placebo on the same schedule. Each subject received a total of three treatments (Day 0, 60 and 120). Subjects received injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial were evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Specifically, investigators used the following tests: the visual analog scale for pain intensity (VASPI), a modified Neuropathy Impairment Score -- Lower Limbs (NIS-LL) scoring system as well as total neuropathy score (TNS) to assess signs and symptoms of the condition. In addition, data from electrophysiological testing using nerve conduction velocity (NCV) to assess the rate at which a nerve can conduct an electrical signal, and quantitative sensory testing (QST) with the Vibratron II instrument, to assess the threshold of detection of vibration were also collected. Skin biopsies were taken to evaluate the direct therapeutic effect of SB-509 on nerve regrowth.

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In 2004, this translated to approximately 71,000 amputations. Diabetes is a growing problem, the Centers for Disease Control estimates that from 1980 through 2007, the number of Americans with diabetes increased from 5.6 million to 23.6 million and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.907.254 von Magnetfeldfredy am 10.11.08 22:12:36

Brutal, after hours: ./. 50 %!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.823.728 von tokajo am 04.11.08 14:50:52

Lebst Du noch nach dem Kurssturz und bleibst Du dabei?

[tokajo]

Antwort auf Beitrag Nr.: 35.921.004 von Magnetfeldfredy am 12.11.08 09:39:16

Hallo Fredy,

ich bin noch dabei, wobei ich jetzt mit Sangamo in die Miese gerutscht bin. Was momentan an der Börse abgeht, hat tlw. nichts mehr mit der Realität zu tun. Die Bewertung richtet sich bei Sangamo derzeit nur auf ein negativ Szenario. So schnell wie die Aktie gefallen ist, so schnell kann der Markt nach allgemeinen positiven Daten wieder steigen.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.923.850 von tokajo am 12.11.08 13:07:27

Na ja, daß glaub ich bei Sangamo kaum, die Phase II Ergebnisse waren nicht besser als bei Placebo-Patienten, das ist der wahre Grund für den Niedergang, oder?

[Bachalor]

was ist nur mit all den hoffnungsvollen biotechs los

hnab-elan sgmo usw

[Riegerparis]

Antwort auf Beitrag Nr.: 35.924.151 von Magnetfeldfredy am 12.11.08 13:31:34

Das ist aber auch keine Ausnahme! Siehe den großen Krankenkassenversuch über Akupunktur vs klassische Medizin: etwa 28% der klassischen Patienten geheilt, knapp 60% der Akupunkturpatienten aber auch etwa 55% der an eindeutig unwirksamen Stellen behandelten Akupunkturpatienten.
Der Versuch zeigt vor allem auch (wie noch viele andere), daß die menschliche Seele eine enorme reale Heilkraft auch im Krebsbereich hat.

Das dürfte vielen Medikamenten in diesem Bereich so gehen. Die Frage ist, ob bei negativer psychischer Verfassung allopatische Medizin Stabilität erzeugt - sagen wir einmal so: die Placebo-Gabe war zu überzeugend....

Ich halte weiter, obwohl inzwischen fast 50% im Mnus.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 35.943.972 von Riegerparis am 14.11.08 07:06:56

Jedoch entscheiden die Daten über Linzesierungen, Kohle....
Ohne guten Daten keine Kohle, Kurs runter....

[therock1]

was ist die prognose der nächsten wochen??

[tokajo]

Antwort auf Beitrag Nr.: 36.118.224 von therock1 am 30.11.08 10:45:17

wird sich erst am Ende der Präsentation heute zeigen

Gruss Tokajo

Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference

RICHMOND, Calif., Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 4:30 pm (ET) on Tuesday, December 2, 2008 at the Piper Jaffray 20th Annual Health Care Conference in New York. The company will also update the financial community on its latest developments in its therapeutic programs and discuss other business matters at its annual Investor and Analyst Briefing to be held from 4:30 to 6:30 pm ET, on Wednesday, December 3, 2008.

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2008 PR Newswire. All rights reserved

[therock1]

schaun mer mal was heute bei der Ankündigung rauskommt

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 36.137.516 von therock1 am 03.12.08 11:58:00

Ich bin raus, Sangamo hat eine revolutionäre Plattform und sicher auch Erfolge jedoch für mich ist entscheidend:

-- Presentation of top line Phase 2 data from repeat dosing study of SB-509 in mild to moderate DN (SB-509-601) demonstrating that the drug is well-tolerated in a repeat-dosing setting; however, no significant differences were observed in improvement in measures of nerve health between placebo and treated subjects at primary evaluation point 180 days post treatment. Analysis of these data is ongoing.

Das Hauptprogramm mit SB-509 zeigt keine Signifikanz zum Placebo!
Damit ist Sangamo für mich mit KZ 5 US Dollar vorerst gescheitert denn ich Bewertung ist viel zu hoch und der Cash Burn reicht nur noch bis 2010!
Schade!

[Riegerparis]

Antwort auf Beitrag Nr.: 36.143.967 von Magnetfeldfredy am 04.12.08 06:44:24

Guter Ausstiegszeitpunkt, wenn man so denkt.

Als Gegengewicht halte ich - bereits gepostet - die Reaktion auf den dem Placebo gleichenden Testergebnis für deutlich überzogen und sehe die Aktie seit nunmehr 2 Wochen in äußerst interessanter charttechnischer Position:
- Bollinger wird immer enger;
- 38 er Marke bleibt vom Kurs überschnitten (= stabile Wende zeichnet sich ab)
- Kurs ist noch in oberer Hälfte Bollinger trotz absinkendem Momentum und geht auf Obergrenze zu.

Das interpretiere ich als deutliche Bodenbildung und - wenn keine neuen negativen Fundamentaldaten - gute Bais für einen Ausbruch innerhalb der kommenden 1 bis 4 Wochen.

Start einer echten Ralley ist ein Kurs über etwa 3,20, Durchbruch Abwärtstrend bei 4,50 - in etwa dort auch der zu erwartende Rebound vor Durchbruch Widerstandsbereich bei 5,70 bis 6,10 und endgültige Stabilisierung bei Kurs ab etwa 7,30€.

Dagegen wäre erst ein Kurs unter etwa 2,20 ein Ende der "Hoffnungssituation".

Warten wir also ab - ich tippe auf Nordwärtsbewegung.

[tokajo]

Antwort auf Beitrag Nr.: 36.350.753 von Riegerparis am 11.01.09 15:14:43

Sangamo BioSciences initiates Phase I HIV trial

Feb 04, 2009 (Datamonitor via COMTEX News Network) --
Sangamo BioSciences, a developer of transcription factors for gene regulation and gene modification, has announced that its collaborators at the University of Pennsylvania have opened a Phase I clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS.

The study is an open-label Phase I clinical trial of the safety and tolerability of a single infusion of autologous CD4+ T cells genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). A total of 12 subjects with HIV will be enrolled in this trial in two treatment cohorts.

The first cohort to be treated comprises six subjects who have failed two or more highly active antiretroviral therapy regimen. The first three subjects in this cohort will be treated sequentially and monitored for the first 21-days post treatment before an additional subject is treated. After this period of evaluation and monitoring has passed successfully, the next three subjects will be treated.

The second cohort comprises six subjects who are responsive to their current therapy regimen who will be treated with CCR5-modified T-cells and undergo a structured therapy interruption or therapy 'break'. The primary objective of the study is to evaluate the safety and tolerability of SB-728-T. In addition to safety monitoring, data will be collected on the expansion and persistence of ZFN-modified cells, CD4+ cell counts and viral load.

Edward Lanphier, president and CEO of Sangamo, said: "Our zinc finger DNA-binding protein (ZFP) technology functions at the DNA level and, as this application demonstrates, enables us to address highly validated therapeutic targets that have proven difficult to drug at the protein and RNA levels. This trial is another important step in establishing our ZFP technology as a major new therapeutic product development platform."


http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Copyright (C) 2009 Datamonitor. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 36.511.628 von tokajo am 04.02.09 16:34:37

Servus Tokajo,

ich bin zwar nicht mehr dabei bei SGMO, verfolge aber alle News!

Das Phase I Programm für Aids ist hoffnungsvoll, interessant wirds Meiner Meinung nach aber erst ab Phase II wenn Endpunkte erreicht werden!
Auch die Milestonezahlungen von DOW sind sehr gering, 1 Million, gemessen an der Marktkapitalisierung!

Herzliche Grüße

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 36.512.918 von Magnetfeldfredy am 04.02.09 18:28:42

http://diepresse.com/home/techscience/wissenschaft/449784/in…

http://www.nation.co.ke/News/-/1056/534184/-/item/1/-/14p2in…

Die erste Meldung ist zwar schon etwas älter, passt aber ganz gut zum Thema.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 36.648.184 von tokajo am 25.02.09 10:42:22

Ja das wär was, aber bevor keine erfolgreiche Phase II nicht abgeschlossen wird investiere ich nicht mehr!

Viele Grüße

[tokajo]

Antwort auf Beitrag Nr.: 36.725.837 von Magnetfeldfredy am 08.03.09 21:30:26

Quartalszahlen sind da.

Gruss Tokajo

Sangamo BioSciences Reports First Quarter 2009 Financial Results

RICHMOND, Calif., April 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2009 financial results and accomplishments.

For the first quarter ended March 31, 2009, Sangamo reported a consolidated net loss of $6.8 million, or $0.17 per share, compared to a net loss of $8.0 million, or $0.20 per share, for the same period in 2008. As of March 31, 2009, the company had cash and cash equivalents, marketable securities and interest receivable of $57.9 million.

Revenues for the first quarter of 2009 were $3.2 million, compared to $2.8 million for the same period in 2008. First quarter 2009 revenues were primarily from Sangamo's agreements with Dow AgroSciences and Sigma-Aldrich Corporation and enabling technology agreements.

Research and development expenses were $7.3 million for the first quarter of 2009, compared to $8.6 million for the same period in 2008. The decrease in research and development expenses is primarily related to lower clinical trial expenses in Sangamo's ongoing SB-509 program in diabetic neuropathy, partially offset by the ramp up for its Phase 1 clinical trial for HIV/AIDS, which opened in the first quarter of 2009, and its planned Phase 1 clinical trial in glioblastoma multiforme. Non-cash employee stock-based compensation included in research and development expenses totaled $0.7 million and $0.9 million in the 2009 and 2008 periods, respectively.

General and administrative expenses were $2.9 million for both the first quarter of 2009 and the corresponding 2008 period. Non-cash employee stock-based compensation included in general and administrative expenses totaled $0.8 million and $0.9 million in the 2009 and 2008 periods, respectively.

Total operating expenses for the first quarter of 2009 were $10.2 million, compared to $11.6 million for the same period in 2008.

Net interest and other income was $0.2 million for the first quarter of 2009, compared to $0.8 million for the same period in 2008. The decrease was due to lower average investment balances and lower interest rates.

First Quarter 2009 Highlights

-- Sangamo and its collaborators at the University of Pennsylvania opened a
Phase 1 clinical trial to evaluate SB-728-T for the treatment of
HIV/AIDS. The study is an open-label Phase 1 clinical trial designed to
evaluate the safety and tolerability of a single infusion of SB-728-T,
autologous (a patient's own) CD4+ T cells genetically modified at
the CCR5 gene by CCR5-specific zinc finger DNA-binding protein nucleases
(ZFNs). A total of twelve subjects with HIV will be enrolled in this
trial in two treatment cohorts. In an animal model of HIV infection,
SB-728-T has been shown to lead to an increase in CD4+ T-cell counts, a
reduction in viral load and expansion of CCR5-modified T-cells,
suggesting resistance to HIV. CCR5 is a co-receptor that enables HIV to
enter and infect cells of the immune system. Individuals carrying a
natural mutation of their CCR5 gene, CCR5-delta32, are highly resistant
to infection by HIV. Brief exposure of cells to Sangamo's ZFNs
results in the permanent disruption of the CCR5 gene. This trial is the
first zinc finger nuclease therapeutic study in humans. Individuals
interested in participating in this trial should visit
http://www.clinicaltrials.gov/
-- Sangamo BioSciences, Inc. and its plant agriculture partner Dow
AgroSciences announce publication in Nature of the successful
application of ZFP technology for the efficient generation of maize
plants with multiple, commercially important traits. In a study
published in the Advance Online edition of Nature, scientists at Dow
AgroSciences and Sangamo used ZFNs to introduce a herbicide tolerance
gene into a pre-determined address in the maize genome, simultaneously
eliminating the expression of an enzyme involved in the production of
phytate, a natural but undesirable compound found in feed crops and a
cause of environmental pollution. In a rapid, single step process the
gene involved in phytate production was disabled and permanently linked
with the acquisition of herbicide tolerance - i.e. stacking the two
desired characteristics in the plant and generating reduced phytate,
herbicide tolerant corn. This new method efficiently targets specific
genes, making it suitable for routine plant gene modification. The paper
can be accessed at
http://www.nature.com/nature/journal/vaop/ncurrent/index.htm…

-- Announcement of achievement of a major production throughput milestone
as part of its agreement with Sigma-Aldrich Corporation in research
reagents. The milestone, which was achieved in December 2008, over a
year ahead of schedule, triggered a payment of $1.0 million to Sangamo.

Conference Call

Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. The webcast replay will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide forward-looking guidance.

The conference call dial-in numbers are 877-340-7913 for domestic callers and 719-325-4907 for international callers. The passcode for the call is 5624956. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on April 29, 2009 to 11:59 p.m. ET on May 6, 2009. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 5624956.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials, human therapeutic and plant applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership with collaborators and anticipated amount of cash and cash equivalents. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, uncertainties arising out of the Company's collaboration with Dow AgroSciences relating to plant agriculture, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


SELECTED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)

Three Months Ended
March 31,
-----------
2009 2008
---- ----
Consolidated Statement of Operations Data:
Revenues
Collaboration agreements $3,157 $2,084
Research grants - 681
--- ---
Total revenues 3,157 2,765

Operating expenses:
Research and development 7,256 8,646
General and administrative 2,926 2,927
----- -----
Total operating expenses 10,182 11,573
------ ------
Loss from operations (7,025) (8,808)
Interest and other income, net 193 836
--- ---
Net loss $(6,832) $(7,972)
======= =======
Basic and diluted net loss per
common share $(0.17) $(0.20)
====== ======
Shares used in computing basic and
diluted net loss per common share 41,066 40,489
====== ======



March 31, December 31,
2009 2008
--------- ------------
(Unaudited)

CONSOLIDATED CONDENSED BALANCE SHEET DATA
Cash and cash equivalents,
marketable securities and
interest receivable $57,866 $65,025
Total assets 60,878 67,850
Total stockholders' equity 49,991 55,396

SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2009 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.071.669 von tokajo am 30.04.09 12:23:22

Servus Tokajo, schon lange nichts mehr voneinander gehört!

Ich habe mit 5000 Stück Dendreon den Deal meine Börsenlebens gemacht, zu ca. 4 EUR gekauft und zu ca. 15 EUR verkauft!
Wahnsinn was da abging, auch am 28.4.09, von 25 US Dollar auf 7,5 und nachbörslich wieder hoch!
Dendreon hat den primary endpoint erreicht und wie`s aussieht wird`s die erste Immuntherapie gegen Prostatakrebs!

Sowas wünsch ich Dir auch für Sangamo!

Viele Grüße Fredy

[tokajo]

Antwort auf Beitrag Nr.: 37.076.385 von Magnetfeldfredy am 30.04.09 20:03:09

Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009

RICHMOND, Calif., June 8, 2009 /PRNewswire via COMTEX News Network/ --
Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints

RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of as yet unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), held in New Orleans, LA, from June 5 to 9, 2009. Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. SB-509 was well-tolerated in both multi-dose studies.

"We have learned a great deal from these data, which demonstrate positive activity of SB-509 in multiple clinically relevant measurements of nerve health," stated Dale Ando, M.D., Sangamo's Vice President of Therapeutic Development and Chief Medical Officer. "Data from our Phase 1 and both Phase 2 clinical trials have shown us that the dual angiogenic and neurotrophic effects of SB-509 are most effective in the later stages of DN when both diabetic microvascular disease and metabolic neuropathy are evident. The statistically significant improvement in SB-509-treated subjects across multiple independent clinical endpoints for DN has enabled definition of a responder group and is particularly encouraging for future trials in this patient population."

"SB-509 is the first drug candidate of its type designed to harness the body's own regenerative potential to address DN, a significant complication for diabetic patients," stated Alan Lewis, Ph.D., President and Chief Executive Officer of the Juvenile Diabetes Research Foundation (JDRF). "A significant part of JDRF's patient-centric funding efforts support the development of therapies to stop or reverse the impact of diabetic complications and we are very pleased to be involved in the SB-509-601 study with Sangamo. Additionally, JDRF funded an ancillary study by Dr. Polydefkis to investigate the effects of SB-509 on nerve fiber density improvement and nerve regeneration. We are very encouraged that SB-509 was associated with an improvement in clinical outcomes in the more severely affected subjects in the trial and that this group showed increased nerve fiber density and nerve regeneration. In future trials we hope these important and encouraging positive effects of SB-509 are reproduced on a broad range of clinically relevant endpoints and translate into real functional gains for people with diabetes."

SANGAMO ABSTRACTS PRESENTED AT THE ADA MEETING

Details of Poster Presentation of Data from Sangamo's SB-509-601 Study (Abst# 859-P): "Vascular Endothelial Growth Factor Zinc Finger Protein Activator (SB-509) in Mild to Moderate Diabetic Peripheral Neuropathy Patients. Interim Phase 2 Results (SB-509-0601 Study)" presented on Saturday, June 6 at 11:30 am CT (12:30 pm ET).

Overall, no difference was seen at 180 days between placebo and SB-509-treated subjects in Sangamo's double-blind, repeat dosing Phase 2 clinical study of SB-509 (SB-509-601) in the following measures of nerve health and function: Abbreviated Neuropathy Impairment Score in the Lower Limbs (A-NIS-LL), Nerve Conduction Velocity (NCV), and Quantitative Sensory Testing (QST). However, analysis of the data demonstrated that subjects entering the SB-509-601 trial had significantly milder DN by neurologic exam (A-NIS-LL) and NCV than subjects in either the Phase 1 SB-509-401 or Phase 2 SB-509-701 studies (p value = 0.0001). Further analysis of the data revealed that subjects with moderate to severe DN had a statistically significant and clinically relevant positive response to treatment with SB-509 over the six-month test period. In addition, new top-line data were presented from epidermal (skin) nerve fiber density (ENFD) and nerve fiber regrowth (ENFDR) studies carried out in collaboration with Michael Polydefkis, M.D., Associate Professor of Neurology, Johns Hopkins University School of Medicine and supported by funding from the Juvenile Diabetes Research Foundation International (JDRF).

ENFD has been shown to be a direct measure of nerve health and growth in DN. Subjects entering the SB-509-601 trial with a median ENFD of less than 18 fibers/mm, a value that separates moderate from mild DN, demonstrated parallel improvement between median sensory (sural) NCV (delta 1.0 M/s) and ENFDR at day 210 (delta =2.0 fibers/mm) with a multi-endpoint p value of 0.05.

Baseline measurements considered to define the threshold of mild and moderate DN of sural NCV (< 47.5 M/s), QST (>7.5 vibration units) and A-NIS-LL (>10) were also used to define SB-509 responder groups within the total population of SB-509 treated subjects. The data from these sub-groups were analyzed and all groups demonstrated clinically relevant improvement in the neurological exam by A-NIS-LL.

Specifically, the following clinically relevant improvements in A-NIS-LL in SB-509-treated subjects compared to placebo at Day 180 were seen for subjects entering the study with the following baseline measurements:

-- Sural NCV of <47.5 M/s, we observed an improvement of 1.1 points compared to 0.2 point worsening for the placebo group (a delta in A-NIS-LL of 1.3 points, p value= 0.08); -- QST of >7.5 v.u., there was a 2.3 point improvement compared to a 1.5 point worsening in the placebo group (a delta in A-NIS-LL of 3.8 points, p value=0.005); -- A-NIS-LL of >10 points, we observed improvement in A-NIS-LL of 2.5 points in SB-509 treated subjects compared to a 0.3 point worsening when compared to SB-509 treated subjects entering the study with a baseline A-NIS-LL of <10 (a delta in A-NIS-LL of 2.8 points, p value=0.003).
In addition, in subjects entering the trial with A-NIS-LL>10 points, we observed sural nerve NCV preservation of 0.02 M/s in SB-509 treated subjects compared to a 2.4 M/s worsening in the placebo-treated group (p value = 0.09).

Details of Oral Presentation of Data from Sangamo's SB-509-701-A Study (Abst# 243-OR, presented 06/07/09): "Reappearance of Nerve Potentials in Severe Diabetic Peripheral Neuropathy Patients with Unmeasurable Nerve Conduction Using Vascular Endothelial Growth Factor Zinc Finger Protein Activator (SB-509): Interim Phase 2 Results (SB-509-0701 Study)" presented on Sunday, June 7 at 6:00 pm CT (7:00pm ET).

Data from the first cohort of Sangamo's single-blind, repeat dosing Phase 2 study of SB-509 (SB-509-701-A) demonstrated that subjects with at least one nerve for which an NCV could not be measured showed a clinically relevant improvement at Day 180 in two NCV-based analyses of SB-509 versus placebo-treated subjects.

Proportional analysis of the percentage of responding subjects with a measurable nerve at 180 days that could not be measured at baseline or who demonstrated a greater than 7 M/s improvement for a baseline measurable nerve revealed a two-fold improvement with SB-509 treatment (47%) compared to placebo (27%) (p value = 0.20).

The mean change in sural NCV at Day 180 compared to baseline demonstrated a clinically relevant improvement in subjects treated with SB-509 compared to placebo-treated subjects (2.8 m/s SB-509, 1.3 m/s placebo, p value=0.20). In addition, relative improvements in sural NCV were maintained at 240 days (3.81 M/s SB-509, 1.98 m/s placebo, p value = 0.24).

"SB-509 has shown unprecedented restoration of NCV in subjects that began the study with nerves for which no induced electrical activity could be measured, a clinical condition that would normally be considered irreversible and untreatable," commented Dr. Ando. "There is both a vascular as well as a neurologic component to severe peripheral neuropathy which appears to be addressed by the activation of VEGF-A by SB-509. It is also very encouraging that effects have been observed across multiple endpoints such as NIS-LL and NCV in the 601 study and NCV in the 701 study which are measurements that have been used as endpoints in previous pivotal large scale trials of other non-analgesic approaches for diabetic neuropathy."

About SB-509

SB-509 is an injectable plasmid encoding a DNA-binding Zinc Finger DNA-binding Protein (ZFP) Transcription Factor (ZFP TF(TM)) designed to upregulate the endogenous expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct angiogenic, neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sural nerve function from disease-induced nerve damage. Sangamo has completed a Phase 1b clinical trial (SB-509-401) that demonstrated statistically significant and clinically relevant improvements in several measurements of nerve health and function in subjects with diabetic neuropathy. For more information about SB-509, visit www.sangamo.com and for further information on Sangamo's clinical trials of this drug visit http://www.clinicaltrials.org.

About Diabetic Neuropathy

Diabetic neuropathy is a progressive degenerative disease that is one of the most frequent complications of diabetes, affecting between 14 and 16.5 million Americans in 2007. High blood glucose levels lead to nerve damage over time, primarily affecting peripheral nerves. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet, which gradually evolve to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot as pressure wounds or injuries go unnoticed. Despite palliative treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In 2004, this translated to approximately 71,000 amputations. Diabetes is a growing problem. The Centers for Disease Control estimates that from 1980 through 2007, the number of Americans with diabetes increased from 5.6 million to 23.6 million and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy.

About Sangamo

Sangamo BioSciences, Inc. is focused on researching and developing Zinc Finger DNA-binding Protein (ZFP) Technology for therapeutic gene regulation and modification. By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow AgroSciences, Sigma-Aldrich Corporation Genentech and Pfizer. For more information about Sangamo and the ZFP Technology, visit www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in it's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo

http://www.clinicaltrials.org

Copyright (C) 2009 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.343.504 von tokajo am 08.06.09 14:43:36

Servus Tokajo,

hört sich gut an, muß aber als primary endpoint erst definiert werden, oder?

Gruß

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 37.356.444 von Magnetfeldfredy am 09.06.09 19:43:12

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

RICHMOND, Calif., June 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines with novel characteristics for pharmaceutical protein production purposes using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. Genentech scientists demonstrated the successful knockout of two preselected genes in a Chinese hamster ovary (CHO) cell line. The milestone achievement triggered a payment from Genentech to Sangamo.

"Achievement of this milestone demonstrates the progress under our agreement with Genentech," said Edward Lanphier, Sangamo's president and chief executive officer. "Our ZFN technology is currently being used by major players in pharmaceutical protein production to streamline the process of cell line production, increase the yield and improve the characteristics of biologic drugs, such as antibodies, that are manufactured in mammalian cells."

"Our ZFNs provide the gold standard technology for specifically editing target genes in mammalian cells," stated Philip Gregory, D. Phil., Sangamo's vice president of research. "Moreover, the efficiency of this approach obviates the need for selection markers, thereby enabling the rapid generation of cell lines in which multiple genes have been knocked out. Our proven ability to quickly and selectively knock out multiple genes in the same cell line creates endless possibilities for biopharmaceutical companies to improve their manufacturing capability."

About Sangamo

Sangamo BioSciences, Inc. is focused on researching and developing zinc finger DNA-binding protein (ZFP) technology for therapeutic gene regulation and modification. By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow AgroSciences, Sigma-Aldrich Corporation Genentech and Pfizer. For more information about Sangamo and the ZFP Technology, visit www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, strategic relationship with collaborators and achievement of research milestones, and research applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and its collaborators to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com
Copyright (C) 2009 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.484.760 von tokajo am 29.06.09 11:24:06

Interessant wäre wie hoch die Zahlung war!

[Riegerparis]

Antwort auf Beitrag Nr.: 37.511.878 von Magnetfeldfredy am 03.07.09 07:22:48

Auch einmal anders gesehen - Kursziel 11 USD:

June 22, 2009 8:57 AM EDT

From Notable Calls

Merriman Curhan Ford is out with a rather positive call on Sangamo Biosciences (NASDAQ: SGMO) reiterating their Buy rating and raising their target range from $5.50-6.50 to $10-11.

Firm believes Sangamo has the potential to be the leader in zinc finger applications both in the therapeutic arena and applications outside of the clinic. While the company’s diabetic neuropathy program is currently in question, they still believe in the therapeutic potential for the zinc finger platform. Additionally, partnerships with Dow Agro- Sciences and Sigma-Aldrich have the potential to provide Sangamo with future royalty streams and milestone payments. Merriman believes SGMO shares should trade to a range of $10-11.

Broad growth opportunity. Sangamo is now entering an interesting chapter in the company’s growth. They continue to believe that the zinc finger technology platform has a broad set of applications in both the therapeutic and non-therapeutic arenas. Firm believes investors are especially not assigning a fair value to the non-therapeutic potential of the zinc finger platform.

Clinical programs. The lead diabetic neuropathy SB-509 program has yielded quite a large dataset of clinically relevant data for a therapeutic indication with no other real treatment options at this point. Merriman sees the downside risk being minimal at this point for this program. Upside potential could come from a potential partner and more visibility on the path forward for a registration pathway. They believe investor excitement continues to grow around the SB-728 HIV program and could represent a transforming program for the company.

Dow AgroSciences (DAS) and Sigma-Aldrich (SA) continuing to gain key visibility in 2009. As part of the growing interest in the non-therapeutic applications of the zinc-finger platform, we expect increased visibility and value creation from the ongoing collaborations with DAS and SA in 2009 and going forward. Merriman believes these programs represent key potential revenue generators for Sangamo

Valuation. Firm reiterates their Buy rating and are raising target range from $5.50- 6.50 to $10-11. This change is based on what they believe to be the current status of the opportunities at Sangamo and currently see the therapeutic and non-therapeutic opportunities split ~50/50 with regard to contribution toward valuation.

Notablecalls: I'm sure that if you have been in this business long enough you have heard the jokes about John Merriman hiring only former quarterbacks as analysts.

Regardless of this, I think SGMO will see buying interesting following this call. It's a small biotech but unlike many of its peers, it's not that binary in nature.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.521.604 von Riegerparis am 06.07.09 07:20:06

Würd mich freuen wenns so wär!

[tokajo]

Antwort auf Beitrag Nr.: 37.542.259 von Magnetfeldfredy am 09.07.09 16:34:42

Hi Fredy,

das wird schon wieder werden. Sangamo ist m.E. aufgrund der Technologie nicht mit anderen Bios zu vergleichen. Das System ist sehr vielseitig und kann in ferner Zukunft für vieles verwendet werden. Daher ist Sangamo für mich eh nur eine Langzeitinvestition und "Altersabsicherung". Die Forschung steht finanziell aufgrund der Meilensteinzahlungen (blödes Wort auf Deutsch) auf sicheren Boden. Wenn das erste Medikament die Zulassung erhält und das Verfahren "generell" freigegeben wird ist Luft bis ganz weit oben.

PS Lumera bzw. Gigaoptix spielen ja auch derzeit verrückt.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.543.461 von tokajo am 09.07.09 18:49:43

Servus Tokajo,

ja, Du hast Recht, die Technologie von Sangamo hat ähnliches Potential wie z.Zeit GigOpitx!
Ich werd mir zu dem Preis wieder mal 500 Stück zulegen!

Viele Grüße und viel Erfolg!

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 37.547.390 von Magnetfeldfredy am 10.07.09 11:36:18

Morgen nach Börsenschluss gibt es wieder Zahlen zum 2. Quartal.
Heute erstmal aktuell 5 % hoch.
Gruss Tokajo

Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast

RICHMOND, Calif., July 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its second quarter 2009 financial results on Wednesday, July 29, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-795-3638 for domestic callers and 719-325-4858 for international callers. The passcode for the call is 9591497. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on July 29, 2009 to midnight ET on August 5, 2009. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 9591497.

About Sangamo

Sangamo BioSciences, Inc. is focused on researching and developing zinc finger DNA-binding protein (ZFP) technology for therapeutic gene regulation and modification. By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow AgroSciences, Sigma-Aldrich Corporation, Genentech and Pfizer. For more information about Sangamo and the ZFP Technology, visit www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2009 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 37.634.118 von tokajo am 23.07.09 18:10:56

Sorry, Zahlen am Mittwoch nach Börsenschluss.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.653.353 von tokajo am 27.07.09 16:36:05

Habs gesehen, kein Problem!

Erwartest Du positive Impulse bzw. Überraschungen?

Ich bin heute mit BioMS auf die Schnauze gefallen, Primary Endpoints nicht erreicht, 86 % minus!

So kanns gehen mit Dendreon top mit Bioms flopp!

[tokajo]

Antwort auf Beitrag Nr.: 37.662.891 von Magnetfeldfredy am 28.07.09 18:00:27

Hi Fredy,
kann passieren. Hast du eigentlich eine vernünftige Seite der FDA bzw. über den Stand der Zulassung. Ich habe nur einige wissenschaftlich Newsletter, wo über die eine oder andere Firma berichtet wird.
Von Sangamo erhoffe ich mir heute zwar noch keine Zulassung, aber weiterhin positive Ergebnisse und die Höhe der letzten Milestone Zahlung sollte mitgeteilt werden.
Vielleicht wird Sangamo sogar noch ohne zugelassenes Medikament profitabel.

Gruss Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 37.666.581 von tokajo am 29.07.09 08:31:23

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

RICHMOND, Calif., July 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported second quarter 2009 financial results and accomplishments.

For the second quarter ended June 30, 2009, Sangamo reported a consolidated net loss of $4.5 million, or $0.11 per share, compared to a consolidated net loss of $7.4 million, or $0.18 per share, for the same period in 2008. As of June 30, 2009, the company had cash, cash equivalents, marketable securities and interest receivable of $52.6 million.

Revenues for the second quarter of 2009 were $4.7 million, compared to $2.8 million for the same period in 2008. Second quarter 2009 revenues were from the Company's collaboration agreements with Dow AgroSciences (DAS) and Sigma-Aldrich Corporation, enabling technology agreements in protein production and research grants. The revenue recognized for the second quarter of 2009 consisted of $4.2 million in collaboration agreements and $0.5 million in research grants.

Research and development expenses were $6.9 million for the second quarter of 2009, compared to $8.3 million for the same period in 2008. The decrease in research and development expenses for the second quarter of 2009 was primarily due to decreased manufacturing and preclinical expenses partially offset by increased clinical trial expenses. Non-cash employee stock-based compensation included in research and development expenses totaled $0.7 million for the second quarters of both 2009 and 2008.

General and administrative expenses were $3.0 million for the second quarter of 2009, compared to $2.5 million for the same period in 2008. The increase in general and administrative expenses was primarily due to increased professional services and personnel costs including non-cash employee stock-based compensation which totaled $0.8 million in the second quarter of 2009 compared to $0.6 million in the same period in 2008.

Total operating expenses for the second quarter of 2009 were $9.9 million, compared to $10.8 million for the same period in 2008.

Net interest and other income was $0.6 million for the second quarters of both 2009 and 2008.

Six Month Results

For the six months ended June 30, 2009, the consolidated net loss was $11.3 million, or $0.28 per share, compared to a consolidated net loss of $15.4 million, or $0.38 per share, for the six-month period ended June 30, 2008. Revenues were $7.9 million for the first half of 2009, compared to $5.6 million in the same period in 2008. Total operating expenses were $20.1 million for the first half of 2009 and $22.4 million in the first half of 2008. The decrease in operating expenses for 2009 was primarily associated with decreased manufacturing, preclinical and decreased lab supply expenses partially offset by increased clinical trial expenses.

Recent Highlights

-- Presentation of positive Phase 2 ZFP Therapeutic data at ADA 2009. Sangamo announced the presentation of previously unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA). Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. The data have enabled the definition of a responder population for SB-509 for future clinical trials. -- Achievement of key milestone in cell engineering agreement with Genentech. A key research milestone was achieved in Sangamo's Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group. Genentech scientists demonstrated the successful knockout of two pre-selected genes in a Chinese hamster ovary (CHO) cell line using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. Genentech is using ZFN technology to generate cell lines with novel characteristics for pharmaceutical protein production purposes. The milestone achievement triggered a payment from Genentech to Sangamo. -- Publication in Nature and Science magazines of data demonstrating the successful application of ZFN technology in plant agriculture and in the generation of novel transgenic animals. Data were published in April in the scientific journal Nature by licensing partner Dow AgroSciences and Sangamo demonstrating the successful application of ZFP technology for the efficient generation of maize plants with multiple, commercially important traits. The techniques described are broadly applicable across plant species and traits and establish a new method for rapid and precise crop development. A second publication in July in the journal Science described a method for the rapid and efficient production of transgenic rats in which specific genes are deleted or knocked out. The technology opens the door for the production of knockout animals in species other than mouse and broadens the possibilities for new animal models of human disease. -- Sangamo awarded Grand Challenges Explorations Grant for Innovative Global Health Research from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Sangamo scientists titled "Zinc Finger Nucleases for In Vivo Treatment of HIV Infection." -- Promotion of Philip D. Gregory, D. Phil. to Chief Scientific Officer in addition to his role as Vice President, Research. Dr. Gregory's promotion became effective July 1, 2009. He has served as Sangamo's Vice President, Research since October 2005 and joined the company in December 2000.
Conference Call

Sangamo will host a conference call today, July 29, 2009 at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. The webcast replay will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide forward-looking guidance with respect to the remainder of 2009.

The conference call dial-in numbers are 877-795-3638 for domestic callers and 719-325-4858 for international callers. The passcode for the call is 9591497. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on July 29, 2009 to midnight ET on August 5, 2009. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 9591497.

About Sangamo

Sangamo BioSciences, Inc. is focused on researching and developing zinc finger DNA-binding protein (ZFP) technology for therapeutic gene regulation and modification. By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP technology, including Dow AgroSciences, Sigma-Aldrich Corporation Genentech and Pfizer. For more information about Sangamo visit www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials, therapeutic and non-therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership with collaborators and anticipated amount of cash and cash equivalents. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable ZFP-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SELECTED CONSOLIDATED FINANCIAL DATA (in thousands, except per share data) (unaudited) STATEMENT OF OPERATIONS DATA: Three Months Ended Six Months Ended June 30, June 30, ----------- ---------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues Collaboration agreements $4,213 $2,378 $7,370 $4,462 Research grants 513 464 513 1,145 ----- ----- ----- ----- Total revenues 4,726 2,842 7,883 5,607 Operating expenses: Research and development 6,877 8,286 14,133 16,929 General and administrative 3,007 2,545 5,933 5,472 Total operating expenses 9,884 10,831 20,066 22,401 ------ ------ ------ ------ Loss from operations (5,158) (7,989) (12,183) (16,794) Interest and other income, net 647 570 840 1,406 Net loss $(4,511) $(7,419) $(11,343) $(15,388) ======= ======= ======== ======== Basic and diluted net loss per common share $(0.11) $(0.18) $(0.28) $(0.38) Shares used in computing basic and diluted net loss per common share 41,123 40,858 41,094 40,673 ====== ====== ====== ======
SELECTED BALANCE SHEET DATA: June 30, 2009 December 31, 2008 ------------- ----------------- Cash, cash equivalents, marketable securities and interest receivable $52,586 $65,025 Total assets 54,938 67,850 Total stockholders' equity 47,176 55,396
SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2009 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 37.674.313 von tokajo am 30.07.09 00:52:06

Das Ganze in Kurzform.
Ich finds absolut positiv.

Gruss Tokajo

Sangamo BioSciences Q2 net loss narrows

Jul 30, 2009 (Datamonitor via COMTEX News Network) --
Sangamo BioSciences, a company engaged in the development and commercialization of transcription factors for gene regulation and gene modification, has reported a net loss of $4.51 million, or $0.11 per share, for the second quarter ended June 30, 2009, compared to a net loss of $7.42 million, or $0.18 per share, for the same period in 2008.

Revenues for the second quarter of 2009 were $4.73 million, compared to $2.84 million for the same period in 2008.

For the six months ended June 30, 2009, the net loss was $11.34 million, or $0.28 per share, compared to a net loss of $15.39 million, or $0.38 per share, for the six-month period ended June 30, 2008. Revenues were $7.88 million for the first half of 2009, compared to $5.61 million for the same period in 2008.


http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Copyright (C) 2009 Datamonitor. All rights reserved

[Riegerparis]

Antwort auf Beitrag Nr.: 37.679.477 von tokajo am 30.07.09 16:25:01

Ja, stabilisiert sich. Gut - und Danke.

[tokajo]

Antwort auf Beitrag Nr.: 37.799.054 von Riegerparis am 18.08.09 07:56:31

http://www.forbes.com/feeds/ap/2009/08/25/business-health-ca…

Die Zusammenarbeit mit Sigma-Aldrich wird vertieft. Kurszielmit outperform auf 15 $ angehoben.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.852.108 von tokajo am 26.08.09 08:56:32

Werd auch mal wieder einsteigen, SGMO soll ein Patent für ihre Zinkfingertechnologie gegen chronische Schmerzen eingerreicht haben?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.864.603 von Magnetfeldfredy am 27.08.09 14:53:48

New Technique Enables Efficient Gene Splicing In Human Embryonic Stem Cells
Main Category: Stem Cell Research
Also Included In: Genetics; Biology / Biochemistry
Article Date: 15 Aug 2009 - 0:00 PDT

email to a friend printer friendly view / write opinions rate article
Ads by Google
--------------------------------------------------------------------------------
Cell fusion generator
Versatile device for cell fusion, nuclear transfer, oocyte activation
www.fbt-Corp.jp
Current Article Ratings:

Patient / Public: 5 (4 votes)

Health Professional:

Article Opinions: 1 posts

A novel technique allows researchers to efficiently and precisely modify or introduce genes into the genomes of human embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells, according to Whitehead scientists. The method uses proteins called zinc finger nucleases and is described in Nature Biotechnology.

For years, scientists have easily swapped genes in and out of mouse ESC or iPS cell genomes, but have had a notoriously difficult time disrupting or inserting genes into their human equivalents.

"It's not clear where this hurdle of genetic manipulation lies; it could be purely technical, but it could also be an inherent difference between human and mouse cells," says Dirk Hockemeyer. Hockemeyer and Frank Soldner are first authors on the article and postdoctoral researchers in Whitehead Member Rudolf Jaensich's lab. "Other people have genetically manipulated these human cells, but the process has been extremely laborious and extremely time consuming. Using the zinc finger nucleases makes the process very easy," says Hockemeyer.

Earlier methods are so inefficient that fewer than 15 genes have been swapped into human ESCs since that cell type was discovered 10 years ago. By comparison, hundreds of genes have been introduced into the genomes of mouse ESCs.

According to Jaenisch, this method could open a new phase in human genetics.

"This is a proof of principle that zinc finger nucleases can be used to swap out many, many additional genes in human ESCs and iPS cells," says Jaenisch, who is also a professor of biology at MIT. "Now human ESC and iPS cell genetics can catch up to mouse genetics, which has had a 20-year headstart."

The inability to alter human ESC and iPS cells' genomes has hindered researchers from routinely creating specific cell types for modeling genetic diseases (e.g., the brain cells affected by Parkinsons's disease) and studying how embryonic stem cells mature into adult cells. (iPS cells are adult cells that have been reprogrammed to an embryonic-stem-cell-like state, so they have similar properties of ESCs: the ability to self-propagate and the ability to mature into any of an adult's approximately 220 cell types. iPS cells have the added benefit of possessing the same genes as the patient who donated the adult cells, thereby accurately reflecting that patient's specific genetic profile.)

To substitute a gene in ESCs and iPS cells, Hockemeyer and Soldner adapted a recently developed technique to cut out one gene from the human ESCs and iPS cells and substitute it with another by putting two zinc finger nucleases and the replacement gene into the ESCs and iPS cells.

Each zinc finger nuclease recognizes a particular sequence in a cell's DNA and then cuts through both strands of DNA at that site. The cell's DNA repair machinery recognizes that the DNA has been cut and tries to fix it using the replacement gene resulting in the desired alteration of the original gene.

In addition to working so efficiently, the method can be tailored to precisely swap nearly any gene in the genome.

"We can produce zinc finger nucleases that out of about three billion DNA base pairs can identify one specific site," says Soldner. "We also spent quite a bit of energy to see if the zinc finger nucleases cut somewhere other than the intended target site, and it was very unlikely."

Notes:

The research was conducted in collaboration with Sangamo BioSciences, Inc., which designed and produced the zinc finger nucleases.

The National Institutes of Health (NIH) and the Life Sciences Research Foundation provided funding for this research.

Rudolf Jaenisch's primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology at Massachusetts Institute of Technology.

Full Citation:

"Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases" Dirk Hockemeyer (1*), Frank Soldner (1*), Caroline Beard (1), Qing Gao (1), Maisam Mitalipova (1), Russell C. DeKelver (3), George E. Katibah (3), Ranier Amora (3), Elizabeth A. Boydston (3), Bryan Zeitler (3), Xiangdong Meng (3), Jeffrey C. Miller (3), Lei Zhang (3), Edward J. Rebar (3), Philip D. Gregory (3), Fyodor D. Urnov (3), and Rudolf Jaenisch (1,2)

1. The Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, 02142 MA, USA

2. Department of Biology, Massachusetts Institute of Technology, 31 Ames Street, Cambridge, MA 02139, USA

3. Sangamo BioSciences, Inc., Pt. Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, CA 94804, USA

* These authors contributed equally to this work

Source:
Nicole Giese
Whitehead Institute for Biomedical Research

[tokajo]

Antwort auf Beitrag Nr.: 37.867.763 von Magnetfeldfredy am 27.08.09 20:39:15

Hi Fredy, schön das du wieder dabei bist.

Ist fast schon so wie früher bei den Goldgräbern. Nicht die Goldsucher verdienen sondern die Ausrüstungsfirmen.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.871.170 von tokajo am 28.08.09 11:04:27

Servus Tokajo,

ja ich bin wieder dabei, die einmalige Zinkfingertechnologie von Sangamo rückt z.Zeit wieder verstärkt in den Blickpunkt!
Entscheidend ist für mich was dabei rauskommt, wann endlich große Revenues von Partnern bezahlt werden...bzw. ein Übernahme kommt...

Ich wünsch uns allen hier den Dendreon Effekt, den ich im April erleben durfte, wow!

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 37.871.170 von tokajo am 28.08.09 11:04:27

Sangamo ist wieder "in" in den USA! Auf www.investorvillage.com ist SGMO an 10-ter Stelle der meistdiskutierten Aktien Amerikas!
Und dort wird spekuliert daß ein "big investor" einsteigt aufgrund der einmaligen Ein-Auschalt-Technik von Genen!
Der Auslöser war wahrscheinlich die Meldung das mit Sangamos Technik bestimmte Ratten für Versuchszwecke viel schneller "kreiert" werden können!

Kursziel US Dollar 15, für mich im Erfolgsfall daß Sangamo gegen HIV works, 50 US Dollar!

So schnell kanns gehen, Versagen beim Phase II für Diabetis, jetzt wieder hipp!

[tokajo]

Antwort auf Beitrag Nr.: 37.912.289 von Magnetfeldfredy am 03.09.09 16:41:45

Hi Fredy,
sieht interessant aus.
Falls Interesse schau dir auch mal Protalix an.

Gruss Tokajo

[nicolani]

sieht doch heute gut hier aus, ganz ohne nachrichten, da kauft sich einer ein, vielleicht ist was dran mit aldrich-sigma, bleibt spannend

[tokajo]

Antwort auf Beitrag Nr.: 37.912.479 von nicolani am 03.09.09 17:01:14

Gruss Tokajo

Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells

--Novel Approach Enables Breakthrough in Human Stem Cell Manipulation for Medical Research and for the Development of Stem Cells as Therapeutics

RICHMOND, Calif., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Scientists from The Whitehead Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, Inc., (Nasdaq: SGMO) to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). Human ESCs and iPSCs are useful tools in drug discovery and development. Scientists also hope to use these cells therapeutically in transplantation medicine and other regenerative applications. The research was described in a paper which appears in today's issue of the scientific journal Nature Biotechnology.

"The application of ZFN technology to human stem cells opens a new phase in human genetics," said Rudolf Jaenisch, M.D., a member of the Whitehead Institute and Professor of Biology at Massachusetts Institute of Technology (MIT). "In contrast to mouse stem cells which have been easy to modify, it has been very difficult and time-consuming to modify genes in human ESCs and iPSCs. This has severely limited their usefulness for the study of cell differentiation and as models for human disease. The work that our team published in Nature Biotechnology demonstrates that ZFNs enable new, rapid, efficient and specific methods to work with stem cells giving researchers the tools to gain valuable insights into how embryonic stem cells differentiate into adult cells and enabling the generation of patient-specific models of human disease."

Stem cells differ from other cell types in two fundamental ways. First, they are unspecialized cells capable of renewing themselves through cell division. Second, under certain conditions, they can be induced to become tissue- or organ-specific cells with special functions. Stem cells have the potential to develop into the body's many different cell types and in many tissues they serve a repair function, differentiating and replacing damaged cells. iPSCs are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state. An advantage of iPSCs is that they can be derived from the adult cells of a person and will possess the same genetic background as that individual.

"These data are another powerful demonstration of the specificity and broad applicability of Sangamo's ZFP technology across medically and commercially relevant cell types," stated Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president of research. "The ability to efficiently modify stem cells enables the generation of valuable new tools for drug screening and the study of human disease as well as therapeutic applications in regenerative medicine."

In the article published today, Dr. Jaenisch and his team demonstrated the broad applicability of gene editing applications enabled by ZFNs in hESCs and hiPSCs. In one example, they generated hESCs that carried a reporter gene. This gave researchers a visual method to clearly identify undifferentiated cells from those that had differentiated to their final cell type. In another example they inserted a new gene into a specific site in the genome of hESCs and demonstrated that ZFNs can be used to generate reporter cells in non-expressed genes in the genomes of hESCs and iPSCs, tools that will be useful in the study of cell fate and differentiation protocols.

("Efficient Targeting of Expressed and Silent Genes in Human ESCs and iPSCs Using Zinc Finger Nucleases" D.Hockemeyer, Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R. C., Katibah, G.E., Amora, R., Boydston, E.A., Zeitler, B., Meng, X., Miller, J.C., Zhang, L., Rebar, E.J., Gregory, P.D, Urnov, F.D., and Jaenisch, R. Nature Biotechnology (2009) Vol 27:September)

About Sangamo Biosciences, Inc.

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic approach for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo also is developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the application of Sangamo's ZFN technology. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and its partners to develop commercially viable products and technological developments by Sangamo's competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

Copyright (C) 2009 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 37.947.667 von tokajo am 09.09.09 16:55:23

Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference

RICHMOND, Calif., Sept 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 1:30 pm ET on Wednesday, September 23, 2009 at the UBS Global Life Sciences Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

[tokajo]

Antwort auf Beitrag Nr.: 38.009.827 von tokajo am 18.09.09 14:38:50

Schöner Kursverlauf in den Tagen vor der Präsentation.

Übrigens im letzten GEO Heft ist ein intersessanter Artikel über Gentechnik in Nahrungsmitteln bzw. Futterpflanzen.

Was die Erdbevölkerung satt machen kann, ist umstritten: genveränderte Lebensmittel - oder eine neue regionale Agrikultur" target="_blank" rel="nofollow ugc noopener">Die "Grüne Revolution": Wer ernährt die Welt?
Was die Erd…

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.023.798 von tokajo am 21.09.09 16:45:31

Servus Tokajo,

top news:

Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Expansion of Program Will Test Repeat Dosing Protocol of SB-728-T

RICHMOND, Calif., Sept 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty percent of all HIV-infected patients in the US and may particularly benefit from this novel T-cell ZFP Therapeutic approach."

Based on Sangamo's zinc finger DNA-binding protein nuclease (ZFN) technology, SB-728-T has been shown in an animal model of HIV infection to lead to an increase in CD4+ T-cell counts, a reduction in viral load and expansion of CCR5-modified T-cells, suggesting resistance to HIV.

"Although it is still early days, we are encouraged by what we have seen in pre-clinical experiments and in the ongoing Phase 1 clinical trial that is being run by collaborators at the University of Pennsylvania," commented Edward Lanphier, Sangamo's president and CEO. "This new study is another important step in our mission to establish ZFP Therapeutics as a major new therapeutic product development platform. Moving our first ZFN technology-based product efficiently through the development process is vital to that goal. SB-728-T represents a new treatment paradigm for the treatment of HIV and we are very excited to expand its clinical development."

CCR5 is a co-receptor that enables HIV to enter and infect cells of the immune system. It has been observed that individuals carrying a natural mutation of their CCR5 gene, CCR5-delta32, are highly resistant to infection by HIV, despite high-risk behaviors. These individuals, lacking a functional CCR5 (approximately 1-2% of the general population), are otherwise immunologically "normal". A variety of small molecule and antibody antagonists of CCR5 binding have been tested and developed as potential therapeutic agents for the treatment of HIV infection. In addition, there is a recent report of a patient who had both HIV infection and leukemia and received a bone marrow transplant from a donor carrying the CCR5 mutation. After the successful bone marrow transplant, HIV treatment was discontinued and the virus could not be found in the circulating blood several months after the procedure. Sangamo's ZFNs are designed to modify the DNA sequence encoding CCR5. This modification can occur directly in T-cells with only a brief exposure to the ZFNs. Once the modification is made to the T-cell's CCR5 gene it is permanently disrupted.

About the SB-728-T Clinical Trial (SB-728-T-902)

The study is an open-label Phase 1 clinical trial to evaluate the safety and tolerability of repeat infusions of autologous (a patient's own) CD4+ T cells genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). The trial will enroll a total of nine HIV infected subjects on long-term, stable anti-retroviral therapy whose virus is undetectable in their blood by conventional methods but who have exhibited suboptimal CD4+ T-cell gains. The trial will have three dosing cohorts. The first cohort to be treated will receive a single dose, the second cohort, two doses at fourteen day intervals and the third cohort, three doses at fourteen day intervals. The subjects in each cohort will be treated sequentially and monitored for 2 months after their last treatment before an additional subject is treated. After this period of evaluation and monitoring has passed successfully, the next cohort will be treated, again sequentially. Subjects will remain on their existing antiviral therapy while receiving treatment with SB-728-T. The primary objective of the study is to evaluate the safety and tolerability of SB-728-T. In addition to safety monitoring, data will be collected on the expansion and persistence of ZFN-modified cells, CD4+ cell counts and viral load.

Preclinical Data

Preclinical data on SB-728-T were published in the journal Nature Biotechnology (Perez E. E. et al., Nat Biotechnol. 2008 Jul; 26(7):808-16.) and presented at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC in October 2008. The results demonstrate that a one-time exposure to CCR5-specific ZFNs resulted in the generation of an HIV-resistant population of human primary T-cells by the permanent genetic modification of the CCR5 gene. These ZFN-modified CD4 T-cells expanded stably in HIV-infected cultures for several weeks and behaved identically to untreated T-cells except that they were resistant to infection by HIV. ZFN treated primary CD4 T-cells and transformed CD4 cell lines resisted infection with R5-tropic HIV (virus that uses the CCR5 co-receptor to enter cells), resulting in enrichment of ZFN-generated CCR5-disrupted cells in the population upon long-term exposure to virus (>50 days). Importantly, in the presence of HIV, ZFN-modified CD4 T-cells also preferentially expanded in a mouse model. The modified cells were infused into mice that lack a normal immune system and thus do not reject human cells. After 33 days, the mice were sacrificed and analyzed for the presence of ZFN-modified cells. Researchers determined that ZFN-modified cells engrafted normally in the mouse and that the proportion of modified cells present at the end of the experiment was greater than two to three fold higher in mice in the presence of HIV infection (p=0.008). In additional experiments, it was determined that 50 days after infection, mice given the ZFN-modified cells had increased numbers of CD4 cells and a statistically significant reduction in viral load in their peripheral blood (P<0.001) compared to mice given control cells. These data suggest that, in the presence of HIV, the ZFN-modified cells have a selective advantage allowing them to evade infection and destruction.

About HIV/AIDS and CCR5

HIV stands for Human Immunodeficiency Virus. HIV infection kills or impairs cells of the immune system progressively destroying the body's ability to fight infections and certain cancers resulting in AIDS (Acquired Immune Deficiency Syndrome). Individuals diagnosed with AIDS are susceptible to life-threatening diseases called opportunistic infections, which are caused by microbes that usually do not cause illness in healthy individuals. According to UNAIDS/WHO, over 2.7 million people were infected with HIV in 2007. There are now over 33 million people living with HIV and AIDS worldwide.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic approach for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to clinical trials of SB-728-T, the potential for further study and development of SB-728-T for the treatment of HIV/AIDS, the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including but not limited to, technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials for Sangamo's HIV/AIDS therapeutic development program, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in Sangamo's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com
Copyright (C) 2009 PR Newswire. All rights reserved


Close window | Back to top

[tokajo]

Antwort auf Beitrag Nr.: 38.039.421 von Magnetfeldfredy am 23.09.09 14:33:54

Servus Fredy,

Hört sich wieder gut an. Wenn man bedenkt, dass von Phase 1 bis zur Zulassung im Schnitt 6 Jahre vergehen können, kann ich bei Erfolg doch ein paar Jahre früher in den Ruhestand

Immerhin sollen die Chancen zur Zulassung von Medikamenten innerhalb klinischer Studien bei ca 20 % liegen.

Gruss Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 38.041.706 von tokajo am 23.09.09 17:40:22

Schade übrigens dass wir hier nicht dabei gewesen sind.

A0NFQV Vermillion

Gruss Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 38.041.789 von tokajo am 23.09.09 17:48:44

Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award

RICHMOND, Calif., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation. The grant, which will be paid over three years, will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."

"ZFN-mediated gene editing is an exciting and now proven technology with the potential to provide a solution for sickle cell anemia and other hemoglobinopathies," said Dr. Kohn. "Despite the fact that sickle-cell anemia was the first genetic disorder for which a molecular cause was identified and one in which every patient has the same gene mutation, the lack of treatment options makes the disease a hugely important problem worldwide. This novel approach will develop the use of efficient ZFN-mediated correction of the sickle mutation in the human beta-globin gene in stem cells from patients with sickle cell disease rather than traditional approaches of gene replacement therapy."

The Doris Duke Innovations in Clinical Research Award (ICRA) provides seed funding for early stage, multi-disciplinary clinical research projects. The 2009 ICRA grants will support a range of approaches to improving the health of patients with sickle cell disease. The research proposed by Dr. Kohn and Sangamo is one of five projects selected to receive grants from the foundation out of a total of 81 applications from 52 teams of investigators for the 2009 ICRA competition.

"We are very pleased that our research proposal was chosen for this prestigious award," commented Dr. Philip Gregory. "Dr. Kohn is a pioneer in the development of hematopoietic stem cell therapies for monogenic diseases and we look forward to continuing our collaboration to develop a novel stem cell therapeutic approach to sickle cell disease."

About Sickle Cell Anemia and Sickle Cell Disease

Sickle cell anemia is a serious disease in which the body makes sickle-shaped red blood cells. This condition is caused by a mutation in the beta-globin gene which leads to the production of abnormal hemoglobin protein. Normal red blood cells are disc-shaped and move easily through blood vessels. Sickle-shaped cells are stiff and sticky and tend to form clumps and get stuck in the blood vessels blocking blood flow to the limbs and organs. Blocked blood vessels can cause pain, serious infections, and organ damage.

Many of the more than 70,000 people living with sickle cell disease in the United States - most of whom are African-American - face a lifetime of painful, debilitating and expensive health problems, with a much-shortened life expectancy. Sickle cell disease takes an even heavier toll in Africa, where approximately 200,000 babies are born with the disease each year. The only FDA-approved drug available for treating sickle cell disease is the anticancer drug hydroxyurea.

About the Doris Duke Charitable Foundation

The mission of the Doris Duke Charitable Foundation is to improve the quality of people's lives through grants supporting the performing arts, environmental conservation, medical research and the prevention of child maltreatment, and through preservation of the cultural and environmental legacy of Doris Duke's properties. Since 1998, the foundation's Medical Research Program has committed approximately $185 million to strengthen and support clinical research, which advances the translation of basic biomedical discoveries into new treatments, preventions and cures for human diseases. To learn more about the program or to receive competition announcements, visit http://www.ddcf.org/mrp.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and their applications in the treatment of sickle cell disease, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2009 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.094.738 von tokajo am 01.10.09 14:17:06

Unser Baby wird!

Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
Sigma-Aldrich to Exclusively Develop and Distribute ZFP-based Cell Lines for Commercial Therapeutic Protein Production

Press Release
Source: Sigma-Aldrich Corporation
On Monday October 5, 2009, 7:00 am EDT
Buzz up! 0 Print
Companies:Sangamo Biosciences Inc.Sigma-Aldrich Corporation
ST. LOUIS and RICHMOND, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL - News) and Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights to certain ZFP-engineered transgenic animals for commercial applications.

Related Quotes
Symbol Price Change
SGMO 7.73 0.00


{"s" : "sgmo,sial","k" : "c10,l10,p20,t10","o" : "","j" : ""} "The zinc finger technology platform developed by Sangamo is a core component of Sigma-Aldrich's growth strategy into high-value biologic tools," said Jai Nagarkatti, Sigma-Aldrich's Chairman, President and CEO. "We have experienced tremendous interest from the academic and biotechnology research community in our CompoZr(TM) zinc finger nuclease (ZFN) platform of reagents. Expanding our capability to provide ZFN-modified cells for the commercial production of therapeutic proteins and vaccines takes us into markets with enormous commercial potential, and we fully intend to maximize the value of these assets."

"ZFN-based gene editing is rapidly emerging as a critical tool in modern biotechnology," said David Smoller, Ph.D., President of Sigma-Aldrich's Research Biotech Business Unit. "The ability to modify genes in essentially any cell type has been established. In addition, we are now able to generate transgenic animals in species in which it was previously impossible to efficiently and specifically carry out genome modification. This opens up endless possibilities for application and commercialization of the ZFP technology platform."

"We are delighted with our partnership with Sigma-Aldrich," said Edward Lanphier, Sangamo's President and CEO. "Sigma-Aldrich has been aggressively developing, marketing and distributing ZFP-based products through their CompoZr website, and we anticipate the same success in these expanded markets of cell line engineering and transgenic animal products. Sangamo's business model enables us to access non-dilutive funding for our core ZFP Therapeutic(TM) programs by monetizing the industrial applications of our ZFP technology with a focused and committed partner. Sigma-Aldrich has proven to be just that."

For more information on Sigma-Aldrich's CompoZr ZFN technology platform, visit http://www.compozrzfn.com or contact a sales representative at [e-mail].

Terms of the License Agreement Amendment

The expanded agreement provides Sigma-Aldrich with exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals for livestock, companion animals and therapeutic protein production. Sangamo retained all rights to ZFP-modified transgenic animals for discovery of novel therapeutics and the right to use ZFPs as therapeutic products. Under this agreement, Sigma-Aldrich will make initial payments of $20.0 million to Sangamo, consisting of an upfront license payment of $15.0 million and $5.0 million through the purchase of 636,133 shares of Sangamo common stock at market price. Market price is determined by the average closing price of Sangamo stock over the past 30 trading days, or $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 million to $10.0 million, up to a total of $25.0 million, based upon cumulative product sales.

About Sigma-Aldrich

Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

[tokajo]

Antwort auf Beitrag Nr.: 38.115.418 von Magnetfeldfredy am 05.10.09 14:59:18

Hi Fredy,hab´s auch gerade gelesen. Auch vorbörslich hat sich schon einiges getan.

Gruss Tokajo

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.115.531 von tokajo am 05.10.09 15:12:44

Hi Tokajo, ich freu mich besonders für Dich,der mich ja auf Sangamo brachte und immer long and strong dabeibleit!


Vielleicht wirds ja mit der Pharmaphantasie eine zweite Dendreon?

Schönen Tag noch!

Fredy

[tokajo]

Antwort auf Beitrag Nr.: 38.115.583 von Magnetfeldfredy am 05.10.09 15:18:17

Sangamo Announces Pricing of Public Offering of Common Stock

RICHMOND, Calif., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of a public offering of 3,000,000 shares of its common stock. The offering is expected to close on or about October 13, 2009, subject to the satisfaction of customary closing conditions. In addition, Sangamo has granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any.

Jefferies & Company, Inc. is acting as sole book-running manager in this offering.

A registration statement relating to the shares of common stock issued in the offering has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC")." A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement relating to this offering, when available, may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022 or at [phone]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic((TM)) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/." target="_blank" rel="nofollow ugc noopener">http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the anticipated timing of the closing of the offering, the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q and Form 8-K. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


http://www.sangamo.com

Copyright (C) 2009 PR Newswire. All rights reserved

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.133.036 von tokajo am 07.10.09 16:55:15

Na ja, war kein guter Tag für Sangamo aber die Zukunft wird gut, sehr sehr gut:

Smell A Rat, er, A Blog
Published: Wednesday, 7 Oct 2009 | 2:31 PM ET Text Size By: Mike Huckman
Reporter


AP
Rats
--------------------------------------------------------------------------------

I’ve said it before, and I know it’s a bad cliché (is there such a thing as a good cliché?), but I learn something new almost every day.

Today, my lesson came in the form of an eye-catching research note out of Leerink Swann, which specializes in covering healthcare-related companies and stocks.

The report is on a company that I really don’t follow all that much: Sangamo Biosciences [SGMO 7.22 -0.78 (-9.75%) ]. But it’s the title that grabbed me. “Knockout Rats Using ZFN Technology Could Become Transgenic Animal Standard.”

I always thought rats are pretty ugly, disgusting, uh, dirty. I’ve never seen a rat I’d describe as a knockout. But, okay, if you say so. Alright, I’m not that dumb. With an assist from my producer, Ruth, (I was too busy on the Nasdaq hamster wheel) I learned that knockout refers to the research practice of knocking out an existing gene in a lab rodent and replacing it. But what in the heck is ZFN? Well, according to Leerink Swann’s report it stands for “Zinc Finger Nuclease.” I think I’m gonna save that lesson for another day.

Obama, Supportive Doctors Push Health Care Reform
So, back to those knockout rats. LS analyst Joseph Schwartz is telling clients, “We believe the market is underappreciating SGMO’s 10.5 percent royalty on all knockout (KO) rats soon to be sold by Sigma-Aldrich [SIAL 53.47 -0.34 (-0.63%) ]. KO rats could represent near-term revenues since FDA approval is not required and SIAL plans to begin selling them this month….” LS makes a market in SGMO and SIAL.

I hope I’m not inviting a flurry of nasty emails from animal rights folks, but this is big business. Schwartz says, “The transgenic animal market is estimated at $700 million-$1 billion.”

That knocks me out.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.135.780 von Magnetfeldfredy am 07.10.09 22:06:45

Update:

Boston (aktiencheck.de AG) - Joseph Schwartz, Analyst von Leerink Swann & Co., stuft die Aktie von Sangamo BioSciences (ISIN US8006771062/ WKN 936386) unverändert mit "outperform" ein. Das Kursziel werde von 9,00 auf 11 USD angehoben. (08.10.2009/ac/a/u)


Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

[tokajo]

Antwort auf Beitrag Nr.: 38.141.647 von Magnetfeldfredy am 08.10.09 17:25:51

Nach der letzten Verkaufsempfehlung von Brean, Murray, Carret & Co mal wieder was Positives.

Gruss Tokajo

Sangamo reports encouraging data from Phase II diabetic neuropathy trial

Oct 22, 2009 (Datamonitor via COMTEX News Network) --
Sangamo BioSciences, a biopharmaceutical company, has reported encouraging topline, statistically significant Phase II clinical data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy or DN.

Topline data from Sangamo's SB-509-601 Phase II clinical trial demonstrated a direct neuroregenerative effect of SB-509 treatment that resulted in a statistically significant (p value=0.02) increase in small unmyelinated nerve fibers in the skin, or intraepidermal nerve fiber density (IENFD), in subjects with DN, the company said.

Data were also presented by the company that provided additional evidence of the positive effect of SB-509 on large fiber sensory nerve health as measured by improvements in nerve conduction velocity (NCV), in subjects with elevated markers of vascular damage (ICAM-1), and improvements in the muscle components of the neurologic exam (NIS-LL) 30 days after each of the three administrations of SB-509, said Sangamo.

Together these data confirm the neuroregenerative activity of SB-509 in patients with DN and define a drug-responsive population for future trials.

Data were also presented that demonstrate that in subjects with more severe neuropathy, as judged by their baseline IENFD, a greater nerve regrowth response to SB-509 treatment was observed compared to regrowth responses in placebo-treated subjects.

In addition, subgroup analyses using baseline severity of disease as a selection criterion demonstrated that SB-509 treatment resulted in correlative clinically relevant improvements in NIS-LL and sural NCV in subjects with moderate to severe disease, according to Sangamo.

Dale Ando, vice president of therapeutic development and chief medical officer at Sangamo BioSciences, said: "The IENFD data presented provide direct histologic evidence of nerve regrowth with SB-509 treatment and a mechanistic proof of concept for the neuroregenerative effects of this ZFP Therapeutic. The relationship between reduced IENFD and severity of DN has been well established and correlates with decreased levels of vascular endothelial growth factor-A and an increase in inflammatory growth factors such as ICAM-1, a marker of vascular disease."


http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Copyright (C) 2009 Datamonitor. All rights reserve

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.232.599 von tokajo am 22.10.09 15:57:16

Servus Tokajo,

das ist für mich die große Unbekannte bei Sangamo, SB-509, ob das Medikament, das ja schon in einer Phase II scheiterte, je was wird?

Die Zinkfingertechnologie ist unumstritten, aber viele trauen SGMO keine großen Revenues zu, oder?

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 38.242.773 von Magnetfeldfredy am 23.10.09 17:57:41

Good news:


Sangamo BioSciences Research Collaborators Awarded Grant From California Institute for Regenerative Medicine to Develop Zinc Finger Nuclease-Based Stem Cell Therapy for HIV/AIDS
$14.5 million award to bring ZFP HIV therapy to the clinic

Press Release
Source: Sangamo BioSciences, Inc.
On 4:02 pm EDT, Wednesday October 28, 2009
Buzz up! 0 Print
Companies:Sangamo Biosciences Inc.
RICHMOND, Calif. Oct. 28 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators led by John Zaia, M.D. the Aaron D. and Edith Miller Chair in Gene Therapy and chair of virology, City of Hope. The grant application entitled "Zinc Finger Nuclease-Based Stem Cell Therapy for AIDS" won the highest score of all grants CIRM received in this 1st round of Disease Team Research Award funding.

Related Quotes
Symbol Price Change
SGMO 5.88 -0.27


{"s" : "sgmo","k" : "c10,l10,p20,t10","o" : "","j" : ""} "Sangamo scientists have developed a ZFN-mediated gene-editing technology that has been demonstrated to make hematopoietic stem cells and mature immune system cells resistant to HIV infection," said Dr. Zaia. "This will be the first test of whether hematopoietic stem cells made HIV resistant using Sangamo's technology can correct the disease. If successful, our work could open the door to ZFN-based cell therapies for other important diseases."

Patients homozygous for a natural mutation (the delta-32 mutation) in the CCR5 gene are resistant to HIV infection by blocking the ability of the virus to enter a cell. Building on this observation, a study published in the New England Journal of Medicine in 2009 reported a potential "cure" in an AIDS patient with leukemia after receiving a bone marrow transplant from a "matched" donor with this delta-32 CCR5 mutation. This approach transferred the hematopoietic stem cells (HSC) residing in the bone marrow from the delta-32 donor, and provided a self-renewable and lifelong source of HIV-resistant immune cells. After transplantation, this patient was able to discontinue all anti-HIV drug treatments, CD4 counts increased, and the viral load dropped to an undetectable level, demonstrating effective transplantation of protection from HIV infection.

This CIRM Disease Team Research Award proposes an approach to modify a patient's own HSC to circumvent the need to find matched donors that carry the delta-32 CCR5 mutation and while providing a renewable and long-lasting source of HIV-resistant cells. Specifically, the grant funds the development of a ZFN approach to treat AIDS patients by first isolating their HSC, modifying them using CCR5-specific ZFNs, and then re-infusing them to reconstitute the immune system with CCR5-negative, HIV-resistant immune cells.

"We are delighted that this research proposal was chosen for funding by CIRM," commented Dr. Philip Gregory, Sangamo's chief scientific officer and vice president, research. "This grant brings together a team of world-renowned experts to develop this novel ZFN-based stem cell therapy for AIDS-related lymphoma through to the clinic. We look forward to working with the team which includes Paula Cannon, Ph.D., associate professor of Molecular Microbiology & Immunology, Keck School of Medicine of the University of Southern California, who has carried out extensive pre-clinical research using our technology in stem cells, and Dr. Zaia and his colleagues at City of Hope who are pioneers in hematopoietic cell transplantation."

"CIRM support for this program is a major validation of our ZFP Therapeutics platform both scientifically and financially and we are very pleased to be part of the exceptional team that received the highest score of all of the grants reviewed by CIRM," said Edward Lanphier, Sangamo's president and CEO.

The CIRM Disease Team Research Awards will fund actively managed multidisciplinary teams engaged in milestone-driven translational research for the development of stem cell-based therapies. The mission of these teams will be to conduct the necessary research and regulatory activities to prepare and file a complete, well supported Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) (and, if desired, other regulatory agencies), to enable Phase I clinical testing.

About Sangamo

[tokajo]

Antwort auf Beitrag Nr.: 38.275.125 von Magnetfeldfredy am 28.10.09 21:25:17

Bin gespannt, was herausgekommen ist.
Gruss Tokajo

Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast

RICHMOND, Calif., Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2009 financial results on Wednesday, November 4, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-879-6209 for domestic callers and 719-325-4830 for international callers. The passcode for the call is 4978837. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on November 4, 2009 to midnight ET on November 11, 2009. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 4978837.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM)( )development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SOURCE Sangamo BioSciences, Inc.

http://www.sangamo.com

Copyright (C) 2009 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 38.282.759 von tokajo am 29.10.09 18:09:35

Sangamo BioSciences Reports Third Quarter 2009 Financial Results

RICHMOND, Calif., Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported third quarter 2009 financial results and accomplishments.

For the third quarter ended September 30, 2009, Sangamo reported a consolidated net loss of $4.9 million, or $0.12 per share, compared to a consolidated net loss of $6.3 million, or $0.15 per share, for the same period in 2008. As of September 30, 2009, the company had cash, cash equivalents, marketable securities and interest receivable of $47.9 million. In October 2009, Sangamo completed an underwritten public offering that resulted in net proceeds of $20.9 million to the company and entered into an expanded agreement with Sigma-Aldrich Corporation under the terms of which Sigma made initial payments of $20.0 million to Sangamo.

Revenues for the third quarter of 2009 were $4.1 million, compared to $3.7 million for the same period in 2008. Third quarter 2009 revenues were from the Company's collaboration agreements with Dow AgroSciences and Sigma-Aldrich Corporation, enabling technology agreements in protein production and research grants. The revenue recognized for the third quarter of 2009 consisted of $4.0 million in collaboration agreements and $51,000 in research grants.

Research and development expenses were $6.2 million for the third quarter of 2009, compared to $7.6 million for the same period in 2008. The decrease in research and development expenses for the third quarter of 2009 was primarily due to decreased manufacturing, preclinical, licensing and consulting expenses partially offset by increased stock based compensation expenses. Non-cash employee stock-based compensation included in research and development expenses totaled $0.8 million for the third quarter of 2009 compared to $0.6 million for the same period in 2008.

General and administrative expenses were $2.7 million for the third quarter of 2009, compared to $2.6 million for the same period in 2008. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation, which totaled $0.9 million in the third quarter of 2009 compared to $0.7 million in the same period in 2008.

Total operating expenses for the third quarter of 2009 were $8.9 million, compared to $10.1 million for the same period in 2008.

Net interest and other income (loss) were recorded as a net loss of $47,000 for the third quarter of 2009 compared to income of $42,000 for the same period in 2008.

Nine Month Results

For the nine months ended September 30, 2009, the consolidated net loss was $16.2 million, or $0.39 per share, compared to a consolidated net loss of $21.7 million, or $0.53 per share, for the nine-months ended September 30, 2008. Revenues were $11.9 million for the nine months ended September 30, 2009, compared to $9.4 million for the same period in 2008. Total operating expenses were $28.9 million for the nine months ended September 30, 2009, compared to $32.5 million for the same period in 2008. The decrease in operating expenses for 2009 was primarily associated with decreased manufacturing, preclinical, consulting and lab supply expenses.

Recent Highlights

-- Presentation of top-line statistically significant Phase 2 ZFP Therapeutic(TM) data at the Society for Neuroscience Meeting. Sangamo presented top-line, statistically significant Phase 2 clinical data from its zinc finger DNA-binding protein (ZFP) Therapeutic program to develop SB-509 for treatment of diabetic neuropathy (DN) at the Society for Neuroscience Annual Meeting held in Chicago. The data demonstrated a direct neuroregenerative effect of SB-509 treatment that resulted in a statistically significant (p value=0.02) increase in small unmyelinated nerve fibers in the skin, or intraepidermal nerve fiber density (IENFD), in subjects with DN. Data were also presented that provided additional evidence of the positive effect of SB-509 on large fiber sensory nerve health as measured by improvements in nerve conduction velocity (NCV), in subjects with elevated markers of vascular damage (ICAM-1), and improvements in the muscle components of the neurologic exam (NIS-LL) 30-days after each of the three administrations of SB-509. Together these data confirm the neuroregenerative activity of SB-509 in patients with DN and define a drug-responsive population for future trials. -- Completion of an underwritten public offering. On October 13, 2009, Sangamo closed an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.20 per share resulting in net proceeds of approximately $20.9 million after deduction of underwriting discounts and commissions and other offering expenses. -- Expansion of licensing agreement with Sigma-Aldrich. Sigma-Aldrich Corporation and Sangamo announced a major expansion of our existing license agreement to include the exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals. Under the expanded agreement, Sigma also obtained rights to certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made initial payments of $20.0 million to Sangamo, consisting of an upfront license fee of $15.0 million and $5.0 million through the purchase of Sangamo's common stock at $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 million to $10.0 million, up to a total of $25.0 million, based upon cumulative product sales. -- Announcement of a second Phase 1 clinical trial of SB-728-T for the treatment of HIV/AIDS. In September 2009, Sangamo announced the successful review and acceptance by the FDA of an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFP nuclease (ZFN)-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic approach. However, subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored. -- Publication of ground-breaking new ZFN-mediated gene editing applications in stem cells. Scientists from The Whitehead Institute led by Dr. Rudolf Jaenisch used ZFNs designed by Sangamo to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). Human ESCs and iPSCs are useful tools in drug discovery and development. Scientists also hope to use these cells therapeutically in transplantation medicine and other regenerative applications. The research was described in a paper published in the scientific journal Nature Biotechnology (Nat Biotechnol. 2009 Sep; 27(9):851-7). -- Sangamo's collaborators awarded significant clinical research awards to advance research into potential ZFP Therapeutics. Sangamo's collaborators at the City of Hope and University of Southern California were awarded a $14.5 million grant from the California Institute of Regenerative Medicine (CIRM). The grant will support the development of a ZFN-based stem cell therapy for HIV/AIDS. In addition, research led by Donald B. Kohn, M.D., Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, was selected to receive an Innovations in Clinical Research Award of $486,000 from the Doris Duke Charitable Foundation. The grant will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."

[tokajo]

Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference

RICHMOND, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 2:30 pm PT (5:30 pm ET) on Wednesday, January 13, 2010 at the 28th Annual J.P. Morgan Healthcare Conference which will be held in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 38.683.874 von tokajo am 07.01.10 14:55:24

Sangamo BioSciences Advances ZFP Therapeutic(TM) Pipeline

RICHMOND, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF). Edward Lanphier, Sangamo's president and CEO, will provide an update on the company's ZFP Therapeutic(TM) pipeline and an overview of the company's business strategy and objectives for 2010 during his presentation at the 28th Annual J.P. Morgan Healthcare Conference at 2:30 pm PT, on Wednesday, January 13, 2010.

"We enter 2010 with a strong balance sheet and a robust clinical pipeline," said Mr. Lanphier. "With the initiation of these two new clinical trials, we continue to increase the value, maturity and visibility of our novel drug development platform."

"We are developing our lead therapeutic, SB-509, for neurological indications including DN and ALS. The data generated to date in DN, our most advanced program, provide direct histologic evidence of nerve regrowth with SB-509 treatment and a mechanistic proof of concept for its neuroregenerative effects. Our enthusiasm for the potential and importance of this drug is shared by JDRF who, after extensive review of the clinical data, has committed to fund a further $3.0 million of development costs for this new Phase 2b trial. While we continue active discussions with potential corporate partners, timely initiation of this trial enables us to maximize the future value of this program. Finally, the Phase 1 glioblastoma trial is our third ZFP Therapeutic and the second zinc finger nuclease (ZFN)-based program to enter the clinic and we are pleased to have achieved this significant milestone."

"Neuropathy is a significant complication of diabetes and represents a major unmet medical need, so developing better treatments would be a tremendous near-term benefit for people with diabetes," stated Alan Lewis, Ph.D., President and Chief Executive Officer of JDRF. "JDRF is excited to move this partnership forward, particularly as it involves a drug candidate designed to harness the body's own regenerative potential to address the nerve loss characteristic of neuropathy."

The Phase 1 glioblastoma trial will be initiated by Sangamo's collaborators at City of Hope and is designed to evaluate the safety and tolerability of a modified CD8+ cytotoxic T lymphocyte (CTL) product that has been made resistant to glucocorticoid steroids using Sangamo's ZFP nuclease ZFN-based technology. The study will accrue subjects with recurrent/refractory malignant glioblastoma multiforme (GBM). The US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate this open-label, multi-dosing Phase 1 clinical trial.

"We look forward to initiating this study to evaluate a promising therapeutic approach for the treatment of malignant brain tumors for which there are currently few effective therapeutic options after surgery," said Michael C.V. Jensen, M.D., Associate Chair, Department of Cancer Immunotherapeutics and Tumor Immunology, City of Hope. "In collaboration with Sangamo, we have successfully generated engineered T-cells that can destroy glioblastoma tumor cells in animals in the presence of glucocorticoids. Treatment of recurrent GBM with modified CTLs, an otherwise promising approach for this cancer, is rendered ineffective by the use of glucocorticoids to control inflammation of the brain due to the tumor and surgery. The ZFN-modification of the glucocorticoid receptor (GR) in our engineered CTLs protects the cells from the effects of steroids, which would normally inhibit T-cell function, but does not alter their cytolytic or tumor-killing properties."

"Our significant clinical, commercial and financial progress in 2009 provides us with a solid foundation upon which to build in 2010," commented Mr. Lanphier. "In the next twelve months, we expect to have final data from two Phase 2 clinical trials of SB-509, one in severe DN (SB-509-701) and one in ALS (SB-509-801). In addition, we expect to have preliminary data from our two ongoing Phase 1 trials of our ZFN-based Therapeutic, SB-728-T for the treatment of HIV/AIDS. We look forward to advancing our clinical pipeline as well as participating in the successful commercial expansion of our ZFP technology through our partnerships in plant agriculture and in the growing area of cell line engineering and transgenic animal model production."

Detail on Phase 2b Trial (SB-509-901) in Diabetic Neuropathy

Sangamo's double blind, repeat-dosing, placebo controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary endpoints for pivotal Phase 3 trials. The trial will accumulate data on approvable endpoints including Neurological Impairment Score in the Lower Limb (NIS-LL), nerve conduction velocity in the sural nerve (sNCV), as well as quality of life assessments (QOL) and intraepidermal nerve fiber density (IENFD). The study will involve a total of 150 subjects who will be randomized 1:1 between placebo and treatment groups and is powered to detect statistical significance for improvements in sNCV. Inclusion criteria for the trial are based upon accumulated data from Sangamo's earlier Phase 1 and Phase 2 clinical trials in subjects with DN.

"The body of clinical data obtained in previous trials of SB-509 has enabled us to design a very focused Phase 2b study that will accrue subjects that we believe are most likely to show a significant response to SB-509 over the 180 day test period," commented Dale Ando, Sangamo's chief medical officer and vice president of therapeutics. "The data generated to date also demonstrated that SB-509 treatment resulted in statistically significant increases in nerve fiber density, nerve regeneration and an improvement in clinical outcomes such as NIS-LL and sNCV. Information collected in our Phase 2b trial will allow us to confirm eligibility criteria and primary clinical endpoints for future Phase 3 trials."

SB-509 is an injectable plasmid encoding a DNA-binding zinc finger DNA-binding protein (ZFP) transcription factor (ZFP TF) designed to upregulate the endogenous expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct angiogenic, neurotrophic and neuroprotective properties. Data from Phase 1 and Phase 2 clinical trials in subjects with DN have demonstrated a direct neuroregenerative effect of SB-509 treatment that resulted in a statistically significant (p value = 0.02) increase in IENFD in subjects with DN. IENFD is a validated, direct histologic measurement of small unmyelinated sensory nerve fibers in the skin, the primary sensory nerves involved in DN. IENFD also correlates with neuropathy severity in diabetes, nerve fiber densities derived from sural nerve biopsies and levels of vascular endothelial growth factor-A (VEGF-A). In subjects with more severe neuropathy, as judged by their baseline IENFD, a greater nerve regrowth response to SB-509 treatment was observed compared to regrowth responses in placebo-treated subjects. In addition, subgroup analyses using baseline severity of disease for both neurologic and vascular disease as a selection criterion demonstrated that SB-509 treatment resulted in correlative, clinically-relevant improvements in NIS-LL and sNCV in subjects with moderate to severe disease.

Detail on Phase 1 Trial Objective in Glioblastoma Multiforme (GBM)

The Phase 1 trial is a repeat-dosing, open-label trial of a modified CD8+ cytotoxic T lymphocyte (CTL) product that has been made resistant to glucocorticoid steroids using Sangamo's ZFP nuclease ZFN-based technology. The study is designed to assess safety and tolerability of treatment in approximately 10 subjects with recurrent or refractory malignant GBM. In addition, data will be collected on the survival of the infused, modified CTLs as well as tumor response and survival. The trial will be conducted exclusively at City of Hope.

About Diabetic Neuropathy

Diabetic neuropathy is a progressive degenerative disease that is one of the most frequent complications of diabetes, affecting between 14 and 16.5 million Americans in 2007. High blood glucose levels lead to nerve damage over time, primarily affecting peripheral nerves. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet, which gradually evolve to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot as pressure wounds or injuries go unnoticed. Despite palliative treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In 2004, this translated to approximately 71,000 amputations. The Centers for Disease Control estimates that from 1980 through 2007, the number of Americans with diabetes increased from 5.6 million to 23.6 million and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy.

About Glioblastoma Multiforme (GBM)

An estimated 40,000 tumors are diagnosed each year; about 22,000 of these will be malignant. Of these primary brain tumors, gliomas are the most common type, approximately 20,000 cases are diagnosed and 13,000 glioma-related deaths occur annually in the US. Glioblastoma multiforme (GBM), a type of glioma, is rapidly progressive and nearly uniformly lethal. Currently, malignant glioma is managed through a combination of chemotherapy, surgery and radiation if the location and size of tumor allow these treatments. With modern combination therapy, the mean duration of survival has increased to 82 weeks, although 5-year survival rates have only increased from 3% to 6%. Approximately 80% of recurrent tumors arise from remnants of the original incompletely resected tumor. The median survival of recurrent glioblastoma multiforme patients that are eligible to be treated with re-resection is 36 weeks. Due to the location of these tumors in the central nervous system, current treatments often exacerbate the already severe morbidities. Immunotherapeutic strategies, such as anti-VEGF and chimaeric T cell receptors, are increasingly being used since they are very tumor specific and limit side effects in the recurrent disease setting.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to clinical trials of ZFP Therapeutics in diabetic neuropathy and glioblastoma, the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP technology platform to specific human disease as well as plant agriculture, high value research reagents and cell-line engineering, establishing strategic partnerships for SB-509 and other therapeutic programs. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation, completion and outcome of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in Sangamo's Annual Report on Form 10-K and most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

[getshorty]

Bin vor kurzem wieder in Sangamo investiert und freue mich schon, wieder mit Euch (Fredy und Tokajo) über die zukünftigen Entwicklungen von Sangamo diskutieren zu dürfen!

Bin momentan schon sehr zufrieden, allein schon aufgrund der Entwicklung des EUR/Dollar.

mit besten Grüßen

[getshorty]

Sangamo BioSciences (SGMO) Announces Preliminary SB-728-T Phase I Data


More News related to Corporate News
Cinemark Holdings (CNK) Appoints Barclays Bank as Administrative Agent to Senior Secured Credit Facility; Seeks to Extend Maturity on Credit Facility
Hightlights Fom Citi's Q4 Conference Call; Enormous Progress Made in Recent Quarter
NexMed (NEXM) Gets Notice of Non-Compliance from Health Canada Related to NDA for Vitaros
Ford/Mazda Squash Rumors That Chinese Joint Venture Will Be Dissolved (F)
Southern First Bancshares (SFST) Reports a Q1 Loss
More News related to Corporate News

January 19, 2010 7:55 AM EST

Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, presented the data as an invited speaker in an NIAID Workshop entitled "The Next Challenge: Elimination of HIV Reservoirs."

"While only representative of a single individual in the trial, these data are very exciting," said Dr. June. "They demonstrate that the ZFN-modified T-cells were well tolerated by the body and persisted in the circulation at stable levels for the duration of our monitoring. In fact, we calculate that more ZFN-modified cells were present at 20 weeks than were initially infused. Total CD4+ T-cell counts were also stable during this time. Interestingly, we also observed ZFN-modified cells in the gut associated lymphoid tissue (GALT) which is a major reservoir of immune cells and a critical reservoir of HIV infection and suggests that the modified cells are functioning and trafficking normally in the body."

Dr. June described data from a single HIV- positive subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy four weeks after SB-728-T treatment. Twelve weeks later, the STI ended and the subject resumed antiviral therapy. During the study, the subject's CD4+ T-cell count, the number of circulating ZFN-modified cells and viral loads were measured periodically. In addition, rectal biopsies were taken prior to treatment and at the end of the STI period to monitor levels of CD4+ and ZFN-modified T-cells in the GALT.

The subject entered the STI period with stable CD4+ and ZFN-modified T-cell levels and an undetectable viral load. Viral load was monitored with biweekly testing and it was observed that the subject experienced a delay in the return of virus, which was first detectable at six weeks post STI initiation. Previous studies have shown that in subjects undergoing an STI, the average time to detection of an increase in viral load is two to four weeks. At twelve weeks post STI, in accordance with the trial protocol, the subject resumed antiretroviral medication and his viral load decreased. During the monitoring period, the subject continued to demonstrate stable CD4+ T-cell counts and stable levels of ZFN-modified T-cells. In rectal biopsy samples taken at the end of the STI period, ZFN-modified cells were found in GALT suggesting that these cells circulate and traffic normally.

"These are the first human data from a ZFN-based therapeutic and, although preliminary, are very encouraging and recapitulate observations that we have made in preclinical studies," stated Dale Ando, Sangamo's vice president of therapeutic development and chief medical officer. "Importantly, ZFN-modified cells expanded over the period that we monitored the subject and were well tolerated. As expected, the subject's viral load increased during the STI. However, the kinetics of this subject's viral rebound was delayed. Presence of ZFN-modified cells in the GALT, an important HIV reservoir, demonstrates that we are achieving our pharmacologic biodistribution target. GALT HIV persistence in CD4+ T-cells is the reason that HIV is not eradicated in patients who are fully suppressed on highly active anti-retroviral treatment, or HAART. Ultimately, having a protected CD4+ T-cell population in the GALT may be extremely important in combating this disease.

"Our ZFN-based technology provides a totally new approach to HIV/AIDS with the aim of providing a reservoir of functional T-cells that are resistant to infection by HIV and available to fight opportunistic infections, and these data are an early indication that this may be possible."

SB-728-T is a cell product based on Sangamo's ZFN technology. CD4+ T-cells are removed from the subject's blood and treated with Sangamo's ZFNs designed to modify the DNA sequence encoding the CCR5 gene. This modification can occur directly in T-cells with only a brief exposure to the ZFNs. Once the CCR5 gene is modified, the gene is permanently disrupted in these cells.


Covered by Street Insider.com

[tokajo]

Antwort auf Beitrag Nr.: 38.768.647 von getshorty am 19.01.10 21:52:35

Am 3.2. gibt es nachbörslich Geschäftszahlen für 2009.

Gruss Tokajo

Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast

RICHMOND, Calif., Jan 27, 2010 /PRNewswire via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2009 financial results on Wednesday, February 3, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 888-819-8046 for domestic callers and 913-312-0671 for international callers. The passcode for the call is 7172741. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 3, 2010 to midnight ET on February 10, 2010. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 7172741.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

[tokajo]

Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results

RICHMOND, Calif., Feb 03, 2010 /PRNewswire via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2009 financial results and accomplishments and provided an outlook for 2010.

For the fourth quarter ended December 31, 2009, Sangamo reported a consolidated net loss of $2.4 million, or $0.05 per share, compared to a net loss of $2.6 million, or $0.06 per share, for the same period in 2008. As of December 31, 2009, the company had cash, cash equivalents, marketable securities and interest receivable of $85.3 million.

Revenues for the fourth quarter of 2009 were $10.2 million, compared to $6.8 million for the same period in 2008. Fourth quarter 2009 revenues were from the Company's collaboration agreements with Sigma-Aldrich Corporation and Dow AgroSciences, enabling technology agreements and research grants. The revenue recognized for the fourth quarter of 2009 consisted of $10.2 million in collaboration agreements and $70,000 in research grants. The increase in revenues was primarily due to the license payment of $15.0 million received from Sigma-Aldrich as part of its expanded agreement with the Company which provides Sigma exclusive rights to develop and distribute zinc finger DNA-binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. The payment is being recognized as revenue over the remaining period of the Company's original research collaboration with Sigma-Aldrich.

Research and development expenses were $8.7 million for the fourth quarter of 2009, compared to $6.7 million for the same period in 2008. The increase in research and development expenses was primarily due to expenses related to the initiation of new clinical trials, including a Phase 2b clinical study of SB-509 in moderately severe diabetic neuropathy (DN) and Sangamo's ZFP Therapeutic for the treatment of recurrent glioblastoma, as well as the prosecution of clinical trials for Sangamo's ZFP Therapeutic for HIV/AIDS and increased personnel costs, including non-cash employee stock-based compensation.

General and administrative expenses were $4.0 million for the fourth quarter of 2009, compared to $2.3 million for the same period in 2008. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation, and professional fees.

Total operating expenses for the fourth quarter of 2009 were $12.7 million, compared to $9.0 million for the same period in 2008.

Net interest income and other income / expense were recorded as income of $22,000 for the fourth quarter of 2009, compared to an expense of $375,000 for the same period in 2008. The increase was due to a foreign currency translation loss during the prior year quarter.

Full Year Results

For the year ended December 31, 2009, the consolidated net loss was $18.6 million, or $0.44 per share, compared to a net loss of $24.3 million, or $0.60 per share, for the year ended December 31, 2008. Revenues were $22.2 million for 2009, compared to $16.2 million in 2008. The increase in revenues for 2009 was primarily attributable to revenues from the Company's expanded agreement with Sigma-Aldrich. Total operating expenses were $41.6 million in both 2009 and 2008.

2009 Accomplishments and Recent Highlights

Therapeutic Programs and Research

Clinical Development Progress in Sangamo's Lead Therapeutic Program in DN and Renewed Program Support from JDRF: In January 2010, Sangamo initiated a Phase 2b trial of SB-509 in subjects with moderately severe DN. The Juvenile Diabetes Research Foundation International (JDRF) also renewed its support for this program and will provide up to $3.0 million of funding for the trial. Sangamo's double blind, repeat-dosing, placebo controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary approvable endpoints for pivotal Phase 3 trials. Inclusion criteria for the trial are based upon accumulated data from Sangamo's earlier Phase 1 and Phase 2 clinical trials in subjects with DN that defined a drug-responsive population. The data included top-line, statistically significant data from the company's Phase 2 trial, SB-509-601, that established a mechanistic proof of concept for the neuroregenerative effects of SB-509 treatment as demonstrated by statistically significant increases in intraepidermal nerve fiber density (IENFD). In addition, improvements in clinically relevant outcomes were observed in Neurologic Impairment Score of the Lower Limb (NIS-LL), a quantification of the neurologic exam, and sural nerve conduction velocity (sNCV).

Presentation of Preliminary Data from Phase 2 Trial to Evaluate SB-509 for the Treatment of Amyotrophic Lateral Sclerosis (ALS): In December 2009, preliminary data were presented from the first subjects enrolled in Sangamo's Phase 2 clinical trial, SB-509-801. The data demonstrated an approximate doubling of the frequency of improved muscle function at day 120 post-treatment in subjects with ALS who received two treatments of SB-509 (32%) compared to matched historic controls (17%).

Initiation of Two Clinical Trials of a ZFP Nuclease (ZFN)-based Therapeutic for HIV and Presentation of Preliminary Data From a Treated Subject: In February 2009, Sangamo and its collaborators at the University of Pennsylvania Medical School initiated the first Phase 1 safety trial of SB-728-T for the treatment of HIV/AIDS and in September 2009, the Company announced the initiation of a second Sangamo-sponsored Phase 1 trial. Preliminary data from the University of Pennsylvania investigator-sponsored study were presented in January 2010. The data were from a single HIV- positive subject treated with SB-728-T who, as part of the study, began a defined structured treatment interruption (STI). During the study, the subject's CD4+ T-cell count, number of circulating ZFN-modified cells and viral load were measured periodically. In addition, rectal biopsies were taken prior to treatment and at the end of the STI period to monitor levels of CD4+ and ZFN-modified T-cells in the gut associated lymphoid tissue (GALT), a major reservoir of immune cells and a critical reservoir of HIV infection. As expected, the subject's viral load increased during the STI period; however, the return of the virus was delayed. CD4+ T-cells and ZFN-modified T-cells were found to be stable and were observed in the GALT. The data suggest that the modified cells were able to expand and were circulating and trafficking normally in the body.

Initiation of Phase 1 Clinical Trial to Evaluate ZFN-Therapeutic for the Treatment of Glioblastoma: Sangamo announced in January 2010 that the US Food and Drug Administration had reviewed and accepted an Investigational New Drug application to initiate this open-label, multi-dosing Phase 1 clinical trial. The Phase 1 glioblastoma trial is being initiated by Sangamo's collaborators at City of Hope and is designed to evaluate the safety and tolerability of a modified CD8+ cytotoxic T lymphocyte (CTL) product that has been made resistant to glucocorticoid steroids using Sangamo's ZFN-based technology. The study will accrue subjects with recurrent/refractory malignant glioblastoma multiforme.

Sangamo Scientists and Collaborators Receive Grant Funding from Several Sources to Develop ZFP Therapeutic Candidates:

Grand Challenges Explorations Grant from the Bill & Melinda Gates Foundation was awarded to Sangamo scientists in May 2009. The grant of $100,000 supports an innovative global health research project conducted by Sangamo scientists and titled "Zinc Finger Nucleases for In Vivo Treatment of HIV Infection."

Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation was awarded to Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research in September 2009. The $486,000 grant, which will be paid over three years, will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."

California Institute for Regenerative Medicine (CIRM) granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its ZFN gene-editing technology in stem cells. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators led by John Zaia, M.D. the Aaron D. and Edith Miller Chair in Gene Therapy and chair of virology, City of Hope. The grant application entitled, "Zinc Finger Nuclease-Based Stem Cell Therapy for AIDS," won the highest score of all grants CIRM received in this first round of Disease Team Research Award funding.

Sangamo Scientists and Their Collaborators Published Groundbreaking Science in Major Journals: Published work included the demonstration of ZFN-mediated gene-editing in plant agriculture, transgenic animals, human embryonic and induced pluripotent stem cells and cell lines for the production of protein pharmaceuticals.

Business

Major Expansion of ZFP Technology License Agreement with Sigma-Aldrich: In October 2009, Sigma-Aldrich Corporation and Sangamo announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights to certain ZFP-engineered transgenic animals for commercial applications. Sigma made initial payments of $20.0 million to Sangamo, consisting of an upfront license payment of $15.0 million and $5.0 million through the purchase of 636,133 shares of Sangamo common stock at the then current market price ($7.86 per share). Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions, and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 million to $10.0 million, up to a total of $25.0 million, based upon cumulative product sales.

Financials and Operations

In October 2009, the Company completed an underwritten public offering of 3.0 million shares of common stock priced at $7.20 per share that resulted in net proceeds of $20.9 million.

In January 2010, the Company expanded its senior clinical development team, appointing Shirley M. Clift to serve as Vice President of Regulatory Affairs and Winson W. Tang, M.D., as Vice President of Clinical Research.

2010 Objectives

In today's conference call members of Sangamo's management team will discuss the company's plans and objectives for 2010 that include:

Therapeutic Programs

Prosecution of Sangamo's ongoing Phase 2b Trial SB-509-901 in moderately severe DN.

Prosecution of a Phase 1 clinical trial of a ZFN-based therapeutic in subjects with recurrent or refractory glioblastoma by Sangamo's collaborators at City of Hope.

Continued prosecution of Sangamo's Phase 1 trial of SB-728-T for HIV/AIDS and of the SB-728-T Phase 1 study by collaborators at the University of Pennsylvania School of Medicine.

Data Presentations from the Company's Phase 2 clinical trials of SB-509 for ALS (SB-509-801) and for severe DN (SB-509-701B).

Data Presentation from the SB-728-T- HIV / AIDS program.

Business - Strategic Collaborations & Enabling Technology Agreements

Achievement of milestones and royalties in agreement with Sigma-Aldrich.

Achievement of commercial sublicenses and milestones in agreement with Dow AgroSciences.

Pursue strategic partnerships in ZFP Therapeutics including SB-509.

Continue to present and publish data from research collaborations in ZFP-platform enabled biology.

Financials and Operations

Maintain year-end 2010 cash and investments balance of at least $60.0 million.

Conference Call

Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to 2010.

The conference call dial-in numbers are 888-819-8046 for domestic callers and 913-312-0671 for international callers. The passcode for the call is 7172741. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 3, 2010 to 11:59 p.m. ET on February 10, 2010. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 7172741.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership and commercial license agreements with collaborators, presentation of data from research collaborations and anticipated cash and investments balance. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

SELECTED CONSOLIDATED FINANCIAL DATA (in thousands, except per share data) (unaudited) STATEMENT OF OPERATIONS DATA: Three Months Ended Twelve Months Ended December 31, December 31, -------------- -------------- 2009 2008 2009 2008 ---- ---- ---- ---- Revenues: Collaboration agreements $10,171 $6,834 $21,553 $14,492 Research grants 70 - 634 1,694 --- --- --- ----- Total revenues 10,241 6,834 22,187 16,186 Operating expenses: Research and development 8,685 6,737 28,984 31,229 General and administrative 3,971 2,296 12,605 10,332 Total operating expenses 12,656 9,033 41,589 41,561 ------ ----- ------ ------ Loss from operations (2,415) (2,199) (19,402) (25,375) Interest and other income / expense, net 22 (375) 815 1,073 --- ---- --- ----- Net loss $(2,393) $(2,574) $(18,587) $(24,302) ======= ======= ======== ======== Basic and diluted net loss per common share $(0.05) $(0.06) $(0.44) $(0.60) Shares used in computing basic and diluted net loss per common share 44,780 41,018 42,048 40,825 ====== ====== ====== ====== SELECTED BALANCE SHEET DATA December 31, December 31, 2009 2008 ------------- ------------- Cash, cash equivalents, marketable securities and interest receivable $85,281 $65,025 Total assets 87,439 67,850 Total stockholders' equity 71,782 55,396
SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 38.876.691 von tokajo am 04.02.10 08:23:00

Quartalszahlen sind da.

Gruss Tokajo

Sangamo BioSciences Reports First Quarter 2010 Financial Results

RICHMOND, Calif., May 3, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2010 financial results and accomplishments.

For the first quarter ended March 31, 2010, Sangamo reported a consolidated net loss of $4.0 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.17 per share, for the same period in 2009. As of March 31, 2010, the company had cash, cash equivalents, marketable securities and interest receivable of $77.0 million.

Revenues for the first quarter of 2010 were $6.6 million, compared to $3.2 million for the same period in 2009. First quarter 2010 revenues were from the Company's collaboration agreements with Sigma-Aldrich Corporation and Dow AgroSciences, enabling technology agreements and research grants. The revenue recognized for the first quarter of 2010 consisted of $6.2 million in collaboration and enabling technology agreements and $449,000 in research grants. The increase in collaboration agreement revenues was primarily due to the license payment received from Sigma-Aldrich as part of its agreement with the Company which was expanded in the fourth quarter of 2009 and provides Sigma exclusive rights to develop and distribute zinc finger DNA-binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. The payment is being recognized as revenue ratably through July 2010, the remaining period of the Company's original research collaboration with Sigma-Aldrich.

Research and development expenses were $7.4 million for the first quarter of 2010, compared to $7.3 million for the same period in 2009. Research and development expenses for the first quarter of 2010 were primarily related to our clinical trials of SB-509 for diabetic neuropathy and SB-728-T for HIV/AIDS. General and administrative expenses were $3.3 million for the first quarter of 2010, compared to $2.9 million for the same period in 2009. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation, and professional fees.

Total operating expenses for the first quarter of 2010 were $10.7 million, compared to $10.2 million for the same period in 2009.

Net interest income and other income was $25,000 for the first quarter of 2010, compared to $193,000 for the same period in 2009. The decrease was due to lower interest rates on investments.

Recent Highlights


•Initiation of New Clinical Trials; Phase 2b study in Diabetic Neuropathy and Phase 1 Trial in Brain Cancer (Glioblastoma) with City of Hope: In January 2010, Sangamo initiated a Phase 2b trial of SB-509 in subjects with moderately severe diabetic neuropathy. The Juvenile Diabetes Research Foundation International (JDRF) also renewed its support for this program and will provide up to $3.0 million of funding for the trial. Sangamo's double blind, repeat-dosing, placebo-controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary approvable endpoints for pivotal Phase 3 trials. Sangamo's collaborators at City of Hope also initiated a Phase 1 clinical trial of SB-313, a cytotoxic T-cell made glucocorticoid resistant using ZFN mediated gene-editing, that is being evaluated in subjects with recurrent or refractory glioblastoma.
•Presentation of Preliminary Data from Sangamo's Phase 1 Safety Trial of SB-728-T for HIV/AIDS: In January 2010, preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, presented the data as an invited speaker in an NIAID Workshop entitled "The Next Challenge: Elimination of HIV Reservoirs." Dr. June described data from a single HIV-positive subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy after being treated with CCR5 negative ZFN-modified T-cells. During the monitoring period, the subject had stable levels of ZFN-modified T-cells which were well-tolerated and stable CD4+ T-cell counts. Interestingly, while the subject's viral load increased as expected during the STI period, the timing of the increase was somewhat delayed. Biopsy samples demonstrated that ZFN-modified cells appeared to circulate and traffic normally.
•Appointment of Two New Members of the Sangamo Board of Directors, Stephen G. Dilly, M.B.B.S, Ph.D. and William R. Ringo as Chairman of the Board: Dr. Dilly, who is currently President and CEO of APT Pharmaceuticals, Inc., a specialty drug company, was appointed to the board of directors effective March 31, 2010. Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas in his previous senior executive positions in drug development at Chiron BioPharma, Genentech Inc. and SmithKline Beecham in the U.K. Mr. Ringo, who recently retired as Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. where he had responsibility for guiding Pfizer's overall strategic planning and business development activities, was appointed as Chairman of the Sangamo Board of Directors on April 16, 2010.

Conference Call

Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to the rest of 2010.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 70476823. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on May 3, 2010 to 11:59 p.m. ET on May 10, 2010. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291, respectively. The conference ID number for the replay is 70476823.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's web site at http://www.sangamo.com/.

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward looking statements include, without limitation, references to the research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership and commercial license agreements with collaborators, presentation of data from research collaborations and anticipated cash and investments balance. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environments. These risks and uncertainties are described more fully in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


SELECTED CONSOLIDATED FINANCIAL DATA
(in thousands, except per share data)
(unaudited)

Statement of Operations Data:

Three Months Ended
March 31,
---------
2010 2009
---- ----

Revenues
Collaboration agreements $6,199 $3,157
Research grants 449 --
--- ---
Total revenues 6,648 3,157

Operating expenses:
Research and development 7,365 7,256
General and administrative 3,286 2,926
-----
Total operating expenses 10,651 10,182
------ ------
Loss from operations (4,003) (7,025)
Interest and other income, net 25 193
--- ---
Net loss $(3,978) $(6,832)
======= =======
Basic and diluted net loss per
common share $(0.09) $(0.17)
====== ======

Shares used in computing basic and
diluted net loss per common share 45,033 41,066
====== ======


March 31, December 31,
2010 2009
---------- -------------
(Unaudited)
SELECTED BALANCE SHEET DATA

Cash, cash equivalents, marketable
securities and interest receivable $76,979 $85,281
Total assets 79,355 87,439
Total stockholders' equity 70,014 71,782



SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

[tokajo]

Antwort auf Beitrag Nr.: 39.449.377 von tokajo am 04.05.10 08:28:33

Neue Ergebnisse diverser vorklinischer Studien.

Gruss Tokajo

Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology

RICHMOND, Calif., May 24, 2010 /PRNewswire via COMTEX News Network/ --
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein (ZFP) Therapeutics(TM) were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The meeting was held in Washington, DC from May 17-22, 2010.

"Sangamo's ZFP technology provides an exciting new approach for the development of novel human therapeutics," said Luigi Naldini, M.D., Ph.D., Director of the San Raffaele Telethon Institute for Gene Therapy, Milan, and the principal investigator on several papers presented at the meeting. "ZFP nucleases (ZFNs) enable us to edit the human genome with unprecedented specificity and efficiency. This opens the way to correction of inherited mutations, a potentially revolutionary approach as it can restore a gene's function while preserving its natural regulation, likely overcoming the risks associated with random gene addition approaches. We are using this technology to investigate novel therapies for monogenic diseases and cancer."

The presentations made at the ASGCT meeting covered research and preclinical data from Sangamo's programs and collaborations in human therapeutics and technology development in primary human cells and stem cells. Therapeutic areas included ZFN-based approaches to infectious diseases such as HIV/AIDS and cytomegalovirus (CMV), monogenic diseases such as sickle cell anemia and epidermolysis bullosa, and oncology. Positive preclinical data were also presented from experiments using Sangamo's gene regulation technology to up-regulate the vascular endothelial growth factor-A (VEGF-A) gene in an animal model of traumatic brain injury. Philip Gregory, D. Phil., Sangamo's vice president of research and chief scientific officer, made a presentation entitled "Stem Cell Modification with Zinc Finger Nucleases," and chaired a session devoted to stem cell modification. All abstracts for the meeting are available online at http://www.asgct.org/am10/

"Sangamo's technology has the potential to revolutionize the field of cell and gene therapy," stated Barrie Carter, Ph.D., a member of Sangamo's scientific advisory board and the current President of ASGCT. "ZFN technology enables an efficient and precise process for making changes to the DNA sequence of a cell, which is necessary for therapeutic applications of gene-editing. ZFN-based therapeutics are already being evaluated by Sangamo in human clinical trials in HIV/AIDS and brain cancer. As this technology functions at the DNA level, it can be applied to address numerous diseases for which target genes have been identified."

"The data presented at this meeting highlight the breadth of potential applications for ZFP Therapeutics," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our ZFP Therapeutic platform is maturing. We have completed four Phase 2 clinical trials, have an ongoing Phase 2b trial of our ZFP activator of VEGF-A, SB-509, in diabetic neuropathy and have three ongoing trials of our ZFN-based technology. At the same time, with our collaborators, we continue to define and develop new therapeutic opportunities."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics and therapeutic applications of Sangamo's ZFP technology platform to specific human diseases. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to whether clinical trials will validate and support tolerability and efficacy of ZFP Therapeutic approaches, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

[Zukertort]

Antwort auf Beitrag Nr.: 39.578.967 von tokajo am 25.05.10 14:22:02

Hi Tokajo ,

Musst nicht denken,dass du als einziger diese Perle entdeckt hast,denn ich bin auch mit von der Partie ! Ich hoffe,dass ich nicht von WO gesperrt werde,sonst musst du nämlich wieder den alleinunterhalter hier machen Sag mal,in den vergangenen Jahren gab es ja massiv schlechte News zur Gentherapie (auch Tote in clinical trials hat es definitiv gegeben! ) Ist dir schon aufgefallen,das mindestens 2 Mitglieder der ehemaligen Cell Genesys zu Sangamo "rübergewandert sind ??!!

MFG
Zuki

[tokajo]

Antwort auf Beitrag Nr.: 39.610.009 von Zukertort am 31.05.10 17:36:49

Hi zukertort,
wenn du dich anständig aufführst, wirst du auch nicht gleich gesperrt werden

Ja Dale Ando und Shirley Clift haben gewechselt.

Das was die Sangamo´s treiben finde ich für mich genial, auch wenn es der Kurs nicht hergibt. Es ist ja sowieso eher eine Revolution der Medizintechnik, die aktuell vorbereitet wird.
Und Revolutionen wachsen im Untergrund, werden selten entdeckt und verändern dann nachhaltig die Welt.

Gruss Tokajo

[Zukertort]

Antwort auf Beitrag Nr.: 39.610.121 von tokajo am 31.05.10 17:54:33

Ja,tokajo,

Sag mal,ist eigentlich "unsere" sangamo die einzige,die noch an Gentherapie arbeitet,(fast) alle anderen mir bekannten werte haben nämlich aufgegeben ! Nunja,also bis jetzt laüft das HIV-Teil doch bestens,stelle dir vor ein Impfstoff gegen HIV für die gesamte Menschheit,mann! Ausserdem die genmanipulierten Pflanzen,vom Namen her klingt ja Sangamo schon so ähnlich wie Monsanto,aber ob wir die fette monsanto irgendwann im Börsenwert überholen werden ?!

DAS wäre es doch .....!

MFG
Zuki

[tokajo]

Antwort auf Beitrag Nr.: 39.611.423 von Zukertort am 31.05.10 21:47:34

Hi Zuki,
es gibt noch einige, die sich damit beschäftigen. Nur der Ansatz ist ein anderer. Interessant finde ich ist noch Protox Therapeutics.

Gruss Tokajo

[tokajo]

Antwort auf Beitrag Nr.: 39.615.241 von tokajo am 01.06.10 17:25:31

Phase 1 zur HIV Studie beginnt.

Gruss Tokajo

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells

Preclinical Animal Data Demonstrates Promising Stem Cell Therapeutic Strategy for HIV/AIDS - Extends ZFP Therapeutic Application



RICHMOND, Calif., July 6, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. The ZFN approach enables the permanent disruption of the CCR5 gene, which encodes an important receptor for HIV infection, in all the cell types comprising the immune system that develop from hematopoietic stem cells (HSCs), and is the basis for a promising therapeutic strategy for the treatment of HIV/AIDS. Sangamo has two ongoing Phase 1 clinical trials to evaluate the safety and clinical efficacy of this approach in CD4+ T-cells.

The work, which was carried out in the laboratory of Paula Cannon, Ph.D., Associate Professor of Molecular Microbiology & Immunology at the Keck School of Medicine of the University of Southern California (USC), in collaboration with Sangamo scientists, was published on July 2, 2010, as an Advance Online Publication (http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.166… in Nature Biotechnology.

"These are very exciting data that provide proof of concept for a new approach to HIV treatment," said John Zaia, M.D., the Aaron D. and Edith Miller Chair in Gene Therapy and Chair of Virology, City of Hope. "The recent example of the 'Berlin Patient' who appears to have been cured of both his HIV and leukemia by receiving a bone marrow transplant (BMT) of stem cells from a donor that had a naturally occurring CCR5 mutation that makes them resistant to HIV infection, provided the model for this approach. However, the paucity of human donors with this natural CCR5 mutation and the risks of allogeneic BMT mean that we need a more practical solution to make this a therapeutic option. Modification of HSCs using ZFNs to recreate the CCR5 mutation is a potential solution."

Dr. Zaia is the leader of the recent $14.5 million Disease Team Research Award granted by the California Institute for Regenerative Medicine (CIRM) to a multidisciplinary team of investigators which includes City of Hope, Dr. Cannon and her colleagues at USC, and Sangamo scientists. The award funds the preclinical development of a ZFN CCR5-targeted approach which aims to complete an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for clinical testing of this ZFN method.

Sangamo's ZFNs are designed to permanently modify the DNA sequence encoding CCR5, a co-receptor that enables HIV to enter and infect cells of the immune system. Individuals carrying a naturally occurring mutation of their CCR5 gene, a variant known as CCR5-delta32, have been shown to be resistant to HIV infection. Building on this observation, a study published in the New England Journal of Medicine in 2009 reported a potential "cure" when an AIDS patient with leukemia received a bone marrow transplant from a "matched" donor with this delta-32 CCR5 mutation. This approach transferred the HSCs residing in the bone marrow from the delta-32 donor, and provided a self-renewable and potentially lifelong source of HIV-resistant immune cells. After transplantation, the patient was able to discontinue all anti-HIV drug treatments, CD4 counts increased, and viral load dropped to an undetectable level, demonstrating effective transplantation of protection from HIV infection. The data reported in the Nature Biotechnology publication replicate these findings for a ZFN-based treatment in a preclinical model.

"The data described in this paper are an important demonstration of the potential therapeutic possibilities of ZFN modification of human stem cells," commented Philip Gregory, D. Phil., Sangamo's vice president of research and chief scientific officer. "We have demonstrated efficient and specific modification of human hematopoietic stem cells, rendering them resistant to infection with HIV-1 while retaining their 'stemness' and ability to differentiate. These data pave the way for the use of this technology in other diseases for which HSC modification may be therapeutically useful."

Data Reported in the Nature Biotechnology Paper

The reported results demonstrate that a one-time exposure to CCR5-specific ZFNs resulted in the generation of an HIV-resistant population of human HSCs by the permanent genetic modification of the CCR5 gene. These ZFN-modified stem cells engrafted in NSG (NOD/SCID/IL2rnull) mice, which lack a normal immune system and are able to tolerate engraftment of human cells and tissues. After 8-12 weeks the engrafted ZFN-modified human cells could be identified as different immune cell types in the peripheral blood, and various tissues of the mouse suggesting that they were functionally normal. Furthermore, the ZFN-modified HSCs produced progeny that could be harvested from one mouse and engrafted into a second animal, demonstrating that the modified HSCs retain their 'stemness' and ability to differentiate. In addition, the animals did not experience any obvious toxicity or ill-health. In HIV challenge experiments, researchers found that the ZFN-modified cells had a selective advantage over unmodified HSCs and not only survived infection but expanded and appeared to traffic normally to various tissues in the mouse. Moreover, the presence of ZFN-modified cells controlled HIV replication in the animals. These data suggest that human HSCs can be modified with ZFNs, expand and differentiate and have a selective advantage in the presence of HIV allowing them to evade infection and destruction leaving them able fight opportunistic infections and HIV itself.

About HIV/AIDS and CCR5

Human Immunodeficiency Virus (HIV) infection kills or impairs cells of the immune system, progressively destroying the body's ability to fight infections and certain cancers resulting in AIDS (Acquired Immune Deficiency Syndrome). Individuals diagnosed with AIDS are susceptible to life-threatening diseases called opportunistic infections, which are caused by microbes that usually do not cause illness in healthy people. According to UNAIDS/WHO, over 2.7 million people were newly infected with HIV in 2007. An estimated 2.0 million people died of AIDS in the same year. There are now over 33 million people living with HIV and AIDS worldwide. The CDC estimates that, in the United States alone, there were 1.2 million people living with HIV/AIDS, approximately 54,000 new infections and 23,000 deaths in 2007.

CCR5 is the chemokine receptor that HIV uses as a co-receptor to gain entry into immune cells. CCR5 is perhaps the most important of the known co-receptors for HIV, since the most commonly transmitted strains of HIV are strains that bind to CCR5 -- so-called "R5" strains. A small fraction of the population carries a mutation in their CCR5 gene, called the delta32 mutation. This mutated version of the gene results in a truncated CCR5 protein which cannot be used by HIV as a co-receptor. Individuals that have mutant delta 32 versions of both of their CCR5 genes are resistant to infection by R5 HIV strains.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP technology platform, the therapeutic potential of ZFNs for the treatment of HIV/AIDS, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the Sangamo's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 39.782.865 von tokajo am 06.07.10 16:20:58

Servus Tokajo,

bin auch wieder mit 1000 Stück dabei, jedoch hatten wir die Aids Story doch schon vor Jahren?

[tokajo]

Antwort auf Beitrag Nr.: 39.852.312 von Magnetfeldfredy am 21.07.10 07:11:27

Hi Fredy, schön dass du wieder dabei bist.
Phase 1 für das HIV Projekt hatten wir damals noch nicht.
Und übrigens am 28.7 gibt mal wieder Zahlen

Gruss Tokajo

Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast

RICHMOND, Calif., July 21, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its second quarter 2010 financial results on Wednesday, July 28, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 84971039. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on July 28, 2010 to midnight ET on August 4, 2010. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 84971039.

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 39.866.989 von tokajo am 23.07.10 12:41:04

Servus Tokajo,

ja schön daß wir wieder kooperieren, ich wünsche Dir und mir meinen Dendreon Effekt, Tenbagger!

[tokajo]

Antwort auf Beitrag Nr.: 39.891.497 von Magnetfeldfredy am 28.07.10 18:00:28

Im aktuellen Heft der Technology Review http://www.heise.de/tr/artikel/Hausverbot-fuer-HIV-1096468.h… ist wieder ein interessanter Artikel über den Stand der HIV Forschung. Paula Cannon hofft in den nächsten drei Jahren HIV besiegen zu können.
Und das Ganze in Zusammenarbeit mit Sangamo BioSciences.
Das HIV Programm von Sangamo wird ebenfalls vorgestellt mit dem Hinweis dass Versuche am Menschen bereits stattgefunden haben.

Gruss Tokajo

[cultom4president]

Antwort auf Beitrag Nr.: 40.248.175 von tokajo am 01.10.10 13:27:41

Danke für den Link. Da SANGAMO im Moment nur die aktuellen Finanzdaten publiziert kommt dieser Lesestoff sehr entgegen.
Schauen wir mal wann es neue Impulse geben wird.

cultom

[cultom4president]

Mal was anderes!

Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs


RICHMOND, Calif., Nov. 3, 2010 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the company has been awarded a total of $978,000 in grants for four qualifying therapeutic projects under the Qualifying Therapeutic Discovery Project Program.

Under the recently enacted Patient Protection and Affordable Care Act, which added section 48D of the Internal Revenue Code, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential to produce new and cost-saving therapies, support job growth and increase U.S. competitiveness in life, biological and medical sciences. Grants were awarded through a competitive application process administered by the Departments of Health and Human Services and the Treasury.

"We believe that the selection of our programs for these grants is a reflection of the potential of our proprietary ZFP technology platform for the development of a novel class of drugs to address unmet medical needs," said Edward Lanphier, Sangamo's president and CEO. "These awards will directly contribute to the development and commercialization of our ZFP Therapeutic programs."

Sangamo submitted applications for four qualifying projects:

* SB-509 for Diabetic Peripheral Neuropathy
* SB-509 for Amyotrophic Lateral Sclerosis (ALS)
* SB-728-T for Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV / AIDS)
* SB-313-xTZ for Recurrent or Refractory Glioblastoma Multiforme


Each project was awarded $244,000 based on qualifying expenses incurred by Sangamo. The total amount awarded is expected to be received, and recognized as research grant revenues, during the fourth quarter of 2010.

[1bull007]

Bin erst vor kurzem auf diese Aktie aufmerksam geworden.

An die Lanzeitinvestierten:

Bitte um Infos über die Firma:

Shares, Management, Glaubwürdigkeit usw.
Danke !

[Carola11]

Antwort auf Beitrag Nr.: 40.604.769 von 1bull007 am 28.11.10 17:13:12

Wow, fast eine Million Shares wurden in den USA gehandelt.
Kommt jetzt die Zulassung?













Keine Kauf- bzw. Verkaufsempfehlung

[cybermitro]

Geht dieser Push um diese Aktie?

Vorläufige Gewinn-Schätzung: +9.769%


Das Unternehmen arbeitet fieberhaft daran, die bahnbrechende Zinkfinger-Methode im Kampf gegen einige der schlimmsten Krankheiten nutzbar zu machen.

25 Millionen Diabetiker warten auf dieses Medikament (und Sie verdienen mit am Verkauf)

Diabetische Neuropathie: Das ist eine der schlimmsten Folgen der weitverbreiteten Diabetes. Eine Schädigung der Nerven, die durch den andauernd erhöhten Blutzuckerspiegel ausgelöst wird.
arbeitet dieses Unternehmen nicht nur an einem Medikament gegen die Folgen der Diabetes.

Natürlich arbeitet dieses Unternehmen nicht nur an einem wirksamen Medikament gegen Aids (darüber zu berichtet fehlt hier der Platz) oder Parkinson (auch dafür fehlt hier der Platz) ...

Bestimmt haben Sie schon 1 und 1 zusammengezählt:

Das Unternehmen arbeitet an einem Mittel gegen Krebs.



Die feinen Blutgefäße, die alle Nerven in Armen und Beinen versorgen, werden dadurch nicht mehr ausreichend mit Sauerstoff versorgt.

Diese Diabetes-Folge ist fürchterlich heimtückisch:

Denn die Erkrankten spüren am Anfang nur ein leichtes Kribbeln oder eine geringe Taubheit in Armen und Beinen. Das nimmt kaum einer ernst. Mit möglicherweise fatalen Folgen:

Die Nerven in Armen und Beinen können dann komplett absterben. Für den betroffenen Menschen heißt das:

Arme und Beine sind komplett gefühllos! Der Betroffene kann keine Schmerzen empfinden – und jede Art von Verletzung kann zu einem Drama werden!

Mit der Zinkfinger-Methode ist diese Geißel wahrscheinlich schon bald besiegt.

Eine Erlösung für die Millionen Diabetiker, die von dieser heimtückischen Folge bedroht sind oder bereits darunter leiden – und für Sie ein weiterer Grund, nun sofort zu handeln und das Dossier mit dem Namen der Aktie anzufordern:

Es gibt bereits ein Präparat auf Basis der Zinkfinger-Methode, das diese Krankheit bekämpft.

Im Klartext:

Dieses Präparat befindet sich bereits in Erprobung!
Und zwar schon in der zweiten Stufe der Erprobung!
Der Schritt zur Marktreife wird bald getan werden!

Und noch besser: Es gibt kein Konkurrenzprodukt. Kein anderes Medikament ist in der Lage, die Ursachen dieser heimtückischen Krankheit zu bekämpfen!

Machen Sie sich bitte klar, was das für unser Unternehmen und Ihre Aktie bedeutet, wenn Sie heute handeln:

Allein in den USA sind heute bereits 25 Millionen Diabetiker direkt von dieser Krankheit bedroht oder leiden bereits darunter, die sich alle auf dieses Medikament stürzen werden! Es wird allein mit diesem Medikament gigantische Summen verdienen.

[mian2005]

Antwort auf Beitrag Nr.: 40.615.045 von cybermitro am 30.11.10 13:22:05

Exakt. Der oder die Pusher haben sich auch nicht viel Mühe gegeben,der Wert war einfach zu recherchieren (Zinkfinger...DNA). Hier dürfte mE noch Zeit für den Einstieg sein... Jetzt hat der Pusher erstmal eingekauft.

[tokajo]

Antwort auf Beitrag Nr.: 40.638.816 von mian2005 am 03.12.10 10:44:55

Wer hat denn hier gepusht ?

Sangamo hat es nicht verdient, als Zockerpapier betrachtet zu werden.

Gruss Tokajo

[_DayTrader_]

Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Four Presentations Highlight Application of ZFP Technology in Improved Immunotherapeutics and ZFP Therapeutics® for Monogenic and Rare Diseases


RICHMOND, Calif., Dec. 7, 2010 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preclinical data that demonstrate the ability to permanently correct a disease gene in an animal using systemic delivery of zinc finger nucleases (ZFNs). The presentation was one of four made by Sangamo's collaborators at the 52nd Annual Meeting of the American Society of Hematology (ASH), which is being held in Orlando, Florida.

Abst.# 647 "Manipulating Higher Order Chromatin Structure of the Beta-Globin Locus by Targeted Tethering of a 'looping' Factor" Oral Session: Thalassemia and Globin Gene Regulation: Regulation of Globin Gene Expression

These data demonstrate the use of zinc finger DNA-binding proteins (ZFPs) as a tool to dissect the role of the physical structure of a chromosome in gene regulation.

Abst.# 3764 "Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia" Poster Session: Gene Therapy and Transfer: Poster II

The study describes a ZFN-based method for improving the potency, specificity and safety of T-cell immunotherapy approaches to cancer immunotherapy.

Abst.# 3766 "HLA and TCR Knockout by Zinc Finger Nucleases: Toward "off-the-Shelf" Allogeneic T-Cell Therapy for CD19+ Malignancies" Poster Session: Gene Therapy and Transfer: Poster II

These data provide proof of concept for the use of ZFN-based gene modification to develop 'off-the-shelf' cell-based immunotherapies to treat individuals of any HLA type.

Abst.# LBA-5 "Phenotypic Correction of a Mouse Model of Hemophilia B by In Vivo Genetic Correction of the F9 Gene" Oral Session: Late-Breaking Abstracts Session

"These data represent important progress in the advancement of systemic ZFN-based therapeutics towards clinical development," said Dale Ando, M.D, Sangamo's vice president of therapeutic development and chief medical officer. "Using a mouse model of hemophilia B, we have demonstrated successful functional correction of a human gene for the clotting factor, Factor IX, by direct systemic delivery into the animal rather than by delivery into cells ex vivo. Our ZFN approach, which enables permanent correction of the disease-related gene in situ, circumvents the problems of traditional gene-addition approaches that result in random insertion and the loss of normal regulation of the gene which may lead to malignancy or other unintended consequences."

Scientists demonstrated efficient ZFN-mediated correction of a defective human Factor IX gene in a mouse model of hemophilia B by delivering ZFNs and a corrected donor DNA sequence directly into the animals. Stable levels of protein made from the corrected human gene could be measured in the plasma of the treated animals and resulted in the restoration of normal rates of blood clotting for the period of the study. The study was carried out in the laboratory of Katherine High, M.D., Investigator, Howard Hughes Medical Institute, Professor of Pediatrics, University of Pennsylvania School of Medicine and Director, Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, in collaboration with Sangamo scientists.

"These data represent a fundamental step forward and provide important proof of concept that ZFNs can be delivered efficiently in vivo and have potential therapeutic value for the treatment of human disease," stated Edward Lanphier, Sangamo's president and chief executive officer. "Our ZFN technology platform is broadly applicable and has been demonstrated to enable permanent gene modification, as in our CCR5 HIV clinical programs and in the studies presented this week at ASH. We believe that this technology, which can be applied to any disease-relevant gene, provides a unique and valuable therapeutic approach to the many human monogenic diseases that are currently classified as unmet medical needs."

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has a Phase 1 / 2 clinical trial and two ongoing Phase 1 clinical trials to evaluate the safety and efficacy for the treatment of HIV/AIDS as well as a Phase 1 trial for the treatment for recurrent glioblastoma multiforme. Other therapeutic programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP tranion factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the potential of ZFNs to treat human monogenic diseases, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo's SEC filings, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.


News Provided by Acquire Media

[1bull007]

Hier warte ich auf einen Rücksetzer auf 2 € dann schlage ich zu !"

[_DayTrader_]

Antwort auf Beitrag Nr.: 40.683.078 von 1bull007 am 09.12.10 18:06:08

Hier warte ich auf einen Rücksetzer auf 2 € dann schlage ich zu !"

Du hast also nicht vor in Sangamo zu investieren, oder was möchtest du damit sagen?

[1bull007]

Antwort auf Beitrag Nr.: 40.684.141 von _DayTrader_ am 09.12.10 20:10:57

... oh doch !

[mian2005]

Global Markets Direct hat doch im November 2010 eine Marktstudie über Sangamo veröffentlicht. Hat jemand Kenntnis vom (englischsprachigen) Inhalt? (Das Teil kostet übrigens 500 Dollar ...) Gehe davon aus, dass der Pusher den Inhalt kennt und daher so euphorisch schreibt.

[geldspender]

Wer hat Infos über revolutionäre Zinkfinger- Methode?
Wer beobachtet diese Aktie schon länger?
Ist jetzt wirklich der Durchbruch geschafft?
Ich beobachte den Wert, mal sehen was geht.

[floppenjoe]

Antwort auf Beitrag Nr.: 40.683.078 von 1bull007 am 09.12.10 18:06:08

wenn glück hast und unter der kreuzung von 38/200 tage linie bleibt kann dann durchaus wieder richtung 2 euro gehen glaube nicht wenn gute news nachgelegt werden gibts kein halten mehr gruß floppenjoe

[tokajo]

Antwort auf Beitrag Nr.: 40.689.869 von geldspender am 10.12.10 15:55:30

Hallo Geldspender,

falls es dich beruhigt, ich bin seit Jahren dabei. Und Durchbruch ? Schaue dir die aktuelle Präsentation zum Stand der Dinge auf Sangamo an. Du wirst sehen, dass es noch ein langer Schritt ist bis dahin.

Gruss Tokajo

[geldspender]

Aktie bewegt sich langsam nach oben, ob da einige kaufen um "dabei" zu
sein?

[cybermitro]

Neueste Nachricht gibt Hoffnung für Parkinsonkranke und Longies:

Sangamo BioSciences Announces Publication of Data From Program to Develop a ZFP Therapeutic® for Parkinson's Disease
Data Support Further Preclinical Development of ZFP Activator of GDNF Funded by The Michael J. Fox Foundation for Parkinson's Research


RICHMOND, Calif., Dec. 13, 2010 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO# announced the publication of preclinical data demonstrating protection of nerve tissue and functional improvements in motor symptoms in a validated rat model of Parkinson's disease #PD# using Sangamo's zinc finger protein #ZFP# technology.

As previously disclosed, the study was supported by funding from The Michael J. Fox Foundation for Parkinson's Research #MJFF#. The data described in the publication were part of a successful application for a second round of funding from MJFF to support the progress of a ZFP approach in a non-human primate model which is the next stage of development for this ZFP Therapeutic to treat PD.

The work, which was carried out in collaboration with scientists from the laboratory of Krystof Bankiewicz, M.D., Ph.D., professor of Neurosurgery and Neurology at the University of California, San Francisco #UCSF) was published on December 8, 2010 in the Journal of Neuroscience.

"We are enthusiastic about the success of this novel ZFP Therapeutic approach to date and hopeful that its further development can take us c

[silvesterstrike]

wenn die news stimmen und davon gehe ich mal aus wie kommt dann jemand auf die idee das die aktie einen rückgang auf 2 euro macht

[geldspender]

So wie es Heute aussieht, sehen wir die € 2,0 nicht mehr so schnell,
höchstens bei einem Split bei 10 oder 20 €!

[silvesterstrike]

gerade deswegen kann ich es mir auch nicht vorstellen schließlich sprechen die news eine andere sprache

[geldspender]

Gibt es in nächster Zeit Forschungsergebnisse?
Es ist erstaunlich ruhig geworden bei diesem Wert.

[_DayTrader_]

Sangamo BioSciences gibt Präsentation auf der JP Morgan Healthcare Conference
Richmond, CA, 5. Januar 2011/ PRNewswire / - Sangamo BioSciences, Inc.(Nasdaq: SGMO) gab heute bekannt...

http://investor.sangamo.com/releasedetail.cfm?ReleaseID=541959
Ich denke da darf man durchaus auf den 13.+14. Januar 2011 gespannt sein

Gruß DT

[geldspender]

Was mir im Moment nicht gefällt, daß in verschiedenen kostenlosen Börsen
briefen mit eingen Tausend% Stimmung gemacht wird. Geht es nur darum,
bestimmten Börsenbriefen Neue Teilnehmer zu zu führen oder sind die Infos wirklich so werthaltig. Wer kann neue Forschungsergebnisse nennen?
Mal sehen wie es hier weitergeht!

[mamba11]

Antwort auf Beitrag Nr.: 40.827.805 von geldspender am 09.01.11 12:37:46

schon bekannt ?

http://www.cnbc.com/id/40998201

[cultom4president]

Mir zumindest nicht!
Tolle Performance bei SGMO, bin gespannt wie sich der Newsflow entwickelt.

[floppenjoe]

wird nachhaltig weiter steigen werden dieses jahr neue höhen erleben wenn alle studien abgeschlossen sowie weitere positive zwischen ergebnisse vorhanden sind warten wir aber vorerst auf donnerstag mittag 12.30 wenn news ergänzt werden lg floppenjoe und allen investierten die an beschwerdenfreie zukunft glauben

[cultom4president]

Der Newsflow im Moment gefällt mir!

http://pr-usa.net/index.php?option=com_content&task=view&id=…

[Rentner]

Das scheint die Aktie zu sein, die vom Gevestor angepriesen wird.
http://rendite.gevestor.de/index.php?id=21225&banner=VT_redL…

[crackischtrend]

ja das ist schon ziemlich lange klar... die aktie wird von vielen gratis Börsenbriefen gepusht... Für mich ist die Rendite mit der gelockt wird unrealistisch.

Es stellt sich jetzt die Frage, ob hier ausschliesslich versucht wird mit dem Verkauf des `` Namens dieser Aktie`` Geld zu verdienen, oder ob wirklich mehr dahinter steckt

was denkt ihr?

[mamba11]

Antwort auf Beitrag Nr.: 40.854.767 von crackischtrend am 13.01.11 13:20:14

es sit, wie es bei allen im wachstum befindlichen unternhemen sit. sie entwickeln produkte, hoffen auf genehmigungen/zulassungen etc....

denke die marktchancen wäre in der tat ziemlich groß. es erscheint mir alles realistisch unter der annahme, dass.....

und das sit auch der entscheiidende punkt. unter annahmen kann hier real viel in der zukunft passieren...aber eben auch nicht.

ich sehe eine chance drin und das das unternehmen zumindest, im gegensatz zu läden wie genta, ordentlich zu arbeitet und fortschritte melden kann. dass sie keine kohle in so einem stadium "hinausblasen" ist mir eigentlich ganz recht :-)

[hahnenkamm69]

Antwort auf Beitrag Nr.: 40.854.767 von crackischtrend am 13.01.11 13:20:14

Der Börsenbrief, der hier Werbung macht für Sangamo (bzw. der Verlag, der das tut um den Börsenbrief zu vermarkten), hat die Aktie seit Ende November im Depot und ist bei € 3,12 eingestiegen (ich weiss das, weil ich damals auch eingestiegen und Kunde des Börsenbriefs bin!, der Herausgeber ist absolut überzeugt von Sangamo und ist absolut kein Pusher sondern sehr erfolgreich mit seinem Brief!

[_DayTrader_]

Shares of Sangamo Biosciences Rank the Highest in terms of Relative Performance in the Biotechnology Industry

http://www.mysmartrend.com/news-briefs/news-watch/shares-sangamo-biosciences-rank-highest-terms-relative-performance-biotechnol

Grüße DT

[cultom4president]

Antwort auf Beitrag Nr.: 40.854.879 von hahnenkamm69 am 13.01.11 13:37:32

Mal ganz ehrlich!

Wer solche Renditen verspricht hat doch nun wirklich einen an der Waffel.
Seriös klingt anders!

[mamba11]

Antwort auf Beitrag Nr.: 40.860.180 von cultom4president am 14.01.11 08:46:17

gut im zweifelsfall steht nun aussage gegen aussage.

der eine sagt es ist so, du schreibst nun....ist geschwafel.....er ist analyst...du bist ???? auf was basiert deine aussage ? was ist deine rediteberechnung und auf basis welcher daten ?

lass mich gerne inhaltlich eines besseren belehren bzw. ich nehme gerne andere meinungen zur kenntnis, wenn sie fundeirt sind

[Rentner]

Antwort auf Beitrag Nr.: 40.860.180 von cultom4president am 14.01.11 08:46:17

Kenne weder den Gevestor noch Sangamo richtig. Das Versprechen solcher Renditen ist unseriös. Zustimmung. Das heißt aber nicht, dass die Aktie nicht großes Potential hat. Was mir bei der Anpreisung vom Gevestor nicht gefiel ist die tatsache, dass er mit der "Heilung" von Krebs wirbt. Die Krebsforschung ist nicht das Hauptgebiet von Sangamo. Im MOment geht es eher um HIV.

[mamba11]

Antwort auf Beitrag Nr.: 40.860.330 von Rentner am 14.01.11 09:12:18

glaube der wirkliche punkt ist hier nicht die jeweile krankheit sondern die technologie, welche ein riesen potential zu haben scheint.

das geplante einsatzspekturm scheint riesig zu sein. und sangamo ist wohl technologisch oben auf.

ob und wie die dinge nun genau und auf das jeweilige prozent genau eintraffen ist mir eigentlich auch ziemlich....

da steckt auf jeden fall ein riesengeschäft dahinter, auch wenn natürlich alle unwägbarkeiten nicht in die betrachtung einbezugen werden können.

[cultom4president]

Antwort auf Beitrag Nr.: 40.860.271 von mamba11 am 14.01.11 09:03:02

Erstens, habe ich nicht negativ über Sangamo versprochen. Diese Aktie besitzt schon seit Jahren ein gehöriges Potential. 2011 wird für Sangamo aufgrund verschiedener Test und Studien recht spannend, darauf zieht der der Hype der letzten Wochen ab.

Zweitens, wer in einem Börsenbrief, den er übrigens auch noch limitiert, eine vorläufige Gewinnschätzung von über 9000% verspricht, hat meiner Meinung nach stark einen an der Waffel. Soetwas ist unseriös und erinnert stark an Abzocke!

Sorry, aber richtige Analysen sehen anders aus, es fehlen Marktbewertungen, Peer-Group-Vergleiche, Einschätzungen der Studienergebnisse. Man findet nur Floskeln, hohle Versprechungen und heisse Luft.

Wenn für dich so eine Analyse ausschaut, dann gute Nacht.

cultom

[crackischtrend]

weiss irgendjemand was von der Pressekonferenz gestern? habe bis jetzt noch nichts gefunden

gruss

[mamba11]

Antwort auf Beitrag Nr.: 40.860.853 von cultom4president am 14.01.11 10:15:37

solange du es alles besser weißt ist doch super. freu dich doch, dass du der profi bist und veröffentlich doch einen börsenbrief. du bist sicher ein kompetenter analyst, wenn du ihm seine fachlichen kompetenzen absprechen kannst, was man grundsätzlich nicht kann, denn wer kann schon die falchliche kompetenz eines anderen beurteilen ? sein verhalten kann man durchaus in frage stellen....soviel zu dem thema.

9000 % sind nicht schwierig....wenn man kein genaues zeitziel hinterstellt ist die aussage zumindest nicht gänlich falsch, es sei denn das unternehmen verschwindet vom markt.

2/3 aller menschen können mit erhebungen statistischer natur und betriebswirtschaftlichen zahlen eh nichts anfangen. also wozu soll man diese veröffentlichen ?

der börsenbrief ist limitiert, weil er seine leistung verkaufen will. ist doch logsich. was hat das nun mit der seriosität zu tun ?

gute nacht ? wieso ? ich hab 2 hochschulabschlüsse. ich muß mich nicht auf einen börsenbrief verlassen....ich kann alles notwendige selbst interpretieren. ausserdem hab ich entsprechende kontakte in die industrie. also denke ich kann mit der "nacht" wirklich gut leben

[hahnenkamm69]

Antwort auf Beitrag Nr.: 40.860.180 von cultom4president am 14.01.11 08:46:17

Hallo und Mahlzeit an alle die hier mitlesen,

natürlich hat es einen unseriösen Nebengeschmack wenn hier von 9.000% gesprochen wird.
Aber Ihr dürft bitte nicht vergessen, dass das nicht vom Herausgeber des Börsenbriefs kommt sondern von einem Verlag, der möglichst viele Interessenten ansprechen und zum Kauf bewegen will. Leider gibt es nun mehr als genug Menschen (dass brauche ich Euch nicht zu erklären weil Ihr es eh wisst, man muss sich ja nur die vielen Foren bei wo anschauen!)die das schnelle Geld verdienen wollen, und die reagieren eben auf so etwas.
Ich bin auch schon sehr lange an der Börse dabei, habe schon sehr viele Briefe getestet, weil hier eins wirklich super ist: Du kannst 4 Wochen Probeabos lesen und zahlst nichts dafür. Nach 4 Wochen rufst Du an oder schickst ein Email und es ist vorbei, keine weiteren Kontakte, nichts, total seriös, ich habe noch nicht einmal etwas negatives erlebt! Genau so habe ich es beim Innovation Investor gemacht, der Redakteur ist total seriös und hat 3 tolle Depots, ich bin von Haus aus auch sehr skeptisch, habe hier aber das Abo angenommen weil ich sehr überzeugt war und das auch weiterhin bin (siehe allein die Performance von Sangamo). Natürlich werden sehr viele durch die 9.000% Pusherei abgeschreckt, aber wahrscheinlich ist rein tingtechnisch das gepushe die bessere Variante, die wissen schon was sie machen, und Ihr seht ja auch was wir hier jetzt alleine darüber diskutieren.

Wünsch allen ein schönes Wochenede!

[hahnenkamm69]

Antwort auf Beitrag Nr.: 40.861.758 von hahnenkamm69 am 14.01.11 12:02:40

tingtechnisch soll natürlich marketingtechnisch heißen und die Analysen, Neuigkeiteen, eigene Erhebungen des Redakteurs etc. zum Unternehmen werden natürlich im Brief veröffentlicht udn man kann jederzeit Fragen stellen!

[cultom4president]

Antwort auf Beitrag Nr.: 40.861.498 von mamba11 am 14.01.11 11:31:31

Gerade da ich es besser weiß, bin ich auf Börsenbriefe dieser Art zum Glück nicht angewiesen. Deine Argumentation hinkt an allen Ecken und Kanten, auch deinen sich anschliessenden "Nachredner" kann ich so nicht zustimmen.

Zwei Hochschulabschlüsse zeugen nicht von wahnsinniger Intelligenz, vorallem wenn man in Argumentationsnöte kommt und sich dahinter verstecken muss. Aber auch dies ist eher zweitrangig.

Vorläufige Gewinnschätzung impliziert nicht beim affinen Leser einen Zeitraum von 30 Jahren. Auch hier kann ich deiner Erklärung nicht Folge leisten, ich möchte es irgendwie auch gar nicht.

Hier geht es einzig und allein um Sangamo und nicht um irgendeine halbgare Sichtweise eines Börsenbriefes mit Marktschreiermenatlität. Jeder soll damit glücklich werden, einen anständige Due Diligence schaut meiner Meinung nach anders aus.

@ crackischtrend

Schau mal hier:

http://investor.sangamo.com/events.cfm

Back to the topic!

[mamba11]

Antwort auf Beitrag Nr.: 40.862.105 von cultom4president am 14.01.11 12:44:02

also ausser allegeimen aussagen deren belege du nach wie vor schuldig bist hab ich nun nichts gelesen. Due Diligence ? hast du schonmal eine in beruflichem alltag erstellt ? wo ist deine für dieses unternehmen ?

komm....erzähl doch nicht....leg sie auf den tisch...ich nehm sie gerne auseinander und schau sie mir an.....gar kein thema. dann sehen wir ja ob du nur lehre worthülsen postest, denn davon geh ich aus.

ach du....meine intelligenz, die kannst du aus der ferne sicher nicht beurteilen und alleine, dass du dir das anmaßen wilslt disqualifiziert dich.

30 jahre was zu "lesen" qualifiziert definitiv mal zu garnichts.

was du kannst oder nicht kannst ist auch vollkommen egal....denn was du hier zum besten gibst sind noch mehr unbelegte behauptungen als dieser bericht, und dass ist fakt.

hast recht...back to topic....mit leeren worthülsen können wir hier keine fakten schaffen.

[cultom4president]

Antwort auf Beitrag Nr.: 40.867.184 von mamba11 am 15.01.11 02:49:37

Ach Mamba11,

dir wieder zu antworten käme einem "Eulen nach Athen tragen" gleich. Darauf habe ich keine Lust.
Dir ist es ja nicht einmal möglich, einfach kausale Zusammenhänge meines Postings ordentlich einzuordnen.

Wünsche dir weiterhin viel Glück!

cultom

[hahnenkamm69]

Hej Leute, wieder plus 5% in US, freut Euch doch einfach und lasst das Säbelraseln, jeder hat seine Philosophie, hier scheint sie für uns alle aufzugehen!
Schönes Wochenende mit viel Sonnenschein!!

[Rentner]

Hört euch die Präsentation an. Da steckt schon Potentail drin.
http://jpmorgan.metameetings.com/webcasts/healthcare11/
Einfach Fantasienamen etc. eingeben, dann klappt es.

[mamba11]

Antwort auf Beitrag Nr.: 40.867.242 von cultom4president am 15.01.11 07:17:27

klar weil du nichts hast...leere worte...keine substanz. deswegen musste ja nun so argumentieren. schade. hätte gerne was mit substanz gesehen...

[Rentner]

Könntet ihr die Streitereien bitte per BM austragen?

[Rentner]

Ich gehe mal davon aus, dass es sich hier um einen Auszug aus dem unten angesprochenen BB handelt.
http://www.de.sharewise.com/aktien/US8006771062-sangamo-bios…

Wenn die Technik funktioniert, dann knallt es in der Tat.

[cultom4president]

Antwort auf Beitrag Nr.: 40.870.341 von mamba11 am 16.01.11 15:11:50

Ich verstehe nicht was du von mir willst!

Schau dir den Thread an, dann siehst du wie lange ich mich mit SGMO beschäftige.
Ich habe lediglich die 9000% des Börsenbriefes bemängelt und dies als unseriös bezeichnet. Für mich ein ganz klarer Fall von Bauernfänger! Dazu stehe ich nach wie vor! Das du dich persönlich angegriffen fühlst, erkläre ich mir damit das du anscheinend sehr nah mit diesem Dienst verbunden sein mußt.

Nun, selbstverständlich habe ich mir eine eigene DD zu diesem Wert zugelegt. Dies war auch der Grund meiner Kaufentscheidung. Für mich sind und waren nach wie vor Studienergebnisse, Peer-Group-Vergleiche, Marktanalysen, Patentzulassungen, Finanzierungsrunden und Markenanmeldungen ein großes Thema bei jedem Investment. Dich scheint dies nicht sonderlich zu interessieren, hier unterscheidet sich eben unser Recherchestil.

Du verlangst aber von mir das ich mein Wissen zu diesem Unternehmen dir hier in diesem Forum unentgeltlich und sofort auf Abruf weitergebe. Warum? Ich kenne dich nicht? Du hast bis dato nichts produktives in diesem Forum zustande gebracht und sei es nur eine berechtigte Frage zum eigentlichen Thema. Ich weiß auch nicht wessen geistiges Kind du bist, welche Werbemaßnahmen dein eigentliches Ziel in diesem Thread hier darstellen. Warum sollte ich dir Informationen zukommen lassen, die über Jahre gesammelt und recherchiert werden? Sorry, aber so einfach läuft das eben nicht.

Diskussionen zur Aktie sind weiterhin willkommen, alles andere ist reine Zeitverschwendung! Denk mal darüber nach.

cultom

[floppenjoe]

kann mal einer zu der presse mitteilung von 13-14jan 2011 hineinstellen wenn einer die infos hat oder auf der homepage gefunden hat lg floppenjoe bin vvoll investiert und dank euch schon im voraus für fleisige googler die sich mit krankheiten wie krebs und sonstigen übel auseinandersetzen oder selber betroffen sind

[mamba11]

Antwort auf Beitrag Nr.: 40.871.022 von cultom4president am 16.01.11 19:20:48

geistiges kind ? was hat der blödsinn hier verloren ? es fehlt dir an der nötigen sachlichkeit.

du hast mit dd hier geprahlt. im gegensatz zu dir hat der bericht wenigstens aussagen. gleich ob man sie für richtig oder falsch hält. ich bin selbst ei kritischer betrachter der zahlen. immerhin hält das papier erstmal die tendenz auf auf das kurzfristig angekündigte ziel. das sit halt nunmal fakt. auch wenn ich mich bei zuvielen variablen schwertue über 9000 % nachzudenken.

ich finde es genauso unseriös von dir hier was zu kritisieren und dann antowrten schuldig zu bleiben. im gegensatz zu dir nennt der bericht wenigstens parameter auf welchen die annahme basiert.

wer die dinge kritisiert, sollte auch die sache beim namen nennen. keine sorge, deine dd benötige ich nicht. ich weiß ja nichtmal ob sie ansatzweise valide und reliabel ist. und von entgeld zu sprechen entbeehrt ja jedem realitätsbezug.

so long...beenden wir es hier an der stelle. du trägst ja auch in deinen posts nichts zum thema bei. insofern halte ich deine geschichten nciht für besser als den bericht. so meine meinung zu dem ganzen. da du einem äusserungszwang zu diesem thema zu unterliegen scheinst, werd ich nun auf dein neuerliches unsachliches posting, zum wohle der mitleser, nicht mehr reagieren.

[Rentner]

Und? Hat sich von euch Helden einer die Präsentation angehört? Keinerlei Cashprobleme für das gesamte Jahr, gute Kooperationen und Baldige Ergebnisse zum gerade beendeten Klinischen Versuch http://investor.sangamo.com/releasedetail.cfm?ReleaseID=5426…

[mamba11]

Antwort auf Beitrag Nr.: 40.874.341 von Rentner am 17.01.11 15:16:09

jepp sogar live :-) helden ? sind die nicht alle bei energulf ? ;-)

[Rentner]

Antwort auf Beitrag Nr.: 40.874.440 von mamba11 am 17.01.11 15:31:38

Ich meinte euch zwei Streithähne. Die =berhelden sind in der Tat an dem von dir beschriebenen Ort. Dort geht auch gerade wieder ein weiterer Push zu Ende.

[cultom4president]

Antwort auf Beitrag Nr.: 40.874.341 von Rentner am 17.01.11 15:16:09

Natürlich wurde die Konferenz verfolgt.
In der Tat liegt der Fokus derzeit auf die Studienergebnisse, alles andere war schon bekannt oder ist von geringem Interesse. Die Erwartungen scheinen hoch zu sein, dies spiegelt sich seit Wochen im Kurs wieder.

Meiner Meinung ist Sangamo mehr als im Plan!

cultom

[hahnenkamm69]

Wahnsinn, aktuell 8,63 USD auf 8,65 USD (plus 8,27%), habe heute um 8,43 USD eine schöne große Portion einverleibt und bleibe doch weiter sehr bullish! Das Volumen hat sich auch schön erhöht, denke wir werden die nächste Zeit viel Freude mit Sangamo haben!

[Rentner]

Mich wundert das bisher geringe interesse an dieser Aktie in D. Das dürfte sich aber bald ändern.

[cultom4president]

Die Aufmerksamkeit in Deutschland sollte bald kommen, obwohl es einem eigentlich egal sein kann. Meine US-Aktien kaufe ich generell nur in den USA und dort wird der Kurs gemacht.

Ein Interessanter Beitrag über Sangamo aus dem Technology Review. Wer ihn noch nicht kennt, sollte ihn unbedingt lesen:

http://www.heise.de/tr/artikel/Hausverbot-fuer-HIV-1158924.h…

cultom

[jokerxl123]

Also ich weiß nicht warum, aber ich bin mit einer kleinen Posi investiert und Sangamo leuchtet als so ziemlich einziger Wert in menem Depot grün auf.

Bin bisher sehr zufrieden mit der Aktie...
Überlege auch, evtl. nohmal nachzustocken.
Was meint ihr zu einem weiteren Einstieg? =P

[crackischtrend]

was ist das wohl für ein Dokument das uns am 31.12.2015 erwartet?

http://www.sec.gov/Archives/edgar/data/1001233/9999999997100…

[Rentner]

Ich könnte mir sehr wohl vorstellen, dass da ein Institutioneller Anleger eingestiegen ist und das geheim bleiben soll.

Confidentiality Period Must Be Reasonable

The Commission is required to delay or prevent disclosure of Form 13F information only to the extent necessary to protect the public interest. Rule 24b-2(b)(2) requires that the applicant justify the time period for which confidential treatment is sought. Every CT Application, therefore, should request confidential treatment only for the limited period of time necessary to effectuate the investment manager's strategy. The CT Application must support the time period for which confidential treatment is requested, in the context of the particular trading strategy involved.

http://www.sec.gov/divisions/investment/guidance/13fpt2.htm

[mamba11]

Antwort auf Beitrag Nr.: 40.887.557 von Rentner am 19.01.11 13:05:35

nachdem ja schon mit einigen marktriesen wie pfizer (wo sind nur meine kleinen blauen pillen hin ?) kooperiert wird, könnte das in verbindung mit deinem post schon der wink mit dem zaunpfahl sein

[Rentner]

Heute knallts drüben aber runter.

[Pinotblanc]

Antwort auf Beitrag Nr.: 40.889.845 von Rentner am 19.01.11 17:05:14

Irgendwann müssen ja Gewinnmitnahmen kommen.
Hoffentlich rauscht das Teil nicht nicht zu weit runter.

[Pinotblanc]

Antwort auf Beitrag Nr.: 40.890.152 von Pinotblanc am 19.01.11 17:37:21

Was mich stört ist, daß es Riesenblöcke sind!